PMID-sentid Pub_year Sent_text comp_official_name comp_offset protein_name organism prot_offset 35619172-10 2022 Furthermore, transcriptomic analysis of RNA-seq revealed that DS treatment up-regulated genes related to Wnt signaling resulting in the activation of Wnt signaling in which SLUG, TWIST, and MMP3/7 were highly expressed, and further inhibited the expression of E-cad. Dextran Sulfate 62-64 matrix metallopeptidase 3 Homo sapiens 190-196 35625855-7 2022 In RASF, THC (>=5 microM) increased intracellular calcium levels/PoPo3 uptake in a TRPA1-dependent manner and reduced interleukin-8 (IL-8) and matrix metalloprotease 3 (MMP-3) production at high concentrations (25 microM). Dronabinol 9-12 matrix metallopeptidase 3 Homo sapiens 143-167 35625855-7 2022 In RASF, THC (>=5 microM) increased intracellular calcium levels/PoPo3 uptake in a TRPA1-dependent manner and reduced interleukin-8 (IL-8) and matrix metalloprotease 3 (MMP-3) production at high concentrations (25 microM). Dronabinol 9-12 matrix metallopeptidase 3 Homo sapiens 169-174 35625855-7 2022 In RASF, THC (>=5 microM) increased intracellular calcium levels/PoPo3 uptake in a TRPA1-dependent manner and reduced interleukin-8 (IL-8) and matrix metalloprotease 3 (MMP-3) production at high concentrations (25 microM). Calcium 50-57 matrix metallopeptidase 3 Homo sapiens 169-174 35359923-11 2022 Twenty-eight proteins were found highly expressed in RA uniquely, pregnancy zone protein (PZP) and stromelysin-1 included, whose bioinformatic analysis was significantly involved in "serine-type endopeptidase inhibitor activity" and "complement and coagulation cascades". Serine 183-189 matrix metallopeptidase 3 Homo sapiens 99-112 35506157-5 2022 Moreover, GAA also suppressed H2O2 induced major matrix degrading proteases (MMP-3, MMP-13, ADAMTS4 and ADAMTS5) associated with NP degradation. Hydrogen Peroxide 30-34 matrix metallopeptidase 3 Homo sapiens 77-82 35315493-8 2022 TG-treated NP cells also exhibited characteristics of increased ECM degradation, supported by observations of increased MMP-1, MMP-3, MMP-9 and A disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS)-4 and ADAMTS-5 expression in addition to decreased collagen-II expression. Thapsigargin 0-2 matrix metallopeptidase 3 Homo sapiens 127-132 35410356-1 2022 Adenosine causes the anti-inflammatory effect of MTX; however, the contributions of synoviocyte adenosine receptors (AdoRs) are unknown, and matrix metalloproteinase 3 (MMP-3) is released by fibroblast-like synoviocytes in response to inflammatory signaling. Methotrexate 49-52 matrix metallopeptidase 3 Homo sapiens 169-174 35410356-5 2022 Similarly, dbcAMP partially inhibited TNFalpha-induced MMP-3 release. Bucladesine 11-17 matrix metallopeptidase 3 Homo sapiens 55-60 35410356-8 2022 We concluded that adenosine signaling via A2A AdoRs, adenylyl cyclase, and cAMP reduces TNFalpha-induced MMP-3 production by interfering with p38 MAPK/ATF-2 activity. Adenosine 18-27 matrix metallopeptidase 3 Homo sapiens 105-110 35410356-8 2022 We concluded that adenosine signaling via A2A AdoRs, adenylyl cyclase, and cAMP reduces TNFalpha-induced MMP-3 production by interfering with p38 MAPK/ATF-2 activity. Cyclic AMP 75-79 matrix metallopeptidase 3 Homo sapiens 105-110 35529854-10 2022 The serum MMP-3 concentration was significantly elevated in patients with higher bilirubin concentration (107.6 +- 85.8 vs 61.6 +- 46.1 ng/mL, p < 0.001) and was correlated with the level of antimitochondrial antibodies specific for PBC. Bilirubin 81-90 matrix metallopeptidase 3 Homo sapiens 10-15 35410356-0 2022 Adenosine inhibits TNFalpha-induced MMP-3 production in MH7A rheumatoid arthritis synoviocytes via A2A receptor signaling. Adenosine 0-9 matrix metallopeptidase 3 Homo sapiens 36-41 35410356-1 2022 Adenosine causes the anti-inflammatory effect of MTX; however, the contributions of synoviocyte adenosine receptors (AdoRs) are unknown, and matrix metalloproteinase 3 (MMP-3) is released by fibroblast-like synoviocytes in response to inflammatory signaling. Adenosine 0-9 matrix metallopeptidase 3 Homo sapiens 141-167 35410356-1 2022 Adenosine causes the anti-inflammatory effect of MTX; however, the contributions of synoviocyte adenosine receptors (AdoRs) are unknown, and matrix metalloproteinase 3 (MMP-3) is released by fibroblast-like synoviocytes in response to inflammatory signaling. Adenosine 0-9 matrix metallopeptidase 3 Homo sapiens 169-174 35410356-1 2022 Adenosine causes the anti-inflammatory effect of MTX; however, the contributions of synoviocyte adenosine receptors (AdoRs) are unknown, and matrix metalloproteinase 3 (MMP-3) is released by fibroblast-like synoviocytes in response to inflammatory signaling. Methotrexate 49-52 matrix metallopeptidase 3 Homo sapiens 141-167 35092909-9 2022 RESULTS: FLA had a significant inhibitory effect on the proliferation of HFLS-RA induced by IL-1beta, which was accompanied by decreased expression levels of TNF-alpha, IL-6, MMP-1, MMP-3, COX-2 and PGE2. fla 9-12 matrix metallopeptidase 3 Homo sapiens 182-187 35176662-10 2022 Decidual macrophage conditioned medium facilitated breakdown of laminin and fibronectin in the CPA model, an effect that was abrogated by the MMP3 inhibitor. cpa 95-98 matrix metallopeptidase 3 Homo sapiens 142-146 35269833-7 2022 We then found increases in mRNA and protein levels, along with activity of matrix metalloprotease (MMP)-1 and MMP-3, which are associated with skin aging following DPE exposure. dpe 164-167 matrix metallopeptidase 3 Homo sapiens 110-115 35269833-10 2022 We identified that ceramide-1-phosphate (C1P) (produced from ceramide by ceramide kinase activation) activates MMP-1 and MMP-3 through activation of arachidonate cascade, followed by STAT 1- and STAT 3-dependent transcriptional activation. ceramide 1-phosphate 19-39 matrix metallopeptidase 3 Homo sapiens 121-126 35269833-10 2022 We identified that ceramide-1-phosphate (C1P) (produced from ceramide by ceramide kinase activation) activates MMP-1 and MMP-3 through activation of arachidonate cascade, followed by STAT 1- and STAT 3-dependent transcriptional activation. ceramide 1-phosphate 41-44 matrix metallopeptidase 3 Homo sapiens 121-126 35269833-10 2022 We identified that ceramide-1-phosphate (C1P) (produced from ceramide by ceramide kinase activation) activates MMP-1 and MMP-3 through activation of arachidonate cascade, followed by STAT 1- and STAT 3-dependent transcriptional activation. Ceramides 61-69 matrix metallopeptidase 3 Homo sapiens 121-126 35269833-10 2022 We identified that ceramide-1-phosphate (C1P) (produced from ceramide by ceramide kinase activation) activates MMP-1 and MMP-3 through activation of arachidonate cascade, followed by STAT 1- and STAT 3-dependent transcriptional activation. Arachidonic Acid 149-161 matrix metallopeptidase 3 Homo sapiens 121-126 34994203-5 2022 Further computational calculations demonstrated the adjustable IPA position in STR1 upon the binding of secologanin, and Tyr151-OH facilitates the productive PSR binding mode via an advantageous hydrogen-bond network. secologanin 104-115 matrix metallopeptidase 3 Homo sapiens 79-83 35188217-7 2022 Lactate identified in the supernatant modulated GAG accumulation and MMP3 expression. Lactic Acid 0-7 matrix metallopeptidase 3 Homo sapiens 69-73 35188217-8 2022 Inhibition of lactate influx by the monocarboxylate transporter (MCT)-1 inhibitor, AZD3965, reversed the effect of lactate on GAG accumulation and MMP3 expression and further improved NP cell degeneration in the NPD model. AZD3965 83-90 matrix metallopeptidase 3 Homo sapiens 147-151 35188217-8 2022 Inhibition of lactate influx by the monocarboxylate transporter (MCT)-1 inhibitor, AZD3965, reversed the effect of lactate on GAG accumulation and MMP3 expression and further improved NP cell degeneration in the NPD model. Lactic Acid 115-122 matrix metallopeptidase 3 Homo sapiens 147-151 35188217-9 2022 Thanks to the homogenous expression of lactate in the model, it was possible to further identified that the combination of lactate and hypoxia enhanced MMP3 expression. Lactic Acid 39-46 matrix metallopeptidase 3 Homo sapiens 152-156 35188217-9 2022 Thanks to the homogenous expression of lactate in the model, it was possible to further identified that the combination of lactate and hypoxia enhanced MMP3 expression. Lactic Acid 123-130 matrix metallopeptidase 3 Homo sapiens 152-156 35094658-8 2022 Moreover, TB-II weakened the mRNA and protein expression of (matrix metalloproteinase) MMPs including MMP-1, MMP-3, and MMP-13, indicating the protection of TB-II against ECM degradation. timosaponin B-II 10-15 matrix metallopeptidase 3 Homo sapiens 109-114 35094658-8 2022 Moreover, TB-II weakened the mRNA and protein expression of (matrix metalloproteinase) MMPs including MMP-1, MMP-3, and MMP-13, indicating the protection of TB-II against ECM degradation. timosaponin B-II 157-162 matrix metallopeptidase 3 Homo sapiens 109-114 35100096-7 2022 Besides, SKL2001 reversed the effects of hydrostatic pressure (3 atm) on inhibiting Wnt-3a, beta-catenin, and MMP3 levels and promoting Collagen-II level in HNPC; whereas, XAV-939 reversed the effects of high hydrostatic pressure (30 atm) on promoting MMP3, Wnt-3a, and beta-catenin levels and inhibiting Collagen-II level and proteoglycan synthesis of HNPCs. 5-furan-2yl-isoxazole-3-carboxylic acid (3-imidazol-1yl-propyl)-amide 9-16 matrix metallopeptidase 3 Homo sapiens 110-114 35100096-7 2022 Besides, SKL2001 reversed the effects of hydrostatic pressure (3 atm) on inhibiting Wnt-3a, beta-catenin, and MMP3 levels and promoting Collagen-II level in HNPC; whereas, XAV-939 reversed the effects of high hydrostatic pressure (30 atm) on promoting MMP3, Wnt-3a, and beta-catenin levels and inhibiting Collagen-II level and proteoglycan synthesis of HNPCs. 5-furan-2yl-isoxazole-3-carboxylic acid (3-imidazol-1yl-propyl)-amide 9-16 matrix metallopeptidase 3 Homo sapiens 252-256 35106811-7 2022 The catabolic enzyme MMP3 (p = 0.0001) and proinflammatory cytokine interleukin 6 (p = 0.036) were downregulated by U0126 in NPCs under inflammatory conditions. U 0126 116-121 matrix metallopeptidase 3 Homo sapiens 21-25 35174094-6 2022 Although all keratinocytes responded very similarly to vemurafenib in their expression profile, particularly with a significant induction of MMP1 and MMP3, only the HrasA5 cells revealed a vemurafenib-dependent pathophysiological shift to tumor progression, i.e., the initiation of invasive growth. Vemurafenib 55-66 matrix metallopeptidase 3 Homo sapiens 150-154 34994203-5 2022 Further computational calculations demonstrated the adjustable IPA position in STR1 upon the binding of secologanin, and Tyr151-OH facilitates the productive PSR binding mode via an advantageous hydrogen-bond network. Hydrogen 195-203 matrix metallopeptidase 3 Homo sapiens 79-83 35082667-13 2021 MMP-3 levels were significantly decreased by Insaponifiable 300 and PIASCLEDINE-ExpASU and significantly increased by Saponic. piascledine 68-79 matrix metallopeptidase 3 Homo sapiens 0-5 35047008-8 2021 Results: A total of 1,373 DEGs in GSE8056 were obtained, and the top 5 upregulated genes were S100A12, CXCL8, CXCL5, MMP3, and MMP1, whereas the top 5 downregulated genes were SCGB1D2, SCGB2A2, DCD, TSPAN8, and KRT25. gse8056 34-41 matrix metallopeptidase 3 Homo sapiens 117-121 34968169-6 2022 Etomidate prevented the IL-1beta-induced increase in the expressions of matrix metalloproteinase-3 (MMP-3) and matrix metalloproteinase-13 (MMP-13) in C28/I2 chondrocytes at both mRNA and protein levels. Etomidate 0-9 matrix metallopeptidase 3 Homo sapiens 72-98 34968169-6 2022 Etomidate prevented the IL-1beta-induced increase in the expressions of matrix metalloproteinase-3 (MMP-3) and matrix metalloproteinase-13 (MMP-13) in C28/I2 chondrocytes at both mRNA and protein levels. Etomidate 0-9 matrix metallopeptidase 3 Homo sapiens 100-105 35108494-0 2021 MMP-3 activation is involved in copper oxide nanoparticle-induced epithelial-mesenchymal transition in human lung epithelial cells. cupric oxide 32-44 matrix metallopeptidase 3 Homo sapiens 0-5 35108494-6 2021 Pretreatment of the cells with ROS scavengers or inhibitors or depleting mitochondrial DNA significantly attenuated Nano-CuO-induced MAPKs activation and MMP-3 upregulation, and pretreatment of cells with MAPKs inhibitors abolished Nano-CuO-induced MMP-3 upregulation, suggesting Nano-CuO-induced MMP-3 upregulation is through Nano-CuO-induced ROS generation and MAPKs activation. ros 31-34 matrix metallopeptidase 3 Homo sapiens 154-159 35108494-6 2021 Pretreatment of the cells with ROS scavengers or inhibitors or depleting mitochondrial DNA significantly attenuated Nano-CuO-induced MAPKs activation and MMP-3 upregulation, and pretreatment of cells with MAPKs inhibitors abolished Nano-CuO-induced MMP-3 upregulation, suggesting Nano-CuO-induced MMP-3 upregulation is through Nano-CuO-induced ROS generation and MAPKs activation. ros 31-34 matrix metallopeptidase 3 Homo sapiens 249-254 35108494-6 2021 Pretreatment of the cells with ROS scavengers or inhibitors or depleting mitochondrial DNA significantly attenuated Nano-CuO-induced MAPKs activation and MMP-3 upregulation, and pretreatment of cells with MAPKs inhibitors abolished Nano-CuO-induced MMP-3 upregulation, suggesting Nano-CuO-induced MMP-3 upregulation is through Nano-CuO-induced ROS generation and MAPKs activation. ros 31-34 matrix metallopeptidase 3 Homo sapiens 297-302 35108494-9 2021 Nano-CuO exposure also caused cells to undergo EMT, which was through Nano-CuO-induced dysregulation of ROS/MAPKs/MMP-3 pathway. ros 104-107 matrix metallopeptidase 3 Homo sapiens 114-119 2834169-6 1988 Proteoglycanase (PGase) was measured either by the release of 35S-labelled proteoglycans from cartilage into the medium, or by enzyme assay using proteoglycan monomer bound to fluorescein-conjugated hyaluronic acid as the substrate. Sulfur-35 62-65 matrix metallopeptidase 3 Homo sapiens 0-15 2675782-5 1989 Immunolocalisation of MMP-3 in rheumatoid synovium and cultured synovial cells was possible when the specimens were treated with a monovalent ionophore, monensin. Monensin 153-161 matrix metallopeptidase 3 Homo sapiens 22-27 3360803-7 1988 We also show that in human synovial fibroblast cultures human recombinant interleukin-1 beta rapidly induces high levels of MMP-3 mRNA and, conversely, that retinoic acid or dexamethasone can suppress the MMP-3 mRNA levels. Tretinoin 157-170 matrix metallopeptidase 3 Homo sapiens 124-129 3360803-7 1988 We also show that in human synovial fibroblast cultures human recombinant interleukin-1 beta rapidly induces high levels of MMP-3 mRNA and, conversely, that retinoic acid or dexamethasone can suppress the MMP-3 mRNA levels. Tretinoin 157-170 matrix metallopeptidase 3 Homo sapiens 205-210 3360803-7 1988 We also show that in human synovial fibroblast cultures human recombinant interleukin-1 beta rapidly induces high levels of MMP-3 mRNA and, conversely, that retinoic acid or dexamethasone can suppress the MMP-3 mRNA levels. Dexamethasone 174-187 matrix metallopeptidase 3 Homo sapiens 124-129 3360803-7 1988 We also show that in human synovial fibroblast cultures human recombinant interleukin-1 beta rapidly induces high levels of MMP-3 mRNA and, conversely, that retinoic acid or dexamethasone can suppress the MMP-3 mRNA levels. Dexamethasone 174-187 matrix metallopeptidase 3 Homo sapiens 205-210 2834169-6 1988 Proteoglycanase (PGase) was measured either by the release of 35S-labelled proteoglycans from cartilage into the medium, or by enzyme assay using proteoglycan monomer bound to fluorescein-conjugated hyaluronic acid as the substrate. Hyaluronic Acid 199-214 matrix metallopeptidase 3 Homo sapiens 17-22 2834169-6 1988 Proteoglycanase (PGase) was measured either by the release of 35S-labelled proteoglycans from cartilage into the medium, or by enzyme assay using proteoglycan monomer bound to fluorescein-conjugated hyaluronic acid as the substrate. Sulfur-35 62-65 matrix metallopeptidase 3 Homo sapiens 17-22 2834169-6 1988 Proteoglycanase (PGase) was measured either by the release of 35S-labelled proteoglycans from cartilage into the medium, or by enzyme assay using proteoglycan monomer bound to fluorescein-conjugated hyaluronic acid as the substrate. Fluorescein 176-187 matrix metallopeptidase 3 Homo sapiens 0-15 2834169-6 1988 Proteoglycanase (PGase) was measured either by the release of 35S-labelled proteoglycans from cartilage into the medium, or by enzyme assay using proteoglycan monomer bound to fluorescein-conjugated hyaluronic acid as the substrate. Fluorescein 176-187 matrix metallopeptidase 3 Homo sapiens 17-22 2834169-6 1988 Proteoglycanase (PGase) was measured either by the release of 35S-labelled proteoglycans from cartilage into the medium, or by enzyme assay using proteoglycan monomer bound to fluorescein-conjugated hyaluronic acid as the substrate. Hyaluronic Acid 199-214 matrix metallopeptidase 3 Homo sapiens 0-15 34022544-9 2021 IL-8 and 5-FU increased MMP-2 and MMP-3 expression, while IL-6 and MTX augmented MMP-2 expression. Fluorouracil 9-13 matrix metallopeptidase 3 Homo sapiens 34-39 34019587-9 2021 Moreover, extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) inhibitor U0126, p38 inhibitor SB205380, JNK inhibitor SP600125 and Akt inhibitor GSK 690693 decreased IL-1beta-induced MMP-3 mRNA and protein expression. GSK690693 156-166 matrix metallopeptidase 3 Homo sapiens 194-199 847294-2 1977 Ion the other hand, the spin labeled acetylcholine analog, SL-1, possesses no agonist activity while it retains the antagonist activity of SL-2. Acetylcholine 37-50 matrix metallopeptidase 3 Homo sapiens 59-63 33984465-7 2021 Finally, warfarin treatment in cartilage increased COL10A1 and reduced SOX9 and MMP3 expression and in subchondral bone reduced COL1A1 and POSTN expression. Warfarin 9-17 matrix metallopeptidase 3 Homo sapiens 80-84 33991363-5 2021 Cumulative biogas and methane production decreased with increasing initial sulfate doses (0 - 3,300 mg S L-1 ). Sulfates 75-82 matrix metallopeptidase 3 Homo sapiens 103-108 33990899-0 2022 MMP-3 plays a major role in calcium pantothenate-promoted wound healing after fractional ablative laser treatment. Pantothenic Acid 28-48 matrix metallopeptidase 3 Homo sapiens 0-5 33990899-4 2022 We revealed an upregulation of MMP-3 protein expression in laser-irradiated skin models receiving aftercare treatment with calcium pantothenate. Pantothenic Acid 123-143 matrix metallopeptidase 3 Homo sapiens 31-36 33990899-8 2022 After fractional ablative laser injury, an aftercare treatment with calcium pantothenate accelerated wound closure in MMP-3 expressing models faster than in MMP-3 knockdown models. Pantothenic Acid 68-88 matrix metallopeptidase 3 Homo sapiens 118-123 33990899-10 2022 For the first time, we could show that calcium pantothenate exerts its wound healing-promoting effects at least partly via MMP-3. Pantothenic Acid 39-59 matrix metallopeptidase 3 Homo sapiens 123-128 33915355-15 2021 Finally, high ALA diet reduced the expression of BBB-degrading and neurotoxic MMP-3 and MMP-9. alpha-Linolenic Acid 14-17 matrix metallopeptidase 3 Homo sapiens 78-83 34017261-7 2021 In this article, we found that XH significantly inhibited inflammatory responses, attenuated catabolic enzymes expression, and ameliorated ECM degradation, as showed by decreased production of NO, PGE2, TNFalpha, and IL-6, decreased expression of MMP-3/-13 and ADAMTS-4/-5, and increased expression of collagen-II and aggrecan. xanthohumol 31-33 matrix metallopeptidase 3 Homo sapiens 247-256 33482178-0 2021 MiR-874-3p plays a protective role in intervertebral disc degeneration by suppressing MMP2 and MMP3. mir-874-3p 0-10 matrix metallopeptidase 3 Homo sapiens 95-99 33627570-0 2021 Cisatracurium attenuates LPS-induced modulation of MMP3 and junctional protein expression in human microvascular endothelial cells. cisatracurium 0-13 matrix metallopeptidase 3 Homo sapiens 51-55 33627570-5 2021 We investigated the effect of cisatracurium on lipopolysaccharide-induced MMP3 expression in human microvascular endothelial cells. cisatracurium 30-43 matrix metallopeptidase 3 Homo sapiens 74-78 33627570-6 2021 In our results, cisatracurium treatment significantly decreased LPS-induced MMP3 expression and increased expression of cell junction proteins such as vascular endothelial cadherin (VE-cadherin) and claudin-5. cisatracurium 16-29 matrix metallopeptidase 3 Homo sapiens 76-80 33482178-5 2021 MiR-874-3p could target and repress MMP2 and MMP3 expression in nucleus pulposus cells. mir-874-3p 0-10 matrix metallopeptidase 3 Homo sapiens 45-49 33485112-5 2021 Furthermore, butyric acid promoted production of MMP-1, MMP-3, and MMP-10 in gingival fibroblasts and suppressed TIMP-2 protein production. Butyric Acid 13-25 matrix metallopeptidase 3 Homo sapiens 56-61 33664330-8 2021 MMP-3 significantly and positively correlated with serum creatinine concentration (r = 0.51, p = 0.011; r = 0.44, p = 0.009; r = -0.66, p < 0.001) and negatively with eGFR (r = -0.5, p = 0.012; r = -0.35, p = 0.039; r = -0.63, p < 0.001) in the Short R, Long R and Control Groups. Creatinine 57-67 matrix metallopeptidase 3 Homo sapiens 0-5 33515544-7 2021 Resveratrol notably inhibited TNF-alpha-induced MMP-1 and MMP-3 upregulation and abrogated TNF-alpha-induced p65 acetylation, leading to the downregulation of MMP-1 and MMP-3 expression in TNF-alpha-treated cells. Resveratrol 0-11 matrix metallopeptidase 3 Homo sapiens 58-63 33515544-7 2021 Resveratrol notably inhibited TNF-alpha-induced MMP-1 and MMP-3 upregulation and abrogated TNF-alpha-induced p65 acetylation, leading to the downregulation of MMP-1 and MMP-3 expression in TNF-alpha-treated cells. Resveratrol 0-11 matrix metallopeptidase 3 Homo sapiens 169-174 33672928-7 2021 Furthermore, collagen type I alpha 1 and type III alpha 1 (COL1A1, COL3A1) were increased after LTAP exposure, but the expression level of matrix metalloproteinase-3 (MMP-3) was reduced. ltap 96-100 matrix metallopeptidase 3 Homo sapiens 167-172 33670968-8 2021 Certain targets of troglitazone such as 3-oxo-5-beta-steroid 4-dehydrogenase, neutrophil collagenase, stromelysin-1, and VLCAD were pinpointed, which could explain its hepatoxicity, with additional ones indicating that its application could lead to the treatment/development of cancer. Troglitazone 19-31 matrix metallopeptidase 3 Homo sapiens 102-115 33728029-3 2021 The results showed that resveratrol suppressed TLR4, MMP3, and MMP9 expression in ox-LDL-activated platelets. Resveratrol 24-35 matrix metallopeptidase 3 Homo sapiens 53-57 33728029-4 2021 The TLR4 inhibitor CLI-095 also inhibited MMP3 and MMP9 expression and secretion in ox-LDL- and lipopolysaccharide- (LPS-) activated platelets. ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate 19-26 matrix metallopeptidase 3 Homo sapiens 42-46 33728029-5 2021 The combination of resveratrol and CLI-095 synergistically suppressed MMP3 and MMP9 expression in ox-LDL- and LPS-activated platelets. Resveratrol 19-30 matrix metallopeptidase 3 Homo sapiens 70-74 33728029-5 2021 The combination of resveratrol and CLI-095 synergistically suppressed MMP3 and MMP9 expression in ox-LDL- and LPS-activated platelets. ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate 35-42 matrix metallopeptidase 3 Homo sapiens 70-74 33728029-6 2021 These findings suggest that the resveratrol-induced inhibition of MMP3 and MMP9 expression is linked to the suppression of TLR4 activation. Resveratrol 32-43 matrix metallopeptidase 3 Homo sapiens 66-70 33404658-10 2021 CONCLUSION: Imbalanced MMP-3 and MMP-12 serum levels are influenced by inflammation and glucocorticoids in SLE patients and associated with JA and distinctive hand MRI changes. jiangrine A 140-142 matrix metallopeptidase 3 Homo sapiens 23-28 33536018-11 2021 Down-regulation of miR-532-3p promoted cell proliferation, migration and invasion, and expressions of MMP-3 and MMP-9, and knockdown of HMGA2 reversed the effect of miR-532-3p inhibitor. mir-532-3p 19-29 matrix metallopeptidase 3 Homo sapiens 102-107 32642826-6 2021 RESULTS: muFAT-treated TCs showed a reduced expression of PTGS2 and MMP-3 with respect to untreated controls. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 23-26 matrix metallopeptidase 3 Homo sapiens 68-73 32896590-9 2021 RESULTS: MMP-3 was significantly increased in rat serum, synovial fluid, cartilages and chondrocytes treated with high-level uric acid. Uric Acid 125-134 matrix metallopeptidase 3 Homo sapiens 9-14 32896590-10 2021 Increased concentration of glycosaminoglycancould be observed in chondrocytes incubated with MMP-3, as well as the remarkable downregulation of proteoglycan expression. glycosaminoglycancould 27-49 matrix metallopeptidase 3 Homo sapiens 93-98 32896590-11 2021 Furthermore, high-level uric acid contributed to the degradation of proteoglycan via the activation of MMP-3. Uric Acid 24-33 matrix metallopeptidase 3 Homo sapiens 103-108 32896590-13 2021 CONCLUSION: Our study showed that MMP-3 was enhanced by high levels of uric acid, which promoted proteoglycan degradation, and induced MSU crystallization in turn. Uric Acid 71-80 matrix metallopeptidase 3 Homo sapiens 34-39 33575345-4 2021 Sudachitin inhibited IL-1beta-induced IL-6, IL-8, CXC chemokine ligand (CXCL)10, CC chemokine ligand (CCL)2, MMP-1, and MMP-3 production in HPDLC. sudachitin 0-10 matrix metallopeptidase 3 Homo sapiens 120-125 33420112-5 2021 Proteomics analysis of OCT-treated skin wounds revealed significant lower levels of key players in tissue remodeling as well as reepithelization after wounding such as pro-inflammatory cytokines (IL-8, IL-6) and matrix-metalloproteinases (MMP1, MMP2, MMP3, MMP9) when compared to controls. octenidine 23-26 matrix metallopeptidase 3 Homo sapiens 251-255 33185166-7 2021 Patients treated with MTX and doxycycline showed lower levels of DAS28, ESR, CRP, MMP-3 and MMP-9 and this was statistically significant. Methotrexate 22-25 matrix metallopeptidase 3 Homo sapiens 82-87 33185166-7 2021 Patients treated with MTX and doxycycline showed lower levels of DAS28, ESR, CRP, MMP-3 and MMP-9 and this was statistically significant. Doxycycline 30-41 matrix metallopeptidase 3 Homo sapiens 82-87 33185166-9 2021 MMP-3 and 9 play a key role in both RA synovitis and cardiovascular changes making them important therapeutic targets especially with safe and cost-effective agents like doxycycline. Doxycycline 170-181 matrix metallopeptidase 3 Homo sapiens 0-11 32990777-11 2020 MMP-3 and MMP-13 were up-regulated, and type 2 collagen was down-regulated by TNF-beta stimulation, which were all reversed by Roflumilast. Roflumilast 127-138 matrix metallopeptidase 3 Homo sapiens 0-5 33392094-0 2020 MicroRNA-18a-5p Suppresses Tumor Growth via Targeting Matrix Metalloproteinase-3 in Cisplatin-Resistant Ovarian Cancer. Cisplatin 84-93 matrix metallopeptidase 3 Homo sapiens 54-80 33392094-11 2020 Small-interfering RNA (siRNA)-mediated silencing of MMP-3 reduced cell viability, cell growth, and the invasiveness potential of cisplatin-resistant ovarian cancer cells. Cisplatin 129-138 matrix metallopeptidase 3 Homo sapiens 52-57 32638534-9 2020 Nicotine decreased the IL-1beta-induced IL-6 and MMP expression, in a dose-dependent manner, in WT chondrocytes but not in Chrna7-/- chondrocytes. Nicotine 0-8 matrix metallopeptidase 3 Homo sapiens 49-52 33199994-6 2020 In addition, DMF also decreased the expression of inflammatory factors [including IL-6, IL-8, matrix metalloproteinase (MMP)3 and MMP13] in NP cells. Dimethyl Fumarate 13-16 matrix metallopeptidase 3 Homo sapiens 94-125 33321982-8 2020 Results: The changes in matrix metalloproteinases (MMPs) were remarkable: among them, MMP-1, MMP-3, MMP-9 and MMP-13 were most strongly induced, whereas their expressions were inhibited by CZE dose dependently. (S)-cetirizine 189-192 matrix metallopeptidase 3 Homo sapiens 93-98 33174050-5 2020 ELISA showed that SFN was associated with a time- and dose-dependent reduction in poly(I:C)-stimulated production of interleukin (IL)-8, chemoattractant protein-1, IL-6, MMP-1 and MMP-3 by HCFs. Poly I-C 82-91 matrix metallopeptidase 3 Homo sapiens 180-185 32156166-0 2020 Examination of sulfonamide-based inhibitors of MMP3 using the conditioned media of invasive glioma cells. Sulfonamides 15-26 matrix metallopeptidase 3 Homo sapiens 47-51 32156166-4 2020 Using the ilomastat Leu-Trp backbone, we have synthesised novel sulphonamides and monitored the performance of these compounds in conditioned media expressing MMP3. ilomastat leu-trp 10-27 matrix metallopeptidase 3 Homo sapiens 159-163 32156166-4 2020 Using the ilomastat Leu-Trp backbone, we have synthesised novel sulphonamides and monitored the performance of these compounds in conditioned media expressing MMP3. Sulfonamides 64-77 matrix metallopeptidase 3 Homo sapiens 159-163 33136246-0 2020 Alterations in the matrix metalloproteinase-3 promoter methylation after common chemotherapeutics: in vitro study of paclitaxel, cisplatin and methotrexate in the MCF-7 and SH-SY5Y cell lines. Paclitaxel 117-127 matrix metallopeptidase 3 Homo sapiens 19-45 33243974-0 2020 Identification of miR-515-3p and its targets, vimentin and MMP3, as a key regulatory mechanism in esophageal cancer metastasis: functional and clinical significance. mir-515-3p 18-28 matrix metallopeptidase 3 Homo sapiens 59-63 32616309-13 2020 Lidocaine also decreased expression of matrix metalloproteinase 3 (MMP3) but not MMP9, whichever anaesthetic was used. Lidocaine 0-9 matrix metallopeptidase 3 Homo sapiens 39-65 32616309-13 2020 Lidocaine also decreased expression of matrix metalloproteinase 3 (MMP3) but not MMP9, whichever anaesthetic was used. Lidocaine 0-9 matrix metallopeptidase 3 Homo sapiens 67-71 32616309-16 2020 perioperative lidocaine decreased postoperative expression of NETosis and MMP3, regardless of general anaesthetic technique. Lidocaine 14-23 matrix metallopeptidase 3 Homo sapiens 74-78 32162384-5 2020 Treatment with teneligliptin significantly reduced IL-1beta-induced expression of tumor necrosis factor alpha, IL-6, and IL-8, generation of reactive oxygen species, increase in metalloproteinase 3 (MMP-3) and MMP-13, reduction of tissue inhibitors of matrix metalloproteinase 1 (TIMP-1) and TIMP-2, release of lactate dehydrogenase, and activation of the mitogen-activated protein kinase p38 and nuclear factor kappaB intracellular signaling pathways, among other things. 3-(4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidine 15-28 matrix metallopeptidase 3 Homo sapiens 178-204 32866785-10 2020 Tyrosol treatment reversed IL-1beta-induced upregulation of MMP-3, MMP-9, and MMP-13, and downregulation of collagen II, SOX-9, and aggrecan in HNPCs. 4-hydroxyphenylethanol 0-7 matrix metallopeptidase 3 Homo sapiens 60-65 33136246-0 2020 Alterations in the matrix metalloproteinase-3 promoter methylation after common chemotherapeutics: in vitro study of paclitaxel, cisplatin and methotrexate in the MCF-7 and SH-SY5Y cell lines. Cisplatin 129-138 matrix metallopeptidase 3 Homo sapiens 19-45 33136246-0 2020 Alterations in the matrix metalloproteinase-3 promoter methylation after common chemotherapeutics: in vitro study of paclitaxel, cisplatin and methotrexate in the MCF-7 and SH-SY5Y cell lines. Methotrexate 143-155 matrix metallopeptidase 3 Homo sapiens 19-45 33136246-8 2020 The MMP-3 promoter methylation status was analayzed with MSP and determined with agarose gel electrophoresis. Sepharose 81-88 matrix metallopeptidase 3 Homo sapiens 4-9 33136246-9 2020 As a result, methotrexate and paclitaxel treatment significantly methylated the MMP-3 promoter; however, cisplatin caused MMP-3 promoter unmethylation in MCF-7 and SH-SY5Y cells. Methotrexate 13-25 matrix metallopeptidase 3 Homo sapiens 80-85 33136246-9 2020 As a result, methotrexate and paclitaxel treatment significantly methylated the MMP-3 promoter; however, cisplatin caused MMP-3 promoter unmethylation in MCF-7 and SH-SY5Y cells. Paclitaxel 30-40 matrix metallopeptidase 3 Homo sapiens 80-85 33136246-9 2020 As a result, methotrexate and paclitaxel treatment significantly methylated the MMP-3 promoter; however, cisplatin caused MMP-3 promoter unmethylation in MCF-7 and SH-SY5Y cells. Cisplatin 105-114 matrix metallopeptidase 3 Homo sapiens 122-127 32993127-7 2020 Concurrent treatment of c-di-AMP and LPS elevated MMP-1 levels, whereas c-di-GMP with LPS suppressed MMP-2 levels but increased MMP-3 levels. bis(3',5')-cyclic diguanylic acid 72-80 matrix metallopeptidase 3 Homo sapiens 128-133 32599142-3 2020 We performed this study to evaluate the function of oxidative stress in NP and to explore the potential mechanism of ROS induced expression of matrix metalloproteinases (MMPs). ros 117-120 matrix metallopeptidase 3 Homo sapiens 170-174 33005006-7 2020 The nasal cell line, CCL-30, was exposed to S100A9 protein, resulting in increased MMP3, MMP7, and CTSK gene expression and elevated proliferation. Cefaclor 21-24 matrix metallopeptidase 3 Homo sapiens 83-87 33120813-1 2020 BACKGROUND: A large number of clinical studies have confirmed that after treatment with traditional Chinese medicine components such as sinomenine (SIN), the matrix -metalloproteinase3 (MMP-3) level of patients with rheumatoid arthritis (RA) shows a significant decrease, whereas MMP-3 can be involved in degrading bone matrix in humans, so in the progression of bone and joint injury in patients with RA, serum MMP-3 can be used as an important biochemical marker. sinomenine 148-151 matrix metallopeptidase 3 Homo sapiens 158-184 33120813-1 2020 BACKGROUND: A large number of clinical studies have confirmed that after treatment with traditional Chinese medicine components such as sinomenine (SIN), the matrix -metalloproteinase3 (MMP-3) level of patients with rheumatoid arthritis (RA) shows a significant decrease, whereas MMP-3 can be involved in degrading bone matrix in humans, so in the progression of bone and joint injury in patients with RA, serum MMP-3 can be used as an important biochemical marker. sinomenine 148-151 matrix metallopeptidase 3 Homo sapiens 280-285 33120813-1 2020 BACKGROUND: A large number of clinical studies have confirmed that after treatment with traditional Chinese medicine components such as sinomenine (SIN), the matrix -metalloproteinase3 (MMP-3) level of patients with rheumatoid arthritis (RA) shows a significant decrease, whereas MMP-3 can be involved in degrading bone matrix in humans, so in the progression of bone and joint injury in patients with RA, serum MMP-3 can be used as an important biochemical marker. sinomenine 148-151 matrix metallopeptidase 3 Homo sapiens 280-285 32948212-16 2020 Our experiment pointed out that RSV could dramatically inhibit the inflammatory response induced by IL-1beta, including the MMP-13, MMP-3, and MMP-1 in human OA chondrocytes by 50%, 35%, and 33% respectively. Resveratrol 32-35 matrix metallopeptidase 3 Homo sapiens 132-137 32948212-17 2020 On the other hand, RSV inhibited cyclooxygenase-2 (COX-2), matrix metalloproteinase-1 (MMP-1), MMP-3, MMP-13, and inducible nitric oxide synthase (iNOs) expression (P < 0.05), while increased collagen-II and aggrecan levels (P < 0.05). Resveratrol 19-22 matrix metallopeptidase 3 Homo sapiens 95-100 32867828-10 2020 Conversely, upregulation of SLC7A5 or tryptophan supplementation enhanced mTOR-P70S6K signals which promoted the protein translation of MMP3 and MMP13 in RA FLS. Tryptophan 38-48 matrix metallopeptidase 3 Homo sapiens 136-140 32924971-4 2020 And the expression of MMP3 was remarkably increased by Smad inhibitor and the protein levels of MMP3 and ICAM were elevated by the JNK inhibitor in GO-treated Hela cells. graphene oxide 148-150 matrix metallopeptidase 3 Homo sapiens 22-26 32924971-4 2020 And the expression of MMP3 was remarkably increased by Smad inhibitor and the protein levels of MMP3 and ICAM were elevated by the JNK inhibitor in GO-treated Hela cells. graphene oxide 148-150 matrix metallopeptidase 3 Homo sapiens 96-100 32922141-12 2020 Collectively, these findings led to the assumption that the downregulation of IL-6/JAK2/STAT3 signaling by cinnamaldehyde, tadalafil, and aliskiren could alleviate joint destruction by MMP-3 and RANKL, reduce iNOS, and enhance eNOS expressions. cinnamaldehyde 107-121 matrix metallopeptidase 3 Homo sapiens 185-190 32922141-12 2020 Collectively, these findings led to the assumption that the downregulation of IL-6/JAK2/STAT3 signaling by cinnamaldehyde, tadalafil, and aliskiren could alleviate joint destruction by MMP-3 and RANKL, reduce iNOS, and enhance eNOS expressions. Tadalafil 123-132 matrix metallopeptidase 3 Homo sapiens 185-190 32922141-12 2020 Collectively, these findings led to the assumption that the downregulation of IL-6/JAK2/STAT3 signaling by cinnamaldehyde, tadalafil, and aliskiren could alleviate joint destruction by MMP-3 and RANKL, reduce iNOS, and enhance eNOS expressions. aliskiren 138-147 matrix metallopeptidase 3 Homo sapiens 185-190 32995615-5 2020 The present study aimed to disclose the unexplored antiaging potentials of C. mangga extract (CME) in oxidative stress-induced human BJ fibroblasts with a focus on collagen protection against pro-inflammatory mediators MMP1, MMP3, and MMP13. cme 94-97 matrix metallopeptidase 3 Homo sapiens 225-229 32995615-8 2020 In addition, the gene expression of pro-inflammatory MMPs arose significantly in BJ fibroblasts after oxidative stress induction using 200 muM H2O2, in which the expression for MMP1, MMP3, and MMP13 increased by 7.10, 38.96, and 2.69 times, respectively. Hydrogen Peroxide 143-147 matrix metallopeptidase 3 Homo sapiens 183-187 32995615-10 2020 In conclusion, CME showed favorable antiaging activities in H2O2-treated human BJ fibroblasts as confirmed by the low levels of gene expression of MPP1, MMP3, and MMP13 after treatment with CME. Hydrogen Peroxide 60-64 matrix metallopeptidase 3 Homo sapiens 153-157 32964957-12 2020 Moreover, relative levels of IL-6, IL-8, TNF-alpha, and MMP3/9/13 were significantly suppressed by SF1670 stimuli compared with IL-1beta group. SF1670 99-105 matrix metallopeptidase 3 Homo sapiens 56-65 32717457-5 2020 RESULTS: In animal experiments, the combined oral administration of CP and EP increased the contents of collagen and elastin in animal skin, accompanying with significantly upregulated expression of hyaluronic acid and hydroxyproline, as well as significantly reduced expression of MMP-3 and IL-1alpha. ep 75-77 matrix metallopeptidase 3 Homo sapiens 282-287 32705171-9 2020 PDTC treatment and p53 knockdown significantly decreased matrix metallopeptidase (MMP)-3, MMP-13, metallopeptidases with thrombospondin type 1 motif (ADAMTS)-4 and ADAMTS-5 expression levels, and increased aggrecan and collagen type II expression levels in IL-1beta-stimulated cells. pyrrolidine dithiocarbamic acid 0-4 matrix metallopeptidase 3 Homo sapiens 57-88 32922141-0 2020 Aliskiren, tadalafil, and cinnamaldehyde alleviate joint destruction biomarkers; MMP-3 and RANKL; in complete Freund"s adjuvant arthritis model: Downregulation of IL-6/JAK2/STAT3 signaling pathway. aliskiren 0-9 matrix metallopeptidase 3 Homo sapiens 81-86 32922141-0 2020 Aliskiren, tadalafil, and cinnamaldehyde alleviate joint destruction biomarkers; MMP-3 and RANKL; in complete Freund"s adjuvant arthritis model: Downregulation of IL-6/JAK2/STAT3 signaling pathway. Tadalafil 11-20 matrix metallopeptidase 3 Homo sapiens 81-86 32922141-0 2020 Aliskiren, tadalafil, and cinnamaldehyde alleviate joint destruction biomarkers; MMP-3 and RANKL; in complete Freund"s adjuvant arthritis model: Downregulation of IL-6/JAK2/STAT3 signaling pathway. cinnamaldehyde 26-40 matrix metallopeptidase 3 Homo sapiens 81-86 32417162-9 2020 Treatment with STA suppressed the production of ECM degrading enzymes including MMP-3, MMP-13, ADAMTS-4, and ADAMTS-5 in IL-1beta-induced chondrocytes. stachydrine 15-18 matrix metallopeptidase 3 Homo sapiens 80-85 32376366-10 2020 Furthermore, we found that DoA could significantly inhibit IL-1beta-induced inflammation in SW982 human synovial cells, as evidenced by the decreased levels of pro-inflammatory mediators (TNF-alpha, IL-6 and COX-2) and MMP-3. dioctyl adipate 27-30 matrix metallopeptidase 3 Homo sapiens 219-224 32764573-5 2020 The inhibition of TG2 enzymatic activity with intra-articular injection of ZDON, the peptide-based specific TG2 inhibitor, ameliorated the severity of surgically induced OA as well as the expression of MMP-3 and MMP-13. zdon 75-79 matrix metallopeptidase 3 Homo sapiens 202-207 32764573-6 2020 ZDON attenuated MMP-3 and MMP-13 expression in TGFbeta- and calcium ionophore-treated chondrocytes in a Runx2-independent manner. zdon 0-4 matrix metallopeptidase 3 Homo sapiens 16-21 32742408-10 2020 In conclusion, the findings of the present study provided evidence to suggest that vitamin D3 may prevent articular cartilage degeneration and osteoarthritic disease progression by inhibiting the expression levels of MMP-3, MMP-13, ADAMTS-4 and ADAMTS-5 through suppressing the Wnt/beta-catenin signaling pathway. Cholecalciferol 83-93 matrix metallopeptidase 3 Homo sapiens 217-222 32515238-5 2020 Dioscin also attenuated the secretion of MMP1 and MMP3. dioscin 0-7 matrix metallopeptidase 3 Homo sapiens 50-54 32360554-8 2020 CID16020046 also dose responsively inhibited AGEs- induced key effectors of cartilage degradation such as MMP-3 and MMP-13. 4-(4-(3-hydroxyphenyl)-3-(4-methylphenyl)-6-oxo-1H,4H,5H,6H-pyrrolo(3,4-c)pyrazol-5-yl)benzoic acid 0-11 matrix metallopeptidase 3 Homo sapiens 106-111 32792961-4 2020 Both TRYP and TRYP-Ox inhibited matrix metalloproteinase (MMP)-3 gene expression in interleukin (IL)-1beta-stimulated primary human FLS, as well as IL-1beta-induced secretion of MMP-1/3 by FLS and synovial SW982 cells and IL-6 by FLS, SW982 cells, human umbilical vein endothelial cells (HUVECs), and monocytic THP-1 cells, although TRYP-Ox was generally more effective and had no cytotoxicity in vitro. tryptanthrine 5-9 matrix metallopeptidase 3 Homo sapiens 32-64 32792961-4 2020 Both TRYP and TRYP-Ox inhibited matrix metalloproteinase (MMP)-3 gene expression in interleukin (IL)-1beta-stimulated primary human FLS, as well as IL-1beta-induced secretion of MMP-1/3 by FLS and synovial SW982 cells and IL-6 by FLS, SW982 cells, human umbilical vein endothelial cells (HUVECs), and monocytic THP-1 cells, although TRYP-Ox was generally more effective and had no cytotoxicity in vitro. tryptanthrine 14-18 matrix metallopeptidase 3 Homo sapiens 32-64 32792961-4 2020 Both TRYP and TRYP-Ox inhibited matrix metalloproteinase (MMP)-3 gene expression in interleukin (IL)-1beta-stimulated primary human FLS, as well as IL-1beta-induced secretion of MMP-1/3 by FLS and synovial SW982 cells and IL-6 by FLS, SW982 cells, human umbilical vein endothelial cells (HUVECs), and monocytic THP-1 cells, although TRYP-Ox was generally more effective and had no cytotoxicity in vitro. tryptanthrine 14-18 matrix metallopeptidase 3 Homo sapiens 32-64 32958125-7 2020 Compared with TNF-alpha in vitro induction, isochlorogenic acid A significantly inhibited the proliferation, invasion, migration and MMP3 secretion of MH7A cells, increased ROS release and promoted MH7A apoptosis. Isochlorogenic acid A 44-65 matrix metallopeptidase 3 Homo sapiens 133-137 31978425-7 2020 We also demonstrate the ability of nobiletin to attenuate IL-21-induced expression of matrix metalloproteinases 3 and 13 (MMP-3, MMP-13), key degradative enzymes involved in RA-associated cartilage destruction. nobiletin 35-44 matrix metallopeptidase 3 Homo sapiens 122-127 32606604-11 2020 Treatment with GW9508 plays a beneficial role in protecting type II Collagen and aggrecan from degeneration by attenuating the expression of MMP-3, MMP-13, ADAMTS-4, and ADAMTS-5. GW9508 15-21 matrix metallopeptidase 3 Homo sapiens 141-146 32179246-4 2020 Our results indicate that alogliptin treatment ameliorated IL-1beta-induced production of reactive oxygen species, the expression of matrix metalloproteinase-3 (MMP-3) and MMP-13, secretions of tumor necrosis factor-alpha (TNF-alpha), IL-6, and IL-8. alogliptin 26-36 matrix metallopeptidase 3 Homo sapiens 133-166 32395651-7 2020 The isolated recombinant CD of MMP-3 unfolds as a single transition at Tm 83.4 C, matching the more stable domain observed in the full-length active form of rMMP-3. rmmp-3 158-164 matrix metallopeptidase 3 Homo sapiens 31-36 33430993-8 2020 The prediction of compound-protein interaction for four matrixmetalloproteases, MMP-3, -9, -12 and -13, in the inhibition assays is performed as a representative case study using kGCN. kgcn 179-183 matrix metallopeptidase 3 Homo sapiens 80-102 32124251-4 2020 Curcumin treatment inhibited the expression of the inflammation mediators IL-6, iNOS, and COX-2 and of the matrix-degrading proteinases MMP-1, MMP-3, MMP-9, MMP-13, ADAMTS-4, and ADAMTS-5 and upregulated the mRNA levels of the cartilage anabolic factors COL2A1 and ACAN after IL-1beta treatment. Curcumin 0-8 matrix metallopeptidase 3 Homo sapiens 143-148 31380578-9 2020 We hereby are the first to prove that OPN3 is the key sensor, responsible for up-regulating MMP1, MMP2, MMP3 and MMP9 in human dermal fibroblasts following UVA exposure via calcium-dependent G protein coupled signaling pathway. Calcium 173-180 matrix metallopeptidase 3 Homo sapiens 104-108 32349768-13 2020 Further analysis of the cellular and molecular mechanisms revealed that DMI mitigated BBB disruption, inhibited MMP3/MMP9 production, suppressed microglia activation, inhibited peripheral Th1/Th17 differentiation, and repressed the CNS infiltration of Th1 and Th17 cells. dimethyl itaconate 72-75 matrix metallopeptidase 3 Homo sapiens 112-116 32222455-4 2020 Additionally, bimatoprost and latanoprost both increased MMP-3 and TIMP-2, while unoprostone had an indeterminate effect on both. Bimatoprost 14-25 matrix metallopeptidase 3 Homo sapiens 57-62 32222455-4 2020 Additionally, bimatoprost and latanoprost both increased MMP-3 and TIMP-2, while unoprostone had an indeterminate effect on both. Latanoprost 30-41 matrix metallopeptidase 3 Homo sapiens 57-62 32332704-8 2020 Further, we found that miR-330-3p directly targeted TNF and restrained the production of matrix-degrading enzymes (MMP3, MMP13, and ADAMTS4). mir-330-3p 23-33 matrix metallopeptidase 3 Homo sapiens 115-119 32382564-0 2020 Plasma Glycosaminoglycan Profiles in Systemic Sclerosis: Associations with MMP-3, MMP-10, TIMP-1, TIMP-2, and TGF-Beta. Glycosaminoglycans 7-24 matrix metallopeptidase 3 Homo sapiens 75-80 31876323-7 2020 Cilengitide suppressed the gene expression of IL-1beta, TNF-alpha, MMP-3 and MMP-13 induced by excessive mechanical stress. Cilengitide 0-11 matrix metallopeptidase 3 Homo sapiens 67-72 32191437-7 2020 Notably, laquinimod prevented the degradation of type II collagen by inhibiting MMP-3 and MMP-13. laquinimod 9-19 matrix metallopeptidase 3 Homo sapiens 80-85 32163856-7 2020 In human rheumatoid arthritis fibroblast-like synoviocytes (RA-FLSs), DEX (250 nM and 500 nM) was found to inhibit the expression of IL-1beta, IL-6, MMP-3, MMP-9, and P-P65 following stimulation with TNF-alpha. Dexmedetomidine 70-73 matrix metallopeptidase 3 Homo sapiens 149-154 31841673-9 2020 In addition to its cytotoxic effect, Yb(III) complex showed antimetastatic properties as it decreased the cellular levels of matrix metalloproteinases MMP-3 and MMP-9. yb(iii) complex 37-52 matrix metallopeptidase 3 Homo sapiens 151-156 32146317-7 2020 Theobromine also suppresses IL-1beta-induced production of the pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha) and monocyte chemoattractant protein-1 (MCP-1), as well as matrix metalloproteinases (MMP)-3 and MMP-13. Theobromine 0-11 matrix metallopeptidase 3 Homo sapiens 189-222 32131874-9 2020 RESULTS: Low-dose NAC (1000 muM) increased the expression of Nrf2 and phospho-p62 in MH7A cells, activating antioxidant genes, suppressing the expression of MMP-3, and inhibiting the phosphorylation of JNK. Acetylcysteine 18-21 matrix metallopeptidase 3 Homo sapiens 157-162 32131874-10 2020 ROS, MMP-3 expression, and IL-6 was suppressed by administering 30 muM of SP600125 (a JNK inhibitor) in MH7A cells. pyrazolanthrone 74-82 matrix metallopeptidase 3 Homo sapiens 5-10 32556009-0 2020 Clinical Study of Sodium Hypochlorite, Polymyxin B And Limewater Effect on MMP-3,-8,-9 In Apical Periodontitis. Sodium Hypochlorite 18-37 matrix metallopeptidase 3 Homo sapiens 75-86 32131874-11 2020 Furthermore, the administration of SP600125 (30 muM) to RA-FLS suppressed MMP-3. pyrazolanthrone 35-43 matrix metallopeptidase 3 Homo sapiens 74-79 31347168-7 2020 Further studies showed that GCDC treatment induced the upregulation of matrix metalloproteinase-3 (MMP3), MMP9, and SOCS3/JAK2/p-STAT3 signal pathway in GBC cells, which could regulate the level of EMT. Glycochenodeoxycholic Acid 28-32 matrix metallopeptidase 3 Homo sapiens 71-97 31465741-5 2020 Although Z and AZ each inhibited in vitro matrix metallopeptidase (MMP)-1, MMP-3, and MMP-12 activity, inhibition of MMP-3 and MMP-12 was greater with AZ. alizarin 15-17 matrix metallopeptidase 3 Homo sapiens 75-80 33458657-10 2020 There were significant decreases in MMP-3, TIMP-1, and hydroxyproline levels after tofacitinib administration (p<0.05). tofacitinib 83-94 matrix metallopeptidase 3 Homo sapiens 36-41 31809475-0 2020 17beta-Estradiol Prevents Extracellular Matrix Degradation by Downregulating MMP3 Expression via PI3K/Akt/FOXO3 Pathway. Estradiol 0-16 matrix metallopeptidase 3 Homo sapiens 77-81 31809475-14 2020 CONCLUSION: E2 prevents the degradation of ECM by upregulating collagen II and aggrecan expression via reducing MMP-3 expression in HNPCs, and PI3K/Akt/FOXO3 pathway is dispensable for MMP-3 downregulated. Estradiol 12-14 matrix metallopeptidase 3 Homo sapiens 112-117 31809475-14 2020 CONCLUSION: E2 prevents the degradation of ECM by upregulating collagen II and aggrecan expression via reducing MMP-3 expression in HNPCs, and PI3K/Akt/FOXO3 pathway is dispensable for MMP-3 downregulated. Estradiol 12-14 matrix metallopeptidase 3 Homo sapiens 185-190 32128354-2 2020 In terms of down-regulating the expression of inducible nitric oxide synthase (iNOS), interleukin (IL)-6, and matrix metalloproteinases (MMPs), pre-treatment with the flavonoid baicalein reportedly protects articular chondrocytes against the cytotoxicity of IL-1beta. Flavonoids 167-176 matrix metallopeptidase 3 Homo sapiens 137-141 31347168-7 2020 Further studies showed that GCDC treatment induced the upregulation of matrix metalloproteinase-3 (MMP3), MMP9, and SOCS3/JAK2/p-STAT3 signal pathway in GBC cells, which could regulate the level of EMT. Glycochenodeoxycholic Acid 28-32 matrix metallopeptidase 3 Homo sapiens 99-103 31706101-9 2020 We found that DHP inhibited IL-1beta-induced upregulation of ROS, TNF-alpha, IL-6, MMP-3, ADAMTS-5. 1,4-dihydropyridine 14-17 matrix metallopeptidase 3 Homo sapiens 83-88 32051736-6 2020 Importantly, we also demonstrate the ability of P2X7R antagonism using A804598 to suppress oxidative stress, expression of interleukin (IL)-1beta, IL-6, MMP-1, MMP-3, MMP-13 as well as activation of the Janus family of tyrosine kinase/signal transducer and activator of transcription (JAK1/STAT3) proinflammatory signaling pathway. 2-cyano-1-((1S)-1-phenylethyl)-3-quinolin-5-ylguanidine 71-78 matrix metallopeptidase 3 Homo sapiens 160-165 31931830-14 2020 CONCLUSION: The findings of this longitudinal study indicate that in the chronic phase of bTBI, levels of IL-8 and MMP3 may be substantially lower than pre-injury. btbi 90-94 matrix metallopeptidase 3 Homo sapiens 115-119 31693860-5 2020 Pan-HDACi suberoylanilide hydroxamic acid (SAHA) and/or ITF2357 (givinostat) significantly reduced TNFalpha- and P. gingivalis-inducible expression and/or production of a cluster of inflammatory mediators in healthy donor GFs (IL1B, CCL2, CCL5, CXCL10, COX2, and MMP3) without affecting cell viability. vorinostat 10-41 matrix metallopeptidase 3 Homo sapiens 263-267 31693860-5 2020 Pan-HDACi suberoylanilide hydroxamic acid (SAHA) and/or ITF2357 (givinostat) significantly reduced TNFalpha- and P. gingivalis-inducible expression and/or production of a cluster of inflammatory mediators in healthy donor GFs (IL1B, CCL2, CCL5, CXCL10, COX2, and MMP3) without affecting cell viability. vorinostat 43-47 matrix metallopeptidase 3 Homo sapiens 263-267 31693860-5 2020 Pan-HDACi suberoylanilide hydroxamic acid (SAHA) and/or ITF2357 (givinostat) significantly reduced TNFalpha- and P. gingivalis-inducible expression and/or production of a cluster of inflammatory mediators in healthy donor GFs (IL1B, CCL2, CCL5, CXCL10, COX2, and MMP3) without affecting cell viability. givinostat hydrochloride 56-63 matrix metallopeptidase 3 Homo sapiens 263-267 31693860-5 2020 Pan-HDACi suberoylanilide hydroxamic acid (SAHA) and/or ITF2357 (givinostat) significantly reduced TNFalpha- and P. gingivalis-inducible expression and/or production of a cluster of inflammatory mediators in healthy donor GFs (IL1B, CCL2, CCL5, CXCL10, COX2, and MMP3) without affecting cell viability. givinostat 65-75 matrix metallopeptidase 3 Homo sapiens 263-267 31927560-8 2019 We found that naringin could significantly reduce the expressions of matrix metalloproteinases (MMP-3, MMP-13, ADAMTS-4, and ADAMTS-5) and inflammatory genes in IL-1ss-stimulated human NP cells, while collagen II and aggrecan were increased at mRNA and protein level. naringin 14-22 matrix metallopeptidase 3 Homo sapiens 96-101 31146598-4 2019 Our findings demonstrate a novel ability of paeonol to inhibit numerous factors of OA, including expressions of IL-6, TNF-alpha, NOX2, PTGS2, NUCB2/nesfatin-1, ICAM-1, VCAM-1, MMP-3/13, degradation of type II collagen, and NF-kappaB activation through the rescue of IkappaBalpha. paeonol 44-51 matrix metallopeptidase 3 Homo sapiens 176-181 31729530-5 2019 Moracin treatments also decreased the levels of matrix degradation enzymes (MMP-3, MMP-13) as indicated by RT-PCR analysis. moracin C 0-7 matrix metallopeptidase 3 Homo sapiens 76-81 31539553-5 2019 We found that agonism of GPR39 using its specific agonist TC-G 1008 significantly ameliorated important markers of RA, including oxidative stress, mitochondrial dysfunction, expression of proinflammatory cytokines including interleukin-1beta (IL-1beta), IL-6, and monocyte chemoattractant protein 1 (MCP-1), and secretion of key matrix metalloproteinases (MMPs) including MMP-1, MMP-3 and MMP-13. GPR39-C3 58-67 matrix metallopeptidase 3 Homo sapiens 379-384 31470141-0 2019 Reversine inhibits MMP-3, IL-6 and IL-8 expression through suppression of ROS and JNK/AP-1 activation in interleukin-1beta-stimulated human gingival fibroblasts. 2-(4-morpholinoanilino)-6-cyclohexylaminopurine 0-9 matrix metallopeptidase 3 Homo sapiens 19-24 31470141-5 2019 We examined the preventive effects of reversine, a 2,6-disubstituted purine derivative, on cytokine and MMP-3 expression in human gingival fibroblasts (HGFs) stimulated with IL-lbeta. 2-(4-morpholinoanilino)-6-cyclohexylaminopurine 38-47 matrix metallopeptidase 3 Homo sapiens 104-109 31392559-9 2019 CONCLUSIONS: It seems that CoQ10 may provide a new complementary approach for RA patients.Key Points CoQ10 supplementation in RA patients attenuated serum MMP-3 level. coenzyme Q10 102-107 matrix metallopeptidase 3 Homo sapiens 156-161 31468982-7 2019 The results showed that juglanin dose-dependently suppressed PGE2, NO, MMP-1, MMP3, MMP13, TNF-alpha and IL-6 production induced by IL-1beta. juglanin 24-32 matrix metallopeptidase 3 Homo sapiens 78-82 31772145-4 2019 In the present study, we treated human nucleus pulposus cells (NPCs) with melatonin and discovered that melatonin could modulate extracellular matrix (ECM) remodeling induced by IL-1beta by enhancing collagen II and aggrecan expression levels and by downregulating matrix metalloproteinase-3 (MMP-3) levels. Melatonin 104-113 matrix metallopeptidase 3 Homo sapiens 265-291 30684191-5 2019 Subsequent to treatment with HGF, a significant increase in expression of MMP2 & MMP3 under normoxia and MMP1 & MMP9 under hypoxia was observed. Adenosine Monophosphate 80-83 matrix metallopeptidase 3 Homo sapiens 85-89 31772145-4 2019 In the present study, we treated human nucleus pulposus cells (NPCs) with melatonin and discovered that melatonin could modulate extracellular matrix (ECM) remodeling induced by IL-1beta by enhancing collagen II and aggrecan expression levels and by downregulating matrix metalloproteinase-3 (MMP-3) levels. Melatonin 104-113 matrix metallopeptidase 3 Homo sapiens 293-298 31260663-8 2019 The results showed that simvastatin downregulated the degradation related genes MMP-3, MMP-13, MMP-2, MMP-9 and TIMP-2 in a dose-dependent manner. Simvastatin 24-35 matrix metallopeptidase 3 Homo sapiens 80-85 31377584-3 2019 It is unknown whether CTF-induced IL6 regulates the expression of MMPs, enzymes needed for tissue remodeling. CHEMBL408967 22-25 matrix metallopeptidase 3 Homo sapiens 66-70 31377584-10 2019 CONCLUSION: Our findings suggest a role of CTF in the modulation of expression of IL6 and MMP3 and thus in the regulation of homeostasis and remodeling of the periodontal ligament. CHEMBL408967 43-46 matrix metallopeptidase 3 Homo sapiens 90-94 31545398-10 2019 Bexarotene treatment exhibited a potential protective effect against cartilage degradation by downregulating the expression of matrix metalloproteinase (MMP)-1, MMP-3 and MMP-13. Bexarotene 0-10 matrix metallopeptidase 3 Homo sapiens 161-166 31708994-7 2019 Initial exposure to H2O2 or TNFalpha enhanced SF senescence and increased mRNA expression of IL6, CXCL8, CCL2 and MMP3 and proteins secretion. Water 20-24 matrix metallopeptidase 3 Homo sapiens 114-118 31411059-12 2019 mRNA expression of proinflammatory and profibrotic factors (TNF-alpha, IL-1, IL-8, MMP3) was elevated by hyperoxia or etoposide. Etoposide 118-127 matrix metallopeptidase 3 Homo sapiens 83-87 31536594-5 2019 Our results showed that in cells transfected with ATF-2 siRNA or treated with the ATF-2 inhibitor SBI-0087702, IL-1beta-induced MMP-3 mRNA expression was reduced. SBI-0087702 98-109 matrix metallopeptidase 3 Homo sapiens 128-133 31480533-9 2019 The produced EGCG microparticles reduced the expression of inflammatory (IL-6, IL-8, COX-2) and catabolic (MMP1, MMP3, MMP13) mediators in pro-inflammatory 3D cell cultures. epigallocatechin gallate 13-17 matrix metallopeptidase 3 Homo sapiens 113-117 31276975-5 2019 The results suggest that celastrol acts against rheumatoid arthritis by regulating the function of several signaling proteins, including MMP-9, COX-2, c-Myc, TGF-beta, c-JUN, JAK-1, JAK-3, IKK-beta, SYK, MMP-3, JNK and MEK1, which regulate the functions of Th1 and Th2 cells, macrophages, fibroblasts and endothelial cells in rheumatoid arthritis. celastrol 25-34 matrix metallopeptidase 3 Homo sapiens 204-209 30997585-2 2019 The aim of this study was to examine whether sudachitin could be used to inhibit the expression of matrix metalloproteinase (MMP)-1 and MMP-3, which are involved in the destruction of periodontal tissues in periodontal lesions, in tumor necrosis factor (TNF)-alpha-stimulated human periodontal ligament cells (HPDLC). sudachitin 45-55 matrix metallopeptidase 3 Homo sapiens 136-141 31383789-6 2019 Chondrocytes were treated with Dex alone or in combination with H2O2 Treatment with Dex alone decreased mRNA expression of COL2A1 and increased that of MMP-3 and MMP-13, thus contributing to cartilage degeneration. Dexmedetomidine 31-34 matrix metallopeptidase 3 Homo sapiens 152-157 31383789-6 2019 Chondrocytes were treated with Dex alone or in combination with H2O2 Treatment with Dex alone decreased mRNA expression of COL2A1 and increased that of MMP-3 and MMP-13, thus contributing to cartilage degeneration. Hydrogen Peroxide 64-68 matrix metallopeptidase 3 Homo sapiens 152-157 31383789-6 2019 Chondrocytes were treated with Dex alone or in combination with H2O2 Treatment with Dex alone decreased mRNA expression of COL2A1 and increased that of MMP-3 and MMP-13, thus contributing to cartilage degeneration. Dexmedetomidine 84-87 matrix metallopeptidase 3 Homo sapiens 152-157 31153059-7 2019 RESULTS: Phloretin (60 muM) showed marked suppression of invasion and migration through downregulation of matrix metalloproteinase (MMP)-2, MMP-3, and cathepsin S in human SiHa cervical cancer cells. Phloretin 9-18 matrix metallopeptidase 3 Homo sapiens 140-145 30997585-3 2019 Sudachitin suppressed TNF-alpha-induced MMP-1 and MMP-3 production in HPDLC. sudachitin 0-10 matrix metallopeptidase 3 Homo sapiens 50-55 30997585-7 2019 These findings indicate that sudachitin reduces MMP-1 and MMP-3 production in TNF-alpha-stimulated HPDLC by inhibiting the Akt pathway. sudachitin 29-39 matrix metallopeptidase 3 Homo sapiens 58-63 30984167-15 2019 Peficitinib decreased also the MMP-3, CXCL8, and CXCL1 release at 5 muM. peficitinib 0-11 matrix metallopeptidase 3 Homo sapiens 31-36 30891836-6 2019 Besides, isofraxidin also inhibited the induction effect of IL-1beta on matrix metalloproteinases (MMP)-3 and MMP-13. isofraxidin 9-20 matrix metallopeptidase 3 Homo sapiens 72-105 31239367-10 2019 miR-142-3p inhibitor significantly decreased the cell viability, the number of cell clones, the migration rate, the number of invasive cells, the contents and expression of IL-6 and MMP-3, and increased the apoptosis rate and the expressions of Bax and Bad, and decreased Bcl-2 expression of TNF-alpha-treated RA-HFLSs. mir-142-3p 0-10 matrix metallopeptidase 3 Homo sapiens 182-187 31155798-6 2019 Kaempferitrin decreased the levels of interleukin (IL)-1beta, IL-6, tumor necrosis factor (TNF)-alpha, matrix metalloproteinase (MMP)-1, and MMP-3 in MH7A cells. lespenefril 0-13 matrix metallopeptidase 3 Homo sapiens 141-146 30825594-6 2019 Consistently, expression of MMP3, a putative downstream effector of syndecan-4 was strongly induced by SF-CM in PPACs. ppacs 112-117 matrix metallopeptidase 3 Homo sapiens 28-32 30825594-7 2019 We identified an MMP3-inducing fraction in the range of 40 kDa after gel filtration, and we confirmed our findings in three-dimensional PPAC cultures, where SF-CM also reduced the glycosaminoglycan content. Glycosaminoglycans 180-197 matrix metallopeptidase 3 Homo sapiens 17-21 31205941-12 2019 TCA 10 mug/ml significantly decreased expression levels of MMP-1, MMP-3, MMP-13, ADAMTS-4, and ADAMTS-5. cinnamaldehyde 0-3 matrix metallopeptidase 3 Homo sapiens 66-71 30994184-1 2021 BACKGROUND: Atherosclerosis is as a systemic inflammatory disease associated with the activation of many mediators, including matrix metalloproteinases (MMPs), and may be amplified by abnormal high serum uric acid (UA) concentration (hyperuricemia, HU). Uric Acid 204-213 matrix metallopeptidase 3 Homo sapiens 153-157 30994184-2 2021 The aim of the study was to determine the relationship between serum UA concentration and activity of MMPs and their correlation with the hypertension-mediated organ damage (HMOD) intensity. Uric Acid 69-71 matrix metallopeptidase 3 Homo sapiens 102-106 30994184-7 2021 Among the studied metalloproteinases only MMP-3 activity positively correlated with serum UA concentration independently of age, body mass index and serum lipids (R2 = 0.11, p = 0.048). Uric Acid 90-92 matrix metallopeptidase 3 Homo sapiens 42-47 30994184-8 2021 Multivariate regression analysis showed positive association between IMT and BP, UA concentration and MMP-3 activity, independently of waist circumference and serum lipids (R2 = 0.328, p < 0.002). Uric Acid 81-83 matrix metallopeptidase 3 Homo sapiens 102-107 30994184-10 2021 CONCLUSIONS: The present results may support the thesis that UA and the increased by UA activity of MMPs may take part in the development of HMOD, especially IMT. Uric Acid 85-87 matrix metallopeptidase 3 Homo sapiens 100-104 30872412-7 2019 Compared with the baseline culture, high glucose culture significantly increased NP cell apoptosis ratio, caspase-3/9 activity, up-regulated expression of Bax, caspase-3, MMP-3, MMP-13 and ADAMTS-4, down-regulated expression of Bcl-2, aggrecan and collagen II, and decreased staining intensity of aggrecan and collagen II. Glucose 41-48 matrix metallopeptidase 3 Homo sapiens 171-176 30776647-3 2019 The results showed that oridonin significantly suppressed IL-1beta-induced MMP1, MMP3, and MMP13 production. oridonin 24-32 matrix metallopeptidase 3 Homo sapiens 81-85 30633353-5 2019 It reduced the migration of MCF-7 cells (by an 18% reduction in invasive behavior) after the treatment with PNU-74654 through perturbation of E-cadherin and MMP3/9. PNU-74654 108-117 matrix metallopeptidase 3 Homo sapiens 157-163 31101341-5 2019 In the study, we found that Iso treatment could protect human dermal fibroblasts (HDFs) against the effects of UVB irradiation by improving cell viability, suppressing MMP1 and MMP3 expression, inhibiting oxidative stress and inducing autophagy. homoorientin 28-31 matrix metallopeptidase 3 Homo sapiens 177-181 31040180-7 2019 Affinity was strengthened by cinching of a reciprocal "tyrosine clasp" formed between the N-terminal domain of TIMP-1 and proximal MMP-3 interface and by changes in secondary structure within the TIMP-1 C-terminal domain that stabilize interdomain interactions and improve complementarity to MMP-3. Tyrosine 55-63 matrix metallopeptidase 3 Homo sapiens 131-136 31040180-7 2019 Affinity was strengthened by cinching of a reciprocal "tyrosine clasp" formed between the N-terminal domain of TIMP-1 and proximal MMP-3 interface and by changes in secondary structure within the TIMP-1 C-terminal domain that stabilize interdomain interactions and improve complementarity to MMP-3. Tyrosine 55-63 matrix metallopeptidase 3 Homo sapiens 292-297 30913036-8 2019 MMP-3 level decreased in adult group (p < 0.0001) but went up in fetal HGFs (p = 0.01) when treated with 150 ng/mL CsA. Cyclosporine 115-118 matrix metallopeptidase 3 Homo sapiens 0-5 30809149-7 2019 In vitro, astragalin inhibited the expression of matrix metalloproteinases (MMP-1, MMP-3, and MMP-13) dose-dependently in TNF-alpha-induced MH7A cells, with no apparent cytotoxicity. astragalin 10-20 matrix metallopeptidase 3 Homo sapiens 83-88 30422384-0 2019 Propeptide glycosylation and galectin-3 binding decrease proteolytic activation of human proMMP-9/progelatinase B. Matrix metalloproteinases (MMPs) are secreted as proenzymes, containing propeptides that interact with the catalytic zinc, thereby controlling MMP activation. propeptide 0-10 matrix metallopeptidase 3 Homo sapiens 142-146 30422384-0 2019 Propeptide glycosylation and galectin-3 binding decrease proteolytic activation of human proMMP-9/progelatinase B. Matrix metalloproteinases (MMPs) are secreted as proenzymes, containing propeptides that interact with the catalytic zinc, thereby controlling MMP activation. propeptide 0-10 matrix metallopeptidase 3 Homo sapiens 92-95 30422384-0 2019 Propeptide glycosylation and galectin-3 binding decrease proteolytic activation of human proMMP-9/progelatinase B. Matrix metalloproteinases (MMPs) are secreted as proenzymes, containing propeptides that interact with the catalytic zinc, thereby controlling MMP activation. propeptides 187-198 matrix metallopeptidase 3 Homo sapiens 142-146 30422384-1 2019 The MMP-9 propeptide is unique in the MMP family because of its post-translational modification with an N-linked oligosaccharide. propeptide 10-20 matrix metallopeptidase 3 Homo sapiens 4-7 30422384-1 2019 The MMP-9 propeptide is unique in the MMP family because of its post-translational modification with an N-linked oligosaccharide. n-linked oligosaccharide 104-128 matrix metallopeptidase 3 Homo sapiens 4-7 30422384-2 2019 ProMMP-9 activation by MMP-3 occurs stepwise by cleavage of the propeptide in an aminoterminal (pro-AT) and carboxyterminal (pro-CT) peptide. propeptide 64-74 matrix metallopeptidase 3 Homo sapiens 23-28 30422384-4 2019 First, we report new cleavage sites in the MMP-9 propeptide by MMP-3 and neutrophil elastase. propeptide 49-59 matrix metallopeptidase 3 Homo sapiens 63-68 30422384-5 2019 Additionally, we demonstrated with the use of western blot analysis a higher resistance of glycosylated versus aglycosyl pro-AT against proteolysis by MMP-3, MMP-9, meprin alpha, neutrophil elastase and by protease-rich synovial fluids from rheumatoid arthritis patients. pro-at 121-127 matrix metallopeptidase 3 Homo sapiens 151-156 30786900-8 2019 RESULTS: We confirmed that I-BET151 could suppress the IL-1beta- or TNF-alpha-induced expression of MMP1, MMP3, MMP13, and ADAMTS4 in SW1353 cells. GSK1210151A 27-35 matrix metallopeptidase 3 Homo sapiens 106-110 32362306-7 2019 MMP-3, MMP-7, TIMP-1, and PAPP-A correlated with serum creatinine. Creatinine 55-65 matrix metallopeptidase 3 Homo sapiens 0-5 30452909-2 2019 The results of our study reveal that vildagliptin reduced degradation of the articular extracellular matrix (ECM) by downregulating IL-1beta-induced expression of matrix metalloproteinases-3 (MMP-3), matrix metalloproteinases-13 (MMP-13), a disintegrin and metalloproteinase with thrombospondin motifs-4 (ADAMTS-4) and a disintegrin and metalloproteinase with thrombospondin motifs-5 (ADAMTS-5). Vildagliptin 37-49 matrix metallopeptidase 3 Homo sapiens 163-197 30560591-0 2019 Curcumin Inhibits Proliferation of Synovial Cells by Downregulating Expression of Matrix Metalloproteinase-3 in Osteoarthritis. Curcumin 0-8 matrix metallopeptidase 3 Homo sapiens 82-108 30560591-8 2019 RESULTS: In the two chips of GSE1919 and GSE55235, the average expression of MMP3 in the osteoarthritis group was 63.7% and 12.9% higher than that of the healthy control, respectively. gse1919 29-36 matrix metallopeptidase 3 Homo sapiens 77-81 30560591-11 2019 Western blot results further showed that the expression of MMP3 was 44% lower in the untreated groups compared with the curcumin group, and the expressions of FN1 and collagen III were increased by 112% and 84%, respectively, which indicated that curcumin inhibited MMP3 expression and decreased osteoarthritis synovial cell activity. Curcumin 120-128 matrix metallopeptidase 3 Homo sapiens 59-63 30560591-11 2019 Western blot results further showed that the expression of MMP3 was 44% lower in the untreated groups compared with the curcumin group, and the expressions of FN1 and collagen III were increased by 112% and 84%, respectively, which indicated that curcumin inhibited MMP3 expression and decreased osteoarthritis synovial cell activity. Curcumin 247-255 matrix metallopeptidase 3 Homo sapiens 59-63 30560591-11 2019 Western blot results further showed that the expression of MMP3 was 44% lower in the untreated groups compared with the curcumin group, and the expressions of FN1 and collagen III were increased by 112% and 84%, respectively, which indicated that curcumin inhibited MMP3 expression and decreased osteoarthritis synovial cell activity. Curcumin 247-255 matrix metallopeptidase 3 Homo sapiens 266-270 30560591-15 2019 Curcumin could reduce cell viability, inhibit cell proliferation, increase cell apoptosis, and eventually alleviate inflammation of osteoarthritis by inhibiting the expression of MMP3. Curcumin 0-8 matrix metallopeptidase 3 Homo sapiens 179-183 30584213-6 2019 Metformin also attenuated IL-1beta-induced expressions of catabolic genes such as matrix metalloproteinase-3 (MMP3) and MMP13 and enhanced the anabolic indicator Collagen II. Metformin 0-9 matrix metallopeptidase 3 Homo sapiens 82-108 30584213-6 2019 Metformin also attenuated IL-1beta-induced expressions of catabolic genes such as matrix metalloproteinase-3 (MMP3) and MMP13 and enhanced the anabolic indicator Collagen II. Metformin 0-9 matrix metallopeptidase 3 Homo sapiens 110-114 30584213-8 2019 Further, the SIRT3 inhibitor 3-TYP effectively inhibited the initiation of mitophagy, as decreased expression of PINK1 and Parkin, decreased the LC3II/LC3I, enhanced the expression of MMP3 and MMP13, and decreased the expression of Collagen II. 3-TYP 29-34 matrix metallopeptidase 3 Homo sapiens 184-188 30485517-11 2018 Meanwhile, the induction of MMPs, including MMP-1, MMP-3, and MMP-13, caused by LPS stimulation was inhibited by carvacrol in RA-FLSs. carvacrol 113-122 matrix metallopeptidase 3 Homo sapiens 51-56 30521963-4 2019 Our results indicate that ivabradine significantly abrogated TNF-alpha-induced up-regulation of matrix metalloproteinase-3 (MMP-3), MMP-13, a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS)-4, and ADAMTS-5 at both the gene and protein levels. Ivabradine 26-36 matrix metallopeptidase 3 Homo sapiens 96-122 30521963-4 2019 Our results indicate that ivabradine significantly abrogated TNF-alpha-induced up-regulation of matrix metalloproteinase-3 (MMP-3), MMP-13, a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS)-4, and ADAMTS-5 at both the gene and protein levels. Ivabradine 26-36 matrix metallopeptidase 3 Homo sapiens 124-129 30349187-1 2018 Purpose: To characterize the effect of prostaglandin analogs (PAs) on tissue specific expression of matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs) in levator aponeurosis resections (LAR) and conjunctiva-Muller muscle resections (CMMR). Prostaglandins 39-52 matrix metallopeptidase 3 Homo sapiens 127-131 30468453-7 2018 Inhibition of NF-kappaBp65 by small interfering RNA or specific inhibitor BAY11-7082 blocked IL-1beta-dependent gene upregulation of MMP-3, MMP-13, ADAMTS-4, and ADAMTS-5 in a hypoxic environment. 3-(4-methylphenylsulfonyl)-2-propenenitrile 74-84 matrix metallopeptidase 3 Homo sapiens 133-138 30172103-6 2018 Abietic acid also concentration-dependently suppressed MMP1, MMP3, and MMP13 production induced by IL-1beta. abietic acid 0-12 matrix metallopeptidase 3 Homo sapiens 61-65 30373163-6 2018 When BlendE was evaluated, the negative impact of the hydrogen peroxide was significantly reduced for the matrix metalloproteinases (MMP 3 and MMP 12), the skin aging and oxidative stress biomarkers, namely FBN2, ANXA1 and HGF. Hydrogen Peroxide 54-71 matrix metallopeptidase 3 Homo sapiens 133-149 30349187-1 2018 Purpose: To characterize the effect of prostaglandin analogs (PAs) on tissue specific expression of matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs) in levator aponeurosis resections (LAR) and conjunctiva-Muller muscle resections (CMMR). Prostaglandins, Synthetic 62-65 matrix metallopeptidase 3 Homo sapiens 127-131 30349187-5 2018 Results: We observed a tissue specific pattern of expression of MMPs and TIMP-2 in relation to PA exposure between CMMR and LAR specimens. Prostaglandins, Synthetic 95-97 matrix metallopeptidase 3 Homo sapiens 64-68 30349187-7 2018 Adipose tissue had a PA-dependent reduced expression of MMP-3 (P<0.022), which was seen in both LAR and CMMR. Prostaglandins, Synthetic 21-23 matrix metallopeptidase 3 Homo sapiens 56-61 30349187-8 2018 Decreased expression of MMP-3 in collagen correlated with increased dermatochalasis (P<0.045) and steatoblepharon (P<0.018). steatoblepharon 101-116 matrix metallopeptidase 3 Homo sapiens 24-29 30349187-9 2018 Conclusion: PA exposure may affect MMP and TIMP expression in a tissue specific manner, and decreased expression of certain MMPs in collagen correlates to increased clinical measures of prostaglandin associated periorbitopathy (PAP). Prostaglandins 186-199 matrix metallopeptidase 3 Homo sapiens 124-128 30276528-8 2018 RT-qPCR and western blot analysis demonstrated that CS/HA/pIL-1Ra nanoparticles were able to increase IL-1Ra expression in primary synoviocytes, and reduce the mRNA and protein levels of matrix metalloproteinase-3 (MMP-3), matrix metalloproteinase-13 (MMP-13), cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) in IL-1beta-induced synoviocytes. Chitosan 52-54 matrix metallopeptidase 3 Homo sapiens 187-213 30285714-6 2018 Moreover, TCE inhibited the H2O2-induced mitogen-activated protein kinase signaling pathway, resulting in the inhibition of c-Jun, c-Fos, matrix metalloproteinase (MMP)-1, MMP-3, MMP-9, and cyclooxygenase-2 expression. Trichloroethylene 10-13 matrix metallopeptidase 3 Homo sapiens 172-177 30285714-6 2018 Moreover, TCE inhibited the H2O2-induced mitogen-activated protein kinase signaling pathway, resulting in the inhibition of c-Jun, c-Fos, matrix metalloproteinase (MMP)-1, MMP-3, MMP-9, and cyclooxygenase-2 expression. Hydrogen Peroxide 28-32 matrix metallopeptidase 3 Homo sapiens 172-177 30533262-10 2018 However, RA treatment decreased the levels of p-ATM, p-p53, GADD45alpha, p21, MMP-3, -9, and -13 and increased the level of COL1A1 in a concentration-dependent manner. Radium 9-11 matrix metallopeptidase 3 Homo sapiens 78-96 30276528-8 2018 RT-qPCR and western blot analysis demonstrated that CS/HA/pIL-1Ra nanoparticles were able to increase IL-1Ra expression in primary synoviocytes, and reduce the mRNA and protein levels of matrix metalloproteinase-3 (MMP-3), matrix metalloproteinase-13 (MMP-13), cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) in IL-1beta-induced synoviocytes. Chitosan 52-54 matrix metallopeptidase 3 Homo sapiens 215-220 29499374-6 2018 BO downregulated the expression of MMP-1, MMP-3, and IL-6, and enhanced TGF-beta1 by modulating activator protein (AP-1) and nuclear factor erythroid 2-related factor 2/antioxidant response element (Nrf2/ARE) signaling in UVB-irradiated NHDFs. boron oxide 0-2 matrix metallopeptidase 3 Homo sapiens 42-47 29890415-6 2018 Montelukast has an inhibitory effect on the inflammatory microenvironment of RA by decreasing the secretion of IL-6, IL-8, MMP-3 and MMP-13 in FLSs induced by IL-1beta. montelukast 0-11 matrix metallopeptidase 3 Homo sapiens 123-128 29553945-0 2018 Celastrol inhibits colorectal cancer cell proliferation and migration through suppression of MMP3 and MMP7 by the PI3K/AKT signaling pathway. celastrol 0-9 matrix metallopeptidase 3 Homo sapiens 93-97 29553945-5 2018 Celastrol treatment also decreased the PI3K/AKT pathway components, and MMP3 and MMP7 expression levels. celastrol 0-9 matrix metallopeptidase 3 Homo sapiens 72-76 29803171-5 2018 Our results demonstrate that gemigliptin treatment inhibited the expression of matrix metalloproteinase 1 (MMP-1), matrix metalloproteinase 3 (MMP-3), and matrix metalloproteinase 13 (MMP-13) at both the gene and protein levels. LC15-0444 29-40 matrix metallopeptidase 3 Homo sapiens 115-141 29803171-5 2018 Our results demonstrate that gemigliptin treatment inhibited the expression of matrix metalloproteinase 1 (MMP-1), matrix metalloproteinase 3 (MMP-3), and matrix metalloproteinase 13 (MMP-13) at both the gene and protein levels. LC15-0444 29-40 matrix metallopeptidase 3 Homo sapiens 143-148 30008912-7 2018 Results demonstrated that beta-elemene-paclitaxel decreased G-protein coupled receptor 124 (GPR124), vascular endothelial growth factor receptor, matrix metallopeptidase (MMP)-3, MMP-9 expression levels and increased endostatin, TIMP metallopeptidase inhibitor (TIMP)-1, TIMP-2 expression in U-2OS cells. beta-elemene 26-38 matrix metallopeptidase 3 Homo sapiens 146-177 30008912-7 2018 Results demonstrated that beta-elemene-paclitaxel decreased G-protein coupled receptor 124 (GPR124), vascular endothelial growth factor receptor, matrix metallopeptidase (MMP)-3, MMP-9 expression levels and increased endostatin, TIMP metallopeptidase inhibitor (TIMP)-1, TIMP-2 expression in U-2OS cells. Paclitaxel 39-49 matrix metallopeptidase 3 Homo sapiens 146-177 29553945-7 2018 Taken together, these findings indicated that the celastrol-induced antitumor effects were mediated through MMP3 and MMP7 by the PI3K/AKT signaling pathway. celastrol 50-59 matrix metallopeptidase 3 Homo sapiens 108-112 28914997-9 2018 Moreover, HA + AA supplementation further significantly decreased MMP-3 and MMP-9 mRNA expression. ha + aa 10-17 matrix metallopeptidase 3 Homo sapiens 66-71 30111029-13 2018 In addition, when BAY11-7082 was used to treat NPCs, the expression of TNF-alpha, IL-1beta, MMP-3 and MMP-13 were significantly decreased. 3-(4-methylphenylsulfonyl)-2-propenenitrile 18-28 matrix metallopeptidase 3 Homo sapiens 92-97 29984093-8 2018 Moreover, the MMP2 and MMP3 expression was found to correlate with the inhibition effect of TMZ. Temozolomide 92-95 matrix metallopeptidase 3 Homo sapiens 23-27 29743895-6 2018 In addition, treatment with 50 and 100 muM osthole for 48 h inhibited 10 ng/ml IL-1beta-stimulated proliferation and migration of SW982, and significantly inhibited the expression of matrix metalloproteinases, such as MMP-1, MMP-3 and MMP-13, as detected by western blot. osthol 43-50 matrix metallopeptidase 3 Homo sapiens 225-230 29963124-0 2018 SB431542 inhibited cigarette smoke extract induced invasiveness of A549 cells via the TGF-beta1/Smad2/MMP3 pathway. 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide 0-8 matrix metallopeptidase 3 Homo sapiens 102-106 29710527-6 2018 Our results indicate that sodium butyrate significantly abrogated IL-1beta-induced up-regulation of MMP-1, MMP-3, and MMP-13 at both the gene and protein levels. Butyric Acid 26-41 matrix metallopeptidase 3 Homo sapiens 107-112 29143360-10 2018 In addition, FPTHQ treatment increased the protein levels of MMP3 and the mRNA levels of IL-6 and IL-8 in A2780 cells, indicating the appearance of senescence-associated secretary phenotype (SASP) in the cells. fpthq 13-18 matrix metallopeptidase 3 Homo sapiens 61-65 29604346-6 2018 Further analysis of the cellular and molecular mechanisms underlying the protective effects of ACDT in EAE revealed that ACDT inhibited pathogenic T cell infiltration, suppressed microglia activation, repressed neurotoxic A1 astrocyte generation, lessened blood-brain barrier disruption, and diminished MMP3/9 production in the CNS of EAE. acdt 95-99 matrix metallopeptidase 3 Homo sapiens 303-307 29604346-6 2018 Further analysis of the cellular and molecular mechanisms underlying the protective effects of ACDT in EAE revealed that ACDT inhibited pathogenic T cell infiltration, suppressed microglia activation, repressed neurotoxic A1 astrocyte generation, lessened blood-brain barrier disruption, and diminished MMP3/9 production in the CNS of EAE. acdt 121-125 matrix metallopeptidase 3 Homo sapiens 303-307 28741989-10 2018 RESULTS: GLS upregulated the expression of GLS itself and of MMP-1, MMP-3, MMP-9, and MMP-13, an effect significantly reduced by treatment with mithramycin. Plicamycin 144-155 matrix metallopeptidase 3 Homo sapiens 68-73 28741989-12 2018 CONCLUSIONS: Mithramycin downregulated the increased expression of GLS and MMP-1, MMP-3, MMP-9, and MMP-13 in FLSs treated with GLS. Plicamycin 13-24 matrix metallopeptidase 3 Homo sapiens 82-87 28756710-0 2018 Steroid therapy and renal dysfunction are independently associated with serum levels of matrix metalloproteinase-3 in patients with rheumatoid arthritis. Steroids 0-7 matrix metallopeptidase 3 Homo sapiens 88-114 29341262-0 2018 Reversine inhibits MMP-1 and MMP-3 expressions by suppressing of ROS/MAPK/AP-1 activation in UV-stimulated human keratinocytes and dermal fibroblasts. 2-(4-morpholinoanilino)-6-cyclohexylaminopurine 0-9 matrix metallopeptidase 3 Homo sapiens 29-34 29341262-3 2018 We examined the preventive effects of reversine on MMP-1 and MMP-3 expressions in NHEKs and NHDFs exposed to UVB irradiation. 2-(4-morpholinoanilino)-6-cyclohexylaminopurine 38-47 matrix metallopeptidase 3 Homo sapiens 61-66 29356224-5 2018 In addition, sauchinone efficiently inhibited IL-1beta-induced MMP-3 and MMP-13 release in human OA chondrocytes. sauchinone 13-23 matrix metallopeptidase 3 Homo sapiens 63-68 29393416-7 2018 In addition, the calix[4]arene-based GC reduced cell colony formation; this was accompanied by the downregulation of the metalloproteinase Mmp3. calix(4)arene 17-30 matrix metallopeptidase 3 Homo sapiens 139-143 29191397-12 2018 Treatment with different concentrations of MQB for 24h inhibited mRNA expression of Wnt5a, Runx2, and MMP3, but Bmp2 mRNA expression was elevated by MQB. 2-(benzofuran-3-yl)acetic acid 43-46 matrix metallopeptidase 3 Homo sapiens 102-106 29191397-13 2018 Further, MQB inhibited phosphorylation of JNK and NF-kappaB p65 as well as MMP3 expression by Western blotting analysis. 2-(benzofuran-3-yl)acetic acid 9-12 matrix metallopeptidase 3 Homo sapiens 75-79 28756710-8 2018 CONCLUSIONS: Our findings suggest that steroid therapy and renal dysfunction affect serum MMP-3 levels in patients with RA. Steroids 39-46 matrix metallopeptidase 3 Homo sapiens 90-95 29348392-5 2018 Rapamycin treatment decreased the gene expression of MMP-3, MMP-13, IL-1beta, IL-6, TNF-alpha, and protein levels of P16 and P21 in bleomycin-treated AFSCs. Sirolimus 0-9 matrix metallopeptidase 3 Homo sapiens 53-58 29434795-13 2018 Additionally, the levels of MMP-1, MMP-3, and MMP-12 had significantly positive correlations with the occurrence of CCEs in CAS patients. cces 116-120 matrix metallopeptidase 3 Homo sapiens 35-40 28828748-2 2018 We sought to determine the utility of MMP-3 with other biomarkers for the prediction of PAs in patients with RA. Aminosalicylic Acid 88-91 matrix metallopeptidase 3 Homo sapiens 38-43 28828748-5 2018 PAs had a fair correlation with MMP-3 (r = 0.53, p < 0.001) and a weak correlation with KL (Krebs von den Lungen)-6 (r = 0.36, p < 0.001) and rheumatoid factor (r = 0.25, p = 0.011). Aminosalicylic Acid 0-3 matrix metallopeptidase 3 Homo sapiens 32-37 28828748-9 2018 When 5 variables (age, MMP-3, C-reactive protein, KL-6, and rheumatoid factor) were used in the multivariate analysis, MMP-3 (partial regression coefficient = 0.553, p < 0.001) emerged as the most important variable related to the elevation of PAs. Aminosalicylic Acid 247-250 matrix metallopeptidase 3 Homo sapiens 119-124 28828748-12 2018 Thus, a close relation of MMP-3 with PAs and PVR indicate that rise in PAs in patients with RA was ascribed to increase in PVR due to underlying systemic inflammation-mediated pulmonary vascular remodeling. Aminosalicylic Acid 37-40 matrix metallopeptidase 3 Homo sapiens 26-31 29257341-4 2018 Carvacrol also suppressed the protein expression levels of matrix metalloproteinase (MMP)-3 and MMP-13 in IL-1beta-stimulated human OA chondrocytes. carvacrol 0-9 matrix metallopeptidase 3 Homo sapiens 59-91 29291551-6 2018 In the current study, our results indicate that Ghrelin reduced IL-1beta-induced expression of MMP-3, MMP-13, ADAMTS-4 and ADAMTS-5 in a concentration-dependent manner. Ghrelin 48-55 matrix metallopeptidase 3 Homo sapiens 95-100 29168867-8 2018 In this study, we found that phloretin significantly inhibited the IL-1beta-induced production of NO, PGE2, TNF-alpha, and IL-6, the expression of COX-2, iNOS, MMP-3, MMP-13, and ADAMTS-5, and the degradation of aggrecan and collagen-II in human OA chondrocytes. Phloretin 29-38 matrix metallopeptidase 3 Homo sapiens 160-165 29348392-5 2018 Rapamycin treatment decreased the gene expression of MMP-3, MMP-13, IL-1beta, IL-6, TNF-alpha, and protein levels of P16 and P21 in bleomycin-treated AFSCs. Bleomycin 132-141 matrix metallopeptidase 3 Homo sapiens 53-58 29323204-4 2018 The Ca-Pi complex increased the production of MMP-3 and MMP-13 in the hypertrophic chondrocytes, which was dependent on nuclear factor-kappa B (NF-kB), p38 and extracellular signal-regulated kinase (Erk) 1/2 mitogen-activated protein (MAP) kinase and Signal transducer and activator of transcription 3 (STAT3) signaling. ca-pi 4-9 matrix metallopeptidase 3 Homo sapiens 46-51 29323204-5 2018 The Ca-Pi complexes increased the expression of endocytosis markers, and the inhibition of the formation of the Ca-Pi complex ameliorated the Ca-Pi complex-mediated increases of MMPs expression in hypertrophic chondrocytes. ca-pi 4-9 matrix metallopeptidase 3 Homo sapiens 178-182 29268768-17 2017 CX3CL1-mediated MMP-3 production was attenuated by c-Raf inhibitors (GW5074) and MEK/ERK inhibitors (PD98059 and U0126). 5-iodo-3-((3,5-dibromo-4-hydroxyphenyl)methylene)-2-indolinone 69-75 matrix metallopeptidase 3 Homo sapiens 16-21 29323204-5 2018 The Ca-Pi complexes increased the expression of endocytosis markers, and the inhibition of the formation of the Ca-Pi complex ameliorated the Ca-Pi complex-mediated increases of MMPs expression in hypertrophic chondrocytes. ca-pi 112-117 matrix metallopeptidase 3 Homo sapiens 178-182 29323204-5 2018 The Ca-Pi complexes increased the expression of endocytosis markers, and the inhibition of the formation of the Ca-Pi complex ameliorated the Ca-Pi complex-mediated increases of MMPs expression in hypertrophic chondrocytes. ca-pi 112-117 matrix metallopeptidase 3 Homo sapiens 178-182 29165854-0 2018 MMP-3 (-1171 5A/6A; Lys45Glu) variants affect serum levels of matrix metalloproteinase (MMP)-3 and correlate with severity of COPD: A study of MMP-3, MMP-7 and MMP-12 in a Tunisian population. lys45glu 20-28 matrix metallopeptidase 3 Homo sapiens 0-5 29165854-0 2018 MMP-3 (-1171 5A/6A; Lys45Glu) variants affect serum levels of matrix metalloproteinase (MMP)-3 and correlate with severity of COPD: A study of MMP-3, MMP-7 and MMP-12 in a Tunisian population. lys45glu 20-28 matrix metallopeptidase 3 Homo sapiens 62-94 29165854-7 2018 Interestingly, both MMP-3 (-1171) 5A/6A and Lys45Glu (A/G) variants were associated with respiratory function, as well as with serum levels of MMP-3 in COPD patients. lys45glu 44-52 matrix metallopeptidase 3 Homo sapiens 143-148 29268768-17 2017 CX3CL1-mediated MMP-3 production was attenuated by c-Raf inhibitors (GW5074) and MEK/ERK inhibitors (PD98059 and U0126). 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 101-108 matrix metallopeptidase 3 Homo sapiens 16-21 29268768-17 2017 CX3CL1-mediated MMP-3 production was attenuated by c-Raf inhibitors (GW5074) and MEK/ERK inhibitors (PD98059 and U0126). U 0126 113-118 matrix metallopeptidase 3 Homo sapiens 16-21 29141665-10 2017 After CZP treatment, the MMP-3 levels and US7 scores were significantly decreased at week 2, and the mean changes in US7 scores at weeks 12 and 24 were significantly higher in both groups with American College of Rheumatology 50% positive response (ACR50) and ACR 70% positive response (ACR70) than in the negative groups. Certolizumab Pegol 6-9 matrix metallopeptidase 3 Homo sapiens 25-30 29208967-4 2017 A selective inhibitor, T-5224, significantly suppressed the interleukin-1beta-induced up-regulation of Mmp-3, Mmp-13 and Adamts-5 transcription in human nucleus pulposus cells and in a mouse explant culture model of IVD degeneration. 3-(5-(4-(cyclopentyloxy)-2-hydroxybenzoyl)-2-((3-hydroxy-1,2-benzisoxazol-6-yl)methoxy)phenyl)propionic acid 23-29 matrix metallopeptidase 3 Homo sapiens 103-108 28756519-5 2017 Lico A inhibited MMP1, MMP3, and MMP13 production in IL-1beta-stimulated chondrocytes. licochalcone A 0-6 matrix metallopeptidase 3 Homo sapiens 23-27 28926925-4 2017 In the current study, we report that roxatidine attenuated TNF-alpha- induced degradation of type II collagen by suppressing the expression of MMP-3 and MMP-13 in human chondrosarcoma cell line SW1353 cells. roxatidine acetate 37-47 matrix metallopeptidase 3 Homo sapiens 143-148 28958132-6 2017 Notably, the CB2R agonists HU308 and JWH133 ameliorated TGF-beta1-induced generation of fibronectin, types I and III collagen, and the expression of matrix metalloproteinase 1 (MMP-1) and MMP-3. HU 308 27-32 matrix metallopeptidase 3 Homo sapiens 188-193 28958132-6 2017 Notably, the CB2R agonists HU308 and JWH133 ameliorated TGF-beta1-induced generation of fibronectin, types I and III collagen, and the expression of matrix metalloproteinase 1 (MMP-1) and MMP-3. 1,1-dimethylbutyl-1-deoxy-Delta(9)-THC 37-43 matrix metallopeptidase 3 Homo sapiens 188-193 29067128-0 2017 I-BET151 inhibits expression of RANKL, OPG, MMP3 and MMP9 in ankylosing spondylitis in vivo and in vitro. GSK1210151A 0-8 matrix metallopeptidase 3 Homo sapiens 44-48 29067128-9 2017 Conversely, levels of RANKL, OPG, MMP3 and MMP9 were significantly inhibited in cells or animals treated with I-BET151. Iodine 110-111 matrix metallopeptidase 3 Homo sapiens 34-38 28934876-8 2017 Both HA and NAC produced comparable reductions in TOS and MMP-3. Hyaluronic Acid 5-7 matrix metallopeptidase 3 Homo sapiens 58-63 28942223-12 2017 We found that baicalin significantly inhibited the IL-1beta-induced production of NO and PGE2, expression of COX-2, iNOS, MMP-3, MMP-13 and ADAMTS-5 and degradation of aggrecan and collagen-II. baicalin 14-22 matrix metallopeptidase 3 Homo sapiens 122-127 28934876-8 2017 Both HA and NAC produced comparable reductions in TOS and MMP-3. Acetylcysteine 12-15 matrix metallopeptidase 3 Homo sapiens 58-63 28150869-6 2017 Greater plasma MMP-3 concentrations after ACL injury and at the 6-month follow-up exam were associated with lesser KAM LSI. lsi 119-122 matrix metallopeptidase 3 Homo sapiens 15-20 28666239-9 2017 We found that CTS significantly inhibited the IL-1beta-induced production of NO and PGE2; expression of COX-2, iNOS, MMP-3, MMP-13, and ADAMTS-5. cryptotanshinone 14-17 matrix metallopeptidase 3 Homo sapiens 117-122 28756264-3 2017 A docking study of the most active compound 8k revealed key interactions between 8k and MMP-3 in which the sulfonamide moiety and the dipeptide group were important for improving activity. Dipeptides 134-143 matrix metallopeptidase 3 Homo sapiens 88-93 28756264-8 2017 Thus, we conclude that DHAA dipeptide derivatives containing the sulfonamide moiety may be the potential MMPs inhibitors with the ability to suppress cells migration. dehydroabietic acid 23-27 matrix metallopeptidase 3 Homo sapiens 105-109 28756264-8 2017 Thus, we conclude that DHAA dipeptide derivatives containing the sulfonamide moiety may be the potential MMPs inhibitors with the ability to suppress cells migration. Dipeptides 28-37 matrix metallopeptidase 3 Homo sapiens 105-109 28756264-8 2017 Thus, we conclude that DHAA dipeptide derivatives containing the sulfonamide moiety may be the potential MMPs inhibitors with the ability to suppress cells migration. Sulfonamides 65-76 matrix metallopeptidase 3 Homo sapiens 105-109 28756264-1 2017 A series of dehydroabietic acid (DHAA) dipeptide derivatives containing the sulfonamide moiety were designed, synthesized and evaluated for inhibition of MMPs as well as the effects of in vitro cell migration. dehydroabietic acid 33-37 matrix metallopeptidase 3 Homo sapiens 154-158 28756264-3 2017 A docking study of the most active compound 8k revealed key interactions between 8k and MMP-3 in which the sulfonamide moiety and the dipeptide group were important for improving activity. Sulfonamides 107-118 matrix metallopeptidase 3 Homo sapiens 88-93 29358561-11 2017 MMP-3-1612 6A5A genotype showed higher risk for development of HAND in alcohol users (0R = 1.65, P = 0.44). Alcohols 71-78 matrix metallopeptidase 3 Homo sapiens 0-5 27869311-7 2017 Moreover, hypoxia abolished SD-induced MMP-3 and MMP-13 expression by inhibiting NF-kappaB activation, p65 translocation, and MMP-3 and MMP-13 promoter activity. SD 0006 28-30 matrix metallopeptidase 3 Homo sapiens 39-44 28829242-7 2017 The transcriptional levels of inducible nitric oxide synthase (iNOS/Nos2), matrix metalloproteinases (MMP)3, and MMP13 were significantly inhibited by BA. baicalin 151-153 matrix metallopeptidase 3 Homo sapiens 75-107 27869311-7 2017 Moreover, hypoxia abolished SD-induced MMP-3 and MMP-13 expression by inhibiting NF-kappaB activation, p65 translocation, and MMP-3 and MMP-13 promoter activity. SD 0006 28-30 matrix metallopeptidase 3 Homo sapiens 126-131 28602782-9 2017 Ghrelin quartiles were also significantly associated with increased IPFP signal intensity alteration (quartile 4 vs 1: OR 3.57, 95% CI 1.55-8.25) and NTXI, PIIINP, MMP3 and MMP13. Ghrelin 0-7 matrix metallopeptidase 3 Homo sapiens 164-168 28602782-11 2017 CONCLUSIONS: Serum levels of ghrelin were significantly associated with increased knee symptoms, IPFP signal intensity alteration and serum levels of MMP3, MMP13, NTXI and PIIINP, suggesting that ghrelin may have a role to play in knee OA. Ghrelin 29-36 matrix metallopeptidase 3 Homo sapiens 150-154 28602782-11 2017 CONCLUSIONS: Serum levels of ghrelin were significantly associated with increased knee symptoms, IPFP signal intensity alteration and serum levels of MMP3, MMP13, NTXI and PIIINP, suggesting that ghrelin may have a role to play in knee OA. Ghrelin 196-203 matrix metallopeptidase 3 Homo sapiens 150-154 28554129-5 2017 Moreover, nimbolide treatment dose-dependently inhibited ERK1/2 activation, decreased Snail and MMP-3 expression, and increased E-cadherin expression. nimbolide 10-19 matrix metallopeptidase 3 Homo sapiens 96-101 28831065-5 2017 Hydrogen peroxide reduced thrombospondin 2 (an MMP-3 suppressor) expression in prostate cancer cells by upregulating microRNA-128. Hydrogen Peroxide 0-17 matrix metallopeptidase 3 Homo sapiens 47-52 28831065-6 2017 To the best of our knowledge, this is the first study to demonstrate the crucial role of reactive oxygen species in the switching expression of MMP-3 in stromal fibroblasts and prostate cancer cells during tumor progression, clarifying how the tumor microenvironment modulates ECM homeostasis control. Reactive Oxygen Species 89-112 matrix metallopeptidase 3 Homo sapiens 144-149 28831065-0 2017 Reactive oxygen species-mediated switching expression of MMP-3 in stromal fibroblasts and cancer cells during prostate cancer progression. Reactive Oxygen Species 0-23 matrix metallopeptidase 3 Homo sapiens 57-62 28831065-3 2017 Furthermore, hydrogen peroxide was characterized as the central modulator for altered MMP-3 expression in prostate cancer cells and CAFs, but through different regulatory mechanisms. Hydrogen Peroxide 13-30 matrix metallopeptidase 3 Homo sapiens 86-91 28831065-4 2017 Treatment of CAFs but not prostate cancer cells with hydrogen peroxide directly inhibited mmp-3 promoter activity with concomitant nuclear translocation of nuclear factor-kappaB (NF-kappaB), indicating that NF-kappaB is the downstream pathway for the transcriptional repression of MMP-3 in CAFs. cafs 13-17 matrix metallopeptidase 3 Homo sapiens 90-95 28831065-4 2017 Treatment of CAFs but not prostate cancer cells with hydrogen peroxide directly inhibited mmp-3 promoter activity with concomitant nuclear translocation of nuclear factor-kappaB (NF-kappaB), indicating that NF-kappaB is the downstream pathway for the transcriptional repression of MMP-3 in CAFs. cafs 13-17 matrix metallopeptidase 3 Homo sapiens 281-286 28554129-8 2017 We also found that DUSP4 knockdown suppressed the effect of nimbolide on MMP-3, Snail and E-cadherin expression. nimbolide 60-69 matrix metallopeptidase 3 Homo sapiens 73-78 28554129-10 2017 Inhibition of ERK1/2 pathway by nimbolide decreases MMP-3 and Snail expression, and increases E-cadherin expression, which finally inhibits NSCLC cell invasion and migration. nimbolide 32-41 matrix metallopeptidase 3 Homo sapiens 52-57 28742830-12 2017 By reducing Cd accumulation in cells, Zn reversed Cd anti-proliferative and anti-inflammatory effects but preserved the low MMP-3/TIMP-1 ratio induced by Cd, which was enhanced by inflammatory conditions. Zinc 38-40 matrix metallopeptidase 3 Homo sapiens 124-129 28781337-3 2017 The MMP3 gene promoter contains an insertion/deletion polymorphism characterised by an array of 5 or 6 adenosine residues (5A/6A) at -1612 position. Adenosine 103-112 matrix metallopeptidase 3 Homo sapiens 4-8 26549403-6 2017 The effect of the multilayered hybrid on MSC remodelling capacity was also evident at the transcription level, where the expression of matrix metalloproteinases and their inhibitor (MMP1, MMP2, MMP3, MMP13 and Timp1) by MSCs within DC-SF-DC were comparable to those on SF and significantly downregulated in comparison to DC, except for Timp1. dc-sf-dc 232-240 matrix metallopeptidase 3 Homo sapiens 194-198 28668088-10 2017 Treatment with the TAK1 inihibitor (5Z)-7-oxozeaenol reduced ADAMTS-4 and MMP3 mRNA (0.5-fold and 0.6-fold, respectively) and protein expression (1.4-fold and 0.5-fold, respectively) in OA synovial cells. 5-7-oxo-zeaenol 36-52 matrix metallopeptidase 3 Homo sapiens 74-78 28728606-11 2017 In contrast, patients treated with chondroitin sulfate with higher levels of MMP-1 and MMP-3, biomarkers of cartilage catabolism, had less cartilage volume loss in the medial compartment, condyle, and plateau (p <= 0.050). Chondroitin Sulfates 35-54 matrix metallopeptidase 3 Homo sapiens 87-92 28693203-0 2017 Involvement of the TGFbeta1/Smad2/MMP3 signaling pathway in SB431542-induced inhibition of cell invasion in multiple myeloma RPMI 8226 cells. 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide 60-68 matrix metallopeptidase 3 Homo sapiens 34-38 28356331-9 2017 Quiescent human prostate stroma exposed to genotoxic agents (e.g., mitoxantrone) in vivo resulted in significant upregulation (2.7- to 5.7-fold; P <= 0.01) of growth factors and cytokines including IL1beta, MMP3, IL6, and IL8. Mitoxantrone 67-79 matrix metallopeptidase 3 Homo sapiens 210-214 28693203-8 2017 SB431542 was able to significantly downregulate the expression of TGFbeta1, phosphorylated (p)-Smad2 and MMP3; however, the overexpression of TGFbeta1 significantly upregulated the expression of TGFbeta1, p-Smad2 and MMP3. 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide 0-8 matrix metallopeptidase 3 Homo sapiens 105-109 28693203-8 2017 SB431542 was able to significantly downregulate the expression of TGFbeta1, phosphorylated (p)-Smad2 and MMP3; however, the overexpression of TGFbeta1 significantly upregulated the expression of TGFbeta1, p-Smad2 and MMP3. 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide 0-8 matrix metallopeptidase 3 Homo sapiens 217-221 28693203-9 2017 In conclusion, SB431542 reduced cell invasion in RPMI 8226 cells, and this effect may be mediated via the TGFbeta1/Smad2/MMP3 signaling pathway. 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide 15-23 matrix metallopeptidase 3 Homo sapiens 121-125 28288492-2 2017 The use of flavonoid derivatives as potential metalloprotease inhibitors has recently increased.Particular plants growing in Sicily are an excellent yielder of the flavonoids luteolin, apigenin, and their respective glycoside derivatives (7-O-rutinoside, 7-O-glucoside, and 7-O-glucuronide).The inhibitory activity of luteolin, apigenin, and their respective glycoside derivatives on the metalloproteases MMP-1, MMP-3, MMP-13, MMP-8, and MMP-9 was assessed and rationalized correlating in vitro target-oriented screening and in silico docking.The flavones apigenin, luteolin, and their respective glucosides have good ability to interact with metalloproteases and can also be lead compounds for further development. Flavonoids 11-20 matrix metallopeptidase 3 Homo sapiens 412-417 28288492-6 2017 The more active compounds are apigenin-7-O-rutinoside on MMP-1 and luteolin-7-O-rutinoside on MMP-3. luteolin-7-O-rutinoside 67-90 matrix metallopeptidase 3 Homo sapiens 94-99 28915567-8 2017 Moreover, melatonin suppressed IL-1beta-induced Sirt1-mediated matrix metalloproteinase (MMP)-3 and MMP-13 production. Melatonin 10-19 matrix metallopeptidase 3 Homo sapiens 63-95 28915567-11 2017 TNF-alpha, IL-1beta, PGE2, or NO decrease caused the similar reduction of MMP-3 and MMP-13 by melatonin in IL-1beta-insulted chondrocytes. Dinoprostone 21-25 matrix metallopeptidase 3 Homo sapiens 74-79 28915567-11 2017 TNF-alpha, IL-1beta, PGE2, or NO decrease caused the similar reduction of MMP-3 and MMP-13 by melatonin in IL-1beta-insulted chondrocytes. Melatonin 94-103 matrix metallopeptidase 3 Homo sapiens 74-79 28188410-10 2017 We also found that simvastatin attenuated IL-1beta-induced expression and MMP-3, MMP-13, ADAMTS-4, and ADAMTS-5 activities and also reduced the decrease in type II collagen and aggrecan expression. Simvastatin 19-30 matrix metallopeptidase 3 Homo sapiens 74-79 27989222-8 2017 RESULTS: aMMP-8 chairside test positivity and three or more >=4 mm pockets were associated with vitamin D receptor (VDR) (rs2228570, P = 0.002, q = 0.04) and MMP3 (rs520540, rs639752, rs679620, P = 0.0009, 0.003, 0.003, q = 0.04, respectively). ammp-8 9-15 matrix metallopeptidase 3 Homo sapiens 161-165 28443720-9 2017 The induction of the expression of MMP-3 and the downregulation of MCP-1 might result in an antiplatelet activity that was not observed for the micronized purified flavonoid fraction. Flavonoids 164-173 matrix metallopeptidase 3 Homo sapiens 35-40 28447732-0 2017 Icariin inhibits MMP-1, MMP-3 and MMP-13 expression through MAPK pathways in IL-1beta-stimulated SW1353 chondrosarcoma cells. icariin 0-7 matrix metallopeptidase 3 Homo sapiens 24-29 28447732-7 2017 The results of the present study demonstrated that Icariin inhibited the expression of MMP-1, MMP-3, MMP-13, P-p38, P-ERK and P-JNK. icariin 51-58 matrix metallopeptidase 3 Homo sapiens 94-99 28447732-8 2017 Furthermore, it was revealed that the inhibition of p38 and ERK contributed to the inhibition of MMP-1 and MMP-3 by Icariin, whereas the inhibition of p38 and JNK contributed to the inhibition of MMP-13. icariin 116-123 matrix metallopeptidase 3 Homo sapiens 107-112 28416823-15 2017 Using cDNA microarray we found that the expression of a panel of invasion/metastasis-related genes was significantly changed, including the increased expression of interleukin (IL)-8 and matrix metalloproteinase-3 (MMP-3) after ATP treatment. Adenosine Triphosphate 228-231 matrix metallopeptidase 3 Homo sapiens 187-213 28416823-15 2017 Using cDNA microarray we found that the expression of a panel of invasion/metastasis-related genes was significantly changed, including the increased expression of interleukin (IL)-8 and matrix metalloproteinase-3 (MMP-3) after ATP treatment. Adenosine Triphosphate 228-231 matrix metallopeptidase 3 Homo sapiens 215-220 28299617-6 2017 In particular, methyl caffeate down-regulated SASP factors such as IL-1alpha, IL-1beta, IL-6, IL-8, GM-CSF, CXCL1, MCP-2, and MMP-3. methyl caffeate 15-30 matrix metallopeptidase 3 Homo sapiens 126-131 28503427-4 2017 RESULTS: MMP-1 and MMP-3 levels determined by ELISA were both significantly higher in the CCh group than that in the control group (P=0.042, 0.022, respectively), so was the levels of TIMP-1 (P=0.010). 1-acetyl-2-(coumariniminecarboxamide-3-yl)hydrazine 90-93 matrix metallopeptidase 3 Homo sapiens 19-24 28503427-6 2017 The expression of MMP-1 and MMP-3 were both up-regulated significantly in the CCh group (P=0.040, 0.001, respectively) on immuno-fluorescence staining. 1-acetyl-2-(coumariniminecarboxamide-3-yl)hydrazine 78-81 matrix metallopeptidase 3 Homo sapiens 28-33 28503427-7 2017 MMP-1 and MMP-3 expression in the fibroblasts were both significantly higher in the CCh group than that in the control group (P=0.027, 0.001, respectively), while neither the TIMP-1 nor TIMP-3 expression was significantly different between the two groups (P=0.421, 0.237, respectively). 1-acetyl-2-(coumariniminecarboxamide-3-yl)hydrazine 84-87 matrix metallopeptidase 3 Homo sapiens 10-15 28503427-8 2017 CONCLUSION: The overexpression of MMP-1 and MMP-3 in conjunctival tissue and fibroblasts may play an important role in the pathogenesis and development of CCh. 1-acetyl-2-(coumariniminecarboxamide-3-yl)hydrazine 155-158 matrix metallopeptidase 3 Homo sapiens 44-49 28445942-0 2017 MMP-3 and MMP-8 single-nucleotide polymorphisms are related to alcohol-induced osteonecrosis of the femoral head in Chinese males. Alcohols 63-70 matrix metallopeptidase 3 Homo sapiens 0-5 28445942-1 2017 Our study investigated the association between MMP-3 and MMP-8 single-nucleotide polymorphisms (SNPs) and alcohol-induced osteonecrosis of the femoral head (ONFH) in 695 Chinese males (299 cases and 396 control subjects). Alcohols 106-113 matrix metallopeptidase 3 Homo sapiens 47-52 28445942-2 2017 The minor allele of MMP-3 rs650108 was associated with a 0.78-fold decrease in alcohol-induced ONFH risk in the allelic model (95% CI = 0.63-0.97, P = 0.026). Alcohols 79-86 matrix metallopeptidase 3 Homo sapiens 20-25 28445942-5 2017 Therefore, among Chinese males, MMP-3 rs650108 and MMP-8 rs2012390 decrease alcohol-induced ONFH risk and MMP-8 rs11225394 increases it. Alcohols 76-83 matrix metallopeptidase 3 Homo sapiens 32-37 25414128-3 2017 We found that O-phenanthroline reduced the expression of MMP3 and MMP13 mRNA levels during chondrogenic differentiation of human chondrocytes (hChs), as well as after TNFalpha/IL-1beta exposure in an explant model. 1,10-phenanthroline 14-30 matrix metallopeptidase 3 Homo sapiens 57-61 28220902-8 2017 We identified a novel mechanism of catabolic reaction where TWIST1 up-regulates MMP3 expression by enriching 5hmC levels at the MMP3 promoter via TET1 induction. 5-hydroxymethylcytosine 109-113 matrix metallopeptidase 3 Homo sapiens 80-84 28220902-8 2017 We identified a novel mechanism of catabolic reaction where TWIST1 up-regulates MMP3 expression by enriching 5hmC levels at the MMP3 promoter via TET1 induction. 5-hydroxymethylcytosine 109-113 matrix metallopeptidase 3 Homo sapiens 128-132 28228690-7 2017 Exposure to cmvIL-10 resulted in higher MMP-3 mRNA levels, greater protein expression, and increased enzymatic activity. cmvil-10 12-20 matrix metallopeptidase 3 Homo sapiens 40-45 28043032-8 2017 Besides, kaempferol elevated LPS-induced reduced level of chondrogenic markers (SOX-9, Collagen II and Aggrecan), decreased the level of matrix-degrading enzymes, i.e., matrix metalloprotease (MMP)-3 and MMP-13, suggesting the osteogenesis of BMSC under kaempferol treatment. kaempferol 9-19 matrix metallopeptidase 3 Homo sapiens 169-199 28228690-8 2017 Treatment with cmvIL-10 also increased expression of both urokinase plasminogen receptor (uPAR) and plasminogen activator inhibitor-1 (PAI-1), which can stimulate MMP-3 activity and have previously been identified as poor prognostic markers in breast cancer patients. cmvil-10 15-23 matrix metallopeptidase 3 Homo sapiens 163-168 28068383-10 2017 Pretreatment with CsA prior to bevacizumab exposure markedly inhibited cell migration and the expression of both MMPs. Cyclosporine 18-21 matrix metallopeptidase 3 Homo sapiens 113-117 27736317-6 2017 OACs in coculture with AMs expressed significantly higher levels of MMP-1, MMP-3, MMP-9, MMP-13, IL-1beta, TNF-alpha, IL-6, IL-8, and IFN-gamma compared to OACs in mono-culture, indicating that proinflammatory macrophages may intensify the abnormal matrix degradation and cytokine secretion already associated with OACs. oacs 0-4 matrix metallopeptidase 3 Homo sapiens 75-80 28068383-11 2017 CsA enhanced the inhibitory effects of bevacizumab on pterygium fibroblast migration in vitro, possibly by inhibiting expression of both MMPs. Cyclosporine 0-3 matrix metallopeptidase 3 Homo sapiens 137-141 27810593-10 2017 Similarly L-Pt-Py suppressed the expression of several matrix metalloproteinases (MMPs) such as MMP-1, MMP-2, MMP-3, MMP-7 and MMP-9 to inhibit lung and breast cancer cell metastasis. l-pt-py 10-17 matrix metallopeptidase 3 Homo sapiens 110-115 28064223-10 2017 Increase in MMP-2 and MMP-3 levels was inhibited by dexamethasone treatment. Dexamethasone 52-65 matrix metallopeptidase 3 Homo sapiens 22-27 28659037-5 2017 We showed that myrcene decreased the production of ROS, MMP-1, MMP-3, and IL-6, and increased TGF-[Formula: see text]1 and type I procollagen secretions. myrcene 15-22 matrix metallopeptidase 3 Homo sapiens 63-68 27558675-3 2017 At the molecular level, the biological and pharmacological activities of melatonin are attributed to the inhibition of nuclear factor-kappaappa beta (NF-kappabeta), c-Fos over expression and down-regulation of matrix metalloproteinases-3 (MMP-3), which are regulators of pro-inflammatory and pro-fibrotic cytokines. Melatonin 73-82 matrix metallopeptidase 3 Homo sapiens 210-244 28002595-10 2016 The 6A/6A genotype from MMP3 polymorphism was absent in patients with calcinosis (P = 0.011), while the MMP3 5A/5A genotype correlated with the presence of anti-topoisomerase I antibodies (P = 0.009) and reduced diffusing capacity for carbon monoxide (P = 0.024). Carbon Monoxide 235-250 matrix metallopeptidase 3 Homo sapiens 104-108 27863298-10 2017 We found that butein significantly inhibited the IL-1beta-induced production of NO and PGE2, expression of COX-2, iNOS, TNF-alpha, IL-6 and MMP-13, degradation of COL-2 and SOX-9 at mRNA and protein levels as well as MMP-1, MMP-3, ADAMTS-4 and ADAMTS-5 gene expression. butein 14-20 matrix metallopeptidase 3 Homo sapiens 224-229 27351676-11 2017 These results suggest that long-term hippocampal E-S potentiation requires transient MMP-3 activity that promotes NMDAR-mediated postsynaptic Ca2+ entry that is vital for the activation of downstream signaling cascades and gene transcription. Einsteinium 49-52 matrix metallopeptidase 3 Homo sapiens 85-90 28105936-4 2016 Moreover, stromelysin/MMP3 and N-acetylglucosaminyltransferase enzyme MGAT1, which initiates the synthesis of hybrid and complex Nglycans, were identified as key orchestrating components in RS and SIPS, respectively. nglycans 129-137 matrix metallopeptidase 3 Homo sapiens 22-26 27863411-4 2016 Sesamin inhibited MMP1, MMP3, and MMP13 production in IL-1beta-stimulated chondrocytes. sesamin 0-7 matrix metallopeptidase 3 Homo sapiens 24-28 28078022-8 2016 The impact of miR-19 on the expression of TLR2, interleukin 6 (IL-6), and matrix metalloproteinase 3 (MMP-3) in FLS were analyzed by cell transfection and Western blot. mir-19 14-20 matrix metallopeptidase 3 Homo sapiens 74-100 28078022-8 2016 The impact of miR-19 on the expression of TLR2, interleukin 6 (IL-6), and matrix metalloproteinase 3 (MMP-3) in FLS were analyzed by cell transfection and Western blot. mir-19 14-20 matrix metallopeptidase 3 Homo sapiens 102-107 28078022-11 2016 Transfection of miR-19 mimic or miR-19 inhibitor obviously suppressed or increased TLR2 expression, and reduced or promoted release of cytokines IL-6 and MMP-3 in FLS, respectively. mir-19 16-22 matrix metallopeptidase 3 Homo sapiens 154-159 28078022-11 2016 Transfection of miR-19 mimic or miR-19 inhibitor obviously suppressed or increased TLR2 expression, and reduced or promoted release of cytokines IL-6 and MMP-3 in FLS, respectively. mir-19 32-38 matrix metallopeptidase 3 Homo sapiens 154-159 27771306-3 2016 We found that the overexpression of HMGB1 A-box significantly decreased the IL-1beta-stimulated the production of MMP-1, MMP-3 and MMP-9, and also reduced the elevated levels of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) associated with the inhibition of prostaglandin E2 (PGE2) and nitric oxide (NO) production in IL-1beta-stimulated chondrocytes. Dinoprostone 280-296 matrix metallopeptidase 3 Homo sapiens 121-126 27771306-3 2016 We found that the overexpression of HMGB1 A-box significantly decreased the IL-1beta-stimulated the production of MMP-1, MMP-3 and MMP-9, and also reduced the elevated levels of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) associated with the inhibition of prostaglandin E2 (PGE2) and nitric oxide (NO) production in IL-1beta-stimulated chondrocytes. Dinoprostone 298-302 matrix metallopeptidase 3 Homo sapiens 121-126 27216977-0 2016 Novel effects of sphingosylphosphorylcholine on invasion of breast cancer: Involvement of matrix metalloproteinase-3 secretion leading to WNT activation. sphingosine phosphorylcholine 17-44 matrix metallopeptidase 3 Homo sapiens 90-116 27208552-15 2016 CONCLUSION: Naringin effectively promotes the proliferation of degenerative human NP cells and improves the recuperation of the cells from degeneration by increasing expression of aggrecan, BMP-2, and Sox6 while inhibiting the expression of TNF-alpha and MMP3. naringin 12-20 matrix metallopeptidase 3 Homo sapiens 255-259 30641006-0 2016 [Efficacy of Hebi Formula Combined Methotrexate on Early Rheumatoid Arthritis Patients with Dis- harmony of Gan and Pi Syndrome and Its Effects on Serum MMP-3 and RANK/RANKL/OPG Expressions]. Methotrexate 35-47 matrix metallopeptidase 3 Homo sapiens 153-158 26991527-8 2016 These 3 molecules, MMP-3, and activin A were all significantly associated with greater improvement in KOOS4 over 3 months, after adjustment for other relevant factors. koos4 102-107 matrix metallopeptidase 3 Homo sapiens 19-24 27216977-14 2016 Wnt inhibitor, FH535 inhibited SPC-induced MMP3 secretion and invasion. FH535 15-20 matrix metallopeptidase 3 Homo sapiens 43-47 27216977-8 2016 An extracellular signal-regulated kinase (ERK) inhibitor, PD98059, significantly suppressed the secretion and the gelatinolytic activity of MMP3, and invasion in MCF10A cells. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 58-65 matrix metallopeptidase 3 Homo sapiens 140-144 27216977-11 2016 The effects of SPC-induced MMP3 secretion on beta-catenin and TCF/lymphoid enhancer factor (LEF) promoter activity were examined since MMP3 indirectly activates canonical Wnt signaling. sphingosine phosphorylcholine 15-18 matrix metallopeptidase 3 Homo sapiens 27-31 27588175-4 2016 The insertion of an adenine (A) base in the promoter of the MMP-3 gene at position -1612/-1617 produces a sequence of six adenines (6A), whereas the other allele has five (5A). Adenine 20-27 matrix metallopeptidase 3 Homo sapiens 60-65 27588175-4 2016 The insertion of an adenine (A) base in the promoter of the MMP-3 gene at position -1612/-1617 produces a sequence of six adenines (6A), whereas the other allele has five (5A). Adenine 122-130 matrix metallopeptidase 3 Homo sapiens 60-65 27562075-11 2016 Protein level of MMP-3 was reduced in both cell lines upon stimulation with 10 mug/ml glucosamine sulfate whereas for MMP-9 a decrease could only be observed in SaOS-2 cells. Glucosamine 86-105 matrix metallopeptidase 3 Homo sapiens 17-22 26553320-10 2016 Compared with the monoculture, MMP-1, MMP-3, interleukin (IL)-1beta, IL-6, IL-17, and IL-21 in supernatant of cocultures were markedly elevated after treatment with nicotine. Nicotine 165-173 matrix metallopeptidase 3 Homo sapiens 38-43 27562075-12 2016 CONCLUSION: In this study, we found a pronounced suppressive effect of glucosamine sulfate particularly on MMP-3 and also MMP-9 mRNA and protein levels in osteosarcoma cell lines in vitro. Glucosamine 71-90 matrix metallopeptidase 3 Homo sapiens 107-112 27322248-5 2016 EAE increased collagen contents through inhibited MMP1 and MMP3 mRNA expression and induced TIMP1, the antagonists of MMPs protein, gene expression. EAE 0-3 matrix metallopeptidase 3 Homo sapiens 59-63 27486852-0 2016 Tiron Inhibits UVB-Induced AP-1 Binding Sites Transcriptional Activation on MMP-1 and MMP-3 Promoters by MAPK Signaling Pathway in Human Dermal Fibroblasts. 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt 0-5 matrix metallopeptidase 3 Homo sapiens 86-91 27486852-2 2016 In this study, we investigated the inhibitory effect of Tiron on matrix metalloproteinase (MMP)-1 and MMP-3 expression in human dermal fibroblast cells. 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt 56-61 matrix metallopeptidase 3 Homo sapiens 102-107 27486852-3 2016 Western blot and ELISA analysis revealed that Tiron inhibited ultraviolet B (UVB)-induced protein expression of MMP-1 and MMP-3. 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt 46-51 matrix metallopeptidase 3 Homo sapiens 122-127 27486852-4 2016 Real-time quantitative PCR confirmed that Tiron could inhibit UVB-induced mRNA expression of MMP-1 and MMP-3. 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt 42-47 matrix metallopeptidase 3 Homo sapiens 103-108 27486852-6 2016 Through the AP-1 binding site mutation, it was found that Tiron could inhibit AP-1-induced upregulation of MMP-1 and MMP-3 expression through blocking AP-1 binding to the AP-1 binding sites in the MMP-1 and MMP-3 promoter region. 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt 58-63 matrix metallopeptidase 3 Homo sapiens 117-122 27486852-6 2016 Through the AP-1 binding site mutation, it was found that Tiron could inhibit AP-1-induced upregulation of MMP-1 and MMP-3 expression through blocking AP-1 binding to the AP-1 binding sites in the MMP-1 and MMP-3 promoter region. 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt 58-63 matrix metallopeptidase 3 Homo sapiens 207-212 27043485-7 2016 Analysis for the non-synonymous MMP3 SNP found significant differences between both CF vs caries experience groups (LCE+ high caries experience (HCE, DMFT>=5)) and LCE vs HCE groups. LCE 116-119 matrix metallopeptidase 3 Homo sapiens 32-36 27043485-7 2016 Analysis for the non-synonymous MMP3 SNP found significant differences between both CF vs caries experience groups (LCE+ high caries experience (HCE, DMFT>=5)) and LCE vs HCE groups. hce 145-148 matrix metallopeptidase 3 Homo sapiens 32-36 27043485-7 2016 Analysis for the non-synonymous MMP3 SNP found significant differences between both CF vs caries experience groups (LCE+ high caries experience (HCE, DMFT>=5)) and LCE vs HCE groups. LCE 167-170 matrix metallopeptidase 3 Homo sapiens 32-36 27043485-7 2016 Analysis for the non-synonymous MMP3 SNP found significant differences between both CF vs caries experience groups (LCE+ high caries experience (HCE, DMFT>=5)) and LCE vs HCE groups. hce 174-177 matrix metallopeptidase 3 Homo sapiens 32-36 26899309-4 2016 Additionally, we found that the activities, mRNA levels, and protein levels of matrix metalloproteinase (MMP)-3 and MMP-8 were inhibited, while the expression of tissue inhibitor of metalloproteinase-2 was enhanced by tangeretin in LPS-stimulated microglia. tangeretin 218-228 matrix metallopeptidase 3 Homo sapiens 79-111 26073357-5 2016 RESULTS: Whilst articaine-MTA sustained hOA proliferation patterns similar to H2 O-MTA, NaOCl-MTA reduced hOA proliferation and significantly increased the expression of MMP1 and MMP3. Sodium Hypochlorite 88-93 matrix metallopeptidase 3 Homo sapiens 179-183 26799369-7 2016 Collagen scaffolds containing hyaluronic acid or amniotic membrane also temper the expression of genes associated with the inflammatory response in normal tendon healing (TNF-alpha, COLI, MMP-3). Hyaluronic Acid 30-45 matrix metallopeptidase 3 Homo sapiens 188-193 26179241-13 2016 [G-HSA+LPS] increased MMP-3 production significantly, vs. LPS (p = 0.0005). g-hsa 1-6 matrix metallopeptidase 3 Homo sapiens 22-27 27262798-8 2016 Increased TF activity, and IL-6, MMP-3, and VEGF secretion induced by thrombin were inhibited by argatroban. argatroban 97-107 matrix metallopeptidase 3 Homo sapiens 33-38 27209430-0 2016 Alteration of matrix metalloproteinase-3 O-glycan structure as a biomarker for disease activity of rheumatoid arthritis. Polysaccharides 43-49 matrix metallopeptidase 3 Homo sapiens 14-40 27037019-7 2016 Notably, it was found that the inhibitory effects of Edaravone on TNF-alpha-induced reduction of type II collagen were mediated by MMP-3 and MMP-13. Edaravone 53-62 matrix metallopeptidase 3 Homo sapiens 131-136 27158245-10 2016 The effects of high concentrations of WIN on cytokine and MMP-3 production were decreased by the calcium chelating agent BAPTA, the AMPK activator metformin, the TRPA1 antagonist A967079 and the CB2 antagonist COR170. Calcium 97-104 matrix metallopeptidase 3 Homo sapiens 58-63 27158245-10 2016 The effects of high concentrations of WIN on cytokine and MMP-3 production were decreased by the calcium chelating agent BAPTA, the AMPK activator metformin, the TRPA1 antagonist A967079 and the CB2 antagonist COR170. 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid 121-126 matrix metallopeptidase 3 Homo sapiens 58-63 27158245-10 2016 The effects of high concentrations of WIN on cytokine and MMP-3 production were decreased by the calcium chelating agent BAPTA, the AMPK activator metformin, the TRPA1 antagonist A967079 and the CB2 antagonist COR170. Metformin 147-156 matrix metallopeptidase 3 Homo sapiens 58-63 26946533-0 2016 Resveratrol attenuated TNF-alpha-induced MMP-3 expression in human nucleus pulposus cells by activating autophagy via AMPK/SIRT1 signaling pathway. Resveratrol 0-11 matrix metallopeptidase 3 Homo sapiens 41-46 26946533-3 2016 The purpose of this study is to investigate whether RSV regulates TNF-alpha-induced matrix metalloproteinase-3 (MMP-3) expression. Resveratrol 52-55 matrix metallopeptidase 3 Homo sapiens 84-110 26946533-3 2016 The purpose of this study is to investigate whether RSV regulates TNF-alpha-induced matrix metalloproteinase-3 (MMP-3) expression. Resveratrol 52-55 matrix metallopeptidase 3 Homo sapiens 112-117 26946533-4 2016 Via quantitative real-time polymerase chain reaction (qRT-PCR) analysis, we found that MMP-3 expression induced by TNF-alpha was inhibited by RSV treatment. Resveratrol 142-145 matrix metallopeptidase 3 Homo sapiens 87-92 26946533-8 2016 Our data showed that RSV attenuated TNF-alpha-induced MMP-3 expression in human NP cells by activating autophagy via AMPK/SIRT1 signaling pathway. Resveratrol 21-24 matrix metallopeptidase 3 Homo sapiens 54-59 26179241-14 2016 NDM inhibited MMP-3 levels in the presence of G-HSA or LPS, and in the presence of [G-HSA+LPS] (p < 0.0001). g-hsa 46-51 matrix metallopeptidase 3 Homo sapiens 14-19 26179241-14 2016 NDM inhibited MMP-3 levels in the presence of G-HSA or LPS, and in the presence of [G-HSA+LPS] (p < 0.0001). g-hsa 84-89 matrix metallopeptidase 3 Homo sapiens 14-19 27222816-10 2016 Finally, although both the TIMP2 rs4789932 and MMP3 rs679620 variants tentatively associated with ATP, there were differences in the direction of association compared to earlier work. Adenosine Triphosphate 98-101 matrix metallopeptidase 3 Homo sapiens 47-51 25393585-6 2015 RESULTS: JNK inhibitor SP601245 markedly inhibited the production of MMP-3 in TNF-alpha-stimulated human dental pulp fibroblasts. sp601245 23-31 matrix metallopeptidase 3 Homo sapiens 69-74 26474180-7 2016 RESULTS: The single-nucleotide polymorphism rs58905141 in TNFAIP3 was consistently associated with time-course and/or dose-response expression of MMP3 and MMP1 in the fibroblasts stimulated with silica particles in both the analysis of Caucasian subjects only and the meta-analysis. Silicon Dioxide 195-201 matrix metallopeptidase 3 Homo sapiens 146-150 26922083-0 2016 MMP-3 as a predictor for structural remission in RA patients treated with MTX monotherapy. Methotrexate 74-77 matrix metallopeptidase 3 Homo sapiens 0-5 26922083-10 2016 CONCLUSIONS: Half of rheumatoid patients treated with MTX monotherapy for 3 years exhibited structural remission, and this outcome can be predicted at the outset by lower serum MMP-3. Methotrexate 54-57 matrix metallopeptidase 3 Homo sapiens 177-182 26353790-10 2016 In PsA explant, tofacitinib significantly decreased spontaneous secretion of IL-6, IL-8, MCP-1, MMP9/MMP2, MMP3 (all p<0.05) and decreased the MMP3/TIMP3 ratio (p<0.05), with no effect observed for IP-10 or IL-10. tofacitinib 16-27 matrix metallopeptidase 3 Homo sapiens 107-111 26353790-10 2016 In PsA explant, tofacitinib significantly decreased spontaneous secretion of IL-6, IL-8, MCP-1, MMP9/MMP2, MMP3 (all p<0.05) and decreased the MMP3/TIMP3 ratio (p<0.05), with no effect observed for IP-10 or IL-10. tofacitinib 16-27 matrix metallopeptidase 3 Homo sapiens 146-150 26156811-6 2015 Thymoquinone also suppressed IL-1beta-induced MMP-1, MMP3, and MMP13 production. thymoquinone 0-12 matrix metallopeptidase 3 Homo sapiens 53-57 26156812-5 2015 Calcitriol inhibited interleukin (IL)-6, IL-8, CC chemokine ligand (CCL) 20, CXC chemokine ligand (CXCL) 10, and matrix metalloproteinase (MMP)-3 release from IL-1beta-stimulated HPDLC. Calcitriol 0-10 matrix metallopeptidase 3 Homo sapiens 113-145 26319019-4 2016 Our observations showed that pretreatment with PQQ significantly inhibited the expression of matrix metalloproteinase (MMP)-1 and MMP-3 and suppressed the production of proinflammatory mediators such as TNF-alpha and IL-6 in IL-1beta-treated SW982 cells. PQQ Cofactor 47-50 matrix metallopeptidase 3 Homo sapiens 130-135 26335175-7 2016 In human endometrial organ cultures (from healthy women), treatment with AS602801 or MPA reduced matrix metalloproteinase-3 (MMP-3) release into culture medium. bentamapimod 73-81 matrix metallopeptidase 3 Homo sapiens 97-123 26335175-7 2016 In human endometrial organ cultures (from healthy women), treatment with AS602801 or MPA reduced matrix metalloproteinase-3 (MMP-3) release into culture medium. bentamapimod 73-81 matrix metallopeptidase 3 Homo sapiens 125-130 26335175-8 2016 In organ cultures established with BWE, PR or MPA failed to inhibit MMP-3 secretion, whereas AS602801 alone or MPA + AS602801 suppressed MMP-3 production. bentamapimod 93-101 matrix metallopeptidase 3 Homo sapiens 137-142 26335175-8 2016 In organ cultures established with BWE, PR or MPA failed to inhibit MMP-3 secretion, whereas AS602801 alone or MPA + AS602801 suppressed MMP-3 production. bentamapimod 117-125 matrix metallopeptidase 3 Homo sapiens 137-142 26391061-6 2015 The results showed that BA dose-dependently inhibited IL-1beta-induced MMP-1, MMP-3, MMP-13, PGE2 and NO productions. betulinic acid 24-26 matrix metallopeptidase 3 Homo sapiens 78-83 26156812-7 2015 Moreover, we found c-jun N-terminal kinase (JNK) phosphorylation and IkappaB-alpha degradation in IL-1beta-stimulated HPDLC were inhibited by calcitriol, and JNK and nuclear factor (NF)-kappaB inhibitors could decrease IL-6, IL-8, CCL20, CXCL10, and MMP-3 productions in IL-1beta-treated HPDLC. Calcitriol 142-152 matrix metallopeptidase 3 Homo sapiens 250-255 26431480-8 2015 Tumor necrosis factor-alpha increased MMP-1 and -2 gene expression, and H2O2 increased MMP-3 and -9 gene expression. Hydrogen Peroxide 72-76 matrix metallopeptidase 3 Homo sapiens 87-99 27089651-7 2015 MMP-3 levels gradually decreased 12 and 24 weeks after successful treatment with MTX (p=0.0188 and p=0.0179, respectively). Methotrexate 81-84 matrix metallopeptidase 3 Homo sapiens 0-5 27089651-12 2015 In addition, serial measurement of MMP-3 maybe helpful to evaluate the effect of treatments with MTX and IFX. Methotrexate 97-100 matrix metallopeptidase 3 Homo sapiens 35-40 26580615-9 2015 Taken together, our results suggest that EVO modulates the activity of the p53 signaling pathway to induce apoptosis and downregulate MMP3 expression by inactivating the JAK2/STAT3 pathway through the downregulation of PGI to inhibit migration of HCT-116 human colorectal cancer cells. evodiamine 41-44 matrix metallopeptidase 3 Homo sapiens 134-138 26542776-8 2015 mRNA expression of catabolic factors such as tumor necrosis factor-alpha (TNF-alpha), matrix metalloprotease-3 (MMP-3), and cyclooxygenase-2 (COX-2) was significantly induced by treatment with H2O2 or buthionine sulfoximine, whereas that of aggrecan, an important chondrogenic proteoglycan, was reduced in a dose-dependent manner. Hydrogen Peroxide 193-197 matrix metallopeptidase 3 Homo sapiens 86-110 26542776-8 2015 mRNA expression of catabolic factors such as tumor necrosis factor-alpha (TNF-alpha), matrix metalloprotease-3 (MMP-3), and cyclooxygenase-2 (COX-2) was significantly induced by treatment with H2O2 or buthionine sulfoximine, whereas that of aggrecan, an important chondrogenic proteoglycan, was reduced in a dose-dependent manner. Hydrogen Peroxide 193-197 matrix metallopeptidase 3 Homo sapiens 112-117 26542776-8 2015 mRNA expression of catabolic factors such as tumor necrosis factor-alpha (TNF-alpha), matrix metalloprotease-3 (MMP-3), and cyclooxygenase-2 (COX-2) was significantly induced by treatment with H2O2 or buthionine sulfoximine, whereas that of aggrecan, an important chondrogenic proteoglycan, was reduced in a dose-dependent manner. Buthionine Sulfoximine 201-223 matrix metallopeptidase 3 Homo sapiens 86-110 26542776-8 2015 mRNA expression of catabolic factors such as tumor necrosis factor-alpha (TNF-alpha), matrix metalloprotease-3 (MMP-3), and cyclooxygenase-2 (COX-2) was significantly induced by treatment with H2O2 or buthionine sulfoximine, whereas that of aggrecan, an important chondrogenic proteoglycan, was reduced in a dose-dependent manner. Buthionine Sulfoximine 201-223 matrix metallopeptidase 3 Homo sapiens 112-117 25916577-4 2015 Normally the constitutive enzymes, MMP-2 and membrane type MMP (MMP-14), are activated in a spatially specific manner and act close to the site of activation, while the inducible enzymes, MMP-3 and MMP-9, become active through the action of free radicals and other enzymes during neuroinflammation. Free Radicals 241-254 matrix metallopeptidase 3 Homo sapiens 188-193 26640594-4 2015 Either hTERT siRNA or BIBR1532 in combination with paclitaxel promoted a synergistic inhibitory effect on cell growth through induction of Annexin V expression and a remarkable reduction in cell invasion through reduction of protein expression of MMP9, MMP2, and MMP3. BIBR 1532 22-30 matrix metallopeptidase 3 Homo sapiens 263-267 26640594-4 2015 Either hTERT siRNA or BIBR1532 in combination with paclitaxel promoted a synergistic inhibitory effect on cell growth through induction of Annexin V expression and a remarkable reduction in cell invasion through reduction of protein expression of MMP9, MMP2, and MMP3. Paclitaxel 51-61 matrix metallopeptidase 3 Homo sapiens 263-267 26284488-9 2015 The search for mediators of senescent HPMC activity showed that increased SW480 cell proliferation was stimulated by IL-6, migration by CXCL8 and CCL2, invasion by IL-6, MMP-3 and uPA, and epithelial-mesenchymal transition by TGF-beta1. Hypromellose Derivatives 38-42 matrix metallopeptidase 3 Homo sapiens 170-175 26431480-12 2015 Also, H2O2 induced MMP-3 and -9 gene expression, but not their protein secretion. Hydrogen Peroxide 6-10 matrix metallopeptidase 3 Homo sapiens 19-31 26141990-9 2015 The upregulation of MMP-1, MMP-3 and MMP-9 in response to hypoxia was significantly (P<0.05) attenuated by andrographolide. andrographolide 110-125 matrix metallopeptidase 3 Homo sapiens 27-32 26057330-0 2015 Cyclosporine A Downregulates MMP-3 and MMP-13 Expression in Cultured Pterygium Fibroblasts. Cyclosporine 0-14 matrix metallopeptidase 3 Homo sapiens 29-34 26420919-0 2015 Curcumin binds in silico to anti-cancer drug target enzyme MMP-3 (human stromelysin-1) with affinity comparable to two known inhibitors of the enzyme. Curcumin 0-8 matrix metallopeptidase 3 Homo sapiens 59-64 26420919-0 2015 Curcumin binds in silico to anti-cancer drug target enzyme MMP-3 (human stromelysin-1) with affinity comparable to two known inhibitors of the enzyme. Curcumin 0-8 matrix metallopeptidase 3 Homo sapiens 72-85 26420919-1 2015 In silico interaction of curcumin with the enzyme MMP-3 (human stromelysin-1) was studied by molecular docking using AutoDock 4.2 as the docking software application. Curcumin 25-33 matrix metallopeptidase 3 Homo sapiens 50-55 26420919-1 2015 In silico interaction of curcumin with the enzyme MMP-3 (human stromelysin-1) was studied by molecular docking using AutoDock 4.2 as the docking software application. Curcumin 25-33 matrix metallopeptidase 3 Homo sapiens 63-76 26420919-3 2015 Interactions of curcumin with MMP-3 were compared to those of two known inhibitors of the enzyme, PBSA and MPPT. Curcumin 16-24 matrix metallopeptidase 3 Homo sapiens 30-35 26420919-8 2015 Thus, curcumin can be considered as a good lead compound in the development of new inhibitors of MMP-3 which is a potential target of anticancer drugs. Curcumin 6-14 matrix metallopeptidase 3 Homo sapiens 97-102 26292290-7 2015 MMP-3, IL-6, NO production and ADAMTS-4 expression were down-regulated in a concentration-dependent manner by carnosol (p<0.01). carnosol 110-118 matrix metallopeptidase 3 Homo sapiens 0-5 26292290-10 2015 In co-culture experiments preincubation of NSC and SC osteoblasts wih carnosol resulted in similar effects to incubation with anti-IL-6 antibody, namely a significant increase in aggrecan and decrease in MMP-3, ADAMTS-4 and -5 gene expression by chondrocytes. carnosol 70-78 matrix metallopeptidase 3 Homo sapiens 204-209 26073022-11 2015 In the cross sectional study, a significant decrease in MK-7 treated group for the levels of undercarboxylated osteocalcin (ucOC), erythrocyte sedimentation rate (ESR), disease activity score assessing 28 joints with ESR (DAS28-ESR), C-reactive protein (CRP) and matrix metalloproteinase (MMP-3) was found. vitamin MK 7 56-60 matrix metallopeptidase 3 Homo sapiens 289-294 25856795-6 2015 We found that acacetin inhibits p38 and JNK phosphorylation and reduces MMP-1, MMP-3 and MMP-13 expression in interleukin-1beta-induced FLSs. acacetin 14-22 matrix metallopeptidase 3 Homo sapiens 79-84 25882230-4 2015 The results revealed that 5-25 muM fisetin inhibits cyclooxygenase-2 (COX-2) and matrix metalloproteinase (MMP)-1, MMP-3, MMP-9 expression induced by ultraviolet B (UVB) irradiation in human skin fibroblasts. fisetin 35-42 matrix metallopeptidase 3 Homo sapiens 115-120 25389358-10 2015 CpdA, similarly to prednisolone, down-regulated endogenous and TNF-alpha-induced IL-6, IL-8, MMP-1 and MMP-3 protein secretion. CPDA 0-4 matrix metallopeptidase 3 Homo sapiens 103-108 25389358-11 2015 The dissociative effect of CpdA was confirmed using chondrocytes with no induction of leptin secretion, but with a significant decrease in IL-6, IL-8, MMP-1 and MMP-3 protein secretion. CPDA 27-31 matrix metallopeptidase 3 Homo sapiens 161-166 25545021-6 2015 Inhibition of KCa3.1 by the selective, pore-blocking inhibitor TRAM-34, (and, in part, by siRNA) significantly reduced cell proliferation, as well as expression and secretion of pro-inflammatory factors (IL-6, IL-8, and MCP1) and the tissue-destructive protease MMP3. TRAM 34 63-70 matrix metallopeptidase 3 Homo sapiens 262-266 25797286-8 2015 Our results demonstrated that taraxasterol dose-dependently suppressed MMP-1, MMP3, MMP13, PGE2 and NO production induced by IL-1beta. taraxasterol 30-42 matrix metallopeptidase 3 Homo sapiens 78-82 25398374-9 2015 Tofacitinib treatment significantly reduced synovial mRNA expression of matrix metalloproteinase (MMP)-1 and MMP-3 (p<0.05) and chemokines CCL2, CXCL10 and CXCL13 (p<0.05). tofacitinib 0-11 matrix metallopeptidase 3 Homo sapiens 109-114 26020773-7 2015 The production of IL-6, IL-8 and MMP-3 by chondrocytes significantly decreased in chitosan-alginate beads compared to alginate beads. Chitosan 82-90 matrix metallopeptidase 3 Homo sapiens 33-38 26020773-7 2015 The production of IL-6, IL-8 and MMP-3 by chondrocytes significantly decreased in chitosan-alginate beads compared to alginate beads. Alginates 91-99 matrix metallopeptidase 3 Homo sapiens 33-38 25940674-7 2015 Increased DhMRs were observed in ~50% of genes previously implicated in OA pathology including MMP3, LRP5, GDF5, and COL11A1. dhmrs 10-15 matrix metallopeptidase 3 Homo sapiens 95-99 26853425-2 2015 A single nucleotide polymorphism rs3025058 at -1171 of the stromelysin-1 (matrix metalloproteinase [MMP]-3) promoter is resulting due to insertion/deletion of adenine thought to have an impact on increasing the risk for tumor formation. Adenine 159-166 matrix metallopeptidase 3 Homo sapiens 59-72 26191174-6 2015 Diosgenin significantly inhibited the IL-1beta-stimulated expression of metalloproteinase-3 (MMP-3), MMP-13, inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) in human OA chondrocytes. Diosgenin 0-9 matrix metallopeptidase 3 Homo sapiens 72-98 25614514-8 2015 TGF-beta induced the release of MMP-1, MMP-2 and MMP-3 by HTFs, and ATRA inhibited these effects of TGF-beta on MMP-1 and MMP-3 release. htfs 58-62 matrix metallopeptidase 3 Homo sapiens 49-54 25614514-8 2015 TGF-beta induced the release of MMP-1, MMP-2 and MMP-3 by HTFs, and ATRA inhibited these effects of TGF-beta on MMP-1 and MMP-3 release. htfs 58-62 matrix metallopeptidase 3 Homo sapiens 122-127 25614514-12 2015 CONCLUSIONS: ATRA inhibited TGF-beta-induced collagen gel contraction mediated by HTFs, likely in part by attenuating the production of MMP-1 and MMP-3 and by stimulating the production of TIMP-1. Tretinoin 13-17 matrix metallopeptidase 3 Homo sapiens 146-151 26853425-5 2015 The genotyping of stromelysin-1 rs3025058 (-1171, 5A/6A) promoter polymorphism was carried out by amplification refractory mutation system-polymerase chain reaction method followed by agarose gel electrophoresis. Sepharose 184-191 matrix metallopeptidase 3 Homo sapiens 18-31 25312247-7 2015 We further found correlations between expression of MMP-1 and MMP-3 and the length of pilocarpine treatment. Pilocarpine 86-97 matrix metallopeptidase 3 Homo sapiens 62-67 26273599-5 2015 Markedly decreased levels of IL-17, retinoid-related orphan receptor C (RORc), and MMP-3 mRNA expression were also observed in IL-6-induced RASFs in the presence of T-614 or MTX compared with those in its absence. T 614 165-170 matrix metallopeptidase 3 Homo sapiens 83-88 24285492-8 2015 RESULTS: In rheumatoid arthritis synovial fibroblasts (RASF), FFA dose-dependently enhanced the secretion of the proinflammatory cytokine IL-6, the chemokines IL-8 and MCP-1, as well as the matrix-degrading enzymes pro-MMP1 and MMP3. Fatty Acids, Nonesterified 62-65 matrix metallopeptidase 3 Homo sapiens 228-232 25469820-7 2015 EPA inhibited SNP-induced chondrocyte apoptosis, caspase 3 and poly(ADP-ribose) polymerase cleavage, phosphorylation of p38 MAPK and p53, and expression of MMP3 and MMP13. Eicosapentaenoic Acid 0-3 matrix metallopeptidase 3 Homo sapiens 156-160 25472536-6 2015 Tyrosyl phosphorylated PAK1 also stimulates invasion of breast cancer cells in response to PRL and three-dimensional (3D) collagen IV via transcription and secretion of MMP-1 and MMP-3 in a MAPK-dependent manner. cyclo(tyrosyl-tyrosyl) 0-7 matrix metallopeptidase 3 Homo sapiens 179-184 26273599-5 2015 Markedly decreased levels of IL-17, retinoid-related orphan receptor C (RORc), and MMP-3 mRNA expression were also observed in IL-6-induced RASFs in the presence of T-614 or MTX compared with those in its absence. Methotrexate 174-177 matrix metallopeptidase 3 Homo sapiens 83-88 25807652-0 2015 Elevated oxidative stress monitored via the albumin-thiol redox state is correlated with matrix metalloproteinase-3 elevation in patients with rheumatoid arthritis. Sulfhydryl Compounds 52-57 matrix metallopeptidase 3 Homo sapiens 89-115 25807652-6 2015 The percentage of oxidized albumin-thiol showed a positive correlation with serum MMP-3 (r = 0.52). Sulfhydryl Compounds 35-40 matrix metallopeptidase 3 Homo sapiens 82-87 25807652-8 2015 CONCLUSIONS: The albumin-thiol redox state was significantly oxidized in correlation with serum MMP-3 elevation in RA. Sulfhydryl Compounds 25-30 matrix metallopeptidase 3 Homo sapiens 96-101 25644385-5 2015 In this study, we found that PB inhibits the expression of MMP-1, MMP-3, and MMP-13 at both mRNA levels and protein levels in human chondrocytes. pinocembrin 29-31 matrix metallopeptidase 3 Homo sapiens 66-71 25751300-0 2015 Effects of Alpha-Lipoic Acid Supplementation on Inflammatory Biomarkers and Matrix Metalloproteinase-3 in Rheumatoid Arthritis Patients. Thioctic Acid 11-28 matrix metallopeptidase 3 Homo sapiens 76-102 25133483-5 2014 We show that ectopic IkappaB kinase e (IKKe) expression in these cells partly restored MMP-3 expression levels and also sensitized MMP-3 transcription to induction by phorbol 12-myristate 13-acetate (PMA). Tetradecanoylphorbol Acetate 167-198 matrix metallopeptidase 3 Homo sapiens 131-136 25289880-5 2014 Treatment with mAAPV resulted in decreased expression of MMP-related genes such as MMP1, MMP3, TIMP1 and TIMP3 and increased expression of collagen genes, including COL1A1, COL1A2, COL3A1, COL5A1 and COL6A3. maapv 15-20 matrix metallopeptidase 3 Homo sapiens 89-93 25135220-4 2014 Here, we showed that beta6 induced phosphorylation of ETS1 via the ERK/MAPK pathways, through which the MMP-3/MMP-9 promoters were stimulated, thereby leading to the up-regulation of MMP-3/MMP-9, and subsequent the invasion of colon cancer cells. beta6 21-26 matrix metallopeptidase 3 Homo sapiens 104-109 25135220-4 2014 Here, we showed that beta6 induced phosphorylation of ETS1 via the ERK/MAPK pathways, through which the MMP-3/MMP-9 promoters were stimulated, thereby leading to the up-regulation of MMP-3/MMP-9, and subsequent the invasion of colon cancer cells. beta6 21-26 matrix metallopeptidase 3 Homo sapiens 183-188 25305493-3 2014 In this study, we found that DMF ameliorated collagen type II degradation by inhibiting the expression of MMP-1, MMP-3, and MMP-13 caused by TNF-alpha. Dimethyl Fumarate 29-32 matrix metallopeptidase 3 Homo sapiens 113-118 24890258-0 2014 Zerumbone suppresses IL-1beta-induced cell migration and invasion by inhibiting IL-8 and MMP-3 expression in human triple-negative breast cancer cells. zerumbone 0-9 matrix metallopeptidase 3 Homo sapiens 89-94 25400590-8 2014 RESULTS: Western blot analysis of the supernatants revealed that MMP-3 released from the dentin matrix small proteoglycans (decorin and biglycan) and dentin sialoprotein (DSP) in the AmF, sodium fluoride, PBS and placebo pretreated groups, but not in the GSE and mouthrinse pretreated groups. amine fluoride 297 183-186 matrix metallopeptidase 3 Homo sapiens 65-70 25400590-8 2014 RESULTS: Western blot analysis of the supernatants revealed that MMP-3 released from the dentin matrix small proteoglycans (decorin and biglycan) and dentin sialoprotein (DSP) in the AmF, sodium fluoride, PBS and placebo pretreated groups, but not in the GSE and mouthrinse pretreated groups. Sodium Fluoride 188-203 matrix metallopeptidase 3 Homo sapiens 65-70 24975507-5 2014 In this study, we found that alpha-LA inhibits the IL-1beta-induced increase in matrix metallopeptidase 3 (MMP-3) and matrix metallopeptidase 13 (MMP-13) expression and activity. Thioctic Acid 29-37 matrix metallopeptidase 3 Homo sapiens 80-112 25130855-6 2014 Results showed that SZNTC could effectively inhibit the Interleukin-1 (IL-1)-mediated induction of metalloproteinase-1 (MMP-1) and MMP-3 and could induce the expression of tissue inhibitor of metalloproteinase-1 (TIMP-1), which demonstrated ability to reduce the progression of OA. szntc 20-25 matrix metallopeptidase 3 Homo sapiens 131-136 25267645-6 2014 Once phosphorylated on serine 472, nuclear RelB dissociates from its interaction with the inhibitory protein IkappaBalpha and binds to the promoter of critical migration-associated genes, such as the matrix metallopeptidase 3 (MMP3). Serine 23-29 matrix metallopeptidase 3 Homo sapiens 200-225 25267645-6 2014 Once phosphorylated on serine 472, nuclear RelB dissociates from its interaction with the inhibitory protein IkappaBalpha and binds to the promoter of critical migration-associated genes, such as the matrix metallopeptidase 3 (MMP3). Serine 23-29 matrix metallopeptidase 3 Homo sapiens 227-231 24671668-4 2014 Sulforaphane inhibits unstimulated and IL-1beta-induced proliferation of RASFs; the expression of MMP-1, MMP-3, and COX-2 mRNA and protein; and the PGE2 production induced by IL-1beta. sulforaphane 0-12 matrix metallopeptidase 3 Homo sapiens 105-110 25332857-7 2014 Although SU11274 suppressed MMP-3 and VEGF production it enhanced PGE2 production by MH7A cells suggesting that negative regulation by c-Met signaling, independent of the MEK-ERK and PI3K-AKT pathways, is involved in PGE2 production. ((3Z)-N-(3-chlorophenyl)-3-((3,5-dimethyl-4-((4-methylpiperazin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-N-methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide) 9-16 matrix metallopeptidase 3 Homo sapiens 28-33 24630484-7 2014 The expression of MMP-9, MMP-2, and MMP-3 decreases in the presence of vitamin D derivatives in UC and CD with the exception of 1,25(OH)2D3 that does not affect the levels of MMP-9 and MMP-2 in CD. Vitamin D 71-80 matrix metallopeptidase 3 Homo sapiens 36-41 24890593-6 2014 Respiratory epithelial cell-derived MMP-3 was suppressed by moxifloxacin, rifampicin, and azithromycin in a dose-dependent manner. Moxifloxacin 60-72 matrix metallopeptidase 3 Homo sapiens 36-41 24890593-6 2014 Respiratory epithelial cell-derived MMP-3 was suppressed by moxifloxacin, rifampicin, and azithromycin in a dose-dependent manner. Rifampin 74-84 matrix metallopeptidase 3 Homo sapiens 36-41 24890593-6 2014 Respiratory epithelial cell-derived MMP-3 was suppressed by moxifloxacin, rifampicin, and azithromycin in a dose-dependent manner. Azithromycin 90-102 matrix metallopeptidase 3 Homo sapiens 36-41 24929023-11 2014 After 4 weeks, MMP3 was significantly reduced by 19.2% +- 24.6% in the H2 group, and increased by 16.9% +- 50.2% in the placebo group. Hydrogen 71-73 matrix metallopeptidase 3 Homo sapiens 15-19 24984269-6 2014 In addition, BAY117082, a special inhibitor of NF-kappaB, suppressed the expression and secretion of MMP-3 stimulated by CCL20/CCR6. 3-(4-methylphenylsulfonyl)-2-propenenitrile 13-22 matrix metallopeptidase 3 Homo sapiens 101-106 24721459-8 2014 RESULTS: The presence of celecoxib normalized the release of PGE2 and diminished the CTS-induced COX-2, MMP-1, MMP-3, MMP-9 and ADAMTS-5 gene expressions while recovered the downregulated type II collagen and aggrecan gene expressions. Celecoxib 25-34 matrix metallopeptidase 3 Homo sapiens 111-116 24670384-5 2014 Fibroblasts cultured on skin-soft silicones displayed low mRNA levels of fibrosis-associated genes and increased expression of the matrix metalloproteinases (MMPs) MMP-1 and MMP-3 as compared with collagen gel and plastic cultures. Silicones 34-43 matrix metallopeptidase 3 Homo sapiens 174-179 24840287-0 2014 Resveratrol inhibits oxygen-glucose deprivation-induced MMP-3 expression and cell apoptosis in primary cortical cells via the NF-kappaB pathway. Resveratrol 0-11 matrix metallopeptidase 3 Homo sapiens 56-61 24840287-0 2014 Resveratrol inhibits oxygen-glucose deprivation-induced MMP-3 expression and cell apoptosis in primary cortical cells via the NF-kappaB pathway. oxygen-glucose 21-35 matrix metallopeptidase 3 Homo sapiens 56-61 24721459-8 2014 RESULTS: The presence of celecoxib normalized the release of PGE2 and diminished the CTS-induced COX-2, MMP-1, MMP-3, MMP-9 and ADAMTS-5 gene expressions while recovered the downregulated type II collagen and aggrecan gene expressions. castanospermine 85-88 matrix metallopeptidase 3 Homo sapiens 111-116 24583398-11 2014 NAC treatment decreased MMP-3 production in CD-ISMEFs and removed the enhancement due to TNFalpha. Acetylcysteine 0-3 matrix metallopeptidase 3 Homo sapiens 24-29 24627579-12 2014 Compared with controls, cells stimulated with interleukin-1 beta (IL-1beta) and treated with ACP showed significantly higher fold changes of MMP-2 (P = .001) and MMP-3 (P = .003) concentrations at 24 hours than did cells treated with GPS. acp 93-96 matrix metallopeptidase 3 Homo sapiens 162-167 25073284-9 2014 The MMP-3 and TNF-alpha contents in patients with different degrees of pain and BME were significantly higher than those in patients of control group (P < 0.05), and significant difference was found between patients with different degrees of pain (P < 0.05), but no significant difference between patients with different degrees of BME (P > 0.05). bme 80-83 matrix metallopeptidase 3 Homo sapiens 4-9 24583398-15 2014 NAC and curcumin normalize MMP-3 levels mainly in TNFalpha stimulated cells. Acetylcysteine 0-3 matrix metallopeptidase 3 Homo sapiens 27-32 24583398-15 2014 NAC and curcumin normalize MMP-3 levels mainly in TNFalpha stimulated cells. Curcumin 8-16 matrix metallopeptidase 3 Homo sapiens 27-32 24583398-16 2014 A modulation of MMP-3 production by NAC and curcumin due to their direct action on transcriptional factors has been also suggested. Acetylcysteine 36-39 matrix metallopeptidase 3 Homo sapiens 16-21 24583398-16 2014 A modulation of MMP-3 production by NAC and curcumin due to their direct action on transcriptional factors has been also suggested. Curcumin 44-52 matrix metallopeptidase 3 Homo sapiens 16-21 24480614-6 2014 We found that astaxanthin reduced the expression of MMP-1, MMP-3 and MMP-13 as well as the phosphorylation of two mitogen-activated protein kinases (MAPK) (p38 and ERK1/2) in IL-1beta-stimulated chondrocytes. astaxanthine 14-25 matrix metallopeptidase 3 Homo sapiens 59-64 24658359-7 2014 Verapamil enhanced gene expressions of chondrogenic markers of ACAN encoding aggrecan, COL2A1 encoding collagen type II alpha1, and SOX9, and suppressed Wnt-responsive AXIN2 and MMP3 in human OA chondrocytes. Verapamil 0-9 matrix metallopeptidase 3 Homo sapiens 178-182 25711032-3 2014 We used the Multifactor Dimensionality Reduction (MDR) analysis to show that 14 allelic combinations of the MMP containing MMP3 (rs3025058) x MMP7 (rs11568818) x MMP9 (rs17576) alleles showed a statistically significant association with an increased risk of EGE, while 10 other combinations correlated with a reduced risk of the disease. 4-azanyl-2-oxidanyl-5-[(~{E})-[4-(pyridin-2-ylsulfamoyl)phenyl]diazenyl]benzoic acid 258-261 matrix metallopeptidase 3 Homo sapiens 123-127 24315792-10 2014 When primary cell cultures were treated with hypoestoxide in conjunction with pro-inflammatory stimulation, p65 activation was reduced as were MMP-1 and MMP-3 production. hypoestoxide 45-57 matrix metallopeptidase 3 Homo sapiens 153-158 24449578-5 2014 Levels of locus-specific 5hmC and 5mC at CpG sites in the matrix metalloproteinase 1 (MMP-1), MMP-3, ADAMTS-5, and hypoxanthine guanine phosphoribosyltransferase 1 (HPRT-1) promoters were quantified using a glucosylation and enzyme digestion-based method followed by quantitative PCR analysis. 5-hydroxymethylcytosine 25-29 matrix metallopeptidase 3 Homo sapiens 94-99 24449578-5 2014 Levels of locus-specific 5hmC and 5mC at CpG sites in the matrix metalloproteinase 1 (MMP-1), MMP-3, ADAMTS-5, and hypoxanthine guanine phosphoribosyltransferase 1 (HPRT-1) promoters were quantified using a glucosylation and enzyme digestion-based method followed by quantitative PCR analysis. 5-Methylcytosine 34-37 matrix metallopeptidase 3 Homo sapiens 94-99 24449578-8 2014 Enrichment of 5hmC was observed in promoters of enzymes critical to OA pathology, MMP-1 and MMP-3. 5-hydroxymethylcytosine 14-18 matrix metallopeptidase 3 Homo sapiens 92-97 24076964-11 2014 In summary, blockade of the proximal PI3K catalytic subunit increases MMP-1 and MMP-9, whereas rapamycin decreased both MMP-1 and MMP-3. Sirolimus 95-104 matrix metallopeptidase 3 Homo sapiens 130-135 24261754-8 2014 Multivariate Cox regression analysis identified low serum IL-6 and normalisation of MMP-3 levels at cessation of TCZ as independent predictive markers for longer duration of LDA. lda 174-177 matrix metallopeptidase 3 Homo sapiens 84-89 24103002-5 2013 Western blot and real-time PCR analyses revealed that DHAvD inhibited UVB-induced MMP-1 and MMP-3 expression. dihydroavenanthramide D 54-59 matrix metallopeptidase 3 Homo sapiens 92-97 24211233-9 2014 RESULTS: Treatment with WIN-55 alone or in combination with IL-1beta, decreased or abolished MMP-3, -13, TIMP-1 and -2 gene expression in human chondrocyte monolayer and alginate bead cultures in both a concentration and time dependent manner. win-55 24-30 matrix metallopeptidase 3 Homo sapiens 93-103 24211233-10 2014 WIN-55 treatment alone, and in combination with IL-1beta, reduced MMP-3 and -13 protein production by chondrocytes cultured in alginate beads. win-55 0-6 matrix metallopeptidase 3 Homo sapiens 66-79 24211233-10 2014 WIN-55 treatment alone, and in combination with IL-1beta, reduced MMP-3 and -13 protein production by chondrocytes cultured in alginate beads. Alginates 127-135 matrix metallopeptidase 3 Homo sapiens 66-79 24211233-12 2014 CONCLUSION: Cannabinoid WIN-55 can reduce both basal and IL-1beta stimulated gene and protein expression of MMP-3 and -13. Cannabinoids 12-23 matrix metallopeptidase 3 Homo sapiens 108-121 24146820-8 2013 RESULTS: Each log-increase in MMP-3 and MMP-12 showed reduced odds of developing WTC-LI by 73% and 54% respectively. wtc-li 81-87 matrix metallopeptidase 3 Homo sapiens 30-35 24146820-11 2013 CONCLUSIONS: Elevated serum levels of MMP-3 and MMP-12 reduce the risk of developing WTC-LI. wtc-li 85-91 matrix metallopeptidase 3 Homo sapiens 38-43 23934131-6 2013 Kaempferol inhibited the proliferation of both unstimulated and IL-1beta-stimulated RASFs, as well as the mRNA and protein expression of MMP-1, MMP-3, COX-2 and PGE2 induced by IL-1beta. kaempferol 0-10 matrix metallopeptidase 3 Homo sapiens 144-149 23838114-11 2013 Piperine significantly decreased the IL-1beta-stimulated gene expression and production of MMP-3, MMP-13, iNOS and COX-2 in human OA chondrocytes. piperine 0-8 matrix metallopeptidase 3 Homo sapiens 91-96 23298307-6 2013 RESULTS: The concentrations of MMP-2, MMP-3, MMP-8, MMP-9 and TIMP-2 in gingival crevicular fluid were significantly higher (p < 0.005) in the DS-G group compared with the HC-G group. ds-g 146-150 matrix metallopeptidase 3 Homo sapiens 38-43 22549898-4 2013 Only UA efficiently suppressed the AMF/PGI-induced Huh7 cell migration and MMP-3 secretion. ursolic acid 5-7 matrix metallopeptidase 3 Homo sapiens 75-80 24053318-13 2013 This effect was reversed by Batimastat, a broad-spectrum MMP inhibitor, and subsequent analyses showed BMP4 to induce the expression of MMP3 and MMP14, that are thus likely to be responsible for the stellate phenotype. batimastat 28-38 matrix metallopeptidase 3 Homo sapiens 136-140 23971790-12 2013 Similarly, treatment with Payena dasyphylla ethyl acetate (EA) fraction (100 mug/ml) inhibited the HYAL1 and HYAL2 mRNA gene expressions as well as MMP-3 and MMP-13 protein expression in a dose dependent manner. payena 26-32 matrix metallopeptidase 3 Homo sapiens 148-153 23001685-6 2013 RESULTS: MMP-3 significantly decreased in the celecoxib-treated patients (p = 0.0031). Celecoxib 46-55 matrix metallopeptidase 3 Homo sapiens 9-14 23971790-12 2013 Similarly, treatment with Payena dasyphylla ethyl acetate (EA) fraction (100 mug/ml) inhibited the HYAL1 and HYAL2 mRNA gene expressions as well as MMP-3 and MMP-13 protein expression in a dose dependent manner. dasyphylla ethyl acetate 33-57 matrix metallopeptidase 3 Homo sapiens 148-153 23971790-12 2013 Similarly, treatment with Payena dasyphylla ethyl acetate (EA) fraction (100 mug/ml) inhibited the HYAL1 and HYAL2 mRNA gene expressions as well as MMP-3 and MMP-13 protein expression in a dose dependent manner. ethyl acetate 59-61 matrix metallopeptidase 3 Homo sapiens 148-153 23967200-0 2013 STAT3 regulates MMP3 in heme-induced endothelial cell apoptosis. Heme 24-28 matrix metallopeptidase 3 Homo sapiens 16-20 23967200-4 2013 In the present study, we further tested the hypothesis that Heme reduces blood-brain barrier integrity during ECM by induction of apoptosis of brain vascular endothelial cells through STAT3 and its target gene matrix metalloproteinase three (MMP3) signaling. Heme 60-64 matrix metallopeptidase 3 Homo sapiens 242-246 23967200-6 2013 A human MMP3 promoter was cloned into a luciferase reporter plasmid, pMMP3, and its activity was examined following exposure to Heme treatment by a luciferase reporter gene assay. Heme 128-132 matrix metallopeptidase 3 Homo sapiens 8-12 23967200-10 2013 STAT3 targeted genes such as MMP3 and C/EBPb (Apoptosis-related genes), are up regulated in HBVEC treated with Heme. Heme 111-115 matrix metallopeptidase 3 Homo sapiens 29-33 23967200-11 2013 (2) Heme-induced HBVEC apoptosis via activation of STAT3 as well as its downstream signaling molecule MMP3 and upregulation of CXCL10 and HO-1 expressions. Heme 4-8 matrix metallopeptidase 3 Homo sapiens 102-106 23328930-0 2013 Resveratrol inhibits TNF-alpha-induced IL-1beta, MMP-3 production in human rheumatoid arthritis fibroblast-like synoviocytes via modulation of PI3kinase/Akt pathway. Resveratrol 0-11 matrix metallopeptidase 3 Homo sapiens 49-54 24062615-7 2013 RESULTS: We have demonstrated that budesonide concentration-dependently (10(-10)-10(-7) M) inhibited IL-6, IL-8, MMP-1, and MMP-3 release by HFL-1 cells in response to IL-1beta plus TNF-alpha. Budesonide 35-45 matrix metallopeptidase 3 Homo sapiens 124-129 23625833-4 2013 Mmp3 mRNA and protein expression was also induced by calcium ionophore (Io) and 2"(3")-O-(4-benzoylbenzoyl) adenosine 5"-triphosphate (Bz-ATP) and Mmp3 upregulation was prevented by the CN inhibitor cyclosporin A (CsA). Calcium 53-60 matrix metallopeptidase 3 Homo sapiens 0-4 23625833-4 2013 Mmp3 mRNA and protein expression was also induced by calcium ionophore (Io) and 2"(3")-O-(4-benzoylbenzoyl) adenosine 5"-triphosphate (Bz-ATP) and Mmp3 upregulation was prevented by the CN inhibitor cyclosporin A (CsA). Calcium 53-60 matrix metallopeptidase 3 Homo sapiens 147-151 23625833-4 2013 Mmp3 mRNA and protein expression was also induced by calcium ionophore (Io) and 2"(3")-O-(4-benzoylbenzoyl) adenosine 5"-triphosphate (Bz-ATP) and Mmp3 upregulation was prevented by the CN inhibitor cyclosporin A (CsA). 2"(3")-o-(4-benzoylbenzoyl) adenosine 5"-triphosphate 80-133 matrix metallopeptidase 3 Homo sapiens 0-4 23625833-4 2013 Mmp3 mRNA and protein expression was also induced by calcium ionophore (Io) and 2"(3")-O-(4-benzoylbenzoyl) adenosine 5"-triphosphate (Bz-ATP) and Mmp3 upregulation was prevented by the CN inhibitor cyclosporin A (CsA). CHEMBL339386 135-141 matrix metallopeptidase 3 Homo sapiens 0-4 23625833-4 2013 Mmp3 mRNA and protein expression was also induced by calcium ionophore (Io) and 2"(3")-O-(4-benzoylbenzoyl) adenosine 5"-triphosphate (Bz-ATP) and Mmp3 upregulation was prevented by the CN inhibitor cyclosporin A (CsA). Cyclosporine 199-212 matrix metallopeptidase 3 Homo sapiens 0-4 23625833-4 2013 Mmp3 mRNA and protein expression was also induced by calcium ionophore (Io) and 2"(3")-O-(4-benzoylbenzoyl) adenosine 5"-triphosphate (Bz-ATP) and Mmp3 upregulation was prevented by the CN inhibitor cyclosporin A (CsA). Cyclosporine 214-217 matrix metallopeptidase 3 Homo sapiens 0-4 23625833-5 2013 Ca(2+) -dependent astrocyte Mmp3 expression was also inhibited by actinomycin D, and a Mmp3 promoter luciferase reporter was efficiently activated by increased [Ca(2+) ]i , indicating regulation at the transcriptional level. Dactinomycin 66-79 matrix metallopeptidase 3 Homo sapiens 28-32 23811451-5 2013 In vitro drug release study of Ibuprofen-polymer conjugate was performed in phosphate buffer PH 7.4 using a roller (Stuart STR 1) placed in an incubator (Stuart SI 60) and the temperature was kept constant at 37 +- 1 C. Among the three polymers, glycerol-adipate-co-pentadecalactone was observed to give a burst release following slow release in the medium. Ibuprofen 31-40 matrix metallopeptidase 3 Homo sapiens 123-128 23328930-2 2013 The present study was designed to investigate the effects of resveratrol on TNF-alpha-induced inflammatory cytokines production of IL-1beta and MMP3 in Rheumatoid arthritis (RA) Fibroblast-like synoviocytes (FLS) and further to explore the role of PI3K/Akt signaling pathway by which resveratrol modulates those cytokines production. Resveratrol 61-72 matrix metallopeptidase 3 Homo sapiens 144-148 23328930-6 2013 Resveratrol inhibited both mRNA and proteins expressions of IL-1beta and MMP-3 on RA FLS in a dose-dependent manner. Resveratrol 0-11 matrix metallopeptidase 3 Homo sapiens 73-78 23328930-8 2013 Activation of PI3K/Akt signaling pathway exists in TNF-alpha-induced production of IL-1beta and MMP3 on RA FLS, which is hampered by PI3K inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 148-156 matrix metallopeptidase 3 Homo sapiens 96-100 23328930-10 2013 Resveratrol attenuates TNF-alpha-induced production of IL-1beta and MMP-3 via inhibition of PI3K-Akt signaling pathway in RA FLS, suggesting that resveratrol plays an anti-inflammatory role and might have beneficial effects in preventing and treating RA. Resveratrol 0-11 matrix metallopeptidase 3 Homo sapiens 68-73 23328930-10 2013 Resveratrol attenuates TNF-alpha-induced production of IL-1beta and MMP-3 via inhibition of PI3K-Akt signaling pathway in RA FLS, suggesting that resveratrol plays an anti-inflammatory role and might have beneficial effects in preventing and treating RA. Resveratrol 146-157 matrix metallopeptidase 3 Homo sapiens 68-73 24066520-5 2013 Resveratrol reduced the expression of MMP-1 (p = 0.022), MMP-3 (p = 0.021), and MMP-9 (p = 0.047). Resveratrol 0-11 matrix metallopeptidase 3 Homo sapiens 57-62 24551546-5 2013 Both the cyclam-marimastat conjugate and its metal complexes exhibited slightly reduced potency against MMP-1, but essentially identical inhibitory activity against MMP-3. Metals 45-50 matrix metallopeptidase 3 Homo sapiens 165-170 23660647-1 2013 An X-ray investigation has been performed with the aim of characterizing the binding sites of a platinum-based inhibitor (K[PtCl3(DMSO)]) of matrix metalloproteinase-3 (stromelysin-1). Platinum 96-104 matrix metallopeptidase 3 Homo sapiens 169-182 23660647-1 2013 An X-ray investigation has been performed with the aim of characterizing the binding sites of a platinum-based inhibitor (K[PtCl3(DMSO)]) of matrix metalloproteinase-3 (stromelysin-1). ptcl3 124-129 matrix metallopeptidase 3 Homo sapiens 169-182 23660647-1 2013 An X-ray investigation has been performed with the aim of characterizing the binding sites of a platinum-based inhibitor (K[PtCl3(DMSO)]) of matrix metalloproteinase-3 (stromelysin-1). Dimethyl Sulfoxide 130-135 matrix metallopeptidase 3 Homo sapiens 169-182 23485680-8 2013 The present study demonstrated the mitigation of augmented serum levels of hyaluronidase and matrix metalloproteinases (MMP-13, MMP-3 and MMP-9) responsible for cartilage degeneration by 4-ME. 4-methylesculetin 187-191 matrix metallopeptidase 3 Homo sapiens 128-133 23980356-7 2013 RESULTS: The level of serum MMP-3 and the MFI of CD147 on the monocyte surface were obviously higher in RA patients of DHBS than in those of CDBS and the normal control group (P < 0.05). Sodium 3,5-dichloro-2-hydroxybenzenesulfonate 119-123 matrix metallopeptidase 3 Homo sapiens 28-33 23058002-4 2013 MATERIAL AND METHODS: Binding and cleavage of fetuin by MMPs were assessed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, in-silico analyses and mass spectrometry. Sodium Dodecyl Sulfate 78-100 matrix metallopeptidase 3 Homo sapiens 56-60 23058002-4 2013 MATERIAL AND METHODS: Binding and cleavage of fetuin by MMPs were assessed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, in-silico analyses and mass spectrometry. polyacrylamide gels 101-119 matrix metallopeptidase 3 Homo sapiens 56-60 23058002-10 2013 CONCLUSION: MMP-7 and, to a lesser extent, MMP-3, affect the ability of fetuin to inhibit the formation of hydroxyapatite in vitro. Durapatite 107-121 matrix metallopeptidase 3 Homo sapiens 43-48 22717739-7 2013 Significantly greater amounts of MMP-1 (47.0 +- 9.2 pg/ml) and MMP-3 (250.0 +- 68.8 pg/ml) were observed in 0.5 % bupivacaine cultures compared with controls (14.3 +- 14.3, p = 0.023 and 72.0 +- 84.9, p = 0.045, respectively). Bupivacaine 114-125 matrix metallopeptidase 3 Homo sapiens 63-68 23980356-10 2013 CONCLUSIONS: Increased serum MMP-3 level of RA patients of DHBS might result in destroy of joint cartilages and sclerotin. Sodium 3,5-dichloro-2-hydroxybenzenesulfonate 59-63 matrix metallopeptidase 3 Homo sapiens 29-34 23396231-6 2013 We found that treatment of primary human osteoarthritic chondrocytes with various concentrations of celastrol resulted in striking decrease in the expression of MMP-1, MMP-3, MMP-13, iNOS-2 and COX-2. celastrol 100-109 matrix metallopeptidase 3 Homo sapiens 168-173 23614750-4 2013 In this study, we investigated the inhibitory effects of curcumin on matrix metalloproteinase (MMP)-1 and MMP-3 expression in human dermal fibroblast cells. Curcumin 57-65 matrix metallopeptidase 3 Homo sapiens 106-111 23614750-5 2013 Western blot analysis revealed that curcumin inhibited ultraviolet (UV) B-induced MMP-1 and MMP-3 expression. Curcumin 36-44 matrix metallopeptidase 3 Homo sapiens 92-97 23794948-5 2013 RESULTS: Multinomial logistic analyses showed that the 5A allele of rs3025058(5A/6A) in MMP3 and the T allele of rs3918242(C-1562T) in MMP9 were significantly associated with isolated systolic hypertension after adjusted by age, triglyceride, low-density lipoprotein (P<0.001, Pcorr<0.003; P=0.009, Pcorr=0.027). Triglycerides 229-241 matrix metallopeptidase 3 Homo sapiens 88-92 23428742-7 2013 Microarray and q PCR analysis showed RA treatment did inhibit the motility of human RPE cells by inhibition of metalloproteinases (MMP) 1, 2, 9, fibronectin-1, transforming growth factor beta, thrombospondin-1, tenascin C, most collagen, integrin, laminin molecules and along enhancing E-cadherin and MMP3 genes expression. Tretinoin 37-39 matrix metallopeptidase 3 Homo sapiens 301-305 23601877-3 2013 Then the dissociation constants (Kd) of these ssDNA were determined and an aptamer (STR1) with highest affinity for streptomycin was identified. Streptomycin 116-128 matrix metallopeptidase 3 Homo sapiens 84-88 23601877-4 2013 Further study showed that aptamer STR1 exhibits very low affinity for other aminoglycoside antibiotics, indicating high specificity. Aminoglycosides 76-90 matrix metallopeptidase 3 Homo sapiens 34-38 24648922-8 2013 In conclusion, these data suggest that MMP-3 is not only involved in the pathological destruction process of TMJ OA combined with DD initially, but also has a positive correlation with the degree of pathological changes. dd 130-132 matrix metallopeptidase 3 Homo sapiens 39-44 23220557-7 2013 The expression levels of 19 genes were statistically significantly correlated with the severity of AC degeneration and changes of SB structure; these included: ADAMTS1, ASPN, BMP6, BMPER, CCL2, CCL8, COL5A1, COL6A3, COL7A1, COL16A1, FRZB, GDF10, MMP3, OGN, OMD, POSTN, PTGES, TNFSF11 and WNT1. Antimony 130-132 matrix metallopeptidase 3 Homo sapiens 246-250 23339380-10 2013 HMG supplementation was able to reduce the catabolic genes" expression in cultured HACs such as matrix metalloproteinases (MMP1 & MMP3), Interleukin 1, 6 and 8 (IL-1, IL-6 & IL-8), cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS). Menotropins 0-3 matrix metallopeptidase 3 Homo sapiens 134-138 23257246-5 2013 RESULTS: Resveratrol dose-dependently inhibited TNF-alpha-induced cyclooxygenase-2 (COX-2), MMP-1, MMP-3, MMP-13 and PGE(2) production in human chondrocytes. Resveratrol 9-20 matrix metallopeptidase 3 Homo sapiens 99-104 22740381-5 2013 Mechanistically, LfcinB attenuated the effects of IL-1beta and FGF-2 on the expression of cartilage-degrading enzymes (MMP-1, MMP-3, and MMP-13), destructive cytokines (IL-1beta and IL-6), and inflammatory mediators (iNOS and TLR2). LFcinB 17-23 matrix metallopeptidase 3 Homo sapiens 126-131 23183108-6 2013 In addition, equivalent concentrations of AS1940477 that inhibited cytokine production also inhibited TNFalpha- and IL-1 beta-induced production of IL-6, PGE(2), and MMP-3 in human synovial stromal cells. 6-(2-(4-fluorophenyl)-6-(hydroxymethyl)-4,5,6,7-tetrahydropyrazolo(1,5-a)pyrimidin-3-yl)-2-(2-methylphenyl)pyridazin-3(2H)-one 42-51 matrix metallopeptidase 3 Homo sapiens 166-171 23100088-9 2013 There was a positive correlation between the plasma MMP-3 level and the prednisolone dose. Prednisolone 72-84 matrix metallopeptidase 3 Homo sapiens 52-57 23017871-6 2013 RESULTS: HDAC inhibitors (TSA: 10 nM, MS-275: 100 nM) suppressed CTS-induced expression of RUNX-2, ADAMTS-5, and MMP-3 at both the mRNA and protein levels within 1h. castanospermine 65-68 matrix metallopeptidase 3 Homo sapiens 113-118 23509928-5 2013 beta-NAD(+) inhibited the expression of MMP-1 and MMP-3 triggered by IL-1alpha at gene and protein levels. NAD 0-11 matrix metallopeptidase 3 Homo sapiens 50-55 24302816-7 2013 Furthermore, both NF- kappa B inhibitor Bay11-7085 and p38 inhibitor SB203580 significantly suppressed the enhanced production of IL-6 and MMPs induced by HMGB1-LPS. BAY 11-7085 40-50 matrix metallopeptidase 3 Homo sapiens 139-143 24302816-7 2013 Furthermore, both NF- kappa B inhibitor Bay11-7085 and p38 inhibitor SB203580 significantly suppressed the enhanced production of IL-6 and MMPs induced by HMGB1-LPS. SB 203580 69-77 matrix metallopeptidase 3 Homo sapiens 139-143 24099040-5 2013 In addition to inhibition of MMP-14, fisetin inhibits MMP-1, MMP-3, MMP-7, and MMP-9, more efficiently than a naturally occurring MMP inhibitor tetracycline. fisetin 37-44 matrix metallopeptidase 3 Homo sapiens 61-66 23025928-6 2013 In these samples, NT levels significantly correlated with ARGS-aggrecan neoepitope generated by aggrecanase cleavage of aggrecan (P <= 0.001), cross-linked C-telopeptides of type II collagen (P < 0.001), MMP-1 (P = 0.008), and MMP-3 (P <= 0.001). 3-nitrotyrosine 18-20 matrix metallopeptidase 3 Homo sapiens 233-238 23285695-10 2012 A significant decrease in MMP-2, MMP-3, MMP-10, MMP-13, and TIMP-1 expression in response to IP6 was observed. Phytic Acid 93-96 matrix metallopeptidase 3 Homo sapiens 33-38 24396567-8 2013 Type I procollagen and type III procollagen protein levels were significantly increased in response to biodynes, TRF, and tocopherol treatment (P < 0.05) with reduction in MMP-1, MMP-2, MMP-3, and MMP-9 activities (P < 0.05). Tocopherols 122-132 matrix metallopeptidase 3 Homo sapiens 189-194 23409137-4 2013 We found that, in addition to MMP9, MMP3 was a new target gene upregulated by Zta. zta 78-81 matrix metallopeptidase 3 Homo sapiens 36-40 23409137-6 2013 Endogenous Zta also contributed to induction of MMP3 expression, migration and invasion of EBV-infected cells. zta 11-14 matrix metallopeptidase 3 Homo sapiens 48-52 23409137-7 2013 Zta activated the MMP3 promoter through three AP-1 elements, and its DNA-binding domain was required for the promoter binding and MMP3 induction. zta 0-3 matrix metallopeptidase 3 Homo sapiens 18-22 23409137-7 2013 Zta activated the MMP3 promoter through three AP-1 elements, and its DNA-binding domain was required for the promoter binding and MMP3 induction. zta 0-3 matrix metallopeptidase 3 Homo sapiens 130-134 23409137-9 2013 Zta-promoted cell migration required MMP3 but not MMP9. zta 0-3 matrix metallopeptidase 3 Homo sapiens 37-41 23409137-10 2013 On the other hand, both MMP3 and MMP9 were essential for Zta-induced cell invasion, and co-expression of the two MMPs synergistically increased cell invasiveness. zta 57-60 matrix metallopeptidase 3 Homo sapiens 24-28 23819335-9 2013 ROC analysis indicated that the normalization of MMP-3 levels in RA patients at 24 weeks of TCZ therapy (a cut-off < or =16.5 ng/ml) was associated with the maintenance of remission/low disease activity from SDAI and CDAI 24 weeks after the drug use (the area under the receiver operating curve was 0.762; 95% confidence interval: 0.548-0.976). sdai 211-215 matrix metallopeptidase 3 Homo sapiens 49-54 23819335-9 2013 ROC analysis indicated that the normalization of MMP-3 levels in RA patients at 24 weeks of TCZ therapy (a cut-off < or =16.5 ng/ml) was associated with the maintenance of remission/low disease activity from SDAI and CDAI 24 weeks after the drug use (the area under the receiver operating curve was 0.762; 95% confidence interval: 0.548-0.976). cdai 220-224 matrix metallopeptidase 3 Homo sapiens 49-54 23819335-11 2013 Serum MMP-3 determination at 24 weeks of therapy may be useful in predicting the maintenance of remission/low activity from SDAI and CDAI after discontinuation of the drug. sdai 124-128 matrix metallopeptidase 3 Homo sapiens 6-11 23819335-11 2013 Serum MMP-3 determination at 24 weeks of therapy may be useful in predicting the maintenance of remission/low activity from SDAI and CDAI after discontinuation of the drug. cdai 133-137 matrix metallopeptidase 3 Homo sapiens 6-11 23285695-11 2012 IP6 down-regulated MMP-9 transcription induced by PMA and decreased the level of both MMP-2 and MMP-3 mRNAs in PMA-stimulated cells. Phytic Acid 0-3 matrix metallopeptidase 3 Homo sapiens 96-101 23285695-14 2012 IP6 exerts an influence of basal mRNA expression of some MMPs and their tissue inhibitors and down-regulates MMP-1, MMP-2, MMP-3 and MMP-9 in cells treated with PMA. Phytic Acid 0-3 matrix metallopeptidase 3 Homo sapiens 123-128 23187000-4 2012 The structural analysis of the catalytic domain of human stromelysin-1 (MMP-3) and human TIMP-1 suggests new possibilities of the role of TIMP-1 glycan moieties as a tuner for the proteolytic activities by MMPs. Polysaccharides 145-151 matrix metallopeptidase 3 Homo sapiens 57-70 23187000-4 2012 The structural analysis of the catalytic domain of human stromelysin-1 (MMP-3) and human TIMP-1 suggests new possibilities of the role of TIMP-1 glycan moieties as a tuner for the proteolytic activities by MMPs. Polysaccharides 145-151 matrix metallopeptidase 3 Homo sapiens 72-77 23187000-4 2012 The structural analysis of the catalytic domain of human stromelysin-1 (MMP-3) and human TIMP-1 suggests new possibilities of the role of TIMP-1 glycan moieties as a tuner for the proteolytic activities by MMPs. Polysaccharides 145-151 matrix metallopeptidase 3 Homo sapiens 206-210 22985855-0 2012 An enthalpic basis of additivity in biphenyl hydroxamic acid ligands for stromelysin-1. biphenyl hydroxamic acid 36-60 matrix metallopeptidase 3 Homo sapiens 73-86 22441579-4 2012 The anti-inflammatory effects of atorvastatin were assessed by measuring the levels of IL-1beta, PGE(2) and MMP-3 by ELISA. Atorvastatin 33-45 matrix metallopeptidase 3 Homo sapiens 108-113 22441579-5 2012 Atorvastatin inhibited the increase in the production of IL-1beta, PGE(2) and MMP-3 in submandibular glands treated with anti-M(3) peptide IgG. Atorvastatin 0-12 matrix metallopeptidase 3 Homo sapiens 78-83 22909087-7 2012 The DMSO-soluble component curcumin, whose occurrence within the DMSO extract was verified by HPLC/MS, reduced levels of IL-1beta, IL-6, IL-8, MMP1, MMP3 and MMP13 and both caused an up-regulation of TNF-alpha. Dimethyl Sulfoxide 4-8 matrix metallopeptidase 3 Homo sapiens 149-153 22909087-7 2012 The DMSO-soluble component curcumin, whose occurrence within the DMSO extract was verified by HPLC/MS, reduced levels of IL-1beta, IL-6, IL-8, MMP1, MMP3 and MMP13 and both caused an up-regulation of TNF-alpha. Curcumin 27-35 matrix metallopeptidase 3 Homo sapiens 149-153 22909087-7 2012 The DMSO-soluble component curcumin, whose occurrence within the DMSO extract was verified by HPLC/MS, reduced levels of IL-1beta, IL-6, IL-8, MMP1, MMP3 and MMP13 and both caused an up-regulation of TNF-alpha. Dimethyl Sulfoxide 65-69 matrix metallopeptidase 3 Homo sapiens 149-153 22492974-7 2012 Simvastatin also reduced the mRNA levels of MMP2, MMP3, and CD44, but increased TIMP2 mRNA; all these effects of simvastatin were partly or entirely reversed in the presence of GGPP. Simvastatin 0-11 matrix metallopeptidase 3 Homo sapiens 50-54 22415590-7 2012 A significant decrease in MMP-13, MMP-3, MMP-2, and TIMP-1 basal expression was achieved by IP6. Phytic Acid 92-95 matrix metallopeptidase 3 Homo sapiens 34-39 22628530-12 2012 On multivariable analysis, VA was independently associated with increasing MMP3 (standardized beta, 0.37; P=0.01). Vanillic Acid 27-29 matrix metallopeptidase 3 Homo sapiens 75-79 22484054-7 2012 Furthermore, the up-regulation of MMP-3 and KIM-1 release by PTEC was associated with generation of reactive oxygen species. Reactive Oxygen Species 100-123 matrix metallopeptidase 3 Homo sapiens 34-39 24750725-3 2012 The antioxidant activity of levan and their derivatives (SL1 and SL2) exhibited a strong free radical scavenging activity with DPPH. levan 28-33 matrix metallopeptidase 3 Homo sapiens 57-60 24750725-3 2012 The antioxidant activity of levan and their derivatives (SL1 and SL2) exhibited a strong free radical scavenging activity with DPPH. 1,1-diphenyl-2-picrylhydrazyl 127-131 matrix metallopeptidase 3 Homo sapiens 57-60 22511625-2 2012 The pathogenic role of Pentraxin 3 (PTX3) in controlling upregulation of matrix metalloproteinase 1 (MMP-1) and MMP-3 in CCh remains undefined. 1-acetyl-2-(coumariniminecarboxamide-3-yl)hydrazine 121-124 matrix metallopeptidase 3 Homo sapiens 112-117 22253074-5 2012 alphavbeta5 or alpha6beta1 monoclonal antibody (mAb), focal adhesion kinase (FAK) inhibitor, and mitogen-activated protein kinase (MEK) inhibitors (PD98059 and U0126) inhibited the Cyr61-induced increase of the migration and MMP-3 up-regulation of OSCC cells. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 148-155 matrix metallopeptidase 3 Homo sapiens 225-230 22607938-10 2012 Matrix metalloproteinase (MMP)-3 in tears was reduced from baseline at week 8 (40% of baseline, P=0.035) in the tofacitinib 0.005% QD group, whereas the vehicle group showed 77% of baseline (P>0.20). tofacitinib 112-123 matrix metallopeptidase 3 Homo sapiens 0-32 22446297-6 2012 Levels of MMP-1 and MMP-3 were decreased significantly after 24 week treatment of T-614 group 2 or MTX group. T 614 82-87 matrix metallopeptidase 3 Homo sapiens 20-25 22402362-0 2012 The mechanisms of cerebral vascular dysfunction and neuroinflammation by MMP-mediated degradation of VEGFR-2 in alcohol ingestion. Alcohols 112-119 matrix metallopeptidase 3 Homo sapiens 73-76 22402362-7 2012 Alcohol-induced degradation of endothelial VEGFR-2 by MMP-3/9 led to a subsequent elevation of cellular/serum VEGF-A level. Alcohols 0-7 matrix metallopeptidase 3 Homo sapiens 54-61 22498097-10 2012 6-OHDA lesioning was associated with an increase in microglia activation and in numbers of MMP-3 immunoreactive cells which was attenuated by pioglitazone and GW855266X. Oxidopamine 0-6 matrix metallopeptidase 3 Homo sapiens 91-96 22498097-10 2012 6-OHDA lesioning was associated with an increase in microglia activation and in numbers of MMP-3 immunoreactive cells which was attenuated by pioglitazone and GW855266X. Pioglitazone 142-154 matrix metallopeptidase 3 Homo sapiens 91-96 22498097-10 2012 6-OHDA lesioning was associated with an increase in microglia activation and in numbers of MMP-3 immunoreactive cells which was attenuated by pioglitazone and GW855266X. gw855266x 159-168 matrix metallopeptidase 3 Homo sapiens 91-96 22446297-12 2012 These results suggest that T-614 inhibits the invasiveness through decreasing the MMP-1 and MMP-3 production. T 614 27-32 matrix metallopeptidase 3 Homo sapiens 92-97 22297496-1 2012 PURPOSE: To investigate the role of anti-inflammatory TSG-6 in controlling MMP-1 and MMP-3, which have been shown to be upregulated in conjunctivochalasis (CCh). 1-acetyl-2-(coumariniminecarboxamide-3-yl)hydrazine 156-159 matrix metallopeptidase 3 Homo sapiens 85-90 22227273-0 2012 Curcumin as anti-endometriotic agent: implication of MMP-3 and intrinsic apoptotic pathway. Curcumin 0-8 matrix metallopeptidase 3 Homo sapiens 53-58 22227273-4 2012 We also checked whether curcumin has potency to regress endometriosis by modulating MMP-3 and apoptotic pathway. Curcumin 24-32 matrix metallopeptidase 3 Homo sapiens 84-89 22227273-9 2012 Curcumin treatment regressed endometriosis by inhibiting NFkappaB translocation and MMP-3 expression. Curcumin 0-8 matrix metallopeptidase 3 Homo sapiens 84-89 22564605-7 2012 RESULTS: MMP-1, MMP-3, MMP-8, MMP-9, and MMP-13 activities were increased after CsA treatment; MMP-1 = 121; MMP-3 = 164; MMP-8 = 133; MMP-9 = 124; and MMP-13 = 121. Cyclosporine 80-83 matrix metallopeptidase 3 Homo sapiens 16-21 22564605-7 2012 RESULTS: MMP-1, MMP-3, MMP-8, MMP-9, and MMP-13 activities were increased after CsA treatment; MMP-1 = 121; MMP-3 = 164; MMP-8 = 133; MMP-9 = 124; and MMP-13 = 121. Cyclosporine 80-83 matrix metallopeptidase 3 Homo sapiens 95-113 22395891-8 2012 The mRNAs of myocilin, SPARC, and MMP-3, which do not have AREs, were more stable after actinomycin D treatment and were not altered with oxidation. Dactinomycin 88-101 matrix metallopeptidase 3 Homo sapiens 34-39 22227567-3 2012 Our previous studies revealed a nexus between metalloproteinases and prostanoids whereby MMP-1 and MMP-3, commonly found in inflammatory and neoplastic foci, stimulate macrophage MMP-9 expression via the release of TNF-alpha and subsequent induction of cyclooxygenase-2 and PGE(2) engagement of EP4 receptor. Prostaglandins 69-80 matrix metallopeptidase 3 Homo sapiens 99-104 22226810-8 2012 This meta-analysis provided evidence that genetic polymorphism of MMP1-1607 1G/2G, MMP3-Gly45lys, MMP3-376 G/C, MMP3-1171 5A/6A, MMP9-1562 C/T and MMP9-R279Q have a small to medium effect on incidence of coronary disease. gly45lys 88-96 matrix metallopeptidase 3 Homo sapiens 83-87 22227567-3 2012 Our previous studies revealed a nexus between metalloproteinases and prostanoids whereby MMP-1 and MMP-3, commonly found in inflammatory and neoplastic foci, stimulate macrophage MMP-9 expression via the release of TNF-alpha and subsequent induction of cyclooxygenase-2 and PGE(2) engagement of EP4 receptor. Prostaglandins E 274-277 matrix metallopeptidase 3 Homo sapiens 99-104 22114952-6 2011 On the contrary, Rp-adenosine-3",5"-cyclic monophosphorothioate (Rp-cAMPs), a competitive cAMP antagonist for cAMP receptors, and H-89, a protein kinase A (PKA) inhibitor, markedly enhanced eotaxin-1-induced MMP-3 expression. rp-adenosine-3",5"-cyclic monophosphorothioate 17-63 matrix metallopeptidase 3 Homo sapiens 208-213 22037182-0 2012 Mechanism of the binding of Z-L-tryptophan and Z-L-phenylalanine to thermolysin and stromelysin-1 in aqueous solutions. z-l-tryptophan 28-42 matrix metallopeptidase 3 Homo sapiens 84-97 22037182-0 2012 Mechanism of the binding of Z-L-tryptophan and Z-L-phenylalanine to thermolysin and stromelysin-1 in aqueous solutions. carbobenzoxyphenylalanine 47-64 matrix metallopeptidase 3 Homo sapiens 84-97 22037182-1 2012 The chemical shift of the carboxylate carbon of Z-tryptophan is increased from 179.85 to 182.82 ppm and 182.87 ppm on binding to thermolysin and stromelysin-1 respectively. carboxylate 26-37 matrix metallopeptidase 3 Homo sapiens 145-158 22037182-1 2012 The chemical shift of the carboxylate carbon of Z-tryptophan is increased from 179.85 to 182.82 ppm and 182.87 ppm on binding to thermolysin and stromelysin-1 respectively. Carbon 38-44 matrix metallopeptidase 3 Homo sapiens 145-158 22037182-1 2012 The chemical shift of the carboxylate carbon of Z-tryptophan is increased from 179.85 to 182.82 ppm and 182.87 ppm on binding to thermolysin and stromelysin-1 respectively. benzyloxycarbonyltryptophan 48-60 matrix metallopeptidase 3 Homo sapiens 145-158 22067128-7 2012 There were increased levels of IL-1beta, IL-6, MMP-1, MMP-3, and MMP-9 and decreased levels of TIMP-1 and TIMP-2 in the tears of PG-treated patients. Prostaglandins 129-131 matrix metallopeptidase 3 Homo sapiens 54-59 21437902-7 2012 The findings further revealed that silica gel stimulates collagen and fibronectin expression, while down-regulates matrix metalloproteinase-1 and -3 (MMP-1 and MMP-3) released in conditioned medium. Silicon Dioxide 35-41 matrix metallopeptidase 3 Homo sapiens 160-165 22175304-6 2012 Three SNPs [rs520540 (Ala362Ala), rs602128 (Asp96Asp), and rs679620 (Lys45Glu)] in the coding region of MMP3 were selected and genotyped by direct sequencing. ala362ala 22-31 matrix metallopeptidase 3 Homo sapiens 104-108 22229634-1 2012 The Pictet-Spenglerase strictosidine synthase (STR1) has been recognized as a key enzyme in the biosynthesis of some 2000 indole alkaloids in plants, some with high therapeutic value. Indole Alkaloids 122-138 matrix metallopeptidase 3 Homo sapiens 47-51 22229634-2 2012 In this study, a novel function of STR1 has been detected which allows for the first time a simple enzymatic synthesis of the strictosidine analogue 3 harboring the piperazino[1,2-a]indole (PI) scaffold and to switch from the common tryptoline (hydrogenated carboline) to the rare PI skeleton. strictosidine 126-139 matrix metallopeptidase 3 Homo sapiens 35-39 22229634-2 2012 In this study, a novel function of STR1 has been detected which allows for the first time a simple enzymatic synthesis of the strictosidine analogue 3 harboring the piperazino[1,2-a]indole (PI) scaffold and to switch from the common tryptoline (hydrogenated carboline) to the rare PI skeleton. piperazino[1,2-a]indole 165-188 matrix metallopeptidase 3 Homo sapiens 35-39 22229634-2 2012 In this study, a novel function of STR1 has been detected which allows for the first time a simple enzymatic synthesis of the strictosidine analogue 3 harboring the piperazino[1,2-a]indole (PI) scaffold and to switch from the common tryptoline (hydrogenated carboline) to the rare PI skeleton. tryptoline 233-243 matrix metallopeptidase 3 Homo sapiens 35-39 22229634-2 2012 In this study, a novel function of STR1 has been detected which allows for the first time a simple enzymatic synthesis of the strictosidine analogue 3 harboring the piperazino[1,2-a]indole (PI) scaffold and to switch from the common tryptoline (hydrogenated carboline) to the rare PI skeleton. hydrogenated carboline 245-267 matrix metallopeptidase 3 Homo sapiens 35-39 22229634-4 2012 STR1 presently provides exclusively access to 3 and can act as a source to generate by chemoenzymatic approaches libraries of this novel class of alkaloids which may have new biological activities. Alkaloids 146-155 matrix metallopeptidase 3 Homo sapiens 0-4 22419431-10 2012 beta-thujaplicin also prevented the up-regulation of MMP-1 and MMP-3 mRNA. beta-thujaplicin 0-16 matrix metallopeptidase 3 Homo sapiens 63-68 22878602-6 2012 VA441 and celecoxib significantly suppressed IL-1beta-stimulated MMP-3 and NO and iNOS gene expression in a dose-dependent manner, while indomethacin did not show any significant effect on MMP-3 and NO production or on iNOS gene expression. 2-methyl-5-(4-methylsulphonyl)phenyl-1-phenyl-3-(2-n-propyloxyethyl)-1H-pyrrole 0-5 matrix metallopeptidase 3 Homo sapiens 65-70 22878602-6 2012 VA441 and celecoxib significantly suppressed IL-1beta-stimulated MMP-3 and NO and iNOS gene expression in a dose-dependent manner, while indomethacin did not show any significant effect on MMP-3 and NO production or on iNOS gene expression. Celecoxib 10-19 matrix metallopeptidase 3 Homo sapiens 65-70 21782982-0 2011 pH stability of the stromelysin-1 catalytic domain and its mechanism of interaction with a glyoxal inhibitor. Glyoxal 91-98 matrix metallopeptidase 3 Homo sapiens 20-33 21920358-9 2011 When the cells were co-incubated with IL-1beta and raloxifene, a significant and dose-dependent increase in proteoglycans and a reduction of MMP-3 and nitric oxide (NO) were detected. Raloxifene Hydrochloride 51-61 matrix metallopeptidase 3 Homo sapiens 141-146 21170958-5 2011 Here, we provide evidence that increased MMP-3 expression by 5-aza-dC is modulated by interleukin-1 (IL-1). Decitabine 61-69 matrix metallopeptidase 3 Homo sapiens 41-46 21170958-7 2011 Furthermore, we showed that increased MMP-3 expression by 5-aza-dC was associated with increased expression and activity of specific transcription factors known to regulate MMP-3 expression. Decitabine 58-66 matrix metallopeptidase 3 Homo sapiens 38-43 21170958-7 2011 Furthermore, we showed that increased MMP-3 expression by 5-aza-dC was associated with increased expression and activity of specific transcription factors known to regulate MMP-3 expression. Decitabine 58-66 matrix metallopeptidase 3 Homo sapiens 173-178 21170958-8 2011 In fact, treatment with 5-aza-dC was obligatory for some transcription factors to trigger an increase in MMP-3 expression, such as Ap-1. Decitabine 24-32 matrix metallopeptidase 3 Homo sapiens 105-110 21935932-6 2011 Preadipocytes were incubated with RPMI 1640 medium (control) or THP-1 macrophage-conditioned (MC) medium (25% and 100%) for 24 h. MC medium markedly increased mRNA levels of MMP1 (up to 122-fold) and MMP3 (up to 59-fold), as well as protein release of MMP1 (up to 378-fold) and MMP3 (up to 10-fold) in a dose-dependent manner. Methylcholanthrene 130-132 matrix metallopeptidase 3 Homo sapiens 200-204 21935932-6 2011 Preadipocytes were incubated with RPMI 1640 medium (control) or THP-1 macrophage-conditioned (MC) medium (25% and 100%) for 24 h. MC medium markedly increased mRNA levels of MMP1 (up to 122-fold) and MMP3 (up to 59-fold), as well as protein release of MMP1 (up to 378-fold) and MMP3 (up to 10-fold) in a dose-dependent manner. Methylcholanthrene 130-132 matrix metallopeptidase 3 Homo sapiens 278-282 21935932-8 2011 Neutralizing IL-1beta abolished the induction of MMP1 and MMP3 in preadipocytes by MC medium while the effects of TNFalpha neutralization were modest. mc medium 83-92 matrix metallopeptidase 3 Homo sapiens 58-62 21935932-10 2011 Inhibition of p38, ERK and JNK reversed the stimulatory effects of MC or IL-1beta on MMP1 and MMP3 production. Methylcholanthrene 67-69 matrix metallopeptidase 3 Homo sapiens 94-98 21782982-6 2011 At pH 5.5-6.5 the glyoxal inhibitor is a potent inhibitor of stromelysin-1 (K(i)=~1muM). Glyoxal 18-25 matrix metallopeptidase 3 Homo sapiens 61-74 21786836-2 2011 Subsequent transformation led to the expedient preparation of enantioenriched thiochroman-4-one and the key intermediate of the potent inhibitor of MMP-3, (R)-gamma-trifluoromethyl gamma-sulfone hydroxamate. Thiochroman-4-one 78-95 matrix metallopeptidase 3 Homo sapiens 148-153 21587103-10 2011 RESULTS: In vitro, resveratrol exhibited an anti-inflammatory and anticatabolic effect on the messenger RNA and protein level for IL-6, IL-8, MMP1, MMP3 and MMP13. Resveratrol 19-30 matrix metallopeptidase 3 Homo sapiens 148-152 21867693-3 2011 Exposure of the human colonic myofibroblast cell line 18Co to TNF-alpha and bradykinin induced synergistic MMP-3 mRNA and protein expression, which were blocked by the preferential PKC inhibitors GF109203X and Go6983 and by the MEK inhibitor U0126. bisindolylmaleimide I 196-205 matrix metallopeptidase 3 Homo sapiens 107-112 21535409-11 2011 Ramiprilate significantly decreased the average total MMP activity level by 42% and suppressed the specific MMP-3 activity by 72%, which is comparable to the effect of GM6001 (87%). ramiprilat 0-11 matrix metallopeptidase 3 Homo sapiens 108-113 21535409-14 2011 Increased functional MMP activity, notably MMP-3 and -9, is present in Crohn"s fistulas and may be inhibited by ramiprilate, a widely available ACE inhibitor. ramiprilat 112-123 matrix metallopeptidase 3 Homo sapiens 43-55 21247370-6 2011 The IL-1beta-induced MMP-3 level was significantly and dose-dependently reduced by >50% by the six plants (P < 0.01: at 100 mug/ mL of CS and LH, P < 0.001: at 10 mug/mL of all plants, and at 100 mug/mL of AC, BC, CF, and SS). Cesium 142-144 matrix metallopeptidase 3 Homo sapiens 21-26 21247370-6 2011 The IL-1beta-induced MMP-3 level was significantly and dose-dependently reduced by >50% by the six plants (P < 0.01: at 100 mug/ mL of CS and LH, P < 0.001: at 10 mug/mL of all plants, and at 100 mug/mL of AC, BC, CF, and SS). Luteinizing Hormone 149-151 matrix metallopeptidase 3 Homo sapiens 21-26 21247370-6 2011 The IL-1beta-induced MMP-3 level was significantly and dose-dependently reduced by >50% by the six plants (P < 0.01: at 100 mug/ mL of CS and LH, P < 0.001: at 10 mug/mL of all plants, and at 100 mug/mL of AC, BC, CF, and SS). Actinium 216-218 matrix metallopeptidase 3 Homo sapiens 21-26 21786836-2 2011 Subsequent transformation led to the expedient preparation of enantioenriched thiochroman-4-one and the key intermediate of the potent inhibitor of MMP-3, (R)-gamma-trifluoromethyl gamma-sulfone hydroxamate. (r)-gamma-trifluoromethyl gamma-sulfone hydroxamate 155-206 matrix metallopeptidase 3 Homo sapiens 148-153 21609408-3 2011 A bioinorganic approach was recently used to identify novel inhibitors based on a maltol zinc-binding group, but accompanying molecular-docking studies failed to explain why one of these inhibitors, AM-6, had approximately 2500-fold selectivity for MMP-3 over MMP-2. CHEMBL489603 199-203 matrix metallopeptidase 3 Homo sapiens 249-254 22146365-10 2011 It is known that the matrix proteins of cartilage (including aggrecan and type II collagen) and matrix metalloproteinases (such as MMP3 and MMP13) are down- and up-regulated by ONOO-, respectively. onoo 177-181 matrix metallopeptidase 3 Homo sapiens 131-135 22146365-12 2011 Conversely, the gene expressions of MMP3 and MMP13 were restoratively down-regulated with H2. Hydrogen 90-92 matrix metallopeptidase 3 Homo sapiens 36-40 21632677-7 2011 Receiver operating characteristic analysis in male patients showed that baseline serum MMP-3 levels had poor accuracy (AUC < 0.7) to discriminate between Assessments in Ankylosing Spondylitis 20 (ASAS20) or ASAS40 responders and nonresponders after 3 or 12 months of treatment. asas20 199-205 matrix metallopeptidase 3 Homo sapiens 87-92 20607595-2 2011 Our aim was to investigate the effects of simvastatin on proinflammatory cytokines and matrix metalloproteinases (MMPs). Simvastatin 42-53 matrix metallopeptidase 3 Homo sapiens 114-118 21632677-7 2011 Receiver operating characteristic analysis in male patients showed that baseline serum MMP-3 levels had poor accuracy (AUC < 0.7) to discriminate between Assessments in Ankylosing Spondylitis 20 (ASAS20) or ASAS40 responders and nonresponders after 3 or 12 months of treatment. asas40 210-216 matrix metallopeptidase 3 Homo sapiens 87-92 21632677-8 2011 The accuracy of change in serum MMP-3 levels from baseline to 3 months in predicting response after 3 or 12 months of treatment was poor for ASAS40 (AUC < 0.7) or moderate for ASAS20 (AUC = 0.752 and 0.744, respectively), and was not superior to the accuracy of change in the currently used objective biomarkers, erythrocyte sedimentation rate and C-reactive protein. asas40 141-147 matrix metallopeptidase 3 Homo sapiens 32-37 21632677-8 2011 The accuracy of change in serum MMP-3 levels from baseline to 3 months in predicting response after 3 or 12 months of treatment was poor for ASAS40 (AUC < 0.7) or moderate for ASAS20 (AUC = 0.752 and 0.744, respectively), and was not superior to the accuracy of change in the currently used objective biomarkers, erythrocyte sedimentation rate and C-reactive protein. asas20 179-185 matrix metallopeptidase 3 Homo sapiens 32-37 20215736-5 2011 Polyacrylamide gel electrophoresis followed by Western immunoblotting allowed for the detection of pro- and active forms of both MMPs. polyacrylamide 0-14 matrix metallopeptidase 3 Homo sapiens 129-133 20599489-4 2011 RESULTS: The acetone extracted Clematis chinensis (CC6) contained the most total saponins compared to other solvent"s extracts and showed significant and dose-dependent inhibitory effects on PGE(2), MMP-3, -13, and COX-2 productions by LPS-stimulated PHC. Acetone 13-20 matrix metallopeptidase 3 Homo sapiens 199-202 21305446-0 2011 Inhibition of stromelysin-1 by caffeic acid derivatives from a propolis sample from Algeria. caffeic acid 31-43 matrix metallopeptidase 3 Homo sapiens 14-27 21305446-5 2011 B (3) was fractionated by HPLC, and one compound, characterized by NMR and mass spectroscopy and not previously identified in propolis, i.e., (+)-chicoric acid, displayed potent IN VITRO MMP-3 inhibitory activity (IC (50) = 6.3 x 10 (-7) M). chicoric acid 142-159 matrix metallopeptidase 3 Homo sapiens 187-192 21305446-6 2011 In addition, both caffeic acid and (+)-chicoric acid methyl ester present in fraction B (3) significantly inhibited UVA-mediated MMP-3 upregulation by fibroblasts. caffeic acid 18-30 matrix metallopeptidase 3 Homo sapiens 129-134 21305446-6 2011 In addition, both caffeic acid and (+)-chicoric acid methyl ester present in fraction B (3) significantly inhibited UVA-mediated MMP-3 upregulation by fibroblasts. (+)-chicoric acid methyl ester 35-65 matrix metallopeptidase 3 Homo sapiens 129-134 21337319-8 2011 Stimulation with poly(I-C) induced the activation of IFN regulatory factor 3 (IRF-3), NF-kappaB, and activator protein 1 (AP-1) c-Jun as well as the subsequent production of IFNbeta, CXCL8, and MMP-3. Poly I-C 17-25 matrix metallopeptidase 3 Homo sapiens 194-199 21349824-7 2011 The increase in EVT invasion correlated with increased placental explant secretion of MMP2 (P = 0.01), MMP3 (P = 0.01), and MMP9 (P = 0.02). EVT 16-19 matrix metallopeptidase 3 Homo sapiens 103-107 21371688-1 2011 BACKGROUND: We demonstrated that serum immunoglobulin G (IgG) from patients with primary Sjogren"s syndrome (pSS), interacting with the second extracellular loop of human glandular M(3) muscarinic acetylcholine receptors (M(3) mAChR), trigger the production of matrix metalloproteinase-3 (MMP-3) and prostaglandin E(2) (PGE(2)). Prostaglandins E 300-316 matrix metallopeptidase 3 Homo sapiens 261-287 21371688-1 2011 BACKGROUND: We demonstrated that serum immunoglobulin G (IgG) from patients with primary Sjogren"s syndrome (pSS), interacting with the second extracellular loop of human glandular M(3) muscarinic acetylcholine receptors (M(3) mAChR), trigger the production of matrix metalloproteinase-3 (MMP-3) and prostaglandin E(2) (PGE(2)). Prostaglandins E 300-316 matrix metallopeptidase 3 Homo sapiens 289-294 21371688-1 2011 BACKGROUND: We demonstrated that serum immunoglobulin G (IgG) from patients with primary Sjogren"s syndrome (pSS), interacting with the second extracellular loop of human glandular M(3) muscarinic acetylcholine receptors (M(3) mAChR), trigger the production of matrix metalloproteinase-3 (MMP-3) and prostaglandin E(2) (PGE(2)). Prostaglandins E 320-323 matrix metallopeptidase 3 Homo sapiens 261-287 21371688-1 2011 BACKGROUND: We demonstrated that serum immunoglobulin G (IgG) from patients with primary Sjogren"s syndrome (pSS), interacting with the second extracellular loop of human glandular M(3) muscarinic acetylcholine receptors (M(3) mAChR), trigger the production of matrix metalloproteinase-3 (MMP-3) and prostaglandin E(2) (PGE(2)). Prostaglandins E 320-323 matrix metallopeptidase 3 Homo sapiens 289-294 21371688-4 2011 RESULTS: An association was observed between serum and anti-M(3) mAChR autoantibodies and serum levels of MMP-3 and PGE(2) in pSS patients. pss 126-129 matrix metallopeptidase 3 Homo sapiens 106-111 21371688-5 2011 Thus, we established that serum anti-M(3) mAChR autoantibodies, MMP-3 and PGE(2) may be considered to be early markers of pSS associated with inflammation. pss 122-125 matrix metallopeptidase 3 Homo sapiens 64-69 21371688-8 2011 This is the first report showing that an antibody interacting with glandular mAChR can induce the production of pro-inflammatory mediators (MMP-3/PGE(2)). Prostaglandins E 146-149 matrix metallopeptidase 3 Homo sapiens 140-145 20921293-10 2011 The measured D/S ratios of MMP-3 nearly corresponded to the expected ratios. Deuterium 13-14 matrix metallopeptidase 3 Homo sapiens 27-32 20921293-10 2011 The measured D/S ratios of MMP-3 nearly corresponded to the expected ratios. Sulfur 15-16 matrix metallopeptidase 3 Homo sapiens 27-32 21330369-9 2011 The results strongly indicate that MMP3 digestion of alpha-synuclein in DA neurons plays a pivotal role in the progression of PD through modulation of alpha-synuclein in aggregation, LB formation, and neurotoxicity. Dopamine 72-74 matrix metallopeptidase 3 Homo sapiens 35-39 21146503-14 2011 Since these derivatives retained, as their oleic acid original counterpart, the capacity to inhibit the amidolytic activity of HLE and plasmin as well as to decrease HLE- and plasmin-mediated pro MMP-3 activation, they might be of therapeutic value to control proteolytic cascades in chronic inflammatory disorders. Oleic Acid 43-53 matrix metallopeptidase 3 Homo sapiens 196-201 21183746-8 2011 CONCLUSIONS: The MMP3 6A/6A genotype is associated with an increased risk of stroke in hypertensive subjects taking lisinopril compared with patients treated with chlorthalidone, whereas a protective effect was found for 5A/5A individuals treated with lisinopril. Lisinopril 116-126 matrix metallopeptidase 3 Homo sapiens 17-21 21183746-8 2011 CONCLUSIONS: The MMP3 6A/6A genotype is associated with an increased risk of stroke in hypertensive subjects taking lisinopril compared with patients treated with chlorthalidone, whereas a protective effect was found for 5A/5A individuals treated with lisinopril. Chlorthalidone 163-177 matrix metallopeptidase 3 Homo sapiens 17-21 21183746-8 2011 CONCLUSIONS: The MMP3 6A/6A genotype is associated with an increased risk of stroke in hypertensive subjects taking lisinopril compared with patients treated with chlorthalidone, whereas a protective effect was found for 5A/5A individuals treated with lisinopril. Lisinopril 252-262 matrix metallopeptidase 3 Homo sapiens 17-21 21480623-5 2011 This study aimed to assess whether the effects of ellagic acid on the fibrotic markers MMP-1 and MMP-3 are modulated by the PKC-ERK-PPAR-gamma signaling pathway in human umbilical vein endothelial cells (HUVECs) that have been exposed to oxLDL. Ellagic Acid 50-62 matrix metallopeptidase 3 Homo sapiens 97-102 21480623-6 2011 It was found that ellagic acid significantly inhibited oxLDL-induced expressions of MMP-1 and MMP-3. Ellagic Acid 18-30 matrix metallopeptidase 3 Homo sapiens 94-99 21480623-10 2011 In conclusion, the data suggest that ellagic acid elicits its protective effects by modulating the PKC-alpha/ERK/PPAR-gamma/NF-kappaB pathway, resulting in the suppression of ROS generation and, ultimately, inhibition of MMP-1 and MMP-3 expression in HUVECs exposed to oxLDL. Ellagic Acid 37-49 matrix metallopeptidase 3 Homo sapiens 231-236 21364906-7 2011 RESULTS: Poly(I:C) induced the secretion of MMP-1 and MMP-3 from corneal fibroblasts in a concentration-dependent manner as well as increased the intracellular abundance of MMP-1 and MMP-3 mRNAs. Poly I-C 9-17 matrix metallopeptidase 3 Homo sapiens 54-59 21364906-7 2011 RESULTS: Poly(I:C) induced the secretion of MMP-1 and MMP-3 from corneal fibroblasts in a concentration-dependent manner as well as increased the intracellular abundance of MMP-1 and MMP-3 mRNAs. Poly I-C 9-17 matrix metallopeptidase 3 Homo sapiens 183-188 21364906-9 2011 The poly(I:C)-induced secretion of MMP-1 and MMP-3 was also attenuated by synthetic inhibitors of MAPK and NF-kappaB signaling pathways. Poly I-C 4-12 matrix metallopeptidase 3 Homo sapiens 45-50 21364906-11 2011 CONCLUSIONS: Triptolide inhibited the poly(I:C)-induced production of MMP-1 and MMP-3 by human corneal fibroblasts. triptolide 13-23 matrix metallopeptidase 3 Homo sapiens 80-85 21364906-11 2011 CONCLUSIONS: Triptolide inhibited the poly(I:C)-induced production of MMP-1 and MMP-3 by human corneal fibroblasts. Poly I-C 38-47 matrix metallopeptidase 3 Homo sapiens 80-85 20630073-3 2010 The purpose of this study was to asses the association of the single nucleotide polymorphism (SNP) adenosine insertion/deletion polymorphism (-1171 5A->6A) in the MMP-3 promoter region in these lesions. Adenosine 99-108 matrix metallopeptidase 3 Homo sapiens 166-171 20617521-7 2010 RESULTS: The expression of catabolic genes (MMP-3 and ADAMTS-4) in AF cells derived from nondegenerated tissue decreased in response to 1.0 Hz of CTS, whereas changing the frequency to 0.33 Hz resulted in a shift toward matrix catabolism. castanospermine 146-149 matrix metallopeptidase 3 Homo sapiens 44-49 20435591-6 2010 The poly(I:C)-induced expression of MMP-1 and MMP-3 was attenuated by a synthetic inhibitor of NF-kappaB signaling and by IL-1 receptor antagonist; the latter also inhibited poly(I:C)-induced phosphorylation of IkappaB-alpha. Poly I-C 4-12 matrix metallopeptidase 3 Homo sapiens 46-51 20435591-6 2010 The poly(I:C)-induced expression of MMP-1 and MMP-3 was attenuated by a synthetic inhibitor of NF-kappaB signaling and by IL-1 receptor antagonist; the latter also inhibited poly(I:C)-induced phosphorylation of IkappaB-alpha. Poly I-C 4-13 matrix metallopeptidase 3 Homo sapiens 46-51 20435591-7 2010 CONCLUSIONS: Poly(I:C) induces the expression of MMP-1 and MMP-3 in human corneal fibroblasts in a manner dependent on activation of the transcription factor NF-kappaB and on IL-1beta secretion. Poly I-C 13-21 matrix metallopeptidase 3 Homo sapiens 59-64 20843335-7 2010 RESULTS: A dose-dependent inhibition of MMP-1, MMP-3, MMP-9, TIMP-1 but not MMP-2 was noted in culture supernatants pretreated with PHT or HPPH prior to LPS challenge. Phenytoin 132-135 matrix metallopeptidase 3 Homo sapiens 47-52 20609072-7 2010 Furthermore, MMP-3 activity that was parallel to c-Fos expression in endometriosis was reduced by melatonin pretreatment as characterized by diminished activator protein (AP)-1 DNA-binding activity. Melatonin 98-107 matrix metallopeptidase 3 Homo sapiens 13-18 20609072-13 2010 Melatonin suppressed MMP-3 activity and amplified apoptosis while regressing endometriosis through a caspase-3 mediated pathway. Melatonin 0-9 matrix metallopeptidase 3 Homo sapiens 21-26 20686355-3 2010 In the latter case, Ets1 molecules bind to palindromic sequences in which two Ets-binding sites (EBS) are separated by four base pairs, for example in the promoters of stromelysin-1 and p53. ethylbenzene 97-100 matrix metallopeptidase 3 Homo sapiens 168-181 20686355-6 2010 Here we report the crystal structure of two Ets1 molecules bound to an EBS palindrome of the stromelysin-1 promoter DNA, providing a plausible explanation for the requirement of exon VII-encoded sequences for Ets1 cooperative DNA binding. ethylbenzene 71-74 matrix metallopeptidase 3 Homo sapiens 93-106 20570834-6 2010 The increase in MMP-1 and MMP-3 was significantly less (p = 0.05; p < 0.01, respectively) in the licofelone group. licofelone 100-110 matrix metallopeptidase 3 Homo sapiens 26-31 20941509-8 2010 Using real-time RT-PCR, it was demonstrated that physiological and supraphysiological doses of 17beta-estradiol suppress mRNA levels of MMP-3 and -13 significantly in articular chondrocytes of female patients. Estradiol 95-111 matrix metallopeptidase 3 Homo sapiens 136-149 20839316-7 2010 PGE(2) decreased mRNA expression for the anti-catabolic factor TIMP-1 while PGF(2alpha) increased mRNAs for catabolic factors MMP-1 and MMP-3. Prostaglandins F 76-79 matrix metallopeptidase 3 Homo sapiens 136-141 20822542-6 2010 The decreases from baseline to week 52 in IL-6, ICAM-1, VEGF, MMP-3, and CRP and increases in IL-12p40 levels were larger in patients receiving placebo infliximab 6 mg/kg +MTX versus infliximab 3 mg/kg + MTX treatment. Methotrexate 172-175 matrix metallopeptidase 3 Homo sapiens 62-67 20822542-8 2010 CONCLUSION: Infliximab + MTX attenuated several inflammatory markers in patients with JIA; larger decreases in ICAM-1, MMP-3, and CRP levels were observed in ACR-Pedi-30 responders versus nonresponders. Methotrexate 25-28 matrix metallopeptidase 3 Homo sapiens 119-124 20619343-10 2010 Pharmacological inhibitors of p38-alpha/beta (SB203580) or p38-alpha/beta/gamma/delta (BIRB-0796) reduced MMP-3 and ADAMTS1 mRNA expression, but neither inhibitor affected MMP-9 levels. SB 203580 46-54 matrix metallopeptidase 3 Homo sapiens 106-111 20619343-10 2010 Pharmacological inhibitors of p38-alpha/beta (SB203580) or p38-alpha/beta/gamma/delta (BIRB-0796) reduced MMP-3 and ADAMTS1 mRNA expression, but neither inhibitor affected MMP-9 levels. doramapimod 87-96 matrix metallopeptidase 3 Homo sapiens 106-111 20630114-13 2010 It was found that, GlcN-HCl and GlcN-S could reduce the expression of both MMP-3 and -13 genes. glcn-hcl 19-27 matrix metallopeptidase 3 Homo sapiens 75-88 20630114-13 2010 It was found that, GlcN-HCl and GlcN-S could reduce the expression of both MMP-3 and -13 genes. Glucosamine 32-38 matrix metallopeptidase 3 Homo sapiens 75-88 20630114-14 2010 The IL-1beta induced-MMP-13 gene expression was decreased maximally by GlcN-S, while the reduction of induced-MMP-3 gene expression was greatest with GlcN-HCl. glcn-hcl 150-158 matrix metallopeptidase 3 Homo sapiens 110-115 20630114-17 2010 GlcN-S and GluN-HCl decreased induced MMP-3 and -13 expressions, while Glc and GlcA increased reduced-AGG and SOX9 expression. Glucosamine 0-6 matrix metallopeptidase 3 Homo sapiens 38-51 20630114-17 2010 GlcN-S and GluN-HCl decreased induced MMP-3 and -13 expressions, while Glc and GlcA increased reduced-AGG and SOX9 expression. glun-hcl 11-19 matrix metallopeptidase 3 Homo sapiens 38-51 20630114-17 2010 GlcN-S and GluN-HCl decreased induced MMP-3 and -13 expressions, while Glc and GlcA increased reduced-AGG and SOX9 expression. Glucose 0-3 matrix metallopeptidase 3 Homo sapiens 38-51 20655856-8 2010 MMP-3 also has enhanced subnanosecond fluctuations in helix A, in the beta-hairpin of strands IV and V, and before and including helix C. Hydrogen exchange protection in the EX2 regime suggests that MMP-3 possesses 2.8 kcal/mol higher folding stability than MMP-12(E219A). Hydrogen 138-146 matrix metallopeptidase 3 Homo sapiens 0-5 20655856-8 2010 MMP-3 also has enhanced subnanosecond fluctuations in helix A, in the beta-hairpin of strands IV and V, and before and including helix C. Hydrogen exchange protection in the EX2 regime suggests that MMP-3 possesses 2.8 kcal/mol higher folding stability than MMP-12(E219A). Hydrogen 138-146 matrix metallopeptidase 3 Homo sapiens 199-204 20661707-0 2010 The inhibitory effect of turmeric curcuminoids on matrix metalloproteinase-3 secretion in human invasive breast carcinoma cells. curcuminoids 34-46 matrix metallopeptidase 3 Homo sapiens 50-76 20661707-3 2010 This study focuses on the comparative effect of Cur, DMC and BDMC on the modulation of MMP-3 activity and its secretion in MDA-MB-231 breast cancer cells. demethoxycurcumin 53-56 matrix metallopeptidase 3 Homo sapiens 87-92 20661707-3 2010 This study focuses on the comparative effect of Cur, DMC and BDMC on the modulation of MMP-3 activity and its secretion in MDA-MB-231 breast cancer cells. bisdemethoxycurcumin 61-65 matrix metallopeptidase 3 Homo sapiens 87-92 20661707-6 2010 ELISA assays showed MMP-3 levels were significantly decreased in all curcuminoid treatments. curcuminoid 69-80 matrix metallopeptidase 3 Homo sapiens 20-25 20661707-7 2010 Using zymography, treatment with non-toxic doses revealed that every curcuminoid compound except Cur reduced MMP-3 levels. curcuminoid 69-80 matrix metallopeptidase 3 Homo sapiens 109-114 20661707-8 2010 Moreover, the result from western blot analysis confirmed that only DMC and BDMC reduced MMP-3 secretion in MDA-MB-231 cells, but Cur did not have any effect. demethoxycurcumin 68-71 matrix metallopeptidase 3 Homo sapiens 89-94 20661707-8 2010 Moreover, the result from western blot analysis confirmed that only DMC and BDMC reduced MMP-3 secretion in MDA-MB-231 cells, but Cur did not have any effect. bisdemethoxycurcumin 76-80 matrix metallopeptidase 3 Homo sapiens 89-94 20661707-11 2010 These results suggest that Cur, DMC, and BDMC may be used as MMP-3 inhibitors to modulate MMP-3 expression. demethoxycurcumin 32-35 matrix metallopeptidase 3 Homo sapiens 61-66 20661707-11 2010 These results suggest that Cur, DMC, and BDMC may be used as MMP-3 inhibitors to modulate MMP-3 expression. demethoxycurcumin 32-35 matrix metallopeptidase 3 Homo sapiens 90-95 20661707-11 2010 These results suggest that Cur, DMC, and BDMC may be used as MMP-3 inhibitors to modulate MMP-3 expression. bisdemethoxycurcumin 41-45 matrix metallopeptidase 3 Homo sapiens 61-66 20661707-11 2010 These results suggest that Cur, DMC, and BDMC may be used as MMP-3 inhibitors to modulate MMP-3 expression. bisdemethoxycurcumin 41-45 matrix metallopeptidase 3 Homo sapiens 90-95 27942289-1 2010 BACKGROUND: This study was to investigate the pathological significance of protein expression of matrix metalloproteinase-1 (MMP1) and matrix metalloproteinase-3 (MMP3) in colon tissues of remission patients of steroid-dependent uncreative colitis (SDUC). Steroids 211-218 matrix metallopeptidase 3 Homo sapiens 135-161 27942289-1 2010 BACKGROUND: This study was to investigate the pathological significance of protein expression of matrix metalloproteinase-1 (MMP1) and matrix metalloproteinase-3 (MMP3) in colon tissues of remission patients of steroid-dependent uncreative colitis (SDUC). Steroids 211-218 matrix metallopeptidase 3 Homo sapiens 163-167 27942289-2 2010 METHODS: To test the possible involvement of MMP-1 and MMP-3 in SDUC, Western- blot and immunohistochemistry were applied to examine the protein expression of MMP-1 and MMP-3 in the colonic healing region from 10 remission patients with SDUC as well as from 10 remission patients with non-SDUC. sduc 64-68 matrix metallopeptidase 3 Homo sapiens 55-60 27942289-5 2010 CONCLUSIONS: Over-expression of MMP-1 and MMP-3 play a critical role in the pathogenesis of SDUC. sduc 92-96 matrix metallopeptidase 3 Homo sapiens 42-47 20419256-5 2010 MMP-3 activity increased by three non-ionic detergents in a dose-dependent manner, and Brij-35 was most effective. Brij 35 87-94 matrix metallopeptidase 3 Homo sapiens 0-5 20353164-8 2010 The LOD for MMP-3 was 0.14 nM in PBS, with a linearity of up to 50 nM. Lead 33-36 matrix metallopeptidase 3 Homo sapiens 12-17 20419256-6 2010 The array-based SPR biosensor was successfully applied to the rapid analysis of dose-dependent MMP-3 activity and its inhibition with tissue inhibitors of metalloproteinase 1 and GM6001, MMP inhibitors. N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide 179-185 matrix metallopeptidase 3 Homo sapiens 95-100 20353164-9 2010 With the use of PBS calibration, MMP-3 was quantified at low nanomolar in undiluted bovine serum. Lead 16-19 matrix metallopeptidase 3 Homo sapiens 33-38 20419256-6 2010 The array-based SPR biosensor was successfully applied to the rapid analysis of dose-dependent MMP-3 activity and its inhibition with tissue inhibitors of metalloproteinase 1 and GM6001, MMP inhibitors. N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide 179-185 matrix metallopeptidase 3 Homo sapiens 95-98 20188714-0 2010 Glycitein inhibits glioma cell invasion through down-regulation of MMP-3 and MMP-9 gene expression. glycitein 0-9 matrix metallopeptidase 3 Homo sapiens 67-72 20188714-3 2010 In the present study, we found that glycitein, a bacterial metabolite of the isoflavone glycitin, inhibits the expression of MMP-3 and MMP-9 at promoter, mRNA, and protein levels in PMA-stimulated U87MG human astroglioma cells. Isoflavones 77-87 matrix metallopeptidase 3 Homo sapiens 125-130 20188714-3 2010 In the present study, we found that glycitein, a bacterial metabolite of the isoflavone glycitin, inhibits the expression of MMP-3 and MMP-9 at promoter, mRNA, and protein levels in PMA-stimulated U87MG human astroglioma cells. glycitin 88-96 matrix metallopeptidase 3 Homo sapiens 125-130 20188714-5 2010 A subsequent Matrigel invasion assay revealed that glycitein suppresses the in vitro invasiveness of glioma cells, which may be at least partly due to the glycitein-mediated inhibition of MMP-3 and MMP-9. glycitein 51-60 matrix metallopeptidase 3 Homo sapiens 188-193 20188714-5 2010 A subsequent Matrigel invasion assay revealed that glycitein suppresses the in vitro invasiveness of glioma cells, which may be at least partly due to the glycitein-mediated inhibition of MMP-3 and MMP-9. glycitein 155-164 matrix metallopeptidase 3 Homo sapiens 188-193 20188714-6 2010 In support of this, treatment of MMP-3- or MMP-9-specific inhibitor significantly suppressed PMA-induced invasion of glioma cells. Tetradecanoylphorbol Acetate 93-96 matrix metallopeptidase 3 Homo sapiens 33-38 20188714-7 2010 Further mechanistic studies revealed that glycitein inhibits the DNA binding and transcriptional activities of NF-kappaB and AP-1, which are important transcription factors for MMP-3 or MMP-9 gene expression. glycitein 42-51 matrix metallopeptidase 3 Homo sapiens 177-182 20188714-8 2010 Furthermore, glycitein suppresses PMA-induced phosphorylation of three types of MAP kinases, which are upstream signaling molecules in MMP gene expressions and NF-kappaB and AP-1 activities in glioma cells. glycitein 13-22 matrix metallopeptidase 3 Homo sapiens 135-138 20188714-8 2010 Furthermore, glycitein suppresses PMA-induced phosphorylation of three types of MAP kinases, which are upstream signaling molecules in MMP gene expressions and NF-kappaB and AP-1 activities in glioma cells. Tetradecanoylphorbol Acetate 34-37 matrix metallopeptidase 3 Homo sapiens 135-138 19835666-1 2010 We demonstrated that circulating antibodies from schizophrenia patients, which interact with cerebral M1 muscarinic acetylcholine receptors (M1 mAChRs), trigger production of nitric oxide (NO), prostaglandin E2 (PGE2) and matrix metalloproteinase-3 (MMP-3), and act as inducers of cyclooxygenase-1 (cox-1) and inducible nitric oxide synthase (iNOS) mRNA expression in the rat frontal cortex. Nitric Oxide 175-187 matrix metallopeptidase 3 Homo sapiens 222-248 19835666-1 2010 We demonstrated that circulating antibodies from schizophrenia patients, which interact with cerebral M1 muscarinic acetylcholine receptors (M1 mAChRs), trigger production of nitric oxide (NO), prostaglandin E2 (PGE2) and matrix metalloproteinase-3 (MMP-3), and act as inducers of cyclooxygenase-1 (cox-1) and inducible nitric oxide synthase (iNOS) mRNA expression in the rat frontal cortex. Nitric Oxide 175-187 matrix metallopeptidase 3 Homo sapiens 250-255 19835666-1 2010 We demonstrated that circulating antibodies from schizophrenia patients, which interact with cerebral M1 muscarinic acetylcholine receptors (M1 mAChRs), trigger production of nitric oxide (NO), prostaglandin E2 (PGE2) and matrix metalloproteinase-3 (MMP-3), and act as inducers of cyclooxygenase-1 (cox-1) and inducible nitric oxide synthase (iNOS) mRNA expression in the rat frontal cortex. Dinoprostone 212-216 matrix metallopeptidase 3 Homo sapiens 222-248 19835666-1 2010 We demonstrated that circulating antibodies from schizophrenia patients, which interact with cerebral M1 muscarinic acetylcholine receptors (M1 mAChRs), trigger production of nitric oxide (NO), prostaglandin E2 (PGE2) and matrix metalloproteinase-3 (MMP-3), and act as inducers of cyclooxygenase-1 (cox-1) and inducible nitric oxide synthase (iNOS) mRNA expression in the rat frontal cortex. Dinoprostone 212-216 matrix metallopeptidase 3 Homo sapiens 250-255 19717156-8 2010 In addition, compared to placebo perindopril significantly reduced latent TGF-beta levels by 14.0+/-4.5ng/ml (p=0.01), active TGF-beta levels by 4+/-1ng/ml (p=0.02), MMP-2 levels by 22+/-6ng/ml (p<0.001), and MMP-3 levels by 5+/-1ng/ml (p<0.001). Perindopril 33-44 matrix metallopeptidase 3 Homo sapiens 212-217 19813262-6 2010 All concentrations of minocycline, but only the highest concentration of doxycycline decreased MMP-3 and MMP-13 expression in synoviocytes but not cartilage, and basal ADAMTS-5 mRNA levels in both synoviocytes and cartilage. Minocycline 22-33 matrix metallopeptidase 3 Homo sapiens 95-100 19813262-6 2010 All concentrations of minocycline, but only the highest concentration of doxycycline decreased MMP-3 and MMP-13 expression in synoviocytes but not cartilage, and basal ADAMTS-5 mRNA levels in both synoviocytes and cartilage. Doxycycline 73-84 matrix metallopeptidase 3 Homo sapiens 95-100 19878610-0 2010 Curcumin suppresses p38 mitogen-activated protein kinase activation, reduces IL-1beta and matrix metalloproteinase-3 and enhances IL-10 in the mucosa of children and adults with inflammatory bowel disease. Curcumin 0-8 matrix metallopeptidase 3 Homo sapiens 90-116 19878610-9 2010 Our aim was to assess the effect of curcumin on key disease mediators p38 mitogen-activated protein kinase (MAPK), IL-1beta, IL-10 and matrix metalloproteinase-3 (MMP-3) in the gut of children and adults with IBD. Curcumin 36-44 matrix metallopeptidase 3 Homo sapiens 163-168 19878610-14 2010 We demonstrate dose-dependent suppression of MMP-3 in CMF with curcumin. Curcumin 63-71 matrix metallopeptidase 3 Homo sapiens 45-50 19874928-0 2010 Hyaluronan oligosaccharide treatment of chondrocytes stimulates expression of both HAS-2 and MMP-3, but by different signaling pathways. hyaluronan oligosaccharide 0-26 matrix metallopeptidase 3 Homo sapiens 93-98 19874928-3 2010 The objective of this study was to determine whether stimulation of HAS-2 and MMP-3 by HA oligosaccharides is due to the activation of a single, cascading pathway or multiple signaling pathways. ha oligosaccharides 87-106 matrix metallopeptidase 3 Homo sapiens 78-83 20188714-3 2010 In the present study, we found that glycitein, a bacterial metabolite of the isoflavone glycitin, inhibits the expression of MMP-3 and MMP-9 at promoter, mRNA, and protein levels in PMA-stimulated U87MG human astroglioma cells. glycitein 36-45 matrix metallopeptidase 3 Homo sapiens 125-130 19836480-6 2010 RESULTS: Recent work has shown that curcumin protects human chondrocytes from the catabolic actions of interleukin-1 beta (IL-1beta) including matrix metalloproteinase (MMP)-3 up-regulation, inhibition of collagen type II and down-regulation of beta1-integrin expression. Curcumin 36-44 matrix metallopeptidase 3 Homo sapiens 143-175 19778329-4 2010 The aim of this study was to investigate whether an association exists between MMP-3 genotypes and gingival enlargement in kidney transplant patients medicated with cyclosporine A. Cyclosporine 165-179 matrix metallopeptidase 3 Homo sapiens 79-84 20836843-10 2010 Similarly, TNFalpha-induced expression of matrix metalloproteinases (MMP1 and MMP3) in synovial fibroblasts from a rheumatoid arthritis patient was suppressed by P-Dex. p-dex 162-167 matrix metallopeptidase 3 Homo sapiens 78-82 20039425-8 2010 CONCLUSION: TCZ combined with MTX reduces systemic bone resorption, cartilage turnover, and proteolytic enzyme MMP-3 levels, which provides evidence of a limitation of joint damage and possible beneficial effects on skeletal structure in patients with established moderate-to-severe RA. Methotrexate 30-33 matrix metallopeptidase 3 Homo sapiens 111-116 19942433-1 2010 We describe a novel single-step method for the purification of stromelysin-1 catalytic domain (SCD) via immobilized metal affinity chromatography under denaturing conditions that inhibit proteolytic activity followed by on-column refolding and spontaneous autolysis of the fusion peptide to yield pure, active stromelysin-1 catalytic domain. Metals 116-121 matrix metallopeptidase 3 Homo sapiens 63-76 19897854-6 2010 Plasmin and MMP-3 activities were significantly reduced by CS in a dose-dependent manner (P < 0.001). cholesteryl sulfate 59-61 matrix metallopeptidase 3 Homo sapiens 12-17 20538267-1 2010 This study was conducted to evaluate the efficacy of hesperetin in regulating interleukin-1beta (IL-1beta)-induced production of the matrix metalloproteinase (MMP)-3 and IL-6 in human synovial cell line, SW982. hesperetin 53-63 matrix metallopeptidase 3 Homo sapiens 133-165 20538267-2 2010 Treatment with hesperetin at 1 or 10 microM significantly (P<0.05) inhibited IL-1beta-induced MMP-3 and IL-6 production when measured by enzyme-linked immunosorbent assay (ELISA). hesperetin 15-25 matrix metallopeptidase 3 Homo sapiens 97-102 22368690-7 2010 Steroid pulse therapy successfully diminished the patient"s pachymeningitis and lowered both RF and MMP-3. Steroids 0-7 matrix metallopeptidase 3 Homo sapiens 100-105 19897854-7 2010 Western blot analysis of the culture media revealed that CS inhibited the conversion by plasmin of MMP-3 from the precursor form to the active form. cholesteryl sulfate 57-59 matrix metallopeptidase 3 Homo sapiens 99-104 19786147-10 2010 Pre-incubation of stigmasterol to IL-1beta-treated cells significantly decreased these effects described above (significant reduction of MMP-3 mRNA in human and mouse, MMP-3 protein in mouse, MMP-13 mRNA in mouse and human, ADAMTS-4 mRNA in human, PGE(2) protein in human and mouse) Finally, stigmasterol was capable of counteracting the IL-1beta-induced NF-kappaB pathway. Stigmasterol 18-30 matrix metallopeptidase 3 Homo sapiens 137-142 19935875-8 2009 The ERK1/2 inhibitor U0126 did not affect contraction, but treatment led to depressed MMP-1, MMP-3, and alpha2 mRNA levels. U 0126 21-26 matrix metallopeptidase 3 Homo sapiens 93-98 20110869-9 2009 The inhibition of MMP3 secretion due to GS plus CS was accompanied by a decrease in TNF-alpha production. Chondroitin Sulfates 48-50 matrix metallopeptidase 3 Homo sapiens 18-22 19935875-6 2009 Treatment with high concentrations of a microtubule depolymerization agent, nocodazole, enhanced early contraction and led to elevated mRNA levels for MMP-3, whereas low concentrations inhibited contraction at later time points and did not affect mRNA levels. Nocodazole 76-86 matrix metallopeptidase 3 Homo sapiens 151-156 20110869-6 2009 Furthermore we have determined the effect of GS and CS alone (100-500 micromol/L each) and in combination on MMP3 mRNA levels and MMP3 secretion in IL-1beta stimulated chondrocytes. Glucosamine 45-47 matrix metallopeptidase 3 Homo sapiens 109-113 20110869-6 2009 Furthermore we have determined the effect of GS and CS alone (100-500 micromol/L each) and in combination on MMP3 mRNA levels and MMP3 secretion in IL-1beta stimulated chondrocytes. Chondroitin Sulfates 52-54 matrix metallopeptidase 3 Homo sapiens 109-113 20110869-8 2009 Similarly a combination of CS and GS was more effective in inhibiting MMP3 gene expression and secretion than the single components. Chondroitin Sulfates 27-29 matrix metallopeptidase 3 Homo sapiens 70-74 20110869-8 2009 Similarly a combination of CS and GS was more effective in inhibiting MMP3 gene expression and secretion than the single components. Glucosamine 34-36 matrix metallopeptidase 3 Homo sapiens 70-74 20110869-9 2009 The inhibition of MMP3 secretion due to GS plus CS was accompanied by a decrease in TNF-alpha production. Glucosamine 40-42 matrix metallopeptidase 3 Homo sapiens 18-22 19830795-4 2009 We adopted the motif sequence of stromelysin-1 and investigated the folding properties of the Trp-labeled peptides WAHEIAHSLGLFHA (STR-W1), AWHEIAHSLGLFHA (STR-W2), AHEIAHSLGWFHA (STR-W11), and AHEIAHSLGLFHWA (STR-W14) in the presence and absence of zinc ions in hydrophobic micellar environments by circular dichroism (CD) measurements. Tryptophan 94-97 matrix metallopeptidase 3 Homo sapiens 33-46 19830795-7 2009 The NMR structural analysis of the apo STR-W14 revealed that the conformation in the C-terminus GXXH region significantly differred between the apo state in the micelle and the reported Zn-bound state of stromelysin-1 in crystal structures. Zinc 186-188 matrix metallopeptidase 3 Homo sapiens 204-217 21172267-0 2009 CC-10004 but not thalidomide or lenalidomide inhibits lamina propria mononuclear cell TNF-alpha and MMP-3 production in patients with inflammatory bowel disease. apremilast 0-8 matrix metallopeptidase 3 Homo sapiens 100-105 19522858-12 2009 The synergistic/additive up-regulation of MMP-3 and TIMP-1 was inhibited by U0126 and SB431542, a Smad pathway inhibitor. U 0126 76-81 matrix metallopeptidase 3 Homo sapiens 42-47 19522858-12 2009 The synergistic/additive up-regulation of MMP-3 and TIMP-1 was inhibited by U0126 and SB431542, a Smad pathway inhibitor. 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide 86-94 matrix metallopeptidase 3 Homo sapiens 42-47 19671596-8 2009 Expression of MMP-2 was significantly reduced by all progestins and MMP-3 by dydrogesterone. Dydrogesterone 77-91 matrix metallopeptidase 3 Homo sapiens 68-73 21172267-2 2009 TNF-alpha driven production of matrix metalloproteinase (MMP)-3 by gut lamina propria mononuclear cells (LPMCs) is a major pathway of tissue injury in IBD; however the effect of thalidomide and newer more potent immunomodulatory derivatives on this pathway has not been studied. Thalidomide 178-189 matrix metallopeptidase 3 Homo sapiens 31-63 19617894-0 2009 Inhibition of MMP-3 activity and invasion of the MDA-MB-231 human invasive breast carcinoma cell line by bioflavonoids. Flavonoids 105-118 matrix metallopeptidase 3 Homo sapiens 14-19 19617894-2 2009 In this study, flavonoids from vegetables and fruits, such as quercetin, kaempferol, genistein, genistin, and daidzein, were tested for their ability to modulate the secretion and activity of MMP-3 in the MDA-MB-231 breast cancer cell line. Flavonoids 15-25 matrix metallopeptidase 3 Homo sapiens 192-197 19617894-11 2009 CONCLUSION: These data show that the flavonols quercetin and kaempferol have higher anti-invasion potency and higher MMP-3 inhibitory activity than isoflavones genistein, genistin and daidzein. Flavonols 37-46 matrix metallopeptidase 3 Homo sapiens 117-122 19617894-2 2009 In this study, flavonoids from vegetables and fruits, such as quercetin, kaempferol, genistein, genistin, and daidzein, were tested for their ability to modulate the secretion and activity of MMP-3 in the MDA-MB-231 breast cancer cell line. Quercetin 62-71 matrix metallopeptidase 3 Homo sapiens 192-197 19617894-11 2009 CONCLUSION: These data show that the flavonols quercetin and kaempferol have higher anti-invasion potency and higher MMP-3 inhibitory activity than isoflavones genistein, genistin and daidzein. Quercetin 47-56 matrix metallopeptidase 3 Homo sapiens 117-122 19617894-2 2009 In this study, flavonoids from vegetables and fruits, such as quercetin, kaempferol, genistein, genistin, and daidzein, were tested for their ability to modulate the secretion and activity of MMP-3 in the MDA-MB-231 breast cancer cell line. kaempferol 73-83 matrix metallopeptidase 3 Homo sapiens 192-197 19617894-11 2009 CONCLUSION: These data show that the flavonols quercetin and kaempferol have higher anti-invasion potency and higher MMP-3 inhibitory activity than isoflavones genistein, genistin and daidzein. kaempferol 61-71 matrix metallopeptidase 3 Homo sapiens 117-122 19617894-2 2009 In this study, flavonoids from vegetables and fruits, such as quercetin, kaempferol, genistein, genistin, and daidzein, were tested for their ability to modulate the secretion and activity of MMP-3 in the MDA-MB-231 breast cancer cell line. Genistein 85-94 matrix metallopeptidase 3 Homo sapiens 192-197 19617894-2 2009 In this study, flavonoids from vegetables and fruits, such as quercetin, kaempferol, genistein, genistin, and daidzein, were tested for their ability to modulate the secretion and activity of MMP-3 in the MDA-MB-231 breast cancer cell line. genistin 96-104 matrix metallopeptidase 3 Homo sapiens 192-197 19617894-2 2009 In this study, flavonoids from vegetables and fruits, such as quercetin, kaempferol, genistein, genistin, and daidzein, were tested for their ability to modulate the secretion and activity of MMP-3 in the MDA-MB-231 breast cancer cell line. daidzein 110-118 matrix metallopeptidase 3 Homo sapiens 192-197 19617894-9 2009 Quercetin and kaempferol also reduced MMP-3 activity in a dose-dependent manner, with IC(50) values in the range of 30 micromol/L and 45 micromol/L, respectively. Quercetin 0-9 matrix metallopeptidase 3 Homo sapiens 38-43 19617894-9 2009 Quercetin and kaempferol also reduced MMP-3 activity in a dose-dependent manner, with IC(50) values in the range of 30 micromol/L and 45 micromol/L, respectively. kaempferol 14-24 matrix metallopeptidase 3 Homo sapiens 38-43 19465391-1 2009 The Stromelysin-1 gene promoter contains a palindrome of two Ets-binding sites (EBS) that bind the p51 and p42 isoforms of the human Ets-1-transcription factor. ethylbenzene 80-83 matrix metallopeptidase 3 Homo sapiens 4-17 19170097-11 2009 BMA resulted in decreased COMP and increased MMP-3 and MMP-13 gene expression. bma 0-3 matrix metallopeptidase 3 Homo sapiens 45-50 19446245-9 2009 Benzene increased MMP-2 and MMP-3 mRNA. Benzene 0-7 matrix metallopeptidase 3 Homo sapiens 28-33 19522467-4 2009 Finally, certain iminodiacetyl-based hydroxamate-benzenesulfonamide conjugates, which were predicted to be active by the 3D-QSAR model, were tested in vitro for MMP3 inhibition; some provided low nanomolar activity. iminodiacetyl-based hydroxamate 17-48 matrix metallopeptidase 3 Homo sapiens 161-165 19522467-4 2009 Finally, certain iminodiacetyl-based hydroxamate-benzenesulfonamide conjugates, which were predicted to be active by the 3D-QSAR model, were tested in vitro for MMP3 inhibition; some provided low nanomolar activity. benzenesulfonamide 49-67 matrix metallopeptidase 3 Homo sapiens 161-165 19542470-9 2009 By chelating Zn(2+), S100A12 significantly inhibited MMP-2, MMP-9, and MMP-3, and the Zn(2+)-induced S100A12 complex colocalized with these in foam cells in human atheroma. Zinc 13-15 matrix metallopeptidase 3 Homo sapiens 71-76 19542470-9 2009 By chelating Zn(2+), S100A12 significantly inhibited MMP-2, MMP-9, and MMP-3, and the Zn(2+)-induced S100A12 complex colocalized with these in foam cells in human atheroma. Zinc 86-88 matrix metallopeptidase 3 Homo sapiens 71-76 19465391-5 2009 The differential stoichiometry of the two Ets-1 isoforms arises from the Stromelysin-1 EBS palindrome. ethylbenzene 87-90 matrix metallopeptidase 3 Homo sapiens 73-86 19361540-6 2009 Furthermore, co-exposure of HEK293 cells to CTN and MAPK pathway inhibitors demonstrated that CTN increased the levels of Gadd45 beta mRNA through ERK1/2 signaling pathway and up-regulated the MMP3 transcripts majorly via JNK pathway. Citrinin 44-47 matrix metallopeptidase 3 Homo sapiens 193-197 19361540-6 2009 Furthermore, co-exposure of HEK293 cells to CTN and MAPK pathway inhibitors demonstrated that CTN increased the levels of Gadd45 beta mRNA through ERK1/2 signaling pathway and up-regulated the MMP3 transcripts majorly via JNK pathway. Citrinin 94-97 matrix metallopeptidase 3 Homo sapiens 193-197 19330880-5 2009 Furthermore, these phlorotannin derivatives (1, 2) inhibited mRNA gene and protein levels of matrix metalloproteinase (MMP-1, MMP-3, and MMP-13), iNOS and COX-2 in casein zymography, Western blot and reverse transcriptase-polymerase chain reaction (RT-PCR) assays. phlorotannin 19-31 matrix metallopeptidase 3 Homo sapiens 126-131 19330880-7 2009 These results suggested the phlorotannin derivatives (1, 2) could promote cell differentiation, attenuate MMP-1, MMP-3, MMP-13 expressions, and inflammatory response via MAPK pathway in chronic articular diseases. phlorotannin 28-40 matrix metallopeptidase 3 Homo sapiens 113-118 19268776-7 2009 Doxycycline treatment reduced aortic wall MMP-3 and MMP-25 messenger RNA expression (P < .045 and P < .014, respectively), selectively suppressed neutrophil collagenase and gelatinase (MMP-8 and MMP-9) protein levels (P < .013 and <.004, respectively), and increased protein levels of the protease inhibitors tissue inhibitor of metalloproteinase 1 and cystatin C (P < .029). Doxycycline 0-11 matrix metallopeptidase 3 Homo sapiens 42-47 19212832-2 2009 Here, we report that lysophosphatidic acid produced by ATX promotes the secretion of matrix metalloproteinase-3 (MMP3) from the human fibrosarcoma cell line HT-1080. lysophosphatidic acid 21-42 matrix metallopeptidase 3 Homo sapiens 85-111 19212832-2 2009 Here, we report that lysophosphatidic acid produced by ATX promotes the secretion of matrix metalloproteinase-3 (MMP3) from the human fibrosarcoma cell line HT-1080. lysophosphatidic acid 21-42 matrix metallopeptidase 3 Homo sapiens 113-117 21172267-6 2009 RESULTS: CC-10004 significantly reduced both TNF-alpha production and MMP-3 production by cultured LPMCs. lpmcs 99-104 matrix metallopeptidase 3 Homo sapiens 70-75 18971237-7 2009 A marked upregulation of MMP-1 and MMP-3 and moderately increased staining for TIMP-2 and TIMP-3 was found in epithelial cells and subepithelial stromal cells of latanoprost-treated eyes. Latanoprost 162-173 matrix metallopeptidase 3 Homo sapiens 35-40 18629644-7 2009 Propionate and butyrate significantly attenuated IL-1 beta- and TNF-alpha-induced MMP-1 and MMP-3 secretion. Butyrates 15-23 matrix metallopeptidase 3 Homo sapiens 92-97 18629644-10 2009 Trichostatin A, a histone-deacetylase inhibitor, reduced IL-1 beta-induced MMP-1 and MMP-3 mRNA expression, and suppressed TNF-alpha-induced MMP-3 mRNA expression. trichostatin A 0-14 matrix metallopeptidase 3 Homo sapiens 85-90 18629644-10 2009 Trichostatin A, a histone-deacetylase inhibitor, reduced IL-1 beta-induced MMP-1 and MMP-3 mRNA expression, and suppressed TNF-alpha-induced MMP-3 mRNA expression. trichostatin A 0-14 matrix metallopeptidase 3 Homo sapiens 141-146 18971237-10 2009 The upregulation of MMP-1 and MMP-3 in latanoprost-treated eyes might explain the reduced extracellular matrix accumulation in the conjunctival stroma. Latanoprost 39-50 matrix metallopeptidase 3 Homo sapiens 30-35 19889203-8 2009 RESULTS: Treatment with curcumin and resveratrol suppressed NF-kappaB-regulated gene products involved in inflammation (cyclooxygenase-2, matrix metalloproteinase (MMP)-3, MMP-9, vascular endothelial growth factor), inhibited apoptosis (Bcl-2, Bcl-xL, and TNF-alpha receptor-associated factor 1) and prevented activation of caspase-3. Curcumin 24-32 matrix metallopeptidase 3 Homo sapiens 138-170 19022222-2 2009 In a study on the stromelysin-1 promoter, we showed that Ets-1 binds cooperatively to two Ets-binding sites (EBS) organized in palindrome, thereby circumventing the need for a binding partner to counteract autoinhibition. ethylbenzene 109-112 matrix metallopeptidase 3 Homo sapiens 18-31 19022222-6 2009 Thus, the cooperative binding model that we initially proposed for the stromelysin-1 promoter may be a general mechanism of Ets-1 binding to palindromic EBS separated by 4bp and a way to counteract binding site degeneracy. ethylbenzene 153-156 matrix metallopeptidase 3 Homo sapiens 71-84 19889203-8 2009 RESULTS: Treatment with curcumin and resveratrol suppressed NF-kappaB-regulated gene products involved in inflammation (cyclooxygenase-2, matrix metalloproteinase (MMP)-3, MMP-9, vascular endothelial growth factor), inhibited apoptosis (Bcl-2, Bcl-xL, and TNF-alpha receptor-associated factor 1) and prevented activation of caspase-3. Resveratrol 37-48 matrix metallopeptidase 3 Homo sapiens 138-170 19678938-12 2009 RasGRF1 overexpression in FLS induced production of MMP-3, and RasGRF1 silencing inhibited spontaneous MMP-3 production. CHEMBL1232769 26-29 matrix metallopeptidase 3 Homo sapiens 52-57 19906289-13 2009 Incubation with IL-1Ra, dexamethasone, or TNF inhibitors significantly decreased levels of all forms of MMP-3 (P < 0.05). Dexamethasone 24-37 matrix metallopeptidase 3 Homo sapiens 104-109 19906289-14 2009 Dexamethasone significantly decreased the ratio of active MMP-3 to total MMP-3 activity. Dexamethasone 0-13 matrix metallopeptidase 3 Homo sapiens 58-63 20067598-3 2009 In a recent issue of Arthritis Research & Therapy, Abreu and colleagues link a well-studied oncogene, Ras, with expression of matrix metalloproteinase-3 (MMP-3) in RA. Adenosine Monophosphate 41-44 matrix metallopeptidase 3 Homo sapiens 130-156 19906289-14 2009 Dexamethasone significantly decreased the ratio of active MMP-3 to total MMP-3 activity. Dexamethasone 0-13 matrix metallopeptidase 3 Homo sapiens 73-78 20067598-3 2009 In a recent issue of Arthritis Research & Therapy, Abreu and colleagues link a well-studied oncogene, Ras, with expression of matrix metalloproteinase-3 (MMP-3) in RA. Adenosine Monophosphate 41-44 matrix metallopeptidase 3 Homo sapiens 158-163 19906289-16 2009 CONCLUSIONS: MMP-3 appears to play a greater role than MMP-1 in DH resorption. 2-(3,5-dihydroxyphenyl)-6-hydroxybenzothiazole 64-66 matrix metallopeptidase 3 Homo sapiens 13-18 19906289-17 2009 Dexamethasone, IL-1-Ra and TNF inhibitor decreased active MMP-3, indicating that the clinical use of these drugs may affect the resorption of DH under certain conditions. Dexamethasone 0-13 matrix metallopeptidase 3 Homo sapiens 58-63 19906289-17 2009 Dexamethasone, IL-1-Ra and TNF inhibitor decreased active MMP-3, indicating that the clinical use of these drugs may affect the resorption of DH under certain conditions. 2-(3,5-dihydroxyphenyl)-6-hydroxybenzothiazole 142-144 matrix metallopeptidase 3 Homo sapiens 58-63 19056796-0 2009 Cordycepin inhibits IL-1beta-induced MMP-1 and MMP-3 expression in rheumatoid arthritis synovial fibroblasts. cordycepin 0-10 matrix metallopeptidase 3 Homo sapiens 47-52 19056796-3 2009 In this study, we aimed at the inhibitory effect of cordycepin on IL-1beta-induced MMP-1 and MMP-3 expression as well as the molecular basis using RA synovial fibroblasts (RASFs). cordycepin 52-62 matrix metallopeptidase 3 Homo sapiens 93-98 19056796-9 2009 RESULTS: Cordycepin inhibited IL-1beta-induced MMP-1 and MMP-3 expressions in RASFs in a dose-dependent manner. cordycepin 9-19 matrix metallopeptidase 3 Homo sapiens 57-62 18606398-6 2008 In this study we provide experimental evidence that resveratrol inhibits the expression of VEGF, MMP-3, MMP-9 and COX-2 in human articular chondrocytes stimulated with the pro-inflammatory cytokine IL-1beta. Resveratrol 52-63 matrix metallopeptidase 3 Homo sapiens 97-102 19126387-7 2009 CONCLUSION: TWEAK can induce RA FLS to synthesize MMP-3 and damage the articular bone and cartilage directly. Radium 29-31 matrix metallopeptidase 3 Homo sapiens 50-55 18223264-6 2008 In contrast, PGE2 upregulated, and had no effect, on BCP crystal stimulated MMP-3 and MMP-1 mRNA expression, respectively. Dinoprostone 13-17 matrix metallopeptidase 3 Homo sapiens 76-81 18223264-6 2008 In contrast, PGE2 upregulated, and had no effect, on BCP crystal stimulated MMP-3 and MMP-1 mRNA expression, respectively. bcp 53-56 matrix metallopeptidase 3 Homo sapiens 76-81 18223264-9 2008 PGE2 had contrasting effects on BCP crystal-stimulated MMP-3 and MMP-13 mRNA expression, mediated in an EP2/EP4/cAMP-dependent manner, suggesting that PGE2 may have beneficial as well as deleterious effects in BCP crystal-associated osteoarthritis. Dinoprostone 0-4 matrix metallopeptidase 3 Homo sapiens 55-60 18223264-9 2008 PGE2 had contrasting effects on BCP crystal-stimulated MMP-3 and MMP-13 mRNA expression, mediated in an EP2/EP4/cAMP-dependent manner, suggesting that PGE2 may have beneficial as well as deleterious effects in BCP crystal-associated osteoarthritis. bcp 32-35 matrix metallopeptidase 3 Homo sapiens 55-60 18979629-7 2008 Similarly, the metal-dependent aminopeptidase amino peptidase N did not turnover N-terminal isoAsp-containing substrates, nor could the endopeptidase matrix metalloproteinase 3 (MMP 3) hydrolyze a serum amyloid A protein-like substrate if the sequence contained isoAsp instead of Asp. Metals 15-20 matrix metallopeptidase 3 Homo sapiens 178-183 18629644-7 2009 Propionate and butyrate significantly attenuated IL-1 beta- and TNF-alpha-induced MMP-1 and MMP-3 secretion. Propionates 0-10 matrix metallopeptidase 3 Homo sapiens 92-97 18496696-3 2008 Here we show that epigallocatechin-3-Gallate (EGCG) suppresses TNF-alpha-induced production of MMP-1 and MMP-3 in RA synovial fibroblasts, which was accompanied by inhibition of mitogen activated protein kinase (MAPK) and activator protein-1 (AP-1) pathways. epigallocatechin gallate 18-44 matrix metallopeptidase 3 Homo sapiens 105-110 18496696-3 2008 Here we show that epigallocatechin-3-Gallate (EGCG) suppresses TNF-alpha-induced production of MMP-1 and MMP-3 in RA synovial fibroblasts, which was accompanied by inhibition of mitogen activated protein kinase (MAPK) and activator protein-1 (AP-1) pathways. epigallocatechin gallate 46-50 matrix metallopeptidase 3 Homo sapiens 105-110 18496696-4 2008 EGCG treatment resulted in dose-dependent inhibition of TNF-alpha-induced production of MMP-1 and MMP-3 at the protein and mRNA levels in RA synovial fibroblast. epigallocatechin gallate 0-4 matrix metallopeptidase 3 Homo sapiens 98-103 18785308-10 2008 Change in CTX-II at 12 weeks also correlated significantly with change in MMP-3 (r=0.41; p<0.0001). ctx-ii 10-16 matrix metallopeptidase 3 Homo sapiens 74-79 18566755-8 2008 Cytochalasin D treatment immediately following release of gels inhibited contraction in a dose-dependent manner as well as prevented upregulation of MMP-1, MMP-3, and alpha2 integrin mRNA levels in contracting gels. Cytochalasin D 0-14 matrix metallopeptidase 3 Homo sapiens 156-161 18810583-10 2008 Among the KD patients, serum MMP-3 levels were higher in children with genotypes CG+GG compared to the CC group, but this difference was not significant. cysteinylglycine 81-83 matrix metallopeptidase 3 Homo sapiens 29-34 18340449-10 2008 The chondroprotective effect of GLN through the decrease in MMP-3 production and stimulation of proteoglycan synthesis may follow another potential signaling pathway of Akt. Glucosamine 32-35 matrix metallopeptidase 3 Homo sapiens 60-65 18340449-1 2008 The purpose of the present study was to elucidate the possible signal transduction pathway involved in the underlying mechanism of glucosamine (GLN)"s influence on the gene expression of matrix metalloproteinases (MMPs) in chondrocytes stimulated with IL-1beta. Glucosamine 131-142 matrix metallopeptidase 3 Homo sapiens 214-218 18340449-1 2008 The purpose of the present study was to elucidate the possible signal transduction pathway involved in the underlying mechanism of glucosamine (GLN)"s influence on the gene expression of matrix metalloproteinases (MMPs) in chondrocytes stimulated with IL-1beta. Glucosamine 144-147 matrix metallopeptidase 3 Homo sapiens 214-218 18340449-2 2008 Using chondrosarcoma cells stimulated with IL-1beta, the effects of GLN on the mRNA and protein levels of MMP-3, the activation of JNK, ERK, p38, NF-kappaB, and AP-1, the nuclear translocation of NF-kappaB/Rel family members, and PI3-kinase/Akt activation were studied. Glucosamine 68-71 matrix metallopeptidase 3 Homo sapiens 106-111 18340449-3 2008 GLN inhibited the expression and the synthesis of MMP-3 induced by IL-1beta, and that inhibition was mediated at the level of transcription involving both the NF-kappaB and AP-1 transcription factors. Glucosamine 0-3 matrix metallopeptidase 3 Homo sapiens 50-55 18629001-6 2008 Recombinant NR1 glycine binding protein was used to identify MMP-3 cleavage sites within the extracellular S1 and S2-domains. Glycine 16-23 matrix metallopeptidase 3 Homo sapiens 61-66 18080123-4 2008 The inhibitors of NF-kappaB, JNK and p38, but not ERK, decreased IL-1beta-enhanced MMP-1, MMP-3 and NO production, respectively, and 100 nM celecoxib down-regulated the phosphorylation of NF-kappaB and JNK but has no effect on either p38 or ERK. Celecoxib 140-149 matrix metallopeptidase 3 Homo sapiens 90-95 18554254-1 2008 A target-ligand QSAR approach using autocorrelation formalism was developed for modeling the inhibitory potency (pIC(50)) toward matrix metalloproteinases (MMP-1, MMP-2, MMP-3, MMP-9, and MMP-13) of N-hydroxy-2-[(phenylsulfonyl)amino]acetamide derivatives. formalism 52-61 matrix metallopeptidase 3 Homo sapiens 170-175 18080123-2 2008 Celecoxib at 100 nM reduced the IL-1beta-induced productions of MMP-1, MMP-3, iNOS, and NO, whereas indomethacin at 100 nM showed no effect. Celecoxib 0-9 matrix metallopeptidase 3 Homo sapiens 71-76 18280068-2 2008 This study describes the formulation of xanthan wafers containing a selective, insoluble MMP-3 inhibitor (UK-370,106) and a non-ionic surfactant, designed to release accurate doses of UK-370,106 directly to a suppurating wound bed. xanthan gum 40-47 matrix metallopeptidase 3 Homo sapiens 89-94 18080123-5 2008 Celecoxib has inhibitory effects on MMP-1, MMP-3 and NO productions, suggesting the protective roles directly on articular chondrocytes. Celecoxib 0-9 matrix metallopeptidase 3 Homo sapiens 43-48 18262287-1 2008 MMP-3 is capable of degrading a variety of proteins, including agrin, which plays a critical role in neuromuscular signalling by controlling acetylcholine receptor clustering. Acetylcholine 141-154 matrix metallopeptidase 3 Homo sapiens 0-5 18080321-3 2008 Our experiments showed that protein production and mRNA expressions of MMP-1, MMP-3, MMP-13, IL-8, MCP-1, and RANTES were downregulated by treatment with glucosamine in HPSFs. Glucosamine 154-165 matrix metallopeptidase 3 Homo sapiens 78-83 18275497-3 2008 METHODS: Serum levels of MMP-3 were measured by enzyme immunoassay in 150 HD patients, 90 without DRA and 60 with DRA, before HD. dra 98-101 matrix metallopeptidase 3 Homo sapiens 25-30 18275497-3 2008 METHODS: Serum levels of MMP-3 were measured by enzyme immunoassay in 150 HD patients, 90 without DRA and 60 with DRA, before HD. dra 114-117 matrix metallopeptidase 3 Homo sapiens 25-30 18275497-5 2008 RESULTS: Serum levels of MMP-3 were significantly higher in HD patients with DRA than in HD patients without DRA (258.2 +/- 118.1 vs 201.5 +/- 98.4 pg/mL, P = 0.0017), and both levels were significantly higher than those of healthy subjects (45.6 +/- 13.4 pg/mL, P < 0.0001). dra 77-80 matrix metallopeptidase 3 Homo sapiens 25-30 18275497-5 2008 RESULTS: Serum levels of MMP-3 were significantly higher in HD patients with DRA than in HD patients without DRA (258.2 +/- 118.1 vs 201.5 +/- 98.4 pg/mL, P = 0.0017), and both levels were significantly higher than those of healthy subjects (45.6 +/- 13.4 pg/mL, P < 0.0001). dra 109-112 matrix metallopeptidase 3 Homo sapiens 25-30 18275497-7 2008 Moreover, serum MMP-3 levels significantly correlated with serum BMG levels in HD patients without DRA (r = 0.341, P = 0.0012), but not in HD patients with DRA. dra 99-102 matrix metallopeptidase 3 Homo sapiens 16-21 18216291-4 2008 In cultured leiomyoma cells, CDB-2914 treatment at concentrations greater than or equal to 10(-8) M significantly increased EMMPRIN, MMP-1 and MMP-8 protein contents and MMP-1, MMP-2, MMP-3 and MMP-9 mRNA levels, and activity of MMP-1, MMP-2, MMP-3 and MMP-9 in the medium. cdb 29-32 matrix metallopeptidase 3 Homo sapiens 184-189 18216291-4 2008 In cultured leiomyoma cells, CDB-2914 treatment at concentrations greater than or equal to 10(-8) M significantly increased EMMPRIN, MMP-1 and MMP-8 protein contents and MMP-1, MMP-2, MMP-3 and MMP-9 mRNA levels, and activity of MMP-1, MMP-2, MMP-3 and MMP-9 in the medium. cdb 29-32 matrix metallopeptidase 3 Homo sapiens 243-248 18029177-1 2007 The design and synthesis of a series of highly selective hydroxamate inhibitors of stromelysin-1 (MMP-3) is described. hydroxamate 57-68 matrix metallopeptidase 3 Homo sapiens 83-96 18063811-7 2008 Pathophysiologic conditions such as serum starvation or heat shock also induced activation of endogenous FOXO3a, leading to activation of MMP-3 and apoptosis, which was reversed by GM6001. N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide 181-187 matrix metallopeptidase 3 Homo sapiens 138-143 18234553-7 2008 MMP-3 was associated with patient age (p<0.001), creatinine (p<0.001) and was higher in males (p<0.001) and hypertensives (p<0.001). Creatinine 52-62 matrix metallopeptidase 3 Homo sapiens 0-5 18536179-12 2008 The aim of this study was to examine if all-trans-retinoic acid (ATRA) effects MMP-1, MMP-2, MMP-3 and MMP-14 gene expression in fibroblasts cultured in vitro. Tretinoin 40-63 matrix metallopeptidase 3 Homo sapiens 93-98 18536179-12 2008 The aim of this study was to examine if all-trans-retinoic acid (ATRA) effects MMP-1, MMP-2, MMP-3 and MMP-14 gene expression in fibroblasts cultured in vitro. Tretinoin 65-69 matrix metallopeptidase 3 Homo sapiens 93-98 18380979-1 2008 OBJECTIVE: To investigate the distribution of antimicrobial agent STR-1 of nanometer level which was incorporated with ball-grinding method in the polymethylmethacrylate (PMMA) denture base, and to study the release mode of silver ions from the base. Polymethyl Methacrylate 147-169 matrix metallopeptidase 3 Homo sapiens 66-71 18380979-1 2008 OBJECTIVE: To investigate the distribution of antimicrobial agent STR-1 of nanometer level which was incorporated with ball-grinding method in the polymethylmethacrylate (PMMA) denture base, and to study the release mode of silver ions from the base. Polymethyl Methacrylate 171-175 matrix metallopeptidase 3 Homo sapiens 66-71 18380979-1 2008 OBJECTIVE: To investigate the distribution of antimicrobial agent STR-1 of nanometer level which was incorporated with ball-grinding method in the polymethylmethacrylate (PMMA) denture base, and to study the release mode of silver ions from the base. Silver 224-230 matrix metallopeptidase 3 Homo sapiens 66-71 17940116-10 2008 SB203580 suppressed TNF-alpha- and IL-1beta-induced MMP-1 and MMP-3 secretion by severalfold. SB 203580 0-8 matrix metallopeptidase 3 Homo sapiens 62-67 18245904-1 2008 OBJECTIVE: To examine the expression of MMP-3 and TIMP-1 in the synovial fluid in knee joints with osteoarthritis before and after being treated with hyaluronic acid(HA), glucosamine sulfate(GS) and arthroscopic de bridment(AD), and to explore the therapeutic mechanism. Hyaluronic Acid 150-165 matrix metallopeptidase 3 Homo sapiens 40-45 18029177-1 2007 The design and synthesis of a series of highly selective hydroxamate inhibitors of stromelysin-1 (MMP-3) is described. hydroxamate 57-68 matrix metallopeptidase 3 Homo sapiens 98-103 18029177-2 2007 Substitution of a 4-biaryl piperidine sulfonamide core, which binds at the S1" subsite of MMP-3, was optimised to give potent inhibitors of MMP-3, with greater than 300-fold selectivity over MMP-1, MMP-2, MMP-9 and MMP-14. 4-biaryl piperidine sulfonamide 18-49 matrix metallopeptidase 3 Homo sapiens 90-95 18029177-2 2007 Substitution of a 4-biaryl piperidine sulfonamide core, which binds at the S1" subsite of MMP-3, was optimised to give potent inhibitors of MMP-3, with greater than 300-fold selectivity over MMP-1, MMP-2, MMP-9 and MMP-14. 4-biaryl piperidine sulfonamide 18-49 matrix metallopeptidase 3 Homo sapiens 140-145 17525979-5 2007 Here we show that the fluorogenic compound (M2300) can be used to perform in vivo proteolytic imaging of the frog neuromuscular junction to directly measure the activity state of MMP3. m2300 44-49 matrix metallopeptidase 3 Homo sapiens 179-183 18006772-12 2007 Whereas the estimated MTDs of temozolomide for Str1 and Str2 were 562 and 407 mg/m(2), respectively, the doses recommended for phase II investigations are 472 and 355 mg/m(2), respectively. Temozolomide 30-42 matrix metallopeptidase 3 Homo sapiens 47-51 17907159-12 2007 In a subset of 50 patients who were treated with methotrexate (MTX) during the followup period, median serum MMP-3 levels decreased after the initiation of MTX therapy (P = 0.0003). Methotrexate 49-61 matrix metallopeptidase 3 Homo sapiens 109-114 17907159-12 2007 In a subset of 50 patients who were treated with methotrexate (MTX) during the followup period, median serum MMP-3 levels decreased after the initiation of MTX therapy (P = 0.0003). Methotrexate 63-66 matrix metallopeptidase 3 Homo sapiens 109-114 17907159-12 2007 In a subset of 50 patients who were treated with methotrexate (MTX) during the followup period, median serum MMP-3 levels decreased after the initiation of MTX therapy (P = 0.0003). Methotrexate 156-159 matrix metallopeptidase 3 Homo sapiens 109-114 17907159-13 2007 CONCLUSION: These results indicate that biochemical markers are useful predictors of radiographic progression in RA and that serum MMP-3 levels decrease significantly with MTX therapy. Methotrexate 172-175 matrix metallopeptidase 3 Homo sapiens 131-136 21783819-4 2007 The expression of human matrix metalloproteinase-3 (MMP-3), a Stats-inducible gene, was found to be up-regulated in human HK-2 cells exposed to cadmium, and suppressed by preincubation with SB203580. Cadmium 144-151 matrix metallopeptidase 3 Homo sapiens 24-50 21783819-4 2007 The expression of human matrix metalloproteinase-3 (MMP-3), a Stats-inducible gene, was found to be up-regulated in human HK-2 cells exposed to cadmium, and suppressed by preincubation with SB203580. Cadmium 144-151 matrix metallopeptidase 3 Homo sapiens 52-57 21783819-4 2007 The expression of human matrix metalloproteinase-3 (MMP-3), a Stats-inducible gene, was found to be up-regulated in human HK-2 cells exposed to cadmium, and suppressed by preincubation with SB203580. SB 203580 190-198 matrix metallopeptidase 3 Homo sapiens 24-50 21783819-4 2007 The expression of human matrix metalloproteinase-3 (MMP-3), a Stats-inducible gene, was found to be up-regulated in human HK-2 cells exposed to cadmium, and suppressed by preincubation with SB203580. SB 203580 190-198 matrix metallopeptidase 3 Homo sapiens 52-57 17525979-7 2007 Blocking presynaptic activity via denervation, or TTX nerve blockade, results in a decreased level of active MMP3 at the neuromuscular junction. Tetrodotoxin 50-53 matrix metallopeptidase 3 Homo sapiens 109-113 17890378-1 2007 Strictosidine beta-D-glucosidase (SG) follows strictosidine synthase (STR1) in the production of the reactive intermediate required for the formation of the large family of monoterpenoid indole alkaloids in plants. Monoterpenes 173-186 matrix metallopeptidase 3 Homo sapiens 70-74 17876544-10 2007 Inhibitors for ERK (PD98059 and U0216) and p38 MAPK (SB203580) significantly reduced the IL-17F-induced IL-6, IL-8, LIF, MMP-1, and MMP-3 secretion. u0216 32-37 matrix metallopeptidase 3 Homo sapiens 132-137 17876544-10 2007 Inhibitors for ERK (PD98059 and U0216) and p38 MAPK (SB203580) significantly reduced the IL-17F-induced IL-6, IL-8, LIF, MMP-1, and MMP-3 secretion. SB 203580 53-61 matrix metallopeptidase 3 Homo sapiens 132-137 17890378-1 2007 Strictosidine beta-D-glucosidase (SG) follows strictosidine synthase (STR1) in the production of the reactive intermediate required for the formation of the large family of monoterpenoid indole alkaloids in plants. Indole Alkaloids 187-203 matrix metallopeptidase 3 Homo sapiens 70-74 17552048-4 2007 RESULTS: Infliximab plus MTX treatment resulted in more rapid decreases in levels of matrix metalloproteinase-3 (MMP-3), intercellular cell adhesion molecule-1, interleukin 8 (IL-8), and tumor necrosis factor-a than treatment with MTX alone. Methotrexate 25-28 matrix metallopeptidase 3 Homo sapiens 85-111 17631696-9 2007 RESULTS: During the 3-week treatment period with nimesulide 100 mg b.i.d., both scavenger GST and the TIMP-1/MMP-3 ratio significantly increased. nimesulide 49-59 matrix metallopeptidase 3 Homo sapiens 109-114 17617837-4 2007 Antisense oligodeoxynucleotides (AODNs) of MMP-3 were used to transfect OSCC (OECM-1 and SCC-9) and esophageal carcinoma (CE81T/VGH) cell lines, and their growth was subsequently analyzed by XTT and soft-agar colony assay. Oligodeoxyribonucleotides 10-31 matrix metallopeptidase 3 Homo sapiens 43-48 17583333-2 2007 [PtCl2(SMP)] and [Pt(dimethylmalonato)(SMP)], characterized by the bisphosphonate-analogue ligand diethyl[(methylsulfinyl)methyl]phosphonate (SMP), are slight inhibitors of MMP-2 (IC50 = 258 +/- 38 and 123 +/- 14 microM, respectively) but markedly inhibit MMP-9 (IC50 = 35.5 +/- 6 and 17 +/- 4 microM), MMP-3 (IC50 = 5.3 +/- 2.9 and 4.4 +/- 2.2 microM), and MMP-12 (IC50 = 10.8 +/- 3 and 6.2 +/- 1.8 microM). pt(dimethylmalonato) 18-38 matrix metallopeptidase 3 Homo sapiens 303-308 17591882-8 2007 The p38 MAP kinase inhibitor SB202190 diminished MMP-3 induction by TNFalpha at all times and at 24 hours by IL-1alpha but potentiated the IL-1alpha-induced increase in MMP-3 at later times. 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole 29-37 matrix metallopeptidase 3 Homo sapiens 49-54 17591882-8 2007 The p38 MAP kinase inhibitor SB202190 diminished MMP-3 induction by TNFalpha at all times and at 24 hours by IL-1alpha but potentiated the IL-1alpha-induced increase in MMP-3 at later times. 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole 29-37 matrix metallopeptidase 3 Homo sapiens 169-174 17608586-8 2007 The lower hydrocortisone concentration induced a 23-fold increase in MMP-3 gene expression, whereas the higher concentration induced less upregulation; however, protein expression was regulated similarly by both hydrocortisone concentrations. Hydrocortisone 10-24 matrix metallopeptidase 3 Homo sapiens 69-74 17552048-4 2007 RESULTS: Infliximab plus MTX treatment resulted in more rapid decreases in levels of matrix metalloproteinase-3 (MMP-3), intercellular cell adhesion molecule-1, interleukin 8 (IL-8), and tumor necrosis factor-a than treatment with MTX alone. Methotrexate 25-28 matrix metallopeptidase 3 Homo sapiens 113-118 17552048-9 2007 MMP-3 levels at different timepoints were consistently associated with clinical improvements at Week 54 in the infliximab plus MTX group, while increases in IL-8 levels correlated with a worsening in vdHSS at Week 54 in the MTX-alone group. Methotrexate 127-130 matrix metallopeptidase 3 Homo sapiens 0-5 17346934-12 2007 RESULTS: The results showed that obovatol stimulated type I procollagen, TGF-beta, and Smad expression and inhibited matrix metalloproteinase-3 (MMP-3) in dose-dependent manner (1-5muM) in UVB-irradiated human fibroblast cells. obovatol 33-41 matrix metallopeptidase 3 Homo sapiens 117-143 17530713-12 2007 MMP-3 was primarily contributory in patients who already had substantial baseline damage (>10 mSASSS units). msasss 97-103 matrix metallopeptidase 3 Homo sapiens 0-5 17672933-1 2007 BACKGROUND & OBJECTIVE: Matrix metalloproteinases (MMPs) are key enzymes involved in tumor development, invasion and metastasis. Adenosine Monophosphate 12-15 matrix metallopeptidase 3 Homo sapiens 55-59 17346934-12 2007 RESULTS: The results showed that obovatol stimulated type I procollagen, TGF-beta, and Smad expression and inhibited matrix metalloproteinase-3 (MMP-3) in dose-dependent manner (1-5muM) in UVB-irradiated human fibroblast cells. obovatol 33-41 matrix metallopeptidase 3 Homo sapiens 145-150 17218328-4 2007 RESULTS: Inhibition of NF-kappaB by a novel agent, RO100 at a dose of 0.1 microM, exerted significant (P < 0.05) repression of IL-6, MMP-1 and MMP-3 production in OA-SF. ro100 51-56 matrix metallopeptidase 3 Homo sapiens 146-151 17319946-7 2007 Nordihydroguaiaretic acid (NDGA), a non-selective lipoxygenase inhibitor, and MK886, a specific inhibitor of 5-lipoxygenase, induced MMP-3 expression synergistically with IL-1. Masoprocol 0-25 matrix metallopeptidase 3 Homo sapiens 133-138 17319946-7 2007 Nordihydroguaiaretic acid (NDGA), a non-selective lipoxygenase inhibitor, and MK886, a specific inhibitor of 5-lipoxygenase, induced MMP-3 expression synergistically with IL-1. Masoprocol 27-31 matrix metallopeptidase 3 Homo sapiens 133-138 17319946-7 2007 Nordihydroguaiaretic acid (NDGA), a non-selective lipoxygenase inhibitor, and MK886, a specific inhibitor of 5-lipoxygenase, induced MMP-3 expression synergistically with IL-1. MK-886 78-83 matrix metallopeptidase 3 Homo sapiens 133-138 17319946-8 2007 However IL-4 was still able to inhibit MMP-3 expression in the presence of NDGA or MK886 and IL-1. Masoprocol 75-79 matrix metallopeptidase 3 Homo sapiens 39-44 17319946-8 2007 However IL-4 was still able to inhibit MMP-3 expression in the presence of NDGA or MK886 and IL-1. MK-886 83-88 matrix metallopeptidase 3 Homo sapiens 39-44 17319946-9 2007 Activation of PPARgamma with pioglitazone not only failed to inhibit IL-1 induced expression of MMP-3 mRNA, but rather super-induced MMP-3 in the presence of IL-1. Pioglitazone 29-41 matrix metallopeptidase 3 Homo sapiens 133-138 17319946-11 2007 Another PPARgamma activator, 15-deoxy-Delta12,14prostaglandin J2 (15dPGJ2), also super-induced MMP-3 mRNA, and this was due at least in part to increased transcription. 14prostaglandin j2 46-64 matrix metallopeptidase 3 Homo sapiens 95-100 17319946-13 2007 Super-induction of MMP-3 by pioglitazone may have important implications for patients using pioglitazone to treat type II diabetes in the presence of chronic inflammation. Pioglitazone 28-40 matrix metallopeptidase 3 Homo sapiens 19-24 17319946-13 2007 Super-induction of MMP-3 by pioglitazone may have important implications for patients using pioglitazone to treat type II diabetes in the presence of chronic inflammation. Pioglitazone 92-104 matrix metallopeptidase 3 Homo sapiens 19-24 17113299-1 2007 The aim of the work was to investigate the mechanism of binding between human metalloproteinase-3 (MMP-3) and new compounds belonging to the benzisothiazolylamidines class. benzisothiazolylamidines 141-165 matrix metallopeptidase 3 Homo sapiens 78-104 17113299-5 2007 The scores assigned by the programs to the interaction between the tested benzisothiazolylamidines and human MMP-3 were consistent with a potential direct enzyme inhibitory activity. benzisothiazolylamidines 74-98 matrix metallopeptidase 3 Homo sapiens 109-114 17184586-0 2007 Triptolide suppresses IL-1beta-induced chemokine and stromelysin-1 gene expression in human colonic subepithelial myofibroblasts. triptolide 0-10 matrix metallopeptidase 3 Homo sapiens 53-66 17184586-1 2007 AIM: To examine the inhibitive effects of triptolide on the expression of IL-8, monocyte chemotactic protein (MCP)-1, and matrix metalloproteinases (MMP)-3 in subepithelial myofibroblasts (SEMF) stimulated with IL-1beta. triptolide 42-52 matrix metallopeptidase 3 Homo sapiens 122-155 17184586-9 2007 These results showed that triptolide inhibited IL-1beta -induced chemokine and MMP-3 expression in SEMF through the NF-kappa B pathway. triptolide 26-36 matrix metallopeptidase 3 Homo sapiens 79-84 17184586-10 2007 CONCLUSION: Triptolide inhibited IL-1beta -induced chemokine and MMP-3 expression in SEMF by preventing the phosphorylation of I kappa B-alpha. triptolide 12-22 matrix metallopeptidase 3 Homo sapiens 65-70 17982269-9 2007 Transplantation of MMP3 or MMP9 siRNA oligonucleotieds-transfected hADSC showed lower blood flow recovery and higher tissue injury than control oligonucelotide-transfected cells. oligonucelotide 144-159 matrix metallopeptidase 3 Homo sapiens 19-23 16927387-10 2007 Secretion of MMP-3 was also suppressed by AjA in both TNFalpha- and IL-1alpha-stimulated PPARgamma+/- and PPARgamma-/- MEF. lenabasum 42-45 matrix metallopeptidase 3 Homo sapiens 13-18 17913746-9 2007 Depletion of endogenous SPBP by siRNA treatment reduced MMP3 secretion by 50% in phorbol ester-stimulated human fibroblasts. Phorbol Esters 81-94 matrix metallopeptidase 3 Homo sapiens 56-60 18604945-7 2007 A disulfide-stabilized structure incorporating a sarafotoxin (SRT) 6b model was examined as a matrix metalloproteinase (MMP)-3 inhibitor. Disulfides 2-11 matrix metallopeptidase 3 Homo sapiens 94-126 17198194-9 2007 Mitogen-activated protein kinase inhibitors (U0126, PD098059, and SB203580) also blocked MMP-3 secretion. U 0126 45-50 matrix metallopeptidase 3 Homo sapiens 89-94 17198194-9 2007 Mitogen-activated protein kinase inhibitors (U0126, PD098059, and SB203580) also blocked MMP-3 secretion. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 52-60 matrix metallopeptidase 3 Homo sapiens 89-94 17198194-9 2007 Mitogen-activated protein kinase inhibitors (U0126, PD098059, and SB203580) also blocked MMP-3 secretion. SB 203580 66-74 matrix metallopeptidase 3 Homo sapiens 89-94 16936101-10 2006 Latanoprost increased MMP-1 (in four of five cultures), MMP-3 (in four of five cultures), MMP-17 (in three of five cultures), MMP-24 (in all five cultures), TIMP-2, -3, and -4 expression (in three of five cultures); MMP-11 and -15 were downregulated. Latanoprost 0-11 matrix metallopeptidase 3 Homo sapiens 56-61 16953394-5 2007 ESR and CRP levels did not change, but serum MMP-3 levels decreased in the glucosamine group. Glucosamine 75-86 matrix metallopeptidase 3 Homo sapiens 45-50 17125518-8 2006 When comparing SA to PF controls, analysis revealed a significant association between MMP3 -1612 ins/delA polymorphism and SA with an increased risk associated with the 6A/6A genotype (OR = 1.67, 95% CI: 1.20-2.34). sa 15-17 matrix metallopeptidase 3 Homo sapiens 86-90 17125518-8 2006 When comparing SA to PF controls, analysis revealed a significant association between MMP3 -1612 ins/delA polymorphism and SA with an increased risk associated with the 6A/6A genotype (OR = 1.67, 95% CI: 1.20-2.34). pf 21-23 matrix metallopeptidase 3 Homo sapiens 86-90 17027562-3 2006 Genotypic analysis was done on DNA using polymerase chain reaction and direct sequencing on the 5 adenines (5A)/6 adenines (6A; -1,171 bp) polymorphism in the MMP-3 gene promoter region. Adenine 98-106 matrix metallopeptidase 3 Homo sapiens 159-164 17027562-3 2006 Genotypic analysis was done on DNA using polymerase chain reaction and direct sequencing on the 5 adenines (5A)/6 adenines (6A; -1,171 bp) polymorphism in the MMP-3 gene promoter region. Adenine 114-122 matrix metallopeptidase 3 Homo sapiens 159-164 16652151-2 2006 The Stromelysin-1 promoter is known to be transactivated by Ets proteins through palindromic head-to-head Ets binding sites (EBS), an unusual configuration among metalloproteinase promoters. ethylbenzene 125-128 matrix metallopeptidase 3 Homo sapiens 4-17 16652151-7 2006 Thus, it is the first demonstration, using this cellular model, that endogenously expressed Ets-1 is actually a main activator of the Stromelysin-1 promoter through its effective binding to the EBS palindrome. ethylbenzene 194-197 matrix metallopeptidase 3 Homo sapiens 134-147 16806336-2 2006 After 7 days of priming and 24h experimental incubation of confluent cultured HESCs, 10(-7) M medroxyprogesterone acetate (P) reduced MMP-1 to 49+/-34% (p<0.05) and MMP-3 to 33+/-22% of basal levels (mean+/-S.E.M., p<0.05, n=5). Medroxyprogesterone Acetate 94-121 matrix metallopeptidase 3 Homo sapiens 168-173 16995741-0 2006 A preliminary in silico lead series of 2-phthalimidinoglutaric acid analogues designed as MMP-3 inhibitors. 2-phthalimidinoglutaric acid 39-67 matrix metallopeptidase 3 Homo sapiens 90-95 16995741-3 2006 Thalidomide was chosen as the skeleton on which to base the new lead series, as it moderately inhibits MMP-3, is antiangiogenic, and lends itself easily to structural modifications. Thalidomide 0-11 matrix metallopeptidase 3 Homo sapiens 103-108 16862547-10 2006 When TBI + BEC recovery was enhanced by the N-methyl-D-aspartate antagonist MK-801, 7-day MMP-3 mRNA was significantly reduced. (2-boronoethyl)-cysteine 11-14 matrix metallopeptidase 3 Homo sapiens 90-95 16862547-10 2006 When TBI + BEC recovery was enhanced by the N-methyl-D-aspartate antagonist MK-801, 7-day MMP-3 mRNA was significantly reduced. N-Methylaspartate 44-64 matrix metallopeptidase 3 Homo sapiens 90-95 16862547-10 2006 When TBI + BEC recovery was enhanced by the N-methyl-D-aspartate antagonist MK-801, 7-day MMP-3 mRNA was significantly reduced. Dizocilpine Maleate 76-82 matrix metallopeptidase 3 Homo sapiens 90-95 16806336-3 2006 Although HESCs were unaffected by 10(-8) M estradiol (E), E+P reduced MMP-1 and MMP-3 levels an additional 2.5-fold from P alone. e+p 58-61 matrix metallopeptidase 3 Homo sapiens 80-85 16806336-4 2006 Tibolone and Delta-4 tibolone were equivalent to E+P in inhibiting MMP-1 and MMP-3 output, whereas 10(-6)M of 3alpha-OH or 3beta-OH tibolone was required to elicit significant inhibition of both MMPs (p<0.05). delta(4)-tibolone 13-29 matrix metallopeptidase 3 Homo sapiens 77-82 16806336-4 2006 Tibolone and Delta-4 tibolone were equivalent to E+P in inhibiting MMP-1 and MMP-3 output, whereas 10(-6)M of 3alpha-OH or 3beta-OH tibolone was required to elicit significant inhibition of both MMPs (p<0.05). e+p 49-52 matrix metallopeptidase 3 Homo sapiens 77-82 16806336-8 2006 Inhibition of MMP-1 and MMP-3 expression by tibolone and Delta-4 tibolone is consistent with the metabolism of tibolone to Delta-4 tibolone, and subsequent binding of Delta-4 tibolone to the progesterone receptor. tibolone 44-52 matrix metallopeptidase 3 Homo sapiens 24-29 16806336-8 2006 Inhibition of MMP-1 and MMP-3 expression by tibolone and Delta-4 tibolone is consistent with the metabolism of tibolone to Delta-4 tibolone, and subsequent binding of Delta-4 tibolone to the progesterone receptor. delta(4)-tibolone 57-73 matrix metallopeptidase 3 Homo sapiens 24-29 16806336-8 2006 Inhibition of MMP-1 and MMP-3 expression by tibolone and Delta-4 tibolone is consistent with the metabolism of tibolone to Delta-4 tibolone, and subsequent binding of Delta-4 tibolone to the progesterone receptor. tibolone 65-73 matrix metallopeptidase 3 Homo sapiens 24-29 16806336-8 2006 Inhibition of MMP-1 and MMP-3 expression by tibolone and Delta-4 tibolone is consistent with the metabolism of tibolone to Delta-4 tibolone, and subsequent binding of Delta-4 tibolone to the progesterone receptor. delta(4)-tibolone 123-139 matrix metallopeptidase 3 Homo sapiens 24-29 16806336-8 2006 Inhibition of MMP-1 and MMP-3 expression by tibolone and Delta-4 tibolone is consistent with the metabolism of tibolone to Delta-4 tibolone, and subsequent binding of Delta-4 tibolone to the progesterone receptor. delta(4)-tibolone 123-139 matrix metallopeptidase 3 Homo sapiens 24-29 16806336-9 2006 Since 3alpha-OH and 3beta-OH tibolone bind exclusively to the estrogen receptor, their inhibition of MMP-1 and MMP-3 suggests metabolism by HESCs to Delta-4 tibolone. 3beta-OH-tibolone 20-37 matrix metallopeptidase 3 Homo sapiens 111-116 16859309-2 2006 The crystal structure of stromelysin-1 (MMP-3) was used to pinpoint areas on the ligands and receptors where steric and electrostatic effects (for CoMFA) and steric, electrostatic, hydrogen-bond donor, hydrogen-bond acceptor, and hydrophobic effects (for CoMSIA) correlate with an increase or decrease in experimental biological activity. Hydrogen 202-210 matrix metallopeptidase 3 Homo sapiens 25-38 16881109-8 2006 Six months" treatment with MTX downregulated serum concentrations of MMP-1 (p < 0.001), MMP-3 (p < 0.001), MMP-9 (p < 0.001), MMP-13 (p < 0.01), and TIMP-1 (p < 0.05) in patients with RA. Methotrexate 27-30 matrix metallopeptidase 3 Homo sapiens 91-96 16778083-2 2006 This study indicates that exposure of human microvascular endothelial cells to 2,2",4,6,6"-pentachlorobiphenyl can stimulate transendothelial migration of tumor cells through up-regulation of matrix metalloproteinase (MMP)-3. 2,2',4,6,6'-pentachlorobiphenyl 79-110 matrix metallopeptidase 3 Homo sapiens 192-224 16449361-10 2006 RESULTS: Production of MMP-1 and MMP-3 by RSF was stimulated by IL-1beta. (3r,3as,6ar)-Hexahydrofuro[2,3-B]furan-3-Ol 42-45 matrix metallopeptidase 3 Homo sapiens 33-38 16648635-6 2006 The secreted Abeta was rapidly degraded through up-regulation of matrix metalloprotease (MMP)-2 and MMP-3 after addition of CQ and Cu(2+). Clioquinol 124-126 matrix metallopeptidase 3 Homo sapiens 100-105 16648635-6 2006 The secreted Abeta was rapidly degraded through up-regulation of matrix metalloprotease (MMP)-2 and MMP-3 after addition of CQ and Cu(2+). Copper 131-133 matrix metallopeptidase 3 Homo sapiens 100-105 16504515-1 2006 The inhibitory activity (IC50) toward matrix metalloproteinases (MMP-1, MMP-2, MMP-3, MMP-9, and MMP-13) of N-hydroxy-2-[(phenylsulfonyl)amino]acetamide derivatives (HPSAAs) has been successfully modeled using 2D autocorrelation descriptors. n-hydroxy-2-[(phenylsulfonyl)amino]acetamide 108-152 matrix metallopeptidase 3 Homo sapiens 79-84 16176868-4 2006 Here, we showed that retinoids inhibit phorbol ester-induced MMP-1 and MMP-3 expression in human breast cancer cells. Retinoids 21-30 matrix metallopeptidase 3 Homo sapiens 71-76 16176868-4 2006 Here, we showed that retinoids inhibit phorbol ester-induced MMP-1 and MMP-3 expression in human breast cancer cells. Phorbol Esters 39-52 matrix metallopeptidase 3 Homo sapiens 71-76 16603129-0 2006 Crystal structures of the catalytic domain of human stromelysin-1 (MMP-3) and collagenase-3 (MMP-13) with a hydroxamic acid inhibitor SM-25453. Hydroxamic Acids 108-123 matrix metallopeptidase 3 Homo sapiens 52-65 16603129-0 2006 Crystal structures of the catalytic domain of human stromelysin-1 (MMP-3) and collagenase-3 (MMP-13) with a hydroxamic acid inhibitor SM-25453. Hydroxamic Acids 108-123 matrix metallopeptidase 3 Homo sapiens 67-72 16603129-1 2006 Crystal structures of the catalytic domain of human stromelysin-1 (MMP-3) and collagenase-3 (MMP-13) with a hydroxamic acid inhibitor SM-25453 have been solved at 2.01 and 2.37A resolutions, respectively. Hydroxamic Acids 108-123 matrix metallopeptidase 3 Homo sapiens 52-65 16603129-1 2006 Crystal structures of the catalytic domain of human stromelysin-1 (MMP-3) and collagenase-3 (MMP-13) with a hydroxamic acid inhibitor SM-25453 have been solved at 2.01 and 2.37A resolutions, respectively. Hydroxamic Acids 108-123 matrix metallopeptidase 3 Homo sapiens 67-72 16603129-0 2006 Crystal structures of the catalytic domain of human stromelysin-1 (MMP-3) and collagenase-3 (MMP-13) with a hydroxamic acid inhibitor SM-25453. SM 25453 134-142 matrix metallopeptidase 3 Homo sapiens 52-65 16603129-1 2006 Crystal structures of the catalytic domain of human stromelysin-1 (MMP-3) and collagenase-3 (MMP-13) with a hydroxamic acid inhibitor SM-25453 have been solved at 2.01 and 2.37A resolutions, respectively. SM 25453 134-142 matrix metallopeptidase 3 Homo sapiens 52-65 16603129-1 2006 Crystal structures of the catalytic domain of human stromelysin-1 (MMP-3) and collagenase-3 (MMP-13) with a hydroxamic acid inhibitor SM-25453 have been solved at 2.01 and 2.37A resolutions, respectively. SM 25453 134-142 matrix metallopeptidase 3 Homo sapiens 67-72 16603129-0 2006 Crystal structures of the catalytic domain of human stromelysin-1 (MMP-3) and collagenase-3 (MMP-13) with a hydroxamic acid inhibitor SM-25453. SM 25453 134-142 matrix metallopeptidase 3 Homo sapiens 67-72 16505029-10 2006 Latanoprost increased MMP-3 (in three of five cultures), MMP-17 (in four of five cultures), and TIMP-3 (in all five cultures); MMP-1, -2, -12, -14, -15, and -16 and TIMP-4 were downregulated. Latanoprost 0-11 matrix metallopeptidase 3 Homo sapiens 22-27 16488093-5 2006 In addition, PGE2 at 100 ng/ml significantly increased the expression of MMP-1 and MMP-3 at both mRNA and protein levels. Dinoprostone 13-17 matrix metallopeptidase 3 Homo sapiens 83-88 16516860-5 2006 Furthermore, treatment of the wild-type cells with DNA methylase inhibitors 5-aza-dC and zebularine also induced mmp-3 gene expression. Decitabine 76-84 matrix metallopeptidase 3 Homo sapiens 113-118 16516860-5 2006 Furthermore, treatment of the wild-type cells with DNA methylase inhibitors 5-aza-dC and zebularine also induced mmp-3 gene expression. pyrimidin-2-one beta-ribofuranoside 89-99 matrix metallopeptidase 3 Homo sapiens 113-118 16580899-7 2006 Ibuprofen produced similar effects on the expression of MMP-1 (23.4 +/- 5.0, P = .016) and MMP-3 (26.3 +/- 4.2, P = .003). Ibuprofen 0-9 matrix metallopeptidase 3 Homo sapiens 91-96 16505029-11 2006 CONCLUSIONS: The transcription of the genes for MMP-3 and -17 is increased by latanoprost treatment. Latanoprost 78-89 matrix metallopeptidase 3 Homo sapiens 48-61 16556677-4 2006 The suppressive effect of T or P4 on MMP-1 and MMP-3 transcript levels was enhanced in the presence of E(2) and attenuated in the presence of RU486, although MMP-1 proteins were unaffected by the presence of RU486, which alone acted as a partial progesterone agonist in these cultures. Mifepristone 142-147 matrix metallopeptidase 3 Homo sapiens 47-52 16401476-1 2006 BACKGROUND & AIMS: The up-regulation of matrix metalloproteinases (MMPs) in the inflamed gut has mainly been associated with mucosal degradation and ulceration. Adenosine Monophosphate 12-15 matrix metallopeptidase 3 Homo sapiens 71-75 16421935-4 2006 The MMP-3 cleavage sites in plasma gelsolin were determined by labeling the C termini generated by in-gel digestion with 50% H2 18O combined with peptide mass mapping, and sequencing of the N-terminal amino acids. h2 18o 125-131 matrix metallopeptidase 3 Homo sapiens 4-9 16543723-0 2006 The active form of leflunomide, HMR1726, facilitates TNF-alpha and IL-17 induced MMP-1 and MMP-3 expression. Leflunomide 19-30 matrix metallopeptidase 3 Homo sapiens 91-96 16543723-0 2006 The active form of leflunomide, HMR1726, facilitates TNF-alpha and IL-17 induced MMP-1 and MMP-3 expression. teriflunomide 32-39 matrix metallopeptidase 3 Homo sapiens 91-96 16856814-3 2006 We investigated expression and possible mechanisms of regulation of different matrix-metalloproteases (MMPs) by EVT in placental bed biopsies from patients with early onset preeclampsia combined with IUGR and healthy pregnant women. EVT 112-115 matrix metallopeptidase 3 Homo sapiens 103-107 16856814-4 2006 Expression of MMP-3 and MMP-7 by EVT was markedly reduced in preeclamptic patients, especially close to spiral arteries. EVT 33-36 matrix metallopeptidase 3 Homo sapiens 14-19 16102944-10 2005 RA decreased the MMP-1 and MMP-3 expression levels to a greater extent than EGCG. Tretinoin 0-2 matrix metallopeptidase 3 Homo sapiens 27-32 16148020-2 2005 We reported previously that the fluoroquinolone ciprofloxacin potentiated interleukin (IL)-1beta-stimulated expression of matrix metalloproteinases (MMP)-3 and MMP-1 in human tendon-derived cells. Fluoroquinolones 32-47 matrix metallopeptidase 3 Homo sapiens 122-155 16148020-2 2005 We reported previously that the fluoroquinolone ciprofloxacin potentiated interleukin (IL)-1beta-stimulated expression of matrix metalloproteinases (MMP)-3 and MMP-1 in human tendon-derived cells. Ciprofloxacin 48-61 matrix metallopeptidase 3 Homo sapiens 122-155 16153831-1 2005 The structure-based design and synthesis of a series of novel biphenyl sulfonamide carboxylic acids as potent MMP-13 inhibitors with selectivity over MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, MMP-14, Aggrecanase 1, and TACE are described. biphenyl sulfonamide carboxylic acids 62-99 matrix metallopeptidase 3 Homo sapiens 164-169 16230520-13 2005 Testosterone increased both gene and protein expression of MMP-3 relative to both control and female sex steroids (P<0.01). Testosterone 0-12 matrix metallopeptidase 3 Homo sapiens 59-64 16243232-8 2005 When they were pre-incubated with IL-1beta, IL-6 or OSM, N osteoblasts inhibited AGG synthesis and increased MMP-3 and -13 gene expression by chondrocytes in alginate beads in a same order of magnitude as SC osteoblasts. Alginates 158-166 matrix metallopeptidase 3 Homo sapiens 109-122 16218585-0 2005 Potent, selective pyrone-based inhibitors of stromelysin-1. Pyrones 18-24 matrix metallopeptidase 3 Homo sapiens 45-58 16046583-3 2005 OBJECTIVE AND DESIGN: To clarify the role of ovarian steroids in the differential regulation of MMP-1, MMP-3, MMP-7, MMP-8, MMP-10, TIMP-1, TIMP-2, and TIMP-3 mRNAs, we compared their variations in the cycling endometrium in vivo with their response to hormone addition or withdrawal in corresponding explants. Steroids 53-61 matrix metallopeptidase 3 Homo sapiens 103-108 15688379-12 2005 LMP1 also induced active MMP3, which can cleave latent MMP1, and AP1-DN and Ets-DN suppressed the MMP3 expression. ets-dn 76-82 matrix metallopeptidase 3 Homo sapiens 98-102 15887216-0 2005 Expression of ets-1 transcription factor in human head and neck squamous cell carcinoma and effect of histamine on metastatic potential of invasive tumor through the regulation of expression of ets-1 and matrix metalloproteinase-3. Histamine 102-111 matrix metallopeptidase 3 Homo sapiens 204-230 15887216-4 2005 We hypothesized that the increased local histamine overproduction contributed to activation of matrix remodeling through the activation of MMP-3 expression of peritumoral fibroblasts by means of ets-1 regulation in head and neck squamous cell carcinomas (HNSCCs). Histamine 41-50 matrix metallopeptidase 3 Homo sapiens 139-144 15887216-11 2005 In in vitro study, histamine upregulates production of ets-1 and MMP-3 in cultured fibroblast, and bFGF can stimulate histamine expression in fibroblast. Histamine 19-28 matrix metallopeptidase 3 Homo sapiens 65-70 21794254-0 2005 [Effect of chondroitin sulfate and hyaluronic acid (500-730 kDa) on synthesis of stromelysin (MMP-3) and MMP-1 in human chondrocyte cultures]. Hyaluronic Acid 35-50 matrix metallopeptidase 3 Homo sapiens 94-99 21794254-5 2005 OBJECTIVES: To analyze the effect of CS and HA (500-730 kDa) on MMP-3 and MMP-1 synthesis induced by interleukin-1beta (IL-1beta) in OA chondrocytes. Chondroitin Sulfates 37-39 matrix metallopeptidase 3 Homo sapiens 64-69 21794254-8 2005 RESULTS: CS and HA inhibited IL-1beta-induced MMP-3 synthesis, without significantly modifying MMP-1. Chondroitin Sulfates 9-11 matrix metallopeptidase 3 Homo sapiens 46-51 21794254-9 2005 CS and HA reduced levels of MMP-3 expression at all the studied concentrations, with no statistically significant differences among these concentrations. Chondroitin Sulfates 0-2 matrix metallopeptidase 3 Homo sapiens 28-33 21794254-9 2005 CS and HA reduced levels of MMP-3 expression at all the studied concentrations, with no statistically significant differences among these concentrations. Hyaluronic Acid 7-9 matrix metallopeptidase 3 Homo sapiens 28-33 21794254-10 2005 CONCLUSIONS: The results of this study show for the first time that CS inhibits MMP-3 synthesis in OA cartilage. Chondroitin Sulfates 68-70 matrix metallopeptidase 3 Homo sapiens 80-85 15897362-10 2005 Ramiprilat also reduced gene and protein (Western) expression of both matrix metalloproteinase (MMP)-2 and MMP-3. ramiprilat 0-10 matrix metallopeptidase 3 Homo sapiens 107-112 15948687-2 2005 In the present study, we investigated whether COX-2-derived PGE2 regulated matrix metalloproteinase (MMP)-3 production in human periodontal ligament (PDL) cells stimulated with interleukin (IL)-1alpha and which EP receptors were involved in PGE2 regulation of IL-1alpha-induced MMP-3 production. Dinoprostone 60-64 matrix metallopeptidase 3 Homo sapiens 75-107 15948687-7 2005 Indomethacin and NS-398 enhanced IL-1alpha-induced MMP-3 production in PDL cells, to the same extent, although both the agents completely inhibited IL-1alpha-induced PGE2 production. Indomethacin 0-12 matrix metallopeptidase 3 Homo sapiens 51-56 15948687-7 2005 Indomethacin and NS-398 enhanced IL-1alpha-induced MMP-3 production in PDL cells, to the same extent, although both the agents completely inhibited IL-1alpha-induced PGE2 production. N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide 17-23 matrix metallopeptidase 3 Homo sapiens 51-56 15948687-8 2005 Exogenous PGE2 reduced IL-1alpha-induced MMP-3 production in a dose-dependent manner. Dinoprostone 10-14 matrix metallopeptidase 3 Homo sapiens 41-46 15948687-9 2005 Butaprost, a selective EP2 agonist, and ONO-AE1-329, a selective EP4 agonist, significantly inhibited IL-1alpha-induced MMP-3 production, although butaprost was less potent than ONO-AE-1-329. ONO-AE1-329 40-51 matrix metallopeptidase 3 Homo sapiens 120-125 15948687-10 2005 Dibutyryl cAMP, a cAMP analog, and forskolin, an adenylate cyclase activator, significantly inhibited IL-1alpha-stimulated MMP-3 production in PDL cells. dibutyryl 0-9 matrix metallopeptidase 3 Homo sapiens 123-128 15948687-10 2005 Dibutyryl cAMP, a cAMP analog, and forskolin, an adenylate cyclase activator, significantly inhibited IL-1alpha-stimulated MMP-3 production in PDL cells. Cyclic AMP 10-14 matrix metallopeptidase 3 Homo sapiens 123-128 15948687-10 2005 Dibutyryl cAMP, a cAMP analog, and forskolin, an adenylate cyclase activator, significantly inhibited IL-1alpha-stimulated MMP-3 production in PDL cells. Cyclic AMP 18-22 matrix metallopeptidase 3 Homo sapiens 123-128 15948687-10 2005 Dibutyryl cAMP, a cAMP analog, and forskolin, an adenylate cyclase activator, significantly inhibited IL-1alpha-stimulated MMP-3 production in PDL cells. Colforsin 35-44 matrix metallopeptidase 3 Homo sapiens 123-128 15948687-11 2005 CONCLUSIONS: These data suggest that COX-2-dependent PGE2 downregulates IL-1alpha-elicited MMP-3 production by cAMP-dependent pathways via EP2/EP4 receptors in human PDL cells. Dinoprostone 53-57 matrix metallopeptidase 3 Homo sapiens 91-96 15948687-11 2005 CONCLUSIONS: These data suggest that COX-2-dependent PGE2 downregulates IL-1alpha-elicited MMP-3 production by cAMP-dependent pathways via EP2/EP4 receptors in human PDL cells. Cyclic AMP 111-115 matrix metallopeptidase 3 Homo sapiens 91-96 29539150-2 2005 In the present study, we investigated whether COX-2-derived PGE2 regulated matrix metalloproteinase (MMP)-3 production in human periodontal ligament (PDL) cells stimulated with interleukin (IL)-1alpha and which EP receptors were involved in PGE2 regulation of IL-1alpha-induced MMP-3 production. Dinoprostone 60-64 matrix metallopeptidase 3 Homo sapiens 75-107 29539150-7 2005 Indomethacin and NS-398 enhanced IL-1alpha-induced MMP-3 production in PDL cells, to the same extent, although both the agents completely inhibited IL-1alpha-induced PGE2 production. Indomethacin 0-12 matrix metallopeptidase 3 Homo sapiens 51-56 29539150-7 2005 Indomethacin and NS-398 enhanced IL-1alpha-induced MMP-3 production in PDL cells, to the same extent, although both the agents completely inhibited IL-1alpha-induced PGE2 production. N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide 17-23 matrix metallopeptidase 3 Homo sapiens 51-56 29539150-8 2005 Exogenous PGE2 reduced IL-1alpha-induced MMP-3 production in a dose-dependent manner. Dinoprostone 10-14 matrix metallopeptidase 3 Homo sapiens 41-46 29539150-9 2005 Butaprost, a selective EP2 agonist, and ONO-AE1-329, a selective EP4 agonist, significantly inhibited IL-1alpha-induced MMP-3 production, although butaprost was less potent than ONO-AE-1-329. ONO-AE1-329 40-51 matrix metallopeptidase 3 Homo sapiens 120-125 29539150-10 2005 Dibutyryl cAMP, a cAMP analog, and forskolin, an adenylate cyclase activator, significantly inhibited IL-1alpha-stimulated MMP-3 production in PDL cells. dibutyryl 0-9 matrix metallopeptidase 3 Homo sapiens 123-128 29539150-10 2005 Dibutyryl cAMP, a cAMP analog, and forskolin, an adenylate cyclase activator, significantly inhibited IL-1alpha-stimulated MMP-3 production in PDL cells. Cyclic AMP 10-14 matrix metallopeptidase 3 Homo sapiens 123-128 29539150-10 2005 Dibutyryl cAMP, a cAMP analog, and forskolin, an adenylate cyclase activator, significantly inhibited IL-1alpha-stimulated MMP-3 production in PDL cells. Cyclic AMP 18-22 matrix metallopeptidase 3 Homo sapiens 123-128 29539150-10 2005 Dibutyryl cAMP, a cAMP analog, and forskolin, an adenylate cyclase activator, significantly inhibited IL-1alpha-stimulated MMP-3 production in PDL cells. Colforsin 35-44 matrix metallopeptidase 3 Homo sapiens 123-128 29539150-11 2005 CONCLUSIONS: These data suggest that COX-2-dependent PGE2 downregulates IL-1alpha-elicited MMP-3 production by cAMP-dependent pathways via EP2 /EP4 receptors in human PDL cells. Dinoprostone 53-57 matrix metallopeptidase 3 Homo sapiens 91-96 29539150-11 2005 CONCLUSIONS: These data suggest that COX-2-dependent PGE2 downregulates IL-1alpha-elicited MMP-3 production by cAMP-dependent pathways via EP2 /EP4 receptors in human PDL cells. Cyclic AMP 111-115 matrix metallopeptidase 3 Homo sapiens 91-96 15698619-7 2005 TBI alone elevated MMP-3 immunobinding over the stratum lacunosum moleculare (SLM), inner molecular layer and hilus, while TBI + BEC generated more robust increases in MMP-3 reactivity within the deafferented SLM and dentate molecular layer (DML). (2-boronoethyl)-cysteine 129-132 matrix metallopeptidase 3 Homo sapiens 168-173 15823277-5 2005 RESULTS: In analysis of covariance (ANCOVA) with age, body mass index, hypertension, diabetes, smoking and alcohol consumption as covariates, a significant interaction between the MMP3 and MMP9 genotypes was observed on area of complicated lesions (P=0.012). Alcohols 107-114 matrix metallopeptidase 3 Homo sapiens 180-184 15867378-7 2005 In addition, 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced transcriptional activity of wild-type MMP-3 promoter was 10-fold higher than the mutants activity. Tetradecanoylphorbol Acetate 13-49 matrix metallopeptidase 3 Homo sapiens 102-107 15867378-7 2005 In addition, 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced transcriptional activity of wild-type MMP-3 promoter was 10-fold higher than the mutants activity. Tetradecanoylphorbol Acetate 51-54 matrix metallopeptidase 3 Homo sapiens 102-107 15867378-8 2005 Dexamethasone inhibited the basal transcriptional activity of wild-type MMP-3 promoter and of the two mutants found in the MSI-H subgroup of colorectal tumors. Dexamethasone 0-13 matrix metallopeptidase 3 Homo sapiens 72-77 15867378-9 2005 Significantly, dexamethasone almost completely blunted the TPA-induced effect on wild-type MMP-3 promoter transcriptional activity and on the mutants, even below their basal activity. Dexamethasone 15-28 matrix metallopeptidase 3 Homo sapiens 91-96 15867378-9 2005 Significantly, dexamethasone almost completely blunted the TPA-induced effect on wild-type MMP-3 promoter transcriptional activity and on the mutants, even below their basal activity. Tetradecanoylphorbol Acetate 59-62 matrix metallopeptidase 3 Homo sapiens 91-96 16032782-7 2005 Transiently increased gamma-GCSh expression using tetracycline-inducible gamma-GCSh adenoviral expression system also showed down-regulation of MMP3 and MMP10, but not MMP1. Tetracycline 50-62 matrix metallopeptidase 3 Homo sapiens 144-148 15757531-1 2005 BACKGROUND & OBJECTIVE: Matrix metalloproteinases (MMPs) might be involved in invasion and metastasis of tumors by degrading extracellular matrix (ECM) and basement membrane (BM). Adenosine Monophosphate 12-15 matrix metallopeptidase 3 Homo sapiens 55-59 15863497-4 2005 Also the addition of nitric oxide-generating compounds to the cells caused the secreted alpha-synuclein to be digested, producing a small fragment whose size was similar to that of the fragment generated during the incubation of alpha-synuclein with various MMPs in vitro. Nitric Oxide 21-33 matrix metallopeptidase 3 Homo sapiens 258-262 15780605-0 2005 QSAR-by-NMR: quantitative insights into structural determinants for binding affinity by analysis of 1H/15N chemical shift differences in MMP-3 ligands. Hydrogen 100-102 matrix metallopeptidase 3 Homo sapiens 137-142 15780605-0 2005 QSAR-by-NMR: quantitative insights into structural determinants for binding affinity by analysis of 1H/15N chemical shift differences in MMP-3 ligands. 15n 103-106 matrix metallopeptidase 3 Homo sapiens 137-142 15780605-3 2005 Essential structural features linked to affinity can be extracted using statistical analysis of (15)N and (1)H amide chemical shift differences in congeneric series relative to uncomplexed protein spectra, as demonstrated for 20 MMP-3 inhibitors in complex with human matrix metalloproteinase stromelysin (MMP-3). Amides 111-116 matrix metallopeptidase 3 Homo sapiens 229-234 15698619-10 2005 In the TBI + BEC model, MMP-3 up-regulation was spatio-temporally correlated with increased enzyme activity, an effect which was attenuated with the neuroprotective compound MK-801. (2-boronoethyl)-cysteine 13-16 matrix metallopeptidase 3 Homo sapiens 24-29 15698619-10 2005 In the TBI + BEC model, MMP-3 up-regulation was spatio-temporally correlated with increased enzyme activity, an effect which was attenuated with the neuroprotective compound MK-801. Dizocilpine Maleate 174-180 matrix metallopeptidase 3 Homo sapiens 24-29 15734282-3 2005 OBJECTIVE: The goal of this research was to determine the effects of 4-hydroxy-Tempo (Tempol), one of nitroxides, in the presence of UVA1 on cytotoxicity, superoxide dismutase enzyme (SOD) activity, lipid peroxidation, and expression of collagen I, collagen III and MMP-1, MMP-3 in human dermal fibroblasts in vitro. TEMPOL-H 69-84 matrix metallopeptidase 3 Homo sapiens 273-278 15734282-3 2005 OBJECTIVE: The goal of this research was to determine the effects of 4-hydroxy-Tempo (Tempol), one of nitroxides, in the presence of UVA1 on cytotoxicity, superoxide dismutase enzyme (SOD) activity, lipid peroxidation, and expression of collagen I, collagen III and MMP-1, MMP-3 in human dermal fibroblasts in vitro. tempol 86-92 matrix metallopeptidase 3 Homo sapiens 273-278 15716694-3 2005 Stromelysin-1 gene expression is partly regulated by a common polymorphism in the promoter region of either five or six consecutive adenosine bases (5A/6A). Adenosine 132-141 matrix metallopeptidase 3 Homo sapiens 0-13 15734256-11 2005 (b) Normal disc tissues after administration of rh MMP-7, MMP-3, and chymopapain showed an extensive loss of Safranin O staining. phenosafranine 109-119 matrix metallopeptidase 3 Homo sapiens 58-63 15715567-5 2005 CONCLUSION: Because MMP-3 (stromelysin) mRNA showed the highest upregulation, our findings suggest that trabecular cells preferentially degrade and turn over the proteoglycan components of the extracellular matrix in response to short-term exposure to increased hydrostatic pressure with and without Dex as a homeostatic mechanism. Dexamethasone 300-303 matrix metallopeptidase 3 Homo sapiens 20-25 15746971-0 2005 Influence of mechanical and biological signals on gene expression in human MG-63 cells: evidence for a complex interplay between hydrostatic compression and vitamin D3 or TGF-beta1 on MMP-1 and MMP-3 mRNA levels. Cholecalciferol 157-167 matrix metallopeptidase 3 Homo sapiens 194-199 15746971-7 2005 Treatment of cells with 1,25-(OH)2D3 resulted in increased (p < 0.001) mRNA levels for osteocalcin and decreased (p < 0.001) mRNA levels for both MMP-1 and MMP-3. Calcitriol 24-36 matrix metallopeptidase 3 Homo sapiens 162-167 15703331-6 2005 Our results provide evidence that levels of zinc, manganese and the amount of MMP-3 in saliva are significantly decreased in the patients with taste disorder compared to the healthy subjects; Zn (p.p.b. Zinc 192-194 matrix metallopeptidase 3 Homo sapiens 78-83 15699632-5 2005 After carefully being analyzed by software "DAVID" and "Pathart," Ets1 was found to be activated by being phosphorylated at theronine 38 by ERK1/2, and in turn, to regulate the following genes: uPA, MMP-3, and prolactin (Ling et al., 2003; Duffy and Daggan, 2004; Maupas-Schwalm et al., 2004; van Themsche et al., 2004). DL-Threonine 124-133 matrix metallopeptidase 3 Homo sapiens 199-204 16035398-0 2004 Effect of nimesulide on the serum levels of hyaluronan and stromelysin-1 in patients with osteoarthritis: a pilot study. nimesulide 10-20 matrix metallopeptidase 3 Homo sapiens 59-72 15987479-3 2005 MMP-3 and MMP-13 gene expression induced by IL-1beta, TNF-alpha and IL-17 was downregulated by mithramycin in human chondrosarcoma SW1353 cells and in primary human and bovine femoral head chondrocytes. Plicamycin 95-106 matrix metallopeptidase 3 Homo sapiens 0-5 15929608-0 2005 Chondroitin sulfate and hyaluronic acid (500-730 kda) inhibit stromelysin-1 synthesis in human osteoarthritic chondrocytes. Chondroitin Sulfates 0-19 matrix metallopeptidase 3 Homo sapiens 62-75 15929608-0 2005 Chondroitin sulfate and hyaluronic acid (500-730 kda) inhibit stromelysin-1 synthesis in human osteoarthritic chondrocytes. Hyaluronic Acid 24-39 matrix metallopeptidase 3 Homo sapiens 62-75 15929608-5 2005 However, there are few studies evaluating the in vitro effect of CS and HA on MMP-3 synthesis in human chondrocyte cultures from OA patients. Chondroitin Sulfates 65-67 matrix metallopeptidase 3 Homo sapiens 78-83 15929608-6 2005 Thus, the aim of the present study was to analyze the effect of CS and HA (500-730 kDa) on MMP-3 synthesis induced by interleukin-1beta (IL-1beta) in chondrocytes from patients with hip OA. Chondroitin Sulfates 64-66 matrix metallopeptidase 3 Homo sapiens 91-96 15929608-8 2005 The results revealed that both CS and HA (500-730 kDa) inhibited MMP-3 synthesis induced by IL-1beta in human OA chondrocytes. Chondroitin Sulfates 31-33 matrix metallopeptidase 3 Homo sapiens 65-70 16128596-7 2005 Nimesulide also reduced the serum levels of both MMP-3 (p < 0.05) and MMP-13 (p < 0.001). nimesulide 0-10 matrix metallopeptidase 3 Homo sapiens 49-54 15517394-7 2005 Our results establish that treatment of cultured human dermal fibroblasts with recombinant fibrillin-1 fragments containing the arginine-glycine-aspartic acid (RGD) integrin-binding motif of fibrillin-1 induces up-regulation of MMP-1 and MMP-3. Arginine 128-136 matrix metallopeptidase 3 Homo sapiens 238-243 15557445-9 2004 Array analysis demonstrated increases of MMP-3 and -10 mRNA after exposure to 100 nM latanoprost and further increases after exposure to 200 nM latanoprost. Latanoprost 85-96 matrix metallopeptidase 3 Homo sapiens 41-54 15659840-7 2004 Upregulation of MMP-3 was inhibited by curcumin in a time-dependent manner. Curcumin 39-47 matrix metallopeptidase 3 Homo sapiens 16-21 15659840-11 2004 Curcumin protected chondrocytes from the catabolic effects of IL-1beta, such as MMP-3 upregulation, and interestingly also relieved cytokine-induced suppression of matrix protein synthesis. Curcumin 0-8 matrix metallopeptidase 3 Homo sapiens 80-85 15378360-4 2004 On incubation with histamine, HACs showed increased production of MMP-3, MMP-13, TNFalpha and PGE(2) (statistical significance P=0.02, 0.005, 0.008 and 0.03, respectively, student"s t-test), but MMP-1 expression was unaffected. Histamine 19-28 matrix metallopeptidase 3 Homo sapiens 66-71 15378360-5 2004 In contrast, the RSF showed a histamine-induced increase in MMP-1 ( P=0.028) and an approximate 10-fold level of MMP-3 and PGE(2) release over that of HACs, each being stimulated by histamine ( P=0.02 and 0.032, respectively, student"s t-test). (3r,3as,6ar)-Hexahydrofuro[2,3-B]furan-3-Ol 17-20 matrix metallopeptidase 3 Homo sapiens 113-118 15476228-16 2004 CONCLUSION: Methotrexate produced a clinical response in PsA by reducing, but not abolishing, the inflammatory infiltrate, adhesion molecule expression, and MMP-3 and proinflammatory cytokine gene expression, particularly IL-8, in the synovium. Methotrexate 12-24 matrix metallopeptidase 3 Homo sapiens 157-162 15491416-1 2004 BACKGROUND: Recent studies have shown that collagen-degrading matrix metalloproteinase (MMP)-1 and MMP-3 are produced by fibroblasts in response to photodynamic therapy (PDT) with 5-aminolaevulinic acid (ALA) and are considered to be involved in the antisclerotic effects of ALA-PDT observed in the treatment of localized scleroderma. Aminolevulinic Acid 180-202 matrix metallopeptidase 3 Homo sapiens 99-104 15491416-1 2004 BACKGROUND: Recent studies have shown that collagen-degrading matrix metalloproteinase (MMP)-1 and MMP-3 are produced by fibroblasts in response to photodynamic therapy (PDT) with 5-aminolaevulinic acid (ALA) and are considered to be involved in the antisclerotic effects of ALA-PDT observed in the treatment of localized scleroderma. Aminolevulinic Acid 204-207 matrix metallopeptidase 3 Homo sapiens 99-104 15491416-1 2004 BACKGROUND: Recent studies have shown that collagen-degrading matrix metalloproteinase (MMP)-1 and MMP-3 are produced by fibroblasts in response to photodynamic therapy (PDT) with 5-aminolaevulinic acid (ALA) and are considered to be involved in the antisclerotic effects of ALA-PDT observed in the treatment of localized scleroderma. Aminolevulinic Acid 275-278 matrix metallopeptidase 3 Homo sapiens 99-104 15491416-6 2004 Fibroblasts treated with keratinocyte-conditioned media after PDT showed an induction of MMP-1 and MMP-3 protein levels up to threefold in both models used, suggesting that ALA-PDT modulates MMP-1 and MMP-3 production via indirect mechanisms. Aminolevulinic Acid 173-176 matrix metallopeptidase 3 Homo sapiens 99-104 15491416-6 2004 Fibroblasts treated with keratinocyte-conditioned media after PDT showed an induction of MMP-1 and MMP-3 protein levels up to threefold in both models used, suggesting that ALA-PDT modulates MMP-1 and MMP-3 production via indirect mechanisms. Aminolevulinic Acid 173-176 matrix metallopeptidase 3 Homo sapiens 201-206 16035398-3 2004 Nimesulide significantly reduced the serum levels of both HA and MMP-3, whereas ibuprofen increased moderately but significantly the serum concentrations of MMP-3 and had no effect on the serum concentrations of HA. nimesulide 0-10 matrix metallopeptidase 3 Homo sapiens 65-70 16035398-3 2004 Nimesulide significantly reduced the serum levels of both HA and MMP-3, whereas ibuprofen increased moderately but significantly the serum concentrations of MMP-3 and had no effect on the serum concentrations of HA. Ibuprofen 80-89 matrix metallopeptidase 3 Homo sapiens 157-162 15472228-7 2004 RT-PCR analysis revealed that the treatment with T(3) increased the expression of MMP-2, MMP-3, fetal FN, and integrin alpha(5)beta(1) mRNA in subsequent 24-h cultured EVTs compared with those in control cultures. evts 168-172 matrix metallopeptidase 3 Homo sapiens 89-94 15383690-0 2004 Hyaluronate inhibits the interleukin-1beta-induced expression of matrix metalloproteinase (MMP)-1 and MMP-3 in human synovial cells. hyaluronate 0-11 matrix metallopeptidase 3 Homo sapiens 102-107 15288123-6 2004 Beta-carotene suppressed UVA-induction of MMP-1, MMP-3, and MMP-10, three major matrix metalloproteases involved in photoaging. beta Carotene 0-13 matrix metallopeptidase 3 Homo sapiens 49-54 15358181-3 2004 After the AP-1 inhibition by curcumin analogs in TPA-treated HT-1080 human fibrosarcoma cells, a decrease in mRNA expression of c-jun and MMP3 (stromelysin-1) has been observed. Curcumin 29-37 matrix metallopeptidase 3 Homo sapiens 138-142 15358181-3 2004 After the AP-1 inhibition by curcumin analogs in TPA-treated HT-1080 human fibrosarcoma cells, a decrease in mRNA expression of c-jun and MMP3 (stromelysin-1) has been observed. Curcumin 29-37 matrix metallopeptidase 3 Homo sapiens 144-157 15358181-3 2004 After the AP-1 inhibition by curcumin analogs in TPA-treated HT-1080 human fibrosarcoma cells, a decrease in mRNA expression of c-jun and MMP3 (stromelysin-1) has been observed. Tetradecanoylphorbol Acetate 49-52 matrix metallopeptidase 3 Homo sapiens 144-157 15185339-10 2004 G-Gly significantly enhanced the production of MMP-3, an activator of MMP-1 and -9, as well as gelatinase MMP-9 activity. g-gly 0-5 matrix metallopeptidase 3 Homo sapiens 47-52 15185339-11 2004 The G-Gly-mediated MMP-9 increase was inhibited by treatment with anti-MMP-3 IgG and MMP-3 siRNA. g-gly 4-9 matrix metallopeptidase 3 Homo sapiens 71-76 15185339-11 2004 The G-Gly-mediated MMP-9 increase was inhibited by treatment with anti-MMP-3 IgG and MMP-3 siRNA. g-gly 4-9 matrix metallopeptidase 3 Homo sapiens 85-90 15185339-16 2004 Together, these results demonstrate that G-Gly renders colon cancer cells more invasive by increasing MMP-1 and MMP-3 expressions via the putative G-Gly receptor and would thus be a good molecular target in a clinical setting. g-gly 41-46 matrix metallopeptidase 3 Homo sapiens 112-117 15472228-8 2004 Immunocytochemical and Western immunoblot analyses revealed that treatment with T(3) increased the expression of MMP-2 and MMP-3 in subsequent 48-h cultured EVTs compared with those in control cultures. Triiodothyronine 80-84 matrix metallopeptidase 3 Homo sapiens 123-128 15472228-8 2004 Immunocytochemical and Western immunoblot analyses revealed that treatment with T(3) increased the expression of MMP-2 and MMP-3 in subsequent 48-h cultured EVTs compared with those in control cultures. evts 157-161 matrix metallopeptidase 3 Homo sapiens 123-128 15194586-0 2004 Simvastatin reduces MMP-3 level in interleukin 1beta stimulated human chondrocyte culture. Simvastatin 0-11 matrix metallopeptidase 3 Homo sapiens 20-25 15194586-4 2004 We thus decided to investigate the effect of simvastatin on the production of MMP-3 from cultured interleukin (IL)1 stimulated human chondrocytes. Simvastatin 45-56 matrix metallopeptidase 3 Homo sapiens 78-83 15194586-8 2004 Incubation with simvastatin was associated with a dose dependent reduction in MMP-3 increase, both in the presence (-15%, -17%, and -26% with 5, 10, and 50 micromol/l, respectively) and in the absence (-32% with 50 micromol/l) of IL1beta. Simvastatin 16-27 matrix metallopeptidase 3 Homo sapiens 78-83 15194586-10 2004 CONCLUSIONS: Our data show that simvastatin, by blocking HMGCoA-reductase and interfering in the prenylation processes, is able to inhibit MMP-3 production from cultured human chondrocytes that have been either unstimulated or stimulated with IL1beta, thus suggesting a possible additional mechanism for statins in counteracting chronic joint disease related cartilage damage. Simvastatin 32-43 matrix metallopeptidase 3 Homo sapiens 139-144 19379421-13 2004 For the evaluation of the pathophysiologic state of DRA, serum MMP-3 may be a useful predictor indicative of chronic inflammation and osteoarticular disorders in DRA patients. dra 52-55 matrix metallopeptidase 3 Homo sapiens 63-68 15163188-0 2004 A molecular basis for the selectivity of thiadiazole urea inhibitors with stromelysin-1 and gelatinase-A from generalized born molecular dynamics simulations. thiadiazole urea 41-57 matrix metallopeptidase 3 Homo sapiens 74-87 15163188-3 2004 In this study, we have used computational methods to model the selectivity for six thiadiazole urea inhibitors with stromelysin-1 and gelatinase-A, two homologous MMPs that have been implicated in breast cancer. thiadiazole urea 83-99 matrix metallopeptidase 3 Homo sapiens 116-129 15163188-3 2004 In this study, we have used computational methods to model the selectivity for six thiadiazole urea inhibitors with stromelysin-1 and gelatinase-A, two homologous MMPs that have been implicated in breast cancer. thiadiazole urea 83-99 matrix metallopeptidase 3 Homo sapiens 163-167 15047712-7 2004 Inhibition of the MAPK pathway using the pharmacological inhibitors PD98059, U0126, and SB203580 in T98G LGI1-null cells inhibits MMP1 and MMP3 production in an ERK1/2-dependent manner. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 68-75 matrix metallopeptidase 3 Homo sapiens 139-143 15047712-7 2004 Inhibition of the MAPK pathway using the pharmacological inhibitors PD98059, U0126, and SB203580 in T98G LGI1-null cells inhibits MMP1 and MMP3 production in an ERK1/2-dependent manner. U 0126 77-82 matrix metallopeptidase 3 Homo sapiens 139-143 15047712-7 2004 Inhibition of the MAPK pathway using the pharmacological inhibitors PD98059, U0126, and SB203580 in T98G LGI1-null cells inhibits MMP1 and MMP3 production in an ERK1/2-dependent manner. SB 203580 88-96 matrix metallopeptidase 3 Homo sapiens 139-143 15196384-1 2004 OBJECTIVE: To investigate the influence of baicalin on the IL-1beta induced pro-MMP-1 in HGF and the effects of baicalin on MMP-3 expression in periodontal ligament cells (PDLCs). baicalin 112-120 matrix metallopeptidase 3 Homo sapiens 124-129 15102660-10 2004 A multivariate analysis, including tumor stage, gender, TP53 mutations, and MMP3 polymorphism, showed that the 6A/6A genotype was an independent factor of response to 5-fluorouracil-cisplatin chemotherapy in head and neck cancer patients with an odds ratio of 6.7 as compared with the 5A/5A genotype. Fluorouracil 167-181 matrix metallopeptidase 3 Homo sapiens 76-80 15102660-10 2004 A multivariate analysis, including tumor stage, gender, TP53 mutations, and MMP3 polymorphism, showed that the 6A/6A genotype was an independent factor of response to 5-fluorouracil-cisplatin chemotherapy in head and neck cancer patients with an odds ratio of 6.7 as compared with the 5A/5A genotype. Cisplatin 182-191 matrix metallopeptidase 3 Homo sapiens 76-80 14981131-2 2004 In the present study, we investigated whether PGE2 regulated interleukin (IL)-1beta-induced matrix metalloproteinase (MMP)-3 production in human gingival fibroblasts (HGF) derived from periodontally healthy subjects and diseased patients. Dinoprostone 46-50 matrix metallopeptidase 3 Homo sapiens 92-124 14981131-3 2004 In HGF from healthy gingiva, PGE2 down-regulated IL-1beta-induced MMP-3 production, whereas in HGF from periodontitis patients, PGE2 enhanced it. Dinoprostone 29-33 matrix metallopeptidase 3 Homo sapiens 66-71 14981131-4 2004 Butaprost (an EP2 agonist) and ONO-AE1-329 (an EP4 agonist) suppressed IL-1beta-induced MMP-3 production, and 17-phenyl-omega-trinor PGE2 (an EP1 agonist) mimicked the PGE(2) effect in HGF from healthy and periodontally diseased tissues, respectively. butaprost 0-9 matrix metallopeptidase 3 Homo sapiens 88-93 14981131-4 2004 Butaprost (an EP2 agonist) and ONO-AE1-329 (an EP4 agonist) suppressed IL-1beta-induced MMP-3 production, and 17-phenyl-omega-trinor PGE2 (an EP1 agonist) mimicked the PGE(2) effect in HGF from healthy and periodontally diseased tissues, respectively. ONO-AE1-329 31-42 matrix metallopeptidase 3 Homo sapiens 88-93 14981131-5 2004 Analysis of these data suggests that, in HGF from healthy tissue, IL-1beta-induced MMP-3 production is down-regulated by PGE2 via EP2 and EP4 receptors, whereas in cells from periodontally diseased tissue, IL-1beta-induced MMP-3 production is up-regulated via EP1 receptors. Dinoprostone 121-125 matrix metallopeptidase 3 Homo sapiens 83-88 14981131-6 2004 Different regulation of IL-1beta-induced MMP-3 production by PGE2 between healthy and periodontally diseased tissues may be involved in the pathogenesis of periodontal disease. Dinoprostone 61-65 matrix metallopeptidase 3 Homo sapiens 41-46 15095982-3 2004 Furthermore, the binding mode of N-isobutyl-N-[4-methoxyphenylsulfonyl]glycyl hydroxamic acid (NNGH), which is one of the most known commercial inhibitors of MMPs, is described for the first time. N-isobutyl-N-(4-methoxyphenylsulfonyl)glycylhydroxamic acid 33-93 matrix metallopeptidase 3 Homo sapiens 158-162 15095982-3 2004 Furthermore, the binding mode of N-isobutyl-N-[4-methoxyphenylsulfonyl]glycyl hydroxamic acid (NNGH), which is one of the most known commercial inhibitors of MMPs, is described for the first time. N-isobutyl-N-(4-methoxyphenylsulfonyl)glycylhydroxamic acid 95-99 matrix metallopeptidase 3 Homo sapiens 158-162 14730623-11 2004 In this cascade, Pyk-2, Src, and p38 kinases transduce MSU-induced NO production and MMP-3 expression. Uric Acid 55-58 matrix metallopeptidase 3 Homo sapiens 85-90 14757164-7 2004 The influence of elaidic acid on the plasmin/MMP-3/MMP-1 proteolytic cascade was assessed ex vivo. elaidic acid 17-29 matrix metallopeptidase 3 Homo sapiens 45-50 14741775-5 2004 AdHuPA transduction resulted in clear-cut expression of human uPA protein detected by immunohistochemistry and induction of up-regulation in the expression of metalloproteinases MMP-3, MMP-9, and MMP-2. adhupa 0-6 matrix metallopeptidase 3 Homo sapiens 178-183 14642591-1 2003 The design, synthesis, and structure-activity relationship (SAR) of a series of novel nonpeptidic cyclic phosphon- and phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases MMP-1, MMP-3, and MMP-9 are presented. cyclic phosphon- and phosphinamide-based hydroxamic acids 98-155 matrix metallopeptidase 3 Homo sapiens 206-211 14611841-0 2003 MMPs inhibitors: new succinylhydroxamates with selective inhibition of MMP-2 over MMP-3. succinylhydroxamates 21-41 matrix metallopeptidase 3 Homo sapiens 82-87 14613270-8 2003 KS epitope content was reduced in direct relation to SM macrophage infiltration in the sublining and lining layers and in the presence of elevated SF MMP-3. Keratan Sulfate 0-2 matrix metallopeptidase 3 Homo sapiens 150-155 12881409-9 2003 MMP-3-mediated processing of proMMP-9 was accelerated by galectin-8, and this effect was inhibited by lactose. Lactose 102-109 matrix metallopeptidase 3 Homo sapiens 0-5 14517614-5 2003 After a specific comparison with one member of the matrix metalloproteases, MMP-3, a common conserved valine residue at the primary S1" subsite was found to be shared between these two otherwise different proteases. Valine 102-108 matrix metallopeptidase 3 Homo sapiens 76-81 14653204-5 2003 On the contrary, two combination assays, "MMP-3 or CARF" and "MMP-3 or anti-CCP", showed the highest sensitivity(86.7%) for RA. Radium 124-126 matrix metallopeptidase 3 Homo sapiens 42-47 14653204-5 2003 On the contrary, two combination assays, "MMP-3 or CARF" and "MMP-3 or anti-CCP", showed the highest sensitivity(86.7%) for RA. Radium 124-126 matrix metallopeptidase 3 Homo sapiens 62-67 14638715-9 2003 An upregulation of MMP-3 and TIMP-2 after latanoprost treatment of the fibroblasts was shown and found to occur on the mRNA and the protein levels. Latanoprost 42-53 matrix metallopeptidase 3 Homo sapiens 19-24 14638715-12 2003 The levels of MMP-3 and TIMP-2 increase after treatment with latanoprost. Latanoprost 61-72 matrix metallopeptidase 3 Homo sapiens 14-19 14611841-1 2003 Some ilomastat analogues featuring an isobutylidene group or a 2-substituted indole nucleus were synthesized to evaluate their inhibitory activities against gelatinase A and stromelysin-1. ilomastat 5-14 matrix metallopeptidase 3 Homo sapiens 174-187 14713188-4 2003 By modeling a natural substrate spanning P4-P4" in complex with the catalytic domains, we aim to compare substrate-specificities between Stromelysin-1 (MMP-3), ADAM-9 and ADAM-10, with the aid of molecular dynamics simulations. p4-p4 41-46 matrix metallopeptidase 3 Homo sapiens 137-150 14713188-4 2003 By modeling a natural substrate spanning P4-P4" in complex with the catalytic domains, we aim to compare substrate-specificities between Stromelysin-1 (MMP-3), ADAM-9 and ADAM-10, with the aid of molecular dynamics simulations. p4-p4 41-46 matrix metallopeptidase 3 Homo sapiens 152-157 12882800-0 2003 Aqueous outflow-enhancing effect of tert-butylhydroquinone: involvement of AP-1 activation and MMP-3 expression. 2-tert-butylhydroquinone 36-58 matrix metallopeptidase 3 Homo sapiens 95-100 12882800-5 2003 RESULTS: AP-1 stimulators, such as beta-naphthoflavone, 3-methylcholanthrene, and tBHQ, significantly upregulated (2-4-fold) TM cell expression of MMP-3. beta-Naphthoflavone 35-54 matrix metallopeptidase 3 Homo sapiens 147-152 12882800-5 2003 RESULTS: AP-1 stimulators, such as beta-naphthoflavone, 3-methylcholanthrene, and tBHQ, significantly upregulated (2-4-fold) TM cell expression of MMP-3. Methylcholanthrene 56-76 matrix metallopeptidase 3 Homo sapiens 147-152 12882800-5 2003 RESULTS: AP-1 stimulators, such as beta-naphthoflavone, 3-methylcholanthrene, and tBHQ, significantly upregulated (2-4-fold) TM cell expression of MMP-3. 2-tert-butylhydroquinone 82-86 matrix metallopeptidase 3 Homo sapiens 147-152 12882800-10 2003 CONCLUSIONS: An AP-1 activator, tBHQ, upregulated expression of MMP-3 in cultured human TM cells and perfused human eyes and enhanced outflow ex vivo. 2-tert-butylhydroquinone 32-36 matrix metallopeptidase 3 Homo sapiens 64-69 12695157-12 2003 CONCLUSION: Leflunomide may modulate the rheumatoid articular process by inhibition of local production of IL1beta, TNFalpha, NO, and MMP-3. Leflunomide 12-23 matrix metallopeptidase 3 Homo sapiens 134-139 12880581-9 2003 DHEA suppressed the expression of MMP-1 significantly at concentrations exceeding 50 micro M. The gene expression of MMP-3 was also suppressed, but this was without statistical significance. Dehydroepiandrosterone 0-4 matrix metallopeptidase 3 Homo sapiens 117-122 12880581-10 2003 The expression of TIMP-1 was significantly increased by DHEA at concentrations exceeding 10 micro M. The effects of DHEA on the gene expressions of MMP-1 and -3 were more prominent in the presence of IL-1beta, in which DHEA suppressed not only MMP-1, but also MMP-3 at the lower concentrations, 10 and 50 micro M, respectively. Dehydroepiandrosterone 116-120 matrix metallopeptidase 3 Homo sapiens 260-265 12880581-10 2003 The expression of TIMP-1 was significantly increased by DHEA at concentrations exceeding 10 micro M. The effects of DHEA on the gene expressions of MMP-1 and -3 were more prominent in the presence of IL-1beta, in which DHEA suppressed not only MMP-1, but also MMP-3 at the lower concentrations, 10 and 50 micro M, respectively. Dehydroepiandrosterone 116-120 matrix metallopeptidase 3 Homo sapiens 260-265 12824028-0 2003 Phosphinic acid-based MMP-13 inhibitors that spare MMP-1 and MMP-3. Phosphinic Acids 0-15 matrix metallopeptidase 3 Homo sapiens 61-66 12824233-1 2003 PURPOSE: This study investigated the regulated expression of collagenases (MMP-1, -8, and -13) and stromelysins (MMP-3, -10, and -11) by human corneal epithelial cells treated with IL-1 beta, TNF-alpha, and doxycycline, a medication used to treat ocular surface diseases. Doxycycline 207-218 matrix metallopeptidase 3 Homo sapiens 113-132 12801609-4 2003 Our results clearly indicate that high glucose (25 mM) induced endothelial cell expression and activity of the collagenase, MMP-1 and the gelatinase, MMP-2, whilst reducing expression of the stromelysin, MMP-3 (P<0.05). Glucose 39-46 matrix metallopeptidase 3 Homo sapiens 204-209 12761889-0 2003 ATP modulates load-inducible IL-1beta, COX 2, and MMP-3 gene expression in human tendon cells. Adenosine Triphosphate 0-3 matrix metallopeptidase 3 Homo sapiens 50-55 12727228-5 2003 Blockade of the ERK pathway by treatment with PD184352, a specific and powerful inhibitor of mitogen-activated protein (MAP) kinase/ERK kinase (MEK), suppressed the expression of MMP-3, MMP-9, MMP-14, and CD44, and inhibited markedly the invasiveness of tumor cells. 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide 46-54 matrix metallopeptidase 3 Homo sapiens 179-184 12855000-3 2003 Peptide Mca-Arg-Pro-Lys-Pro-Val-Glu-Nva-Trp-Arg-Lys(Dnp)-NH(2) is a matrix-metalloproteinase 3 (MMP-3) enzyme substrate that the authors have labeled with a CyDye pair, Cy3/Cy5Q. Arginine 12-15 matrix metallopeptidase 3 Homo sapiens 68-94 12777073-8 2003 HCEC show a decrease of MMP-3 and MMP-2 protein when treated with SU5416, a VEGF-R2 (KDR/flk-1) inhibitor, whereas MMP expression remained unchanged in HUVEC. Semaxinib 66-72 matrix metallopeptidase 3 Homo sapiens 24-29 12608905-8 2003 Induction of MMP-3 after the stimulation with bFGF was observed as early as 12 h with maximal at 24 h. Thereafter, the MMP-3 mRNA level gradually decreased until 72 h. Cycloheximide blocked the induction of MMP-3 by bFGF, indicating the requirement of de novo protein synthesis for this stimulation. Cycloheximide 168-181 matrix metallopeptidase 3 Homo sapiens 13-18 12608905-8 2003 Induction of MMP-3 after the stimulation with bFGF was observed as early as 12 h with maximal at 24 h. Thereafter, the MMP-3 mRNA level gradually decreased until 72 h. Cycloheximide blocked the induction of MMP-3 by bFGF, indicating the requirement of de novo protein synthesis for this stimulation. Cycloheximide 168-181 matrix metallopeptidase 3 Homo sapiens 119-124 12608905-8 2003 Induction of MMP-3 after the stimulation with bFGF was observed as early as 12 h with maximal at 24 h. Thereafter, the MMP-3 mRNA level gradually decreased until 72 h. Cycloheximide blocked the induction of MMP-3 by bFGF, indicating the requirement of de novo protein synthesis for this stimulation. Cycloheximide 168-181 matrix metallopeptidase 3 Homo sapiens 119-124 12608905-9 2003 Furthermore, MMP-3 expression induced by bFGF was abrogated by U0126, a specific inhibitor of MEK1/2 and ERK1/2 in mitogen-activated protein (MAP) kinase pathway, not by PD98059, a specific inhibitor of MEK1. U 0126 63-68 matrix metallopeptidase 3 Homo sapiens 13-18 12634064-2 2003 The interaction of N-TIMP-1 with the catalytic domain of MMP-3 has been investigated by titration calorimetry and 15N NMR. 15n 114-117 matrix metallopeptidase 3 Homo sapiens 57-62 12855000-3 2003 Peptide Mca-Arg-Pro-Lys-Pro-Val-Glu-Nva-Trp-Arg-Lys(Dnp)-NH(2) is a matrix-metalloproteinase 3 (MMP-3) enzyme substrate that the authors have labeled with a CyDye pair, Cy3/Cy5Q. Arginine 12-15 matrix metallopeptidase 3 Homo sapiens 96-101 12855000-3 2003 Peptide Mca-Arg-Pro-Lys-Pro-Val-Glu-Nva-Trp-Arg-Lys(Dnp)-NH(2) is a matrix-metalloproteinase 3 (MMP-3) enzyme substrate that the authors have labeled with a CyDye pair, Cy3/Cy5Q. 2,4-Dinitrophenol 52-55 matrix metallopeptidase 3 Homo sapiens 68-94 12855000-3 2003 Peptide Mca-Arg-Pro-Lys-Pro-Val-Glu-Nva-Trp-Arg-Lys(Dnp)-NH(2) is a matrix-metalloproteinase 3 (MMP-3) enzyme substrate that the authors have labeled with a CyDye pair, Cy3/Cy5Q. 2,4-Dinitrophenol 52-55 matrix metallopeptidase 3 Homo sapiens 96-101 12855000-3 2003 Peptide Mca-Arg-Pro-Lys-Pro-Val-Glu-Nva-Trp-Arg-Lys(Dnp)-NH(2) is a matrix-metalloproteinase 3 (MMP-3) enzyme substrate that the authors have labeled with a CyDye pair, Cy3/Cy5Q. cy3 169-172 matrix metallopeptidase 3 Homo sapiens 68-94 12855000-3 2003 Peptide Mca-Arg-Pro-Lys-Pro-Val-Glu-Nva-Trp-Arg-Lys(Dnp)-NH(2) is a matrix-metalloproteinase 3 (MMP-3) enzyme substrate that the authors have labeled with a CyDye pair, Cy3/Cy5Q. cy3 169-172 matrix metallopeptidase 3 Homo sapiens 96-101 12594231-3 2003 When RSF in monolayer culture were incubated with COOH-HBFN-f, COOH-HBFN-f stimulated the production of MMP-1, MMP-3, and MMP-13 by RSF in association with activation of extracellular signal-regulated kinase, p38 MAPK, and c-Jun NH(2)-terminal kinase. (3r,3as,6ar)-Hexahydrofuro[2,3-B]furan-3-Ol 5-8 matrix metallopeptidase 3 Homo sapiens 111-116 12594231-3 2003 When RSF in monolayer culture were incubated with COOH-HBFN-f, COOH-HBFN-f stimulated the production of MMP-1, MMP-3, and MMP-13 by RSF in association with activation of extracellular signal-regulated kinase, p38 MAPK, and c-Jun NH(2)-terminal kinase. (3r,3as,6ar)-Hexahydrofuro[2,3-B]furan-3-Ol 132-135 matrix metallopeptidase 3 Homo sapiens 111-116 12952186-15 2003 24R,25(OH)2D3 inhibits PKCzeta in MV from resting zone cell cultures and inhibits MMP-3 release. 24,25-Dihydroxyvitamin D 3 0-13 matrix metallopeptidase 3 Homo sapiens 82-87 12825130-7 2003 A c-Jun/activating protein-1 (AP-1) inhibitor, curcumin, reduced the IL-17-, IL-1beta-, and TNF-alpha-induced MMP-3 mRNA expression, and mitogen-activated protein (MAP) kinase inhibitors (U0126, PD098059, and SB203580) also blocked MMP-3 secretion. Curcumin 47-55 matrix metallopeptidase 3 Homo sapiens 110-115 12745675-5 2003 Incubation in 10(-7) and 10(-5) M fluoride resulted in a decrease in expression of the 45-kD MMP, sharp increases in the expression of MMP-3, and the appearance of a band at 110 kD, which showed immunoreactivity for MMP-9. Fluorides 34-42 matrix metallopeptidase 3 Homo sapiens 135-140 12825130-7 2003 A c-Jun/activating protein-1 (AP-1) inhibitor, curcumin, reduced the IL-17-, IL-1beta-, and TNF-alpha-induced MMP-3 mRNA expression, and mitogen-activated protein (MAP) kinase inhibitors (U0126, PD098059, and SB203580) also blocked MMP-3 secretion. Curcumin 47-55 matrix metallopeptidase 3 Homo sapiens 232-237 12440501-9 2002 The addition of dexamethasone to IL-1beta-stimulated chondrocytes further reduced the PG concentration by 19% at 10(-5) M and by 17% at 10(-7) M. The MMP-3 expression was inhibited between 27-53% and the AGG expression between 30-46% by dexamethasone. Dexamethasone 16-29 matrix metallopeptidase 3 Homo sapiens 150-155 12477346-1 2002 The NMR-based discovery of biaryl hydroxamate inhibitors of the matrix metalloproteinase stromelysin (MMP-3) has been previously described (Hajduk et al. biaryl hydroxamate 27-45 matrix metallopeptidase 3 Homo sapiens 102-107 12510357-3 2002 Recent reports indicated that methotrexate or anti-TNF alpha therapy effectively suppressed the serum MMP-3 level during the course of the treatment, whereas corticosteroid didn"t. Methotrexate 30-42 matrix metallopeptidase 3 Homo sapiens 102-107 12401069-3 2002 As a structural reference, X-ray data on the stromelysin-1 catalytic domain (SCD) complexed to the transition state analogue diphenyl piperidine sulfonamide inhibitor was used. diphenyl piperidine sulfonamide 125-156 matrix metallopeptidase 3 Homo sapiens 45-58 12485830-8 2002 Finally, a potentially novel aspect in UVB irradiation-mediated expression of interstitial collagenase and stromelysin-1-namely, the involvement of reactive nitrogen species (RNS)-is discussed. Reactive Nitrogen Species 175-178 matrix metallopeptidase 3 Homo sapiens 107-120 12428247-9 2002 Preincubation with ciprofloxacin potentiated IL-1beta-stimulated MMP-3 output, reflecting a similar effect on MMP-3 mRNA expression. Ciprofloxacin 19-32 matrix metallopeptidase 3 Homo sapiens 65-70 12428247-9 2002 Preincubation with ciprofloxacin potentiated IL-1beta-stimulated MMP-3 output, reflecting a similar effect on MMP-3 mRNA expression. Ciprofloxacin 19-32 matrix metallopeptidase 3 Homo sapiens 110-115 12440501-9 2002 The addition of dexamethasone to IL-1beta-stimulated chondrocytes further reduced the PG concentration by 19% at 10(-5) M and by 17% at 10(-7) M. The MMP-3 expression was inhibited between 27-53% and the AGG expression between 30-46% by dexamethasone. Dexamethasone 237-250 matrix metallopeptidase 3 Homo sapiens 150-155 12440501-10 2002 In osteoarthrotic chondrocytes, dexamethasone in an appropriate dose range reduced the expression of MMP-3 and AGG at the same time. Dexamethasone 32-45 matrix metallopeptidase 3 Homo sapiens 101-106 12204805-1 2002 Matrix metalloproteinase 3 (MMP3) is expressed in human coronary atherosclerotic lesions and is known to be involved in degradation of the plaque and to be co-localized with calcium and fibrin deposits in advanced lesions, indicating a possible role of MMP3 in arterial calcification. Calcium 174-181 matrix metallopeptidase 3 Homo sapiens 0-26 12204805-1 2002 Matrix metalloproteinase 3 (MMP3) is expressed in human coronary atherosclerotic lesions and is known to be involved in degradation of the plaque and to be co-localized with calcium and fibrin deposits in advanced lesions, indicating a possible role of MMP3 in arterial calcification. Calcium 174-181 matrix metallopeptidase 3 Homo sapiens 28-32 12364474-9 2002 However, in vitro treatments with retinoic acid and TGF beta restored the ability of progesterone to suppress MMPs in vitro and prevented the establishment of experimental disease. Tretinoin 34-47 matrix metallopeptidase 3 Homo sapiens 110-114 12364474-9 2002 However, in vitro treatments with retinoic acid and TGF beta restored the ability of progesterone to suppress MMPs in vitro and prevented the establishment of experimental disease. Progesterone 85-97 matrix metallopeptidase 3 Homo sapiens 110-114 12117684-4 2002 RESULTS: The HAC cultures showed a significant increase in MMP-13 and MMP-3 production (2.2- and 1.9-fold, respectively) after treatment with 20 microM histamine for 24 hours, but MMP-1 and MMP-8 were unaffected. Histamine 152-161 matrix metallopeptidase 3 Homo sapiens 70-75 12060661-3 2002 Inhibition of p38 activity by SB203580 markedly (by 80-90%) inhibited induction of MMP-1 and MMP-3 expression by tumor necrosis factor-alpha, whereas blocking the activation of ERK1/2 by PD98059 had no effect. SB 203580 30-38 matrix metallopeptidase 3 Homo sapiens 93-98 12117684-7 2002 CONCLUSIONS: Histamine exposure increased both MMP-13 and MMP-3 production by HAC in vitro, thereby suggesting a pathophysiological role in the chondrocytic phenotype associated with degenerative changes in osteoarthritis. Histamine 13-22 matrix metallopeptidase 3 Homo sapiens 58-63 12165097-4 2002 Incubation of FLS with a synthetic PPARgamma ligand, troglitazone, inhibited endogenous production of TNF-alpha, IL-6 and IL-8, as well as matrix metalloprotease-3 (MMP-3), without inducing apoptosis of the cells. Troglitazone 53-65 matrix metallopeptidase 3 Homo sapiens 139-163 12071839-5 2002 Preincubation of fibroblasts with DRB prior to UVB irradiation lowered MMP-1 by 49-69% and MMP-3 protein levels by 55-63% compared with UVB-irradiated controls. Dichlororibofuranosylbenzimidazole 34-37 matrix metallopeptidase 3 Homo sapiens 91-96 12165097-4 2002 Incubation of FLS with a synthetic PPARgamma ligand, troglitazone, inhibited endogenous production of TNF-alpha, IL-6 and IL-8, as well as matrix metalloprotease-3 (MMP-3), without inducing apoptosis of the cells. Troglitazone 53-65 matrix metallopeptidase 3 Homo sapiens 165-170 12206592-6 2002 In addition, MMP-1 and MMP-3 production, induced by IL-1beta, TNFalpha or EGF, was strongly reduced by the presence of the glucocorticoid dexamethasone. Dexamethasone 138-151 matrix metallopeptidase 3 Homo sapiens 23-28 12009331-7 2002 Inhibitor of JNK, AP-1 and NF-kappa B, curcumin, achieved 48-99% suppression of MMP-3 and 45-97% of MMP-13 in human and 8-100% (MMP-3) and 32-100% (MMP-13) in bovine chondrocytes. Curcumin 39-47 matrix metallopeptidase 3 Homo sapiens 80-85 12437092-5 2002 Investigation of MMP family hydrolysis of THPs showed kcat/Km values in the order of MMP-13 > MMP-1 approximately MMP-1(delta243-450) approximately MMP-2 >> MMP-3. tetramethylolphosphonium chloride 42-46 matrix metallopeptidase 3 Homo sapiens 166-171 12166616-6 2002 During treatment with nimesulide, in addition to clinical improvement and less pain, serum levels of MMP-3, MMP-8 and COMP fell indicating a beneficial effect on cartilage catabolism. nimesulide 22-32 matrix metallopeptidase 3 Homo sapiens 101-106 12051699-8 2002 LY294002, a PI3K inhibitor, reduced PDGF-BB-stimulated MMP-3 expression in PAE cells expressing wild-type PDGF receptors. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 matrix metallopeptidase 3 Homo sapiens 55-60 12051699-9 2002 In contrast, PDGF-BB induced MMP-3 expression in the presence of U-73122, a PLCgamma inhibitor. 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione 65-72 matrix metallopeptidase 3 Homo sapiens 29-34 11854269-5 2002 Cleavage at the Asn(341)-Phe(342) site in these incubations was due to bona fide ADAMTS4 activity (and not a contaminating MMP) because the cleavage was inhibited by TIMP-3 (a potent inhibitor of ADAMTS4), but not by TIMP-1 and TIMP-2, at concentrations that totally blocked MMP-3-mediated cleavage at this site. Asparagine 16-19 matrix metallopeptidase 3 Homo sapiens 275-280 11854269-5 2002 Cleavage at the Asn(341)-Phe(342) site in these incubations was due to bona fide ADAMTS4 activity (and not a contaminating MMP) because the cleavage was inhibited by TIMP-3 (a potent inhibitor of ADAMTS4), but not by TIMP-1 and TIMP-2, at concentrations that totally blocked MMP-3-mediated cleavage at this site. Phenylalanine 25-28 matrix metallopeptidase 3 Homo sapiens 275-280 12022344-0 2002 Serum matrix metalloproteinase 3 levels during treatment with sulfasalazine or combination of methotrexate and sulfasalazine in patients with early rheumatoid arthritis. Sulfasalazine 62-75 matrix metallopeptidase 3 Homo sapiens 6-32 12022344-0 2002 Serum matrix metalloproteinase 3 levels during treatment with sulfasalazine or combination of methotrexate and sulfasalazine in patients with early rheumatoid arthritis. Methotrexate 94-106 matrix metallopeptidase 3 Homo sapiens 6-32 12022344-0 2002 Serum matrix metalloproteinase 3 levels during treatment with sulfasalazine or combination of methotrexate and sulfasalazine in patients with early rheumatoid arthritis. Sulfasalazine 111-124 matrix metallopeptidase 3 Homo sapiens 6-32 12022344-1 2002 OBJECTIVE: To determine the effects of treatment with sulfasalazine (SSZ) or the combination of methotrexate (MTX) and SSZ on serum matrix metalloproteinase 3 (MMP-3) levels in patients with early rheumatoid arthritis (RA). Sulfasalazine 54-67 matrix metallopeptidase 3 Homo sapiens 132-158 12022344-1 2002 OBJECTIVE: To determine the effects of treatment with sulfasalazine (SSZ) or the combination of methotrexate (MTX) and SSZ on serum matrix metalloproteinase 3 (MMP-3) levels in patients with early rheumatoid arthritis (RA). Sulfasalazine 54-67 matrix metallopeptidase 3 Homo sapiens 160-165 12022344-1 2002 OBJECTIVE: To determine the effects of treatment with sulfasalazine (SSZ) or the combination of methotrexate (MTX) and SSZ on serum matrix metalloproteinase 3 (MMP-3) levels in patients with early rheumatoid arthritis (RA). Sulfasalazine 69-72 matrix metallopeptidase 3 Homo sapiens 132-158 12022344-1 2002 OBJECTIVE: To determine the effects of treatment with sulfasalazine (SSZ) or the combination of methotrexate (MTX) and SSZ on serum matrix metalloproteinase 3 (MMP-3) levels in patients with early rheumatoid arthritis (RA). Sulfasalazine 69-72 matrix metallopeptidase 3 Homo sapiens 160-165 12022344-1 2002 OBJECTIVE: To determine the effects of treatment with sulfasalazine (SSZ) or the combination of methotrexate (MTX) and SSZ on serum matrix metalloproteinase 3 (MMP-3) levels in patients with early rheumatoid arthritis (RA). Methotrexate 96-108 matrix metallopeptidase 3 Homo sapiens 132-158 12022344-1 2002 OBJECTIVE: To determine the effects of treatment with sulfasalazine (SSZ) or the combination of methotrexate (MTX) and SSZ on serum matrix metalloproteinase 3 (MMP-3) levels in patients with early rheumatoid arthritis (RA). Methotrexate 96-108 matrix metallopeptidase 3 Homo sapiens 160-165 12022344-1 2002 OBJECTIVE: To determine the effects of treatment with sulfasalazine (SSZ) or the combination of methotrexate (MTX) and SSZ on serum matrix metalloproteinase 3 (MMP-3) levels in patients with early rheumatoid arthritis (RA). Methotrexate 110-113 matrix metallopeptidase 3 Homo sapiens 132-158 12022344-1 2002 OBJECTIVE: To determine the effects of treatment with sulfasalazine (SSZ) or the combination of methotrexate (MTX) and SSZ on serum matrix metalloproteinase 3 (MMP-3) levels in patients with early rheumatoid arthritis (RA). Methotrexate 110-113 matrix metallopeptidase 3 Homo sapiens 160-165 12022344-11 2002 CONCLUSION: Serum MMP-3 levels decrease in patients with early RA who respond to SSZ or to the combination of MTX and SSZ. Methotrexate 110-113 matrix metallopeptidase 3 Homo sapiens 18-23 11836255-5 2002 Because protein kinase C (PKC) is known to play an important role in signal transduction, we investigated the participation of this pathway in the BCP crystal induction of MMP-1 and MMP-3 mRNA and protein expressions in human fibroblasts. bcp 147-150 matrix metallopeptidase 3 Homo sapiens 182-187 11836255-6 2002 Using reverse transcription/polymerase chain reaction (RT-PCR) and Northern and Western blotting techniques, we show here that BCP crystal stimulation of MMP-1 and MMP-3 mRNA and protein expressions in human fibroblasts is dependent upon the calcium-dependent PKC signal transduction pathway and that the PKC alpha isozyme is specifically involved in the pathway. bcp 127-130 matrix metallopeptidase 3 Homo sapiens 164-169 11836255-6 2002 Using reverse transcription/polymerase chain reaction (RT-PCR) and Northern and Western blotting techniques, we show here that BCP crystal stimulation of MMP-1 and MMP-3 mRNA and protein expressions in human fibroblasts is dependent upon the calcium-dependent PKC signal transduction pathway and that the PKC alpha isozyme is specifically involved in the pathway. Calcium 242-249 matrix metallopeptidase 3 Homo sapiens 164-169 11836255-7 2002 We have previously shown that BCP crystal induction of MMP-1 and MMP-3 is also dependent on the p44/42 mitogen-activated protein kinase (p44/42 MAPK) signal transduction pathway. bcp 30-33 matrix metallopeptidase 3 Homo sapiens 65-70 12009331-4 2002 The ERK-MAPK pathway inhibitor, PD98059, attained 46-53% (MMP-3) and 59-66% (MMP-13) inhibition of RNA induction in human OA and 47-52% (MMP-3) and 69-73% (MMP-13) inhibition in bovine chondrocytes. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 32-39 matrix metallopeptidase 3 Homo sapiens 58-63 12009331-4 2002 The ERK-MAPK pathway inhibitor, PD98059, attained 46-53% (MMP-3) and 59-66% (MMP-13) inhibition of RNA induction in human OA and 47-52% (MMP-3) and 69-73% (MMP-13) inhibition in bovine chondrocytes. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 32-39 matrix metallopeptidase 3 Homo sapiens 137-142 12009331-5 2002 U0126 conferred 37-77% (MMP-3) and 43-73% (MMP-13) suppression in human and 77-100% (MMP-3) and 96-100% (MMP-13) in bovine chondrocytes. U 0126 0-5 matrix metallopeptidase 3 Homo sapiens 24-29 12009331-5 2002 U0126 conferred 37-77% (MMP-3) and 43-73% (MMP-13) suppression in human and 77-100% (MMP-3) and 96-100% (MMP-13) in bovine chondrocytes. U 0126 0-5 matrix metallopeptidase 3 Homo sapiens 85-90 12009331-6 2002 P38 and JNK inhibitor, SB203580 caused 35-37% reduction of MMP-3 and MMP-13 RNA in human and 36-46% (MMP-3) and 60-88% (MMP-13) in bovine chondrocytes. SB 203580 23-31 matrix metallopeptidase 3 Homo sapiens 59-64 12009331-6 2002 P38 and JNK inhibitor, SB203580 caused 35-37% reduction of MMP-3 and MMP-13 RNA in human and 36-46% (MMP-3) and 60-88% (MMP-13) in bovine chondrocytes. SB 203580 23-31 matrix metallopeptidase 3 Homo sapiens 101-106 12009331-7 2002 Inhibitor of JNK, AP-1 and NF-kappa B, curcumin, achieved 48-99% suppression of MMP-3 and 45-97% of MMP-13 in human and 8-100% (MMP-3) and 32-100% (MMP-13) in bovine chondrocytes. Curcumin 39-47 matrix metallopeptidase 3 Homo sapiens 128-133 12009331-8 2002 NF-kappaB inhibitor, pyrrolidine dithiocarbamate yielded 83-84% reduction of MMP-3 and 38-55% for MMP-13 in human chondrocytes. pyrrolidine dithiocarbamic acid 21-48 matrix metallopeptidase 3 Homo sapiens 77-82 12009335-11 2002 Addition of the general MMP inhibitor GM6001 to SCC9 beta 6/PTF co-cultures dramatically increased fibronectin matrix assembly in a similar fashion as incubation with anti-alpha v beta 6 antibodies. N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide 38-44 matrix metallopeptidase 3 Homo sapiens 24-27 11984068-1 2002 Bisphosphonates (clodronate, alendronate, pamidronate and zoledronate) at therapeutically attainable non-cytotoxic concentrations inhibited MMP-3, -12, -13 and -20 as well as MMP-1, -2, -8 and -9, but not urokinase-type plasminogen activator (uPA), a serine proteinase and a pro-MMP activator. Diphosphonates 0-15 matrix metallopeptidase 3 Homo sapiens 140-163 11984068-1 2002 Bisphosphonates (clodronate, alendronate, pamidronate and zoledronate) at therapeutically attainable non-cytotoxic concentrations inhibited MMP-3, -12, -13 and -20 as well as MMP-1, -2, -8 and -9, but not urokinase-type plasminogen activator (uPA), a serine proteinase and a pro-MMP activator. Clodronic Acid 17-27 matrix metallopeptidase 3 Homo sapiens 140-163 11984068-1 2002 Bisphosphonates (clodronate, alendronate, pamidronate and zoledronate) at therapeutically attainable non-cytotoxic concentrations inhibited MMP-3, -12, -13 and -20 as well as MMP-1, -2, -8 and -9, but not urokinase-type plasminogen activator (uPA), a serine proteinase and a pro-MMP activator. Alendronate 29-40 matrix metallopeptidase 3 Homo sapiens 140-163 11984068-1 2002 Bisphosphonates (clodronate, alendronate, pamidronate and zoledronate) at therapeutically attainable non-cytotoxic concentrations inhibited MMP-3, -12, -13 and -20 as well as MMP-1, -2, -8 and -9, but not urokinase-type plasminogen activator (uPA), a serine proteinase and a pro-MMP activator. Pamidronate 42-53 matrix metallopeptidase 3 Homo sapiens 140-163 11984068-1 2002 Bisphosphonates (clodronate, alendronate, pamidronate and zoledronate) at therapeutically attainable non-cytotoxic concentrations inhibited MMP-3, -12, -13 and -20 as well as MMP-1, -2, -8 and -9, but not urokinase-type plasminogen activator (uPA), a serine proteinase and a pro-MMP activator. Zoledronic Acid 58-69 matrix metallopeptidase 3 Homo sapiens 140-163 11831904-4 2002 The modeling study using X-ray structure of MMP-3 suggested the possible binding mode of the phosphonamide-based inhibitors. phosphonamide 93-106 matrix metallopeptidase 3 Homo sapiens 44-49 11439334-10 2001 Furthermore, trichostatin A, a potent histone deacetylase inhibitor, impaired TEL-dependent repression of the stromelysin-1 promoter. trichostatin A 13-27 matrix metallopeptidase 3 Homo sapiens 110-123 11984068-0 2002 Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines. Diphosphonates 0-15 matrix metallopeptidase 3 Homo sapiens 24-37 11984068-0 2002 Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines. Diphosphonates 0-15 matrix metallopeptidase 3 Homo sapiens 39-44 11689071-0 2001 Three-dimensional quantitative structure-activity relationship (3D-QSAR) models for a novel class of piperazine-based stromelysin-1 (MMP-3) inhibitors: applying a "divide and conquer" strategy. Piperazine 101-111 matrix metallopeptidase 3 Homo sapiens 118-131 11689071-0 2001 Three-dimensional quantitative structure-activity relationship (3D-QSAR) models for a novel class of piperazine-based stromelysin-1 (MMP-3) inhibitors: applying a "divide and conquer" strategy. Piperazine 101-111 matrix metallopeptidase 3 Homo sapiens 133-138 11713105-8 2001 Retinoic acid attenuated the induction and activation of MMP-1 and MMP-3. Tretinoin 0-13 matrix metallopeptidase 3 Homo sapiens 67-72 11691580-4 2001 Disruption of the actin stress fibers by CD induced a moderate increase of MMP-2 mRNA and a much larger stimulation of MMP-3, -9, -13 and -14 mRNAs. Cytochalasin D 41-43 matrix metallopeptidase 3 Homo sapiens 119-141 11568071-10 2001 In the EVG group, a statistically significant difference at 6-month follow-up in MMP-9 and MMP-3 mean plasma values was detected in patients who had endoleakage in comparison with patients without endoleakage (44.3+/-20.7 versus 14.6+/-7.0 ng/mL, 2P<0.005; 25+/-11.5 versus 10.3+/-5.4 ng/mL, 2P<0.005). elvitegravir 7-10 matrix metallopeptidase 3 Homo sapiens 91-96 11568071-11 2001 CONCLUSIONS: After EVG exclusion, MMP-9 and MMP-3 levels decreased to a level similar to that of patients undergoing OSR. elvitegravir 19-22 matrix metallopeptidase 3 Homo sapiens 44-49 11796404-0 2002 Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Steroids 105-112 matrix metallopeptidase 3 Homo sapiens 10-36 11796404-4 2002 MMP-3 serum levels were normal in steroid-free patients with active cutaneo-articular or renal SLE, systemic sclerosis, and vasculitides but were significantly increased in steroid treated patients. Steroids 34-41 matrix metallopeptidase 3 Homo sapiens 0-5 11796404-4 2002 MMP-3 serum levels were normal in steroid-free patients with active cutaneo-articular or renal SLE, systemic sclerosis, and vasculitides but were significantly increased in steroid treated patients. Steroids 173-180 matrix metallopeptidase 3 Homo sapiens 0-5 11802203-8 2002 We also found that the presence of melanin, a pigment produced by melanocytes, correlated with high expression levels of MMP-1 (p = 0.0002), MMP-3 (p < 0.0001) and MMP-13 (p = 0.0009). Melanins 35-42 matrix metallopeptidase 3 Homo sapiens 141-146 11903311-16 2001 The mechanisms mediating such gender differences have not been established, but the known regulatory role of sex steroids with respect to MMPs likely contributes. Steroids 113-121 matrix metallopeptidase 3 Homo sapiens 138-142 11410276-1 2001 Matrix metalloproteinase-3 (MMP-3 or stromelysin-1) hydrolyzes the Met(374)-Ser(375) (P3-P2), Glu(416)-Leu(417) and Ser(432)-Leu(433) peptide bonds in human alpha(2)-antiplasmin (alpha(2)-AP), the main physiological plasmin inhibitor. Serine 76-79 matrix metallopeptidase 3 Homo sapiens 0-33 11410276-1 2001 Matrix metalloproteinase-3 (MMP-3 or stromelysin-1) hydrolyzes the Met(374)-Ser(375) (P3-P2), Glu(416)-Leu(417) and Ser(432)-Leu(433) peptide bonds in human alpha(2)-antiplasmin (alpha(2)-AP), the main physiological plasmin inhibitor. Serine 76-79 matrix metallopeptidase 3 Homo sapiens 37-50 11410276-1 2001 Matrix metalloproteinase-3 (MMP-3 or stromelysin-1) hydrolyzes the Met(374)-Ser(375) (P3-P2), Glu(416)-Leu(417) and Ser(432)-Leu(433) peptide bonds in human alpha(2)-antiplasmin (alpha(2)-AP), the main physiological plasmin inhibitor. Glutamic Acid 94-97 matrix metallopeptidase 3 Homo sapiens 0-33 11410276-1 2001 Matrix metalloproteinase-3 (MMP-3 or stromelysin-1) hydrolyzes the Met(374)-Ser(375) (P3-P2), Glu(416)-Leu(417) and Ser(432)-Leu(433) peptide bonds in human alpha(2)-antiplasmin (alpha(2)-AP), the main physiological plasmin inhibitor. Glutamic Acid 94-97 matrix metallopeptidase 3 Homo sapiens 37-50 11410276-1 2001 Matrix metalloproteinase-3 (MMP-3 or stromelysin-1) hydrolyzes the Met(374)-Ser(375) (P3-P2), Glu(416)-Leu(417) and Ser(432)-Leu(433) peptide bonds in human alpha(2)-antiplasmin (alpha(2)-AP), the main physiological plasmin inhibitor. Serine 116-119 matrix metallopeptidase 3 Homo sapiens 0-33 11410276-1 2001 Matrix metalloproteinase-3 (MMP-3 or stromelysin-1) hydrolyzes the Met(374)-Ser(375) (P3-P2), Glu(416)-Leu(417) and Ser(432)-Leu(433) peptide bonds in human alpha(2)-antiplasmin (alpha(2)-AP), the main physiological plasmin inhibitor. Serine 116-119 matrix metallopeptidase 3 Homo sapiens 37-50 11410276-2 2001 Cleavage is completely abolished in the presence of the MMP inhibitors EDTA or 1,10-phenanthroline. Edetic Acid 71-75 matrix metallopeptidase 3 Homo sapiens 56-59 11410276-2 2001 Cleavage is completely abolished in the presence of the MMP inhibitors EDTA or 1,10-phenanthroline. 1,10-phenanthroline 79-98 matrix metallopeptidase 3 Homo sapiens 56-59 11410276-4 2001 alpha(2)-AP cleaved by MMP-3 does no longer form a stable complex with plasmin, as shown by SDS-PAGE, and does no longer interact with plasminogen, as shown by crossed immunoelectrophoresis with plasminogen added to the gel. Sodium Dodecyl Sulfate 92-95 matrix metallopeptidase 3 Homo sapiens 23-28 11434385-6 2001 In contrast, plasma MMP-2 (Rs = 0.181, p = 0.014) and MMP-3 (Rs = 0.260, p = 0.0004) levels were positively correlated with HDL-cholesterol levels. Cholesterol 128-139 matrix metallopeptidase 3 Homo sapiens 54-59 11275992-6 2001 BAY 12-9566 has inhibitory activity toward MMP-2, MMP-3 and MMP-9. Bay 12-9566 0-11 matrix metallopeptidase 3 Homo sapiens 50-55 11327602-0 2001 Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors. 5,5-disubstitutedpyrimidine-2,4,6-triones 6-47 matrix metallopeptidase 3 Homo sapiens 61-64 11327602-1 2001 The 5,5-disubstitutedpyrimidine-2,4,6-triones represent a new class of MMP inhibitors showing selectivity for the gelatinases A and B, collagenase-3, and human neutrophil collagenase. 5,5-disubstitutedpyrimidine-2,4,6-triones 4-45 matrix metallopeptidase 3 Homo sapiens 71-74 11332153-2 2001 We undertook a phase I study of BAY 12-9566, an inhibitor of MMP-2, MMP-9, and MMP-3, in patients with solid tumors to determine its safety, pharmacokinetics, and effects on potential surrogate markers of biologic activity. Bay 12-9566 32-43 matrix metallopeptidase 3 Homo sapiens 79-84 11229773-0 2001 Selectivity of inhibition of matrix metalloproteases MMP-3 and MMP-2 by succinyl hydroxamates and their carboxylic acid analogues is dependent on P3" group chirality. succinyl hydroxamates 72-93 matrix metallopeptidase 3 Homo sapiens 53-58 11207308-9 2001 Curcumin also inhibited OSM-induced MMP-1, MMP-3, MMP-13, and TIMP-3 gene expression. Curcumin 0-8 matrix metallopeptidase 3 Homo sapiens 43-48 11229774-1 2001 Structure activity relationships are described for a series of succinyl hydroxamic acids 4a-o as potent and selective inhibitors of matrix metalloprotease-3 (stromelysin-1). succinyl hydroxamic acids 63-88 matrix metallopeptidase 3 Homo sapiens 158-171 11229773-0 2001 Selectivity of inhibition of matrix metalloproteases MMP-3 and MMP-2 by succinyl hydroxamates and their carboxylic acid analogues is dependent on P3" group chirality. Carboxylic Acids 104-119 matrix metallopeptidase 3 Homo sapiens 53-58 11229773-1 2001 Structure-activity relationships are described for a series of succinyl hydroxamic acids 1a-o and their carboxylic acid analogues 2a-o as inhibitors of matrix metalloproteases MMP-3 and MMP-2. succinyl hydroxamic acids 63-88 matrix metallopeptidase 3 Homo sapiens 176-181 11229773-1 2001 Structure-activity relationships are described for a series of succinyl hydroxamic acids 1a-o and their carboxylic acid analogues 2a-o as inhibitors of matrix metalloproteases MMP-3 and MMP-2. Carboxylic Acids 104-119 matrix metallopeptidase 3 Homo sapiens 176-181 11229774-0 2001 Discovery of potent and selective succinyl hydroxamate inhibitors of matrix metalloprotease-3 (stromelysin-1). succinyl hydroxamate 34-54 matrix metallopeptidase 3 Homo sapiens 95-108 11112695-5 2001 The metalloproteinases matrilysin and stromelysin-1 both cleave E-cadherin at the cell surface and release sE-CAD into the medium. se-cad 107-113 matrix metallopeptidase 3 Homo sapiens 38-51 11460480-7 2001 Thus, stromelysin-1 (MMP-3) cleaves a 55-kDa kringle 1-4 fragment, containing the lysine binding site(s) involved in cellular binding, from plasminogen and removes a 17-kDa NH2-terminal fragment, containing the cellular receptor binding site, from urokinase (u-PA). Lysine 82-88 matrix metallopeptidase 3 Homo sapiens 6-19 11460480-7 2001 Thus, stromelysin-1 (MMP-3) cleaves a 55-kDa kringle 1-4 fragment, containing the lysine binding site(s) involved in cellular binding, from plasminogen and removes a 17-kDa NH2-terminal fragment, containing the cellular receptor binding site, from urokinase (u-PA). Lysine 82-88 matrix metallopeptidase 3 Homo sapiens 21-26 11928230-5 2001 Serum MMP-3 is increased in diseases characterized by synovitis but also by steroid therapy. Steroids 76-83 matrix metallopeptidase 3 Homo sapiens 6-11 10967118-1 2000 Matrix metalloproteinase-3 (MMP-3 or stromelysin-1) specifically hydrolyzes the Ser(337)-Ser(338) (P10-P9) and Val(341)-Ile(342) (P6-P5) peptide bonds in human plasminogen activator inhibitor-1 (PAI-1). Serine 80-83 matrix metallopeptidase 3 Homo sapiens 0-33 11694815-5 2001 Dexamethasone attenuated both IL-1beta- and TGF-beta1-stimulated expressions of MMP-3 and TIMP-3. Dexamethasone 0-13 matrix metallopeptidase 3 Homo sapiens 80-85 11797317-7 2001 RESULTS: Topical prostaglandin administration that reduced scleral collagen also increased scleral MMP-1, MMP-2, and MMP-3 by 63 +/- 35%, 267 +/- 210%, and 729 +/- 500%, respectively. Prostaglandins 17-30 matrix metallopeptidase 3 Homo sapiens 117-122 10967118-1 2000 Matrix metalloproteinase-3 (MMP-3 or stromelysin-1) specifically hydrolyzes the Ser(337)-Ser(338) (P10-P9) and Val(341)-Ile(342) (P6-P5) peptide bonds in human plasminogen activator inhibitor-1 (PAI-1). Serine 80-83 matrix metallopeptidase 3 Homo sapiens 37-50 10967118-1 2000 Matrix metalloproteinase-3 (MMP-3 or stromelysin-1) specifically hydrolyzes the Ser(337)-Ser(338) (P10-P9) and Val(341)-Ile(342) (P6-P5) peptide bonds in human plasminogen activator inhibitor-1 (PAI-1). Serine 89-92 matrix metallopeptidase 3 Homo sapiens 0-33 10967118-1 2000 Matrix metalloproteinase-3 (MMP-3 or stromelysin-1) specifically hydrolyzes the Ser(337)-Ser(338) (P10-P9) and Val(341)-Ile(342) (P6-P5) peptide bonds in human plasminogen activator inhibitor-1 (PAI-1). Serine 89-92 matrix metallopeptidase 3 Homo sapiens 37-50 11069732-13 2000 As previously reported, the inhibition of NO synthesis by the competitive inhibitor L-NMMA led to enhancement of IL-6, IL-8 and PGE(2)production by IL-1 beta treated chondrocytes, but did not significantly modify IL-10, PG and MMP-3 productions. omega-N-Methylarginine 84-90 matrix metallopeptidase 3 Homo sapiens 227-232 11052988-0 2000 Butyrate upregulates stromelysin-1 production by intestinal mesenchymal cells. Butyrates 0-8 matrix metallopeptidase 3 Homo sapiens 21-34 11052988-3 2000 We hypothesized that butyrate might enhance production of MMPs, thus amplifying their response to signals in inflammatory conditions. Butyrates 21-29 matrix metallopeptidase 3 Homo sapiens 58-62 11052988-7 2000 We showed that butyrate selectively enhanced the protein production and mRNA expression of stromelysin-1 in tumor necrosis factor-alpha- or interleukin-1beta-stimulated mesenchymal cells. Butyrates 15-23 matrix metallopeptidase 3 Homo sapiens 91-104 11052988-11 2000 Although butyrate is a major source of nutrient for the colonic epithelial cells, it modulates intestinal inflammation through the secretion of stromelysin-1 in stimulated stromal cells via the inhibition of histone deacetylase. Butyrates 9-17 matrix metallopeptidase 3 Homo sapiens 144-157 11035124-8 2000 CONCLUSIONS: High-dose pulse methylprednisolone therapy is associated with a rapid (within 24 h) and substantial decrease in the expression of MMP-1 and TIMP-1 but not MMP-3 in the synovial membrane in RA. Methylprednisolone 29-47 matrix metallopeptidase 3 Homo sapiens 168-173 11043401-5 2000 Moreover, the induction of MMP-1, MMP-3 and MMP-9 mRNA expression was observed in the presence of cycloheximide, an inhibitor of protein synthesis. Cycloheximide 98-111 matrix metallopeptidase 3 Homo sapiens 34-39 11866933-11 2000 And MMP-3 may participate in calcium minerali-zation in arteries. Calcium 29-36 matrix metallopeptidase 3 Homo sapiens 4-9 11027004-6 2000 RESULTS: Treatment of explant organ cultures with 10 micrograms/ml of latanoprost induced a mean upregulation of MMP-2 by 36%, MMP-3 by 112% and MMP-9 by 156% as seen by zymography. Latanoprost 70-81 matrix metallopeptidase 3 Homo sapiens 127-132 10924354-3 2000 A thiol inhibitor MAG-283 had IC(50) values of 480, 3, 280, 14, 1.1, and 2.3 nM against human interstitial collagenase (MMP-1), gelatinase A (MMP-2), stromelysin (MMP-3), matrilysin (MMP-7), neutrophil collagenase (MMP-8), and gelatinase B (MMP-9), respectively. Sulfhydryl Compounds 2-7 matrix metallopeptidase 3 Homo sapiens 163-168 10924354-3 2000 A thiol inhibitor MAG-283 had IC(50) values of 480, 3, 280, 14, 1.1, and 2.3 nM against human interstitial collagenase (MMP-1), gelatinase A (MMP-2), stromelysin (MMP-3), matrilysin (MMP-7), neutrophil collagenase (MMP-8), and gelatinase B (MMP-9), respectively. MAG 283 18-25 matrix metallopeptidase 3 Homo sapiens 163-168 11041228-0 2000 Circulating sex hormones and endometrial stromelysin-1 (matrix metalloproteinase-3) at the start of bleeding episodes in levonorgestrel-implant users. Levonorgestrel 121-135 matrix metallopeptidase 3 Homo sapiens 41-54 10960024-6 2000 METHODS: MMP-1 and MMP-3 were assessed in cultured human periodontal ligament cells treated with a bisphosphonate, tiludronate. tiludronic acid 115-126 matrix metallopeptidase 3 Homo sapiens 19-24 10960024-10 2000 RESULTS: Tiludronate significantly inhibited both MMP-1 and MMP-3 activity in a concentration-dependent manner. tiludronic acid 9-20 matrix metallopeptidase 3 Homo sapiens 60-65 10960024-14 2000 CONCLUSIONS: This study demonstrates an inhibitory effect of tiludronate on the activity of both MMP-1 and MMP-3. tiludronic acid 61-72 matrix metallopeptidase 3 Homo sapiens 107-112 11027004-7 2000 Dexamethasone 500 nm reduced the amounts of secreted MMP-2 by 13%, MMP-3 by 69%. Dexamethasone 0-13 matrix metallopeptidase 3 Homo sapiens 67-72 11027004-9 2000 The addition of 10 micrograms/ml of latanoprost to dexamethasone-treated cultures increased MMP-2 by 14%, MMP-3 by 43% and MMP-9 by 49%. Latanoprost 36-47 matrix metallopeptidase 3 Homo sapiens 106-111 11027004-9 2000 The addition of 10 micrograms/ml of latanoprost to dexamethasone-treated cultures increased MMP-2 by 14%, MMP-3 by 43% and MMP-9 by 49%. Dexamethasone 51-64 matrix metallopeptidase 3 Homo sapiens 106-111 11027004-11 2000 Latanoprost treatment caused an increase of 29% in MMP-2 (p < 0.0001), 98% in MMP-3 (p < 0.0001) and 108% in MMP-9 (p < 0.0001). Latanoprost 0-11 matrix metallopeptidase 3 Homo sapiens 81-86 11027004-12 2000 Dexamethasone reduced the staining for MMP-2 by 32% (p < 0.0001), for MMP-3 by 33% (p < 0.0001) and for MMP-9 by 83% (p < 0.0001). Dexamethasone 0-13 matrix metallopeptidase 3 Homo sapiens 73-78 10808127-3 2000 In this paper, to investigate the relationship between DHEA and skin aging, we examined the effects of DHEA on the regulation of collagen, collegians and stromelysin-1 genes in cultured human skin fibroblasts. Dehydroepiandrosterone 103-107 matrix metallopeptidase 3 Homo sapiens 154-167 10808127-7 2000 Interestingly, DHEA differently regulated collagenase and stromelysin-1 gene expression. Dehydroepiandrosterone 15-19 matrix metallopeptidase 3 Homo sapiens 58-71 10808127-9 2000 Similar results were obtained for chloramphenicol acetyltransferase assay (CAT); maximal promoter activation of stromelysin-1 gene occurred at 10(-6) M DHEA, 4.5-fold higher than control. Dehydroepiandrosterone 152-156 matrix metallopeptidase 3 Homo sapiens 112-125 10793091-3 2000 When monocytes/macrophages were subjected to 4% strain at 1 Hz for 24 hours, neither matrix metalloproteinase (MMP)-1 nor MMP-3 was induced; however, in the presence of phorbol myristate acetate, strain augmented MMP-1 expression by 5.1 +/- 0.7-fold (P < 0.05) and MMP-3 expression by 1. Tetradecanoylphorbol Acetate 169-194 matrix metallopeptidase 3 Homo sapiens 268-273 10877850-2 2000 The active site glutamic acid of the MMPs is conserved throughout the family and plays a pivotal role in the catalytic mechanism. Glutamic Acid 16-29 matrix metallopeptidase 3 Homo sapiens 37-41 10877850-3 2000 The structural and functional consequences of a glutamate to glutamine substitution in the active site of stromelysin-1 were investigated in this study. Glutamic Acid 48-57 matrix metallopeptidase 3 Homo sapiens 106-119 10877850-3 2000 The structural and functional consequences of a glutamate to glutamine substitution in the active site of stromelysin-1 were investigated in this study. Glutamine 61-70 matrix metallopeptidase 3 Homo sapiens 106-119 10770206-0 2000 Progesterone exposure prevents matrix metalloproteinase-3 (MMP-3) stimulation by interleukin-1alpha in human endometrial stromal cells. Progesterone 0-12 matrix metallopeptidase 3 Homo sapiens 31-57 10770206-0 2000 Progesterone exposure prevents matrix metalloproteinase-3 (MMP-3) stimulation by interleukin-1alpha in human endometrial stromal cells. Progesterone 0-12 matrix metallopeptidase 3 Homo sapiens 59-64 10770206-2 2000 Several laboratories have shown that inflammatory cytokines, including interleukin-lalpha (IL-1alpha), can oppose progesterone suppression of MMPs in the human endometrium. Progesterone 114-126 matrix metallopeptidase 3 Homo sapiens 142-146 10770206-4 2000 The current study extends these findings, revealing a previously unrecognized interrelationship between progesterone and IL-1alpha in regulation of MMP-3. Progesterone 104-116 matrix metallopeptidase 3 Homo sapiens 148-153 10770206-5 2000 Although IL-1alpha is a potent stimulator of MMP-3 in proliferative phase endometrium in organ culture, we demonstrate that progesterone exposure in vivo reduces IL-1alpha stimulation of MMP-3 in secretory phase tissue. Progesterone 124-136 matrix metallopeptidase 3 Homo sapiens 187-192 10770206-7 2000 The antiprogestin, onapristone, partially blocked the ability of progesterone to prevent stimulation of MMP-3 by IL-1alpha. onapristone 19-30 matrix metallopeptidase 3 Homo sapiens 104-109 10521266-0 1999 Analysis of the binding of hydroxamic acid and carboxylic acid inhibitors to the stromelysin-1 (matrix metalloproteinase-3) catalytic domain by isothermal titration calorimetry. Hydroxamic Acids 27-42 matrix metallopeptidase 3 Homo sapiens 81-94 10579815-2 1999 It was applied to 2-arylsulfonyl-1,2,3, 4-tetrahydro-isoquinoline-3-carboxylates and -hydroxamates as inhibitors of the matrix metalloproteinases MMP-3 (stromelysin-1) and MMP-8 (human neutrophil collagenase). 2-arylsulfonyl-1,2,3, 4-tetrahydro-isoquinoline-3-carboxylates 18-80 matrix metallopeptidase 3 Homo sapiens 146-151 10579815-2 1999 It was applied to 2-arylsulfonyl-1,2,3, 4-tetrahydro-isoquinoline-3-carboxylates and -hydroxamates as inhibitors of the matrix metalloproteinases MMP-3 (stromelysin-1) and MMP-8 (human neutrophil collagenase). 2-arylsulfonyl-1,2,3, 4-tetrahydro-isoquinoline-3-carboxylates 18-80 matrix metallopeptidase 3 Homo sapiens 153-166 10579815-2 1999 It was applied to 2-arylsulfonyl-1,2,3, 4-tetrahydro-isoquinoline-3-carboxylates and -hydroxamates as inhibitors of the matrix metalloproteinases MMP-3 (stromelysin-1) and MMP-8 (human neutrophil collagenase). -hydroxamates 85-98 matrix metallopeptidase 3 Homo sapiens 146-151 10579815-2 1999 It was applied to 2-arylsulfonyl-1,2,3, 4-tetrahydro-isoquinoline-3-carboxylates and -hydroxamates as inhibitors of the matrix metalloproteinases MMP-3 (stromelysin-1) and MMP-8 (human neutrophil collagenase). -hydroxamates 85-98 matrix metallopeptidase 3 Homo sapiens 153-166 10660603-5 2000 The FRAP kinase inhibitor rapamycin and the DNA repair inhibitor aphidicolin significantly suppressed the UVB-mediated increase in p70 ribosomal S6 kinase activity by 50-65% and MMP-1 and MMP-3 protein levels by 34-68% and 42-88% compared with UVB-irradiated fibroblasts. Sirolimus 26-35 matrix metallopeptidase 3 Homo sapiens 188-193 10660603-5 2000 The FRAP kinase inhibitor rapamycin and the DNA repair inhibitor aphidicolin significantly suppressed the UVB-mediated increase in p70 ribosomal S6 kinase activity by 50-65% and MMP-1 and MMP-3 protein levels by 34-68% and 42-88% compared with UVB-irradiated fibroblasts. Aphidicolin 65-76 matrix metallopeptidase 3 Homo sapiens 188-193 10669564-4 2000 X-ray crystallography data obtained for MMP-3 cocrystallized with 20 gave detailed information on key binding interactions defining an overall scaffold geometry for piperazine-based MMP inhibitors. Piperazine 165-175 matrix metallopeptidase 3 Homo sapiens 40-45 10791709-4 2000 Our results obtained from the Western blot assays demonstrated clearly that the production of MMP-1 and MMP-3 was significantly inhibited by CyA at similar concentrations found in the serum of patients undergoing CyA-treatment. Cyclosporine 141-144 matrix metallopeptidase 3 Homo sapiens 104-109 10623708-1 2000 PURPOSE: To evaluate the feasibility of administering BAY 12-9566, a matrix metalloproteinase (MMP) inhibitor with relative specificity against MMP-2, MMP-3, and MMP-9, on a protracted oral daily dosing schedule in patients with advanced solid malignancies. Bay 12-9566 54-65 matrix metallopeptidase 3 Homo sapiens 151-156 12075434-2 2000 The hydrophobic fluorescence probe ANS could bind to stromelysin-1, with a dissociation constant of 26.3 &mgr;mol/L, but could not bind to collagenase-1, indicating that there exists a hydrophobic site on the surface of stromelysin-1. 1-anilino-8-naphthalenesulfonate 35-38 matrix metallopeptidase 3 Homo sapiens 53-66 12075434-2 2000 The hydrophobic fluorescence probe ANS could bind to stromelysin-1, with a dissociation constant of 26.3 &mgr;mol/L, but could not bind to collagenase-1, indicating that there exists a hydrophobic site on the surface of stromelysin-1. 1-anilino-8-naphthalenesulfonate 35-38 matrix metallopeptidase 3 Homo sapiens 224-237 12075434-2 2000 The hydrophobic fluorescence probe ANS could bind to stromelysin-1, with a dissociation constant of 26.3 &mgr;mol/L, but could not bind to collagenase-1, indicating that there exists a hydrophobic site on the surface of stromelysin-1. Adenosine Monophosphate 106-109 matrix metallopeptidase 3 Homo sapiens 53-66 10639284-3 1999 This effect was noted in compounds that contained a functionalized oxime moiety or an exomethylene at C-4, and the potencies were typically <10 nM for MMP-3 and <100 nM for MMP-1. Oximes 67-72 matrix metallopeptidase 3 Homo sapiens 154-159 10521266-0 1999 Analysis of the binding of hydroxamic acid and carboxylic acid inhibitors to the stromelysin-1 (matrix metalloproteinase-3) catalytic domain by isothermal titration calorimetry. Carboxylic Acids 47-62 matrix metallopeptidase 3 Homo sapiens 81-94 10443472-5 1999 In addition, MMP-1 and MMP-3 were suppressed by dexamethasone treatment in a similar range of concentrations. Dexamethasone 48-61 matrix metallopeptidase 3 Homo sapiens 23-28 10395291-8 1999 Treatment of HF with PD98059 blocks the induction of crystal-stimulated collagenase 1 (MMP-1) and stromelysin (MMP-3) expression. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 21-28 matrix metallopeptidase 3 Homo sapiens 111-116 10395291-10 1999 Likewise, PD98059 treatment of HF blocked the epidermal growth factor (EGF)- and crystal-induced increases in MMP-1 and MMP-3 protein expression and secretion as demonstrated by Western blotting and zymography. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 10-17 matrix metallopeptidase 3 Homo sapiens 120-125 10428843-4 1999 After incubation with MMP-3, -7, or -12, the ability of HDL(3) to induce the high affinity component of cholesterol efflux from the macrophage foam cells was strongly reduced, whereas preincubation with MMP-1 reduced cholesterol efflux only slightly and preincubation with MMP-9 had no effect. Cholesterol 104-115 matrix metallopeptidase 3 Homo sapiens 22-27 10428843-4 1999 After incubation with MMP-3, -7, or -12, the ability of HDL(3) to induce the high affinity component of cholesterol efflux from the macrophage foam cells was strongly reduced, whereas preincubation with MMP-1 reduced cholesterol efflux only slightly and preincubation with MMP-9 had no effect. Cholesterol 217-228 matrix metallopeptidase 3 Homo sapiens 22-27 10446063-13 1999 MMP-3 was cytoplasmic in most cells and colocalized with calcium and fibrin deposits. Calcium 57-64 matrix metallopeptidase 3 Homo sapiens 0-5 10415716-1 1999 Differences in proteinase susceptibility between free TIMP-1 and the TIMP-1-MMP-3 complex and mutagenesis studies suggested that the residues around the disulfide bond between Cys1 and Cys70 in TIMP-1 may interact with MMPs. Disulfides 153-162 matrix metallopeptidase 3 Homo sapiens 76-81 10429942-9 1999 For the MMPs, IL-1 treatment resulted in an approximately two to threefold increase in human and porcine MMP-3 and MMP-13 mRNAs, while retinoic acid treatment caused a statistically significant increase in human MMP-3 mRNA levels, but no significant change in transcript levels for porcine MMP-3 nor human or porcine MMP-13. Tretinoin 135-148 matrix metallopeptidase 3 Homo sapiens 212-217 10429942-9 1999 For the MMPs, IL-1 treatment resulted in an approximately two to threefold increase in human and porcine MMP-3 and MMP-13 mRNAs, while retinoic acid treatment caused a statistically significant increase in human MMP-3 mRNA levels, but no significant change in transcript levels for porcine MMP-3 nor human or porcine MMP-13. Tretinoin 135-148 matrix metallopeptidase 3 Homo sapiens 212-217 10226801-9 1999 Recombinant human matrix metalloproteinase-3 (MMP-3) proteolyzed recombinant human IGFBP-3 or endogenous rat IGFBP-3 in non-pregnancy serum pretreated with AEBSF to inactivate endogenous serine proteases. 4-(2-aminoethyl)benzenesulfonylfluoride 156-161 matrix metallopeptidase 3 Homo sapiens 18-44 10187802-3 1999 The large interaction interface in the TIMP-1.MMP-3 complex includes a contiguous region of TIMP-1 around the disulfide bond between Cys1 and Cys70 that inserts into the active site of MMP-3. Disulfides 110-119 matrix metallopeptidase 3 Homo sapiens 46-51 10187802-3 1999 The large interaction interface in the TIMP-1.MMP-3 complex includes a contiguous region of TIMP-1 around the disulfide bond between Cys1 and Cys70 that inserts into the active site of MMP-3. Disulfides 110-119 matrix metallopeptidase 3 Homo sapiens 185-190 10187802-4 1999 The effects of fifteen different substitutions for threonine 2 of this region reveal that this residue makes a large contribution to the stability of complexes with MMPs and has a dominant influence on the specificity for different MMPs. Threonine 51-60 matrix metallopeptidase 3 Homo sapiens 165-169 10187802-4 1999 The effects of fifteen different substitutions for threonine 2 of this region reveal that this residue makes a large contribution to the stability of complexes with MMPs and has a dominant influence on the specificity for different MMPs. Threonine 51-60 matrix metallopeptidase 3 Homo sapiens 232-236 10187802-6 1999 Threonine 2 of TIMP-1 interacts with the S1" specificity pocket of MMP-3, which is a key to substrate specificity, but the structural requirements in TIMP-1 residue 2 for MMP binding differ greatly from those for the corresponding residue of a peptide substrate. Threonine 0-9 matrix metallopeptidase 3 Homo sapiens 67-72 10211881-10 1999 In animals treated with AdvIL-10, the MMP-3-TIMP-1 balance was partially restored, independent of the effect on mRNA expression of tumor necrosis factor a, IL-1, IL-6, or IL-8. advil-10 24-32 matrix metallopeptidase 3 Homo sapiens 38-43 10319995-10 1999 The effect of AGN 193109 on genes inhibited by retinoid agonists in NHKs is also selective; expression of the differentiation markers transglutaminase 1 and keratin 6 is not down-regulated by AGN 193109 whereas stromelysin-1 expression is suppressed. Retinoids 47-55 matrix metallopeptidase 3 Homo sapiens 211-224 10321809-1 1999 Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) are involved in normal menstruation, while MMP-1 and MMP-3 production by human endometrial stromal cells (HESCs) is repressed in vitro by progesterone. Progesterone 207-219 matrix metallopeptidase 3 Homo sapiens 122-127 10321809-4 1999 Zymographic and enzyme-linked immunosorbent analysis of culture medium after 2 weeks showed that both natural progesterone and all of the synthetic progestins tested maintained a significant inhibition of MMP-1 and MMP-3 production. Progesterone 110-122 matrix metallopeptidase 3 Homo sapiens 215-220 10190398-0 1999 Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis. Pravastatin 52-63 matrix metallopeptidase 3 Homo sapiens 14-27 10190398-4 1999 The stromelysin-1 genotype was determined for 496 men with coronary artery disease and cholesterol levels between 4.0 and 8.0 mmol/L, participating in the Regression Growth Evaluation Statin Study (REGRESS) study, a clinical trial assessing the effect of the lipid-lowering drug pravastatin on the progression of atherosclerosis. Cholesterol 87-98 matrix metallopeptidase 3 Homo sapiens 4-17 10226801-9 1999 Recombinant human matrix metalloproteinase-3 (MMP-3) proteolyzed recombinant human IGFBP-3 or endogenous rat IGFBP-3 in non-pregnancy serum pretreated with AEBSF to inactivate endogenous serine proteases. 4-(2-aminoethyl)benzenesulfonylfluoride 156-161 matrix metallopeptidase 3 Homo sapiens 46-51 10406070-5 1999 Medroxyprogesterone acetate (MPA) inhibited the catalytic activity of urokinase-type PA (uPA) and tissue-type PA (tPA) as well as the expression of such MMPs as interstitial collagenase (MMP-1) and stromelysin-1 (MMP-3). Medroxyprogesterone Acetate 0-27 matrix metallopeptidase 3 Homo sapiens 198-211 9888808-0 1999 Role of His-224 in the anomalous pH dependence of human stromelysin-1. Histidine 8-11 matrix metallopeptidase 3 Homo sapiens 56-69 9888808-4 1999 HS is the only known MMP that has a histidine in this position. hassio 0-2 matrix metallopeptidase 3 Homo sapiens 21-24 9888808-4 1999 HS is the only known MMP that has a histidine in this position. Histidine 36-45 matrix metallopeptidase 3 Homo sapiens 21-24 9920023-6 1999 There was an inverse correlation between the delta di-CS6:delta di-CS4 ratio and the concentration of MMP-3. delta di-cs6 45-57 matrix metallopeptidase 3 Homo sapiens 102-107 9920023-6 1999 There was an inverse correlation between the delta di-CS6:delta di-CS4 ratio and the concentration of MMP-3. delta di-cs4 58-70 matrix metallopeptidase 3 Homo sapiens 102-107 10406070-5 1999 Medroxyprogesterone acetate (MPA) inhibited the catalytic activity of urokinase-type PA (uPA) and tissue-type PA (tPA) as well as the expression of such MMPs as interstitial collagenase (MMP-1) and stromelysin-1 (MMP-3). Medroxyprogesterone Acetate 0-27 matrix metallopeptidase 3 Homo sapiens 213-218 10406070-11 1999 As expected, steroid withdrawal reversed progestin-inhibited PA activity as well as the expression of MMP-1 and MMP-3 and progestin-enhanced PAI-1; much greater reversal was observed in medium supplemented with RU 486. Steroids 13-20 matrix metallopeptidase 3 Homo sapiens 112-117 10406070-11 1999 As expected, steroid withdrawal reversed progestin-inhibited PA activity as well as the expression of MMP-1 and MMP-3 and progestin-enhanced PAI-1; much greater reversal was observed in medium supplemented with RU 486. Ruthenium 211-213 matrix metallopeptidase 3 Homo sapiens 112-117 10406070-14 1999 Conversely, steroid withdrawal elicited increases in uPA, MMP-1 and MMP-3 activities would promote endometrial sloughing by degrading the mixture of decidual cell-derived basement membrane-like proteins and interstitial components that comprise the stromal ECM of the perimenstrual endometrium. Steroids 12-19 matrix metallopeptidase 3 Homo sapiens 68-73 9827576-1 1998 Here, we describe the influence of heparin(s) on the interleukin-1-beta (IL-1beta)-induced expression of collagenase (matrix metalloproteinase-1, MMP-1), stromelysin-1 (matrix metalloproteinase-3, MMP-3) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in human gingival fibroblasts (HGF). Heparin 35-42 matrix metallopeptidase 3 Homo sapiens 154-202 9827576-0 1998 Influence of heparin(s) on the interleukin-1-beta-induced expression of collagenase, stromelysin-1, and tissue inhibitor of metalloproteinase-1 in human gingival fibroblasts. Heparin 13-20 matrix metallopeptidase 3 Homo sapiens 85-98 9832620-8 1998 SB203580, a specific inhibitor of p38 MAP kinase, significantly inhibited IL-1beta-induced IL-6 and stromelysin-1 production by both parental FLSs and MH7A cells; although PD098059, an inhibitor of the p42/p44 MAP kinase pathway, did not affect it. SB 203580 0-8 matrix metallopeptidase 3 Homo sapiens 100-113 9844107-4 1998 Hydroxyapatite crystals alone and in BAG-75-hydroxyapatite complexes induced the autolytic degradation of both active and precursor forms of MMP-1 and MMP-3. Durapatite 0-14 matrix metallopeptidase 3 Homo sapiens 151-156 9844107-4 1998 Hydroxyapatite crystals alone and in BAG-75-hydroxyapatite complexes induced the autolytic degradation of both active and precursor forms of MMP-1 and MMP-3. Durapatite 44-58 matrix metallopeptidase 3 Homo sapiens 151-156 9844107-6 1998 The fate of MMP-3 incubated with hydroxyapatite depends upon the time of incubation, the free calcium concentration, and the concentration of crystals. Durapatite 33-47 matrix metallopeptidase 3 Homo sapiens 12-17 9844107-6 1998 The fate of MMP-3 incubated with hydroxyapatite depends upon the time of incubation, the free calcium concentration, and the concentration of crystals. Calcium 94-101 matrix metallopeptidase 3 Homo sapiens 12-17 9844107-8 1998 Autolysis was maximal in the presence of 150 microg/ml hydroxyapatite where MMP-3 was only partially bound to crystals. Durapatite 55-69 matrix metallopeptidase 3 Homo sapiens 76-81 9844107-10 1998 The effect of hydroxyapatite appears to be specific for MMP-1 and MMP-3 since the catalytic activity of chymotrypsin, trypsin, papain, and thermolysin remained unchanged after exposure to hydroxyapatite. Durapatite 14-28 matrix metallopeptidase 3 Homo sapiens 66-71 9853686-0 1998 The constituent tryptophans and bisANS as fluorescent probes of the active site and of a secondary binding site of stromelysin-1 (MMP-3). Tryptophan 16-27 matrix metallopeptidase 3 Homo sapiens 115-128 9853686-0 1998 The constituent tryptophans and bisANS as fluorescent probes of the active site and of a secondary binding site of stromelysin-1 (MMP-3). 5,5'-bis(8-(phenylamino)-1-naphthalenesulfonate) 32-38 matrix metallopeptidase 3 Homo sapiens 115-128 9853686-1 1998 The active site of the catalytic domain of stromelysin-1 (matrix metalloproteinase-3, MMP-3) was probed by fluorescence quenching, lifetime, and polarization of its three intrinsic tryptophans and by the environmentally sensitive fluorescent reporter molecule bisANS. Tryptophan 181-192 matrix metallopeptidase 3 Homo sapiens 43-84 9853686-1 1998 The active site of the catalytic domain of stromelysin-1 (matrix metalloproteinase-3, MMP-3) was probed by fluorescence quenching, lifetime, and polarization of its three intrinsic tryptophans and by the environmentally sensitive fluorescent reporter molecule bisANS. Tryptophan 181-192 matrix metallopeptidase 3 Homo sapiens 86-91 9853686-1 1998 The active site of the catalytic domain of stromelysin-1 (matrix metalloproteinase-3, MMP-3) was probed by fluorescence quenching, lifetime, and polarization of its three intrinsic tryptophans and by the environmentally sensitive fluorescent reporter molecule bisANS. 5,5'-bis(8-(phenylamino)-1-naphthalenesulfonate) 260-266 matrix metallopeptidase 3 Homo sapiens 43-84 9853686-1 1998 The active site of the catalytic domain of stromelysin-1 (matrix metalloproteinase-3, MMP-3) was probed by fluorescence quenching, lifetime, and polarization of its three intrinsic tryptophans and by the environmentally sensitive fluorescent reporter molecule bisANS. 5,5'-bis(8-(phenylamino)-1-naphthalenesulfonate) 260-266 matrix metallopeptidase 3 Homo sapiens 86-91 9792098-1 1998 The binding of two 5-substituted-1,3,4-thiadiazole-2-thione inhibitors to the matrix metalloproteinase stromelysin (MMP-3) have been characterized by protein crystallography. 5-substituted-1,3,4-thiadiazole-2-thione 19-59 matrix metallopeptidase 3 Homo sapiens 116-121 9716571-6 1998 Mast cell-conditioned medium added to stromal cell culture medium in vitro along with added heparin (which stabilizes tryptase activity) resulted in the appearance of molecular weight forms indicative of active MMP-3 and MMP-1. Heparin 92-99 matrix metallopeptidase 3 Homo sapiens 211-216 9658109-1 1998 The dimerization initiation site (DIS), downstream of the long terminal repeat within the human immunodeficiency virus type 1 (HIV-1) genome, can form a stem-loop structure (SL1) that has been shown to be involved in the packaging of viral RNA. dis 34-37 matrix metallopeptidase 3 Homo sapiens 174-177 9657677-9 1998 N-TIMP-1 binding causes the amide of Tyr223 of MMP-3(DeltaC) bound by N-TIMP-1 to exchange with water rapidly, implying a lack of the hydrogen bond observed in the crystal structure. Water 96-101 matrix metallopeptidase 3 Homo sapiens 47-52 9714180-7 1998 Priming of these cells with beta-estradiol potentiated their MMP-inductive response to relaxin such that the maximal expression of collagenase-1 and stromelysin-1 occurred at 10- to 100-fold lower concentrations of relaxin in estrogen-primed than in unprimed cells. Estradiol 28-42 matrix metallopeptidase 3 Homo sapiens 149-162 9657677-1 1998 Surfaces of the 173 residue catalytic domain of human matrix metalloproteinase 3 (MMP-3(DeltaC)) affected by binding of the N-terminal, 126 residue inhibitory domain of human TIMP-1 (N-TIMP-1) have been investigated using an amide-directed, NMR-based approach. Amides 225-230 matrix metallopeptidase 3 Homo sapiens 94-95 9657677-5 1998 Residues Tyr155, Asn162, Val163, Leu164, His166, Ala167, Ala169, and Phe210 of MMP-3(DeltaC) are protected from broadening by the Gd-EDTA probe by binding to N-TIMP-1. gadolinium EDTA 130-137 matrix metallopeptidase 3 Homo sapiens 91-92 9657677-6 1998 N-TIMP-1-induced exposure of backbone amides of Asp238, Asn240, Gly241, and Ser244 of helix C of MMP-3(DeltaC) to Gd-EDTA confirms that the displacement of the N-terminus of MMP-3(DeltaC) occurs not only in the crystal but also in solution. Amides 38-44 matrix metallopeptidase 3 Homo sapiens 109-110 9657677-6 1998 N-TIMP-1-induced exposure of backbone amides of Asp238, Asn240, Gly241, and Ser244 of helix C of MMP-3(DeltaC) to Gd-EDTA confirms that the displacement of the N-terminus of MMP-3(DeltaC) occurs not only in the crystal but also in solution. Amides 38-44 matrix metallopeptidase 3 Homo sapiens 97-102 9657677-6 1998 N-TIMP-1-induced exposure of backbone amides of Asp238, Asn240, Gly241, and Ser244 of helix C of MMP-3(DeltaC) to Gd-EDTA confirms that the displacement of the N-terminus of MMP-3(DeltaC) occurs not only in the crystal but also in solution. gadolinium EDTA 114-121 matrix metallopeptidase 3 Homo sapiens 109-110 9657677-6 1998 N-TIMP-1-induced exposure of backbone amides of Asp238, Asn240, Gly241, and Ser244 of helix C of MMP-3(DeltaC) to Gd-EDTA confirms that the displacement of the N-terminus of MMP-3(DeltaC) occurs not only in the crystal but also in solution. gadolinium EDTA 114-121 matrix metallopeptidase 3 Homo sapiens 97-102 9657677-8 1998 Novel N-TIMP-1-dependent changes in hydrogen bonding near the active site of MMP-3(DeltaC) are reported. Hydrogen 36-44 matrix metallopeptidase 3 Homo sapiens 77-82 9657677-9 1998 N-TIMP-1 binding causes the amide of Tyr223 of MMP-3(DeltaC) bound by N-TIMP-1 to exchange with water rapidly, implying a lack of the hydrogen bond observed in the crystal structure. Amides 28-33 matrix metallopeptidase 3 Homo sapiens 47-52 9657677-9 1998 N-TIMP-1 binding causes the amide of Tyr223 of MMP-3(DeltaC) bound by N-TIMP-1 to exchange with water rapidly, implying a lack of the hydrogen bond observed in the crystal structure. Hydrogen 134-142 matrix metallopeptidase 3 Homo sapiens 47-52 9657677-11 1998 N-TIMP-1 binding dramatically increases the rate of amide hydrogen exchange of Asp177 of the fifth beta strand of MMP-3(DeltaC), disrupting its otherwise stable hydrogen bond. Amides 52-57 matrix metallopeptidase 3 Homo sapiens 126-127 9657677-11 1998 N-TIMP-1 binding dramatically increases the rate of amide hydrogen exchange of Asp177 of the fifth beta strand of MMP-3(DeltaC), disrupting its otherwise stable hydrogen bond. Hydrogen 58-66 matrix metallopeptidase 3 Homo sapiens 126-127 9699891-0 1998 The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP-3) gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gemfibrozil study. Gemfibrozil 169-180 matrix metallopeptidase 3 Homo sapiens 46-59 9699891-0 1998 The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP-3) gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gemfibrozil study. Gemfibrozil 169-180 matrix metallopeptidase 3 Homo sapiens 61-66 9706420-5 1998 The MMP-3 levels were significantly higher in SLE patients who had a history of the following abnormalities: persistent proteinuria, cellular casts, anti-double stranded DNA antibodies, decreased C3, decreased creatinine clearance (p < 0.001), circulating immune complex (p < 0.01), malar rash, hypoalbuminemia, or decreased C4 (p < 0.05). Creatinine 210-220 matrix metallopeptidase 3 Homo sapiens 4-9 9706420-6 1998 The serum MMP-3 level in patients with SLE at admission showed direct correlations with serum uric acid, total cholesterol (p < 0.001), triglyceride, the white blood cell count, and the neutrophil count (p < 0.05), as well as inverse correlations with the total protein (p < 0.01), and IgG (p < 0.05). Uric Acid 94-103 matrix metallopeptidase 3 Homo sapiens 10-15 9706420-6 1998 The serum MMP-3 level in patients with SLE at admission showed direct correlations with serum uric acid, total cholesterol (p < 0.001), triglyceride, the white blood cell count, and the neutrophil count (p < 0.05), as well as inverse correlations with the total protein (p < 0.01), and IgG (p < 0.05). Cholesterol 111-122 matrix metallopeptidase 3 Homo sapiens 10-15 9706420-6 1998 The serum MMP-3 level in patients with SLE at admission showed direct correlations with serum uric acid, total cholesterol (p < 0.001), triglyceride, the white blood cell count, and the neutrophil count (p < 0.05), as well as inverse correlations with the total protein (p < 0.01), and IgG (p < 0.05). Triglycerides 139-151 matrix metallopeptidase 3 Homo sapiens 10-15 9873367-1 1998 A series of P1 C alpha gem-disubstituted succinamide hydroxamate matrix metalloproteinase inhibitors were prepared stereoselectively and evaluated in vitro for their ability to inhibit MMP-1, MMP-2, and MMP-3. succinamide hydroxamate 41-64 matrix metallopeptidase 3 Homo sapiens 203-208 9642125-5 1998 Sequencing of activation intermediates demonstrated cleavage on the NH2-terminal side of certain basic residues in the MMP-3 propeptide. propeptide 125-135 matrix metallopeptidase 3 Homo sapiens 119-124 9642125-8 1998 Dibasic sites also exist in the propeptides of several MMPs including proMMP-3. propeptides 32-43 matrix metallopeptidase 3 Homo sapiens 55-59 9585535-2 1998 The conversion is completely abolished in the presence of the MMP inhibitors EDTA or 1,10-phenanthroline. Edetic Acid 77-81 matrix metallopeptidase 3 Homo sapiens 62-65 9585535-2 1998 The conversion is completely abolished in the presence of the MMP inhibitors EDTA or 1,10-phenanthroline. 1,10-phenanthroline 85-104 matrix metallopeptidase 3 Homo sapiens 62-65 9585535-5 1998 tcu-PA and tcu-PA-32k moieties derived from scu-PA-32k by plasmin or from tcu-PA by MMP-3 have comparable amidolytic activities toward the chromogenic substrate S-2444 (kcat/Km of 110 and 160 mM-1 s-1, respectively) and similar plasminogen activating activities in a coupled chromogenic substrate assay. tcu-pa 0-6 matrix metallopeptidase 3 Homo sapiens 84-89 9585535-5 1998 tcu-PA and tcu-PA-32k moieties derived from scu-PA-32k by plasmin or from tcu-PA by MMP-3 have comparable amidolytic activities toward the chromogenic substrate S-2444 (kcat/Km of 110 and 160 mM-1 s-1, respectively) and similar plasminogen activating activities in a coupled chromogenic substrate assay. tcu-pa 11-17 matrix metallopeptidase 3 Homo sapiens 84-89 9585535-5 1998 tcu-PA and tcu-PA-32k moieties derived from scu-PA-32k by plasmin or from tcu-PA by MMP-3 have comparable amidolytic activities toward the chromogenic substrate S-2444 (kcat/Km of 110 and 160 mM-1 s-1, respectively) and similar plasminogen activating activities in a coupled chromogenic substrate assay. tcu-pa 11-17 matrix metallopeptidase 3 Homo sapiens 84-89 9585535-7 1998 Thus, MMP-3 removes a functional NH2-terminal u-PAR-binding domain from u-PA without affecting its enzymatic properties. Uranium 2-3 matrix metallopeptidase 3 Homo sapiens 6-11 9585535-7 1998 Thus, MMP-3 removes a functional NH2-terminal u-PAR-binding domain from u-PA without affecting its enzymatic properties. 4-(2-pyridylazo)resorcinol 48-51 matrix metallopeptidase 3 Homo sapiens 6-11 9605178-4 1998 Pretreatment of synovial fibroblasts with cycloheximide prevented SAA-mediated MMP-2 and MMP-3 secretion. Cycloheximide 42-55 matrix metallopeptidase 3 Homo sapiens 89-94 9871727-2 1998 Incorporation of a terminal alpha-mercaptoketone or alpha-mercaptoalcohol in the zinc binding domain of a series of inhibitors led to compounds exhibiting low nanomolar activity against collagenase-1 (MMP-1), stromelysin (MMP-3), and gelatinase-B (MMP-9). alpha-mercaptoketone 28-48 matrix metallopeptidase 3 Homo sapiens 222-227 9871727-2 1998 Incorporation of a terminal alpha-mercaptoketone or alpha-mercaptoalcohol in the zinc binding domain of a series of inhibitors led to compounds exhibiting low nanomolar activity against collagenase-1 (MMP-1), stromelysin (MMP-3), and gelatinase-B (MMP-9). alpha-mercaptoalcohol 52-73 matrix metallopeptidase 3 Homo sapiens 222-227 9478985-0 1998 Central role of Ferrous/Ferric iron in the ultraviolet B irradiation-mediated signaling pathway leading to increased interstitial collagenase (matrix-degrading metalloprotease (MMP)-1) and stromelysin-1 (MMP-3) mRNA levels in cultured human dermal fibroblasts. ammonium ferrous sulfate 16-23 matrix metallopeptidase 3 Homo sapiens 189-202 9548733-2 1998 The conversion is completely abolished in the presence of the MMP inhibitors EDTA or 1,10-phenanthroline. Edetic Acid 77-81 matrix metallopeptidase 3 Homo sapiens 62-65 9548733-2 1998 The conversion is completely abolished in the presence of the MMP inhibitors EDTA or 1,10-phenanthroline. 1,10-phenanthroline 85-104 matrix metallopeptidase 3 Homo sapiens 62-65 9695737-7 1998 MMP-2 was not modulated by any of the short chain fatty acids while MMP-1 was modulated only by butyrate and MMP-3 by propionate. Propionates 118-128 matrix metallopeptidase 3 Homo sapiens 109-114 9478985-0 1998 Central role of Ferrous/Ferric iron in the ultraviolet B irradiation-mediated signaling pathway leading to increased interstitial collagenase (matrix-degrading metalloprotease (MMP)-1) and stromelysin-1 (MMP-3) mRNA levels in cultured human dermal fibroblasts. ammonium ferrous sulfate 16-23 matrix metallopeptidase 3 Homo sapiens 204-209 9478985-0 1998 Central role of Ferrous/Ferric iron in the ultraviolet B irradiation-mediated signaling pathway leading to increased interstitial collagenase (matrix-degrading metalloprotease (MMP)-1) and stromelysin-1 (MMP-3) mRNA levels in cultured human dermal fibroblasts. Ferric enterobactin ion 24-30 matrix metallopeptidase 3 Homo sapiens 189-202 9478985-0 1998 Central role of Ferrous/Ferric iron in the ultraviolet B irradiation-mediated signaling pathway leading to increased interstitial collagenase (matrix-degrading metalloprotease (MMP)-1) and stromelysin-1 (MMP-3) mRNA levels in cultured human dermal fibroblasts. Ferric enterobactin ion 24-30 matrix metallopeptidase 3 Homo sapiens 204-209 9478985-0 1998 Central role of Ferrous/Ferric iron in the ultraviolet B irradiation-mediated signaling pathway leading to increased interstitial collagenase (matrix-degrading metalloprotease (MMP)-1) and stromelysin-1 (MMP-3) mRNA levels in cultured human dermal fibroblasts. Iron 31-35 matrix metallopeptidase 3 Homo sapiens 189-202 9478985-0 1998 Central role of Ferrous/Ferric iron in the ultraviolet B irradiation-mediated signaling pathway leading to increased interstitial collagenase (matrix-degrading metalloprotease (MMP)-1) and stromelysin-1 (MMP-3) mRNA levels in cultured human dermal fibroblasts. Iron 31-35 matrix metallopeptidase 3 Homo sapiens 204-209 9478985-6 1998 The iron-driven generation of lipid peroxides and hydroxyl radicals were identified as early events in the downstream signaling pathway of the UVB response leading to a 15-fold increase in JNK2 activity, a 3.5-fold increase in c-jun, to a 6-fold increase in MMP-1, and a 3.8-fold increase in MMP-3 mRNA levels, while virtually no alteration of c-fos mRNA levels were observed. Iron 4-8 matrix metallopeptidase 3 Homo sapiens 292-297 9478985-6 1998 The iron-driven generation of lipid peroxides and hydroxyl radicals were identified as early events in the downstream signaling pathway of the UVB response leading to a 15-fold increase in JNK2 activity, a 3.5-fold increase in c-jun, to a 6-fold increase in MMP-1, and a 3.8-fold increase in MMP-3 mRNA levels, while virtually no alteration of c-fos mRNA levels were observed. Lipid Peroxides 30-45 matrix metallopeptidase 3 Homo sapiens 292-297 9478985-6 1998 The iron-driven generation of lipid peroxides and hydroxyl radicals were identified as early events in the downstream signaling pathway of the UVB response leading to a 15-fold increase in JNK2 activity, a 3.5-fold increase in c-jun, to a 6-fold increase in MMP-1, and a 3.8-fold increase in MMP-3 mRNA levels, while virtually no alteration of c-fos mRNA levels were observed. Hydroxyl Radical 50-67 matrix metallopeptidase 3 Homo sapiens 292-297 9478985-7 1998 Diminished generation of reactive oxygen species resulted in a significant reduction of JNK2 activity, c-jun, MMP-1, and MMP-3 mRNA levels after UVB irradiation compared with UVB-irradiated cells. Reactive Oxygen Species 25-48 matrix metallopeptidase 3 Homo sapiens 121-126 9374866-2 1997 Amide chemical shift changes were measured on formation of a stable complex with the catalytic domain of stromelysin-1 (N-MMP-3). Amides 0-5 matrix metallopeptidase 3 Homo sapiens 105-118 9422744-5 1998 Residues 568-631 of the progelatinase A C-terminal domain are important in formation of the heparin binding site, since replacement of this region with the corresponding stromelysin-1 sequence abolished binding to heparin and the potentiation of activation. Heparin 92-99 matrix metallopeptidase 3 Homo sapiens 170-183 9422744-5 1998 Residues 568-631 of the progelatinase A C-terminal domain are important in formation of the heparin binding site, since replacement of this region with the corresponding stromelysin-1 sequence abolished binding to heparin and the potentiation of activation. Heparin 214-221 matrix metallopeptidase 3 Homo sapiens 170-183 9395517-7 1997 MMP-3 released soluble 12-kDa immunoreactive and mitogenic HB-EGF within 30 min. 12-kda 23-29 matrix metallopeptidase 3 Homo sapiens 0-5 9461346-1 1997 By exploiting the thiol function of L-cysteine as a chelating group of the active-site zinc atom of matrix metalloproteinases (MMPs), N- and C-terminal derivatization of this amino acid with aliphatic and aromatic groups allowed us to explore the selectivity of the S and/or S" binding subsites of human neutrophil collagenase (MMP8) and stromelysin (MMP3). Sulfhydryl Compounds 18-23 matrix metallopeptidase 3 Homo sapiens 127-131 9461346-1 1997 By exploiting the thiol function of L-cysteine as a chelating group of the active-site zinc atom of matrix metalloproteinases (MMPs), N- and C-terminal derivatization of this amino acid with aliphatic and aromatic groups allowed us to explore the selectivity of the S and/or S" binding subsites of human neutrophil collagenase (MMP8) and stromelysin (MMP3). Cysteine 36-46 matrix metallopeptidase 3 Homo sapiens 127-131 9461346-1 1997 By exploiting the thiol function of L-cysteine as a chelating group of the active-site zinc atom of matrix metalloproteinases (MMPs), N- and C-terminal derivatization of this amino acid with aliphatic and aromatic groups allowed us to explore the selectivity of the S and/or S" binding subsites of human neutrophil collagenase (MMP8) and stromelysin (MMP3). Cysteine 36-46 matrix metallopeptidase 3 Homo sapiens 351-355 9418730-10 1997 Treatment with 200 nM PGF2 alpha, 11-deoxy-PGE1, or PhXA85 for 72 hours increased the combined density scores for MMP-1 and MMP-2 by 37%, 64%, and 27%; the density scores for MMP-9 by 268%, 253%, and 125%; and the density scores for MMP-3 by 35%, 71%, and 22%, respectively. Dinoprost 22-32 matrix metallopeptidase 3 Homo sapiens 233-238 9418730-10 1997 Treatment with 200 nM PGF2 alpha, 11-deoxy-PGE1, or PhXA85 for 72 hours increased the combined density scores for MMP-1 and MMP-2 by 37%, 64%, and 27%; the density scores for MMP-9 by 268%, 253%, and 125%; and the density scores for MMP-3 by 35%, 71%, and 22%, respectively. 11-deoxyprostaglandin E1 34-47 matrix metallopeptidase 3 Homo sapiens 233-238 9418730-10 1997 Treatment with 200 nM PGF2 alpha, 11-deoxy-PGE1, or PhXA85 for 72 hours increased the combined density scores for MMP-1 and MMP-2 by 37%, 64%, and 27%; the density scores for MMP-9 by 268%, 253%, and 125%; and the density scores for MMP-3 by 35%, 71%, and 22%, respectively. PhXa 85 52-58 matrix metallopeptidase 3 Homo sapiens 233-238 9288970-8 1997 Cys 1 bidentally coordinates this zinc, and the Thr-2 side chain extends into the large specificity pocket of MMP-3. Threonine 48-51 matrix metallopeptidase 3 Homo sapiens 110-115 9350653-5 1997 In vitro glycation by glucose severely inhibited the release of soluble collagen cleavage peptides by MMP-3 and MMP-9. Glucose 22-29 matrix metallopeptidase 3 Homo sapiens 102-107 9449028-5 1997 For this purpose, human matrix metalloproteinase-3 (MMP-3), a proteinase that degrades IGFBP-3 in human fibroblast cultures, was first electrophoresed through a polyacrylamide gel containing IGFBP-3 as substrate and then analyzed for its ability to degrade the substrate into immunoreactive fragments that were absorbed onto a polyvinylidene difluoride membrane. polyacrylamide 161-175 matrix metallopeptidase 3 Homo sapiens 24-50 9268350-3 1997 Mutations that produce the largest increases in the Ki for a C-terminally truncated form of stromelysin 1, MMP-3(DeltaC), but do not disturb the conformation involve substitutions of residues that are located in a ridge that is centered around the disulfide bond between Cys1 and Cys70. Disulfides 248-257 matrix metallopeptidase 3 Homo sapiens 92-105 9449028-5 1997 For this purpose, human matrix metalloproteinase-3 (MMP-3), a proteinase that degrades IGFBP-3 in human fibroblast cultures, was first electrophoresed through a polyacrylamide gel containing IGFBP-3 as substrate and then analyzed for its ability to degrade the substrate into immunoreactive fragments that were absorbed onto a polyvinylidene difluoride membrane. polyacrylamide 161-175 matrix metallopeptidase 3 Homo sapiens 52-57 9279690-2 1997 The treatment of dbcAMP increased MMP-1 and MMP-3 mRNA levels but decreased TIMP-1 mRNA levels in time and dose dependent manners. Bucladesine 17-23 matrix metallopeptidase 3 Homo sapiens 44-49 9610890-0 1997 ETS sites in the promoters of the matrix metalloproteinases collagenase (MMP-1) and stromelysin (MMP-3) are auxiliary elements that regulate basal and phorbol-induced transcription. phorbol 151-158 matrix metallopeptidase 3 Homo sapiens 97-102 9449028-5 1997 For this purpose, human matrix metalloproteinase-3 (MMP-3), a proteinase that degrades IGFBP-3 in human fibroblast cultures, was first electrophoresed through a polyacrylamide gel containing IGFBP-3 as substrate and then analyzed for its ability to degrade the substrate into immunoreactive fragments that were absorbed onto a polyvinylidene difluoride membrane. polyvinylidene fluoride 327-352 matrix metallopeptidase 3 Homo sapiens 24-50 9449028-5 1997 For this purpose, human matrix metalloproteinase-3 (MMP-3), a proteinase that degrades IGFBP-3 in human fibroblast cultures, was first electrophoresed through a polyacrylamide gel containing IGFBP-3 as substrate and then analyzed for its ability to degrade the substrate into immunoreactive fragments that were absorbed onto a polyvinylidene difluoride membrane. polyvinylidene fluoride 327-352 matrix metallopeptidase 3 Homo sapiens 52-57 9449028-7 1997 Using the zymogram as a template, MMP-3 was identified in a standard SDS-polyacrylamide gel run in parallel with the zymogram, and the corresponding area of the gel was excised. Sodium Dodecyl Sulfate 69-72 matrix metallopeptidase 3 Homo sapiens 34-39 9449028-7 1997 Using the zymogram as a template, MMP-3 was identified in a standard SDS-polyacrylamide gel run in parallel with the zymogram, and the corresponding area of the gel was excised. polyacrylamide 73-87 matrix metallopeptidase 3 Homo sapiens 34-39 9148753-5 1997 The N-terminal sequence of the two fragments generated by MMP-2 and MMP-3 is Leu211-Lys-Gly-Leu-Asn, but that of the others is Asp1-Glu-Ala-Ser-Gly. Glycine 88-91 matrix metallopeptidase 3 Homo sapiens 68-73 9148753-5 1997 The N-terminal sequence of the two fragments generated by MMP-2 and MMP-3 is Leu211-Lys-Gly-Leu-Asn, but that of the others is Asp1-Glu-Ala-Ser-Gly. Leucine 77-80 matrix metallopeptidase 3 Homo sapiens 68-73 9148753-5 1997 The N-terminal sequence of the two fragments generated by MMP-2 and MMP-3 is Leu211-Lys-Gly-Leu-Asn, but that of the others is Asp1-Glu-Ala-Ser-Gly. Asparagine 96-99 matrix metallopeptidase 3 Homo sapiens 68-73 9148753-5 1997 The N-terminal sequence of the two fragments generated by MMP-2 and MMP-3 is Leu211-Lys-Gly-Leu-Asn, but that of the others is Asp1-Glu-Ala-Ser-Gly. Glutamic Acid 132-135 matrix metallopeptidase 3 Homo sapiens 68-73 9148753-5 1997 The N-terminal sequence of the two fragments generated by MMP-2 and MMP-3 is Leu211-Lys-Gly-Leu-Asn, but that of the others is Asp1-Glu-Ala-Ser-Gly. Alanine 136-139 matrix metallopeptidase 3 Homo sapiens 68-73 9148753-5 1997 The N-terminal sequence of the two fragments generated by MMP-2 and MMP-3 is Leu211-Lys-Gly-Leu-Asn, but that of the others is Asp1-Glu-Ala-Ser-Gly. Serine 140-143 matrix metallopeptidase 3 Homo sapiens 68-73 9148753-5 1997 The N-terminal sequence of the two fragments generated by MMP-2 and MMP-3 is Leu211-Lys-Gly-Leu-Asn, but that of the others is Asp1-Glu-Ala-Ser-Gly. Glycine 144-147 matrix metallopeptidase 3 Homo sapiens 68-73 9224642-0 1997 Involvement of a region near valine-69 of tissue inhibitor of metalloproteinases (TIMP)-1 in the interaction with matrix metalloproteinase 3 (stromelysin 1). Valine 29-35 matrix metallopeptidase 3 Homo sapiens 142-155 9224642-5 1997 However, cleavage of this bond by neutrophil elastase was prevented when TIMP-1 formed a complex with the catalytic domain of MMP-3, and full TIMP-1 activity was restored after dissociation of the complex at pH 3.0 in the presence of EDTA. Edetic Acid 234-238 matrix metallopeptidase 3 Homo sapiens 126-131 9120270-7 1997 SB 203580 also inhibited the stimulation of collagenase-1 and stromelysin-1 production by IL-1 without affecting synthesis of the tissue inhibitor of metalloproteinases (TIMP)-1. SB 203580 0-9 matrix metallopeptidase 3 Homo sapiens 62-75 9120270-8 1997 SB 203580 prevented the increase in collagenase-1 and stromelysin-1 mRNA stimulated by IL-1. SB 203580 0-9 matrix metallopeptidase 3 Homo sapiens 54-67 9101722-2 1997 Truncated fibroblast-type collagenase (mini-CL), truncated stromelysin-1 (mini-SL-1), and matrilysin, like their native counterparts, could be activated by organomercurials, trypsin, or SDS. Sodium Dodecyl Sulfate 186-189 matrix metallopeptidase 3 Homo sapiens 59-72 9070253-5 1997 Pretreatment of synovial fibroblasts with cycloheximide, an inhibitor of protein synthesis, prevented MMP-3 secretion from rheumatoid synovial cells suggesting that protein synthesis was required for SEA-induced MMP-3 secretion after SEA binding to MHC class II molecules. Cycloheximide 42-55 matrix metallopeptidase 3 Homo sapiens 102-107 9070253-5 1997 Pretreatment of synovial fibroblasts with cycloheximide, an inhibitor of protein synthesis, prevented MMP-3 secretion from rheumatoid synovial cells suggesting that protein synthesis was required for SEA-induced MMP-3 secretion after SEA binding to MHC class II molecules. Cycloheximide 42-55 matrix metallopeptidase 3 Homo sapiens 212-217 8989257-0 1997 Biological mechanisms underlying the clinical effects of RU 486: modulation of cultured endometrial stromal cell stromelysin-1 and prolactin expression. Mifepristone 57-63 matrix metallopeptidase 3 Homo sapiens 113-126 8989257-1 1997 During in vitro decidualization of human endometrial stromal cells (HESCs), medroxyprogesterone acetate (MPA) inhibits expression of the potent extracellular matrix (ECM)-degrading protease stromelysin-1 (MMP-3), but enhances PRL expression. Medroxyprogesterone Acetate 76-103 matrix metallopeptidase 3 Homo sapiens 190-203 8989257-1 1997 During in vitro decidualization of human endometrial stromal cells (HESCs), medroxyprogesterone acetate (MPA) inhibits expression of the potent extracellular matrix (ECM)-degrading protease stromelysin-1 (MMP-3), but enhances PRL expression. Medroxyprogesterone Acetate 76-103 matrix metallopeptidase 3 Homo sapiens 205-210 8989257-3 1997 In the current study, immunoblot analysis revealed that coincubation with 10(-6) M RU 486 blocked the inhibition in HESC-secreted MMP-3 levels (50,000 mol wt) evoked by 10(-8) M E2 + 10(-7) M MPA. Mifepristone 83-89 matrix metallopeptidase 3 Homo sapiens 130-135 8989257-9 1997 Extrapolation of these in vitro observations to endometrial events following RU 486 administration suggests that coordinate enhancement of MMP-3 and plasminogen activator expression promotes proteolysis of the stromal/decidual ECM, which leads to endometrial sloughing. Mifepristone 77-83 matrix metallopeptidase 3 Homo sapiens 139-144 8989257-13 1997 Interleukin-1 beta counteracted E2 + MPA-mediated inhibition of secreted MMP-3 levels, implying that leukocyte/trophoblast-derived cytokines can modulate steroid-regulated MMP-3 expression by stromal/decidual cells during menstruation and pregnancy. Steroids 154-161 matrix metallopeptidase 3 Homo sapiens 73-78 8989257-13 1997 Interleukin-1 beta counteracted E2 + MPA-mediated inhibition of secreted MMP-3 levels, implying that leukocyte/trophoblast-derived cytokines can modulate steroid-regulated MMP-3 expression by stromal/decidual cells during menstruation and pregnancy. Steroids 154-161 matrix metallopeptidase 3 Homo sapiens 172-177 8976346-12 1996 Stromelysin-1 was up-regulated by nicotine and cotinine at 12 and 18 hours (1.5-fold to 7.0-fold). Nicotine 34-42 matrix metallopeptidase 3 Homo sapiens 0-13 8900407-6 1996 MMP-3 release was elevated with a peak at Day 6 and a profile similar to that for the Fn-f-induced cartilage PG depletion. Fenofibrate 86-90 matrix metallopeptidase 3 Homo sapiens 0-5 8855941-7 1996 NH2-terminal sequence analysis of they gamma-chain of the D monomer-like fragment and of a dipeptide isolated from the MMP-3 digest of XL-fibrin identified the hydrolysis of the gamma Gly 404-Ala 405 peptide bond. Dipeptides 91-100 matrix metallopeptidase 3 Homo sapiens 119-124 8895151-0 1996 Effects of indomethacin on the production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1 by human articular chondrocytes. Indomethacin 11-23 matrix metallopeptidase 3 Homo sapiens 45-71 8751977-4 1996 After irradiation of uroporphyrin-pretreated fibroblasts, specific mRNAs of MMP-1 and MMP-3 increased concomitantly up to 2.7-fold compared with ultraviolet-irradiated cells and up to 10-fold compared with mock-irradiated or uroporphyrin I-treated controls. Uroporphyrins 21-33 matrix metallopeptidase 3 Homo sapiens 86-91 8751977-4 1996 After irradiation of uroporphyrin-pretreated fibroblasts, specific mRNAs of MMP-1 and MMP-3 increased concomitantly up to 2.7-fold compared with ultraviolet-irradiated cells and up to 10-fold compared with mock-irradiated or uroporphyrin I-treated controls. uroporphyrin I 225-239 matrix metallopeptidase 3 Homo sapiens 86-91 8780527-0 1996 APMA (4-aminophenylmercuric acetate) activation of stromelysin-1 involves protein interactions in addition to those with cysteine-75 in the propeptide. 4-aminophenylmercuriacetate 0-4 matrix metallopeptidase 3 Homo sapiens 51-64 8780527-0 1996 APMA (4-aminophenylmercuric acetate) activation of stromelysin-1 involves protein interactions in addition to those with cysteine-75 in the propeptide. 4-aminophenylmercuriacetate 6-35 matrix metallopeptidase 3 Homo sapiens 51-64 8780527-0 1996 APMA (4-aminophenylmercuric acetate) activation of stromelysin-1 involves protein interactions in addition to those with cysteine-75 in the propeptide. cysteine-75 121-132 matrix metallopeptidase 3 Homo sapiens 51-64 8780527-0 1996 APMA (4-aminophenylmercuric acetate) activation of stromelysin-1 involves protein interactions in addition to those with cysteine-75 in the propeptide. propeptide 140-150 matrix metallopeptidase 3 Homo sapiens 51-64 8780527-5 1996 [(1993) Biochemistry 32, 10289-10295] demonstrated that modification of this cysteine residue in the propeptide of stromelysin-1 by sulfhydryl reagents did not result in an active enzyme as predicted. Cysteine 77-85 matrix metallopeptidase 3 Homo sapiens 115-128 8780527-5 1996 [(1993) Biochemistry 32, 10289-10295] demonstrated that modification of this cysteine residue in the propeptide of stromelysin-1 by sulfhydryl reagents did not result in an active enzyme as predicted. propeptide 101-111 matrix metallopeptidase 3 Homo sapiens 115-128 8780527-6 1996 To investigate the roles that this cysteine residue and the propeptide salt bridge (R74 to D79) might play in the APMA-induced activation of stromelysin-1, we have changed these residues by site-directed mutagenesis. Cysteine 35-43 matrix metallopeptidase 3 Homo sapiens 141-154 8780527-6 1996 To investigate the roles that this cysteine residue and the propeptide salt bridge (R74 to D79) might play in the APMA-induced activation of stromelysin-1, we have changed these residues by site-directed mutagenesis. propeptide 60-70 matrix metallopeptidase 3 Homo sapiens 141-154 8780527-8 1996 The wild-type stromelysin-1 and the cysteine mutants (C75S and C75H) underwent APMA-induced activation as determined by the characteristic reduction in molecular weight associated with activation and by their ability to cleave casein only when activated. 4-aminophenylmercuriacetate 79-83 matrix metallopeptidase 3 Homo sapiens 14-27 8780527-10 1996 These results demonstrate that APMA-induced activation of stromelysin-1 involves protein interactions in addition to those with cysteine-75 in the propeptide and also suggest that the R74 to D79 salt bridge may play a role. Cysteine 128-136 matrix metallopeptidase 3 Homo sapiens 58-71 8780527-10 1996 These results demonstrate that APMA-induced activation of stromelysin-1 involves protein interactions in addition to those with cysteine-75 in the propeptide and also suggest that the R74 to D79 salt bridge may play a role. propeptide 147-157 matrix metallopeptidase 3 Homo sapiens 58-71 8639603-8 1996 Apo mature MMP3 appears to form a native-like stable intermediate structure in which one or more of the tryptophan side chains is more solvent-exposed than in the holo form. Tryptophan 104-114 matrix metallopeptidase 3 Homo sapiens 11-15 8816911-0 1996 Vitamin D3 regulation of stromelysin-1 (MMP-3) in chondrocyte cultures is mediated by protein kinase C. Matrix metalloproteinases (MMPs) are a group of enzymes with the potential to degrade extracellular matrix proteins. Cholecalciferol 0-10 matrix metallopeptidase 3 Homo sapiens 131-135 8816911-1 1996 One of the MMPs, stromelysin-1 (MMP-3) has been localized to extracellular matrix vesicles in growth plate chondrocyte cultures, suggesting involvement of this enzyme in remodeling of the extracellular matrix during endochondral development, a process which is regulated by the vitamin D metabolites, 1,25-(OH)2D3 and 24,25-(OH)2D3. Vitamin D 278-287 matrix metallopeptidase 3 Homo sapiens 11-15 8816911-1 1996 One of the MMPs, stromelysin-1 (MMP-3) has been localized to extracellular matrix vesicles in growth plate chondrocyte cultures, suggesting involvement of this enzyme in remodeling of the extracellular matrix during endochondral development, a process which is regulated by the vitamin D metabolites, 1,25-(OH)2D3 and 24,25-(OH)2D3. Calcitriol 301-313 matrix metallopeptidase 3 Homo sapiens 11-15 8816911-1 1996 One of the MMPs, stromelysin-1 (MMP-3) has been localized to extracellular matrix vesicles in growth plate chondrocyte cultures, suggesting involvement of this enzyme in remodeling of the extracellular matrix during endochondral development, a process which is regulated by the vitamin D metabolites, 1,25-(OH)2D3 and 24,25-(OH)2D3. 24,25-(oh)2d3 318-331 matrix metallopeptidase 3 Homo sapiens 11-15 8921230-2 1996 In cultured human ciliary muscle cells, PGF2 alpha induces the expression of the protooncogene c-fos which is known to induce the transcription of genes such as matrix metalloproteinase-1 (MMP-1) and MMP-3 in other cell systems. Dinoprost 40-44 matrix metallopeptidase 3 Homo sapiens 200-205 8976346-12 1996 Stromelysin-1 was up-regulated by nicotine and cotinine at 12 and 18 hours (1.5-fold to 7.0-fold). Cotinine 47-55 matrix metallopeptidase 3 Homo sapiens 0-13 8692902-6 1996 The basic motif of these newt MMP genes was similar to mammalian counterparts and contained regions encoding a putative signal sequence, a propeptide, an active site with three zinc-binding histidine residues, a calcium-binding domain, a hemopexin region, and three key cysteine residues. propeptide 139-149 matrix metallopeptidase 3 Homo sapiens 30-33 8692902-6 1996 The basic motif of these newt MMP genes was similar to mammalian counterparts and contained regions encoding a putative signal sequence, a propeptide, an active site with three zinc-binding histidine residues, a calcium-binding domain, a hemopexin region, and three key cysteine residues. Histidine 190-199 matrix metallopeptidase 3 Homo sapiens 30-33 8692902-6 1996 The basic motif of these newt MMP genes was similar to mammalian counterparts and contained regions encoding a putative signal sequence, a propeptide, an active site with three zinc-binding histidine residues, a calcium-binding domain, a hemopexin region, and three key cysteine residues. Calcium 212-219 matrix metallopeptidase 3 Homo sapiens 30-33 8692902-6 1996 The basic motif of these newt MMP genes was similar to mammalian counterparts and contained regions encoding a putative signal sequence, a propeptide, an active site with three zinc-binding histidine residues, a calcium-binding domain, a hemopexin region, and three key cysteine residues. Cysteine 270-278 matrix metallopeptidase 3 Homo sapiens 30-33 8662692-1 1996 There is a common polymorphism in the promoter sequence of the human stromelysin-1 gene, with one allele having a run of six adenosines (6A) and the other five adenosines (5A). Adenosine 125-135 matrix metallopeptidase 3 Homo sapiens 69-82 8662692-1 1996 There is a common polymorphism in the promoter sequence of the human stromelysin-1 gene, with one allele having a run of six adenosines (6A) and the other five adenosines (5A). Adenosine 160-170 matrix metallopeptidase 3 Homo sapiens 69-82 8662692-4 1996 In transient transfection experiments, a stromelysin-1 promoter construct with 6A at the polymorphic site was found to express less of the chloramphenicol acetyltransferase reporter gene than a construct containing 5A. Chloramphenicol 139-154 matrix metallopeptidase 3 Homo sapiens 41-54 8639603-10 1996 The apo mature MMP3 intermediate can be unfolded with heat, subsequently refolded, and reactivated by addition of zinc and calcium. Calcium 123-130 matrix metallopeptidase 3 Homo sapiens 15-19 8804571-6 1996 These results suggest that fibroblast-type collagenase and matrilysin may be physiologically relevant activators of progelatinase A; the maintenance of latency and the process of activation for progelatinase A may occur through the cysteine-switch mechanism, and the proteolytic activation of procollagenase by matrilysin resulted in the same amino terminus as produced by stromelysin-1. Cysteine 232-240 matrix metallopeptidase 3 Homo sapiens 373-386 8631880-0 1996 Characterization of the 46-kDa intermediates of matrix metalloproteinase 3 (stromelysin 1) obtained by site-directed mutation of phenylalanine 83. Phenylalanine 129-142 matrix metallopeptidase 3 Homo sapiens 76-89 8631880-4 1996 The proMMP-3(H82R) mutant was activated by chymotrypsin, elastase, and 4-aminophenylmercuric acetate to the 45-kDa MMP-3 with similar mechanism and kinetics as the wild-type. Acetates 93-100 matrix metallopeptidase 3 Homo sapiens 7-12 8796270-4 1996 MMP-3 cleaved T-kininogen into a 57 kDa fragment as measured by SDS-PAGE and Western blot analysis using anti-T-kininogen antiserum. Sodium Dodecyl Sulfate 64-67 matrix metallopeptidase 3 Homo sapiens 0-5 7752115-4 1995 Extracellular signals (e.g., IL-1, phorbol myristic acetate) that result in the activation of cytoplasmic PKC augment in tandem the expression and synthesis of MMP-1, MMP-3, and TIMP-1 in human synovial fibroblasts. phorbol myristic acetate 35-59 matrix metallopeptidase 3 Homo sapiens 167-172 8706790-4 1996 In both young and old cells, phorbol myristoyl-13 acetate (PMA) induced the expression of transcripts of collagenase, stromelysin-1, gelatinase-B, TIMP-1, and TIMP-3. phorbol myristoyl-13 acetate 29-57 matrix metallopeptidase 3 Homo sapiens 118-131 8706790-4 1996 In both young and old cells, phorbol myristoyl-13 acetate (PMA) induced the expression of transcripts of collagenase, stromelysin-1, gelatinase-B, TIMP-1, and TIMP-3. Tetradecanoylphorbol Acetate 59-62 matrix metallopeptidase 3 Homo sapiens 118-131 8547882-3 1995 Neutral-lipophilic Tc-99m chelates with both SL1 and SL2 were formed in high yields (95-97%) as a single species ascertained by electrophoresis and reversed-phase HPLC. Technetium 19-21 matrix metallopeptidase 3 Homo sapiens 45-48 8547882-7 1995 Even though the Tc-99m chelates of SL1 and SL2 formed at tracer levels are not identical to the Re-chelates (different synthons were used), the Re data suggests complexation of Tc-99m by these hydrazido-thiol ligands will be similar to N,S ligand systems previously used. Technetium 16-18 matrix metallopeptidase 3 Homo sapiens 35-38 8547882-7 1995 Even though the Tc-99m chelates of SL1 and SL2 formed at tracer levels are not identical to the Re-chelates (different synthons were used), the Re data suggests complexation of Tc-99m by these hydrazido-thiol ligands will be similar to N,S ligand systems previously used. tc-99 16-21 matrix metallopeptidase 3 Homo sapiens 35-38 8547882-8 1995 The good in vitro and in vivo stability and high yields of the Tc-99m complexes of SL1 and SL2 indicate the potential hydrazido-thiols hold for use as a basis in formulating new Tc-99m radiopharmaceuticals, particularly when thiol moieties are used in conjunction with multi-functional phosphorous hydrazide compounds. tc-99 63-68 matrix metallopeptidase 3 Homo sapiens 83-86 8547882-8 1995 The good in vitro and in vivo stability and high yields of the Tc-99m complexes of SL1 and SL2 indicate the potential hydrazido-thiols hold for use as a basis in formulating new Tc-99m radiopharmaceuticals, particularly when thiol moieties are used in conjunction with multi-functional phosphorous hydrazide compounds. hydrazido-thiols 118-134 matrix metallopeptidase 3 Homo sapiens 83-86 8547882-8 1995 The good in vitro and in vivo stability and high yields of the Tc-99m complexes of SL1 and SL2 indicate the potential hydrazido-thiols hold for use as a basis in formulating new Tc-99m radiopharmaceuticals, particularly when thiol moieties are used in conjunction with multi-functional phosphorous hydrazide compounds. tc-99 178-183 matrix metallopeptidase 3 Homo sapiens 83-86 8547882-8 1995 The good in vitro and in vivo stability and high yields of the Tc-99m complexes of SL1 and SL2 indicate the potential hydrazido-thiols hold for use as a basis in formulating new Tc-99m radiopharmaceuticals, particularly when thiol moieties are used in conjunction with multi-functional phosphorous hydrazide compounds. Sulfhydryl Compounds 128-133 matrix metallopeptidase 3 Homo sapiens 83-86 8547882-8 1995 The good in vitro and in vivo stability and high yields of the Tc-99m complexes of SL1 and SL2 indicate the potential hydrazido-thiols hold for use as a basis in formulating new Tc-99m radiopharmaceuticals, particularly when thiol moieties are used in conjunction with multi-functional phosphorous hydrazide compounds. phosphorous hydrazide 286-307 matrix metallopeptidase 3 Homo sapiens 83-86 7547939-5 1995 The catalyzed hydrolysis of substrate, corrected for the effect of hydrophobic partitioning, was demonstrated to be sixth order in water for gelatinase A and third order in water for stromelysin 1. Water 131-136 matrix metallopeptidase 3 Homo sapiens 183-196 7547939-5 1995 The catalyzed hydrolysis of substrate, corrected for the effect of hydrophobic partitioning, was demonstrated to be sixth order in water for gelatinase A and third order in water for stromelysin 1. Water 173-178 matrix metallopeptidase 3 Homo sapiens 183-196 7629179-8 1995 When MMP-3 is in excess, the propeptide is completely processed, and the full activity of MMP-9 is detected. propeptide 29-39 matrix metallopeptidase 3 Homo sapiens 5-10 7629179-9 1995 Similarly, the proMMP-9.TIMP-1 complex inhibits MMP-1 (interstitial collagenase) and in turn renders the proMMP-9 activable by a catalytic amount of MMP-3. prommp 15-21 matrix metallopeptidase 3 Homo sapiens 149-154 7772054-9 1995 The removal of the propeptide of the proMMP-2* bound to TIMP-2 was also observed by MMP-3 (stromelysin 1), but not by MMP-1 (interstitial collagenase). propeptide 19-29 matrix metallopeptidase 3 Homo sapiens 84-89 7772054-9 1995 The removal of the propeptide of the proMMP-2* bound to TIMP-2 was also observed by MMP-3 (stromelysin 1), but not by MMP-1 (interstitial collagenase). propeptide 19-29 matrix metallopeptidase 3 Homo sapiens 91-104 9084672-14 1996 Further, MMP and plasminogen activator activities in MVs and PMs are regulated by vitamin D metabolites. Vitamin D 82-91 matrix metallopeptidase 3 Homo sapiens 9-12 7732485-5 1995 Serum MMP-3 significantly correlated with serum BUN or serum creatinine levels in SLE patients but not in RA patients. Creatinine 61-71 matrix metallopeptidase 3 Homo sapiens 6-11 7929438-0 1994 Multiple sites of the propeptide region of human stromelysin-1 are required for maintaining a latent form of the enzyme. propeptide 22-32 matrix metallopeptidase 3 Homo sapiens 49-62 7986224-6 1994 In the OA patients (n = 33), the serum levels of MMP-3, but not of MMP-1 or TIMP-1, were significantly elevated and correlated strongly with the articular index but poorly with objective and subjective functional capacity scores as well as with serum levels of antigenic KS and systemic parameters of inflammation. Keratan Sulfate 271-273 matrix metallopeptidase 3 Homo sapiens 49-54 7929438-1 1994 Latency of matrix metalloproteinase 3 (MMP-3) is regulated by the interaction of a free cysteine residue (Cys-75) in the conserved amino acid sequence Pro-Arg-Cys-Gly-Val-Pro-Asp located in the COOH-terminal portion of the propeptide with a chelated zinc atom in the active site of the catalytic domain. Cysteine 88-96 matrix metallopeptidase 3 Homo sapiens 11-37 7929438-1 1994 Latency of matrix metalloproteinase 3 (MMP-3) is regulated by the interaction of a free cysteine residue (Cys-75) in the conserved amino acid sequence Pro-Arg-Cys-Gly-Val-Pro-Asp located in the COOH-terminal portion of the propeptide with a chelated zinc atom in the active site of the catalytic domain. Cysteine 88-96 matrix metallopeptidase 3 Homo sapiens 39-44 7929438-1 1994 Latency of matrix metalloproteinase 3 (MMP-3) is regulated by the interaction of a free cysteine residue (Cys-75) in the conserved amino acid sequence Pro-Arg-Cys-Gly-Val-Pro-Asp located in the COOH-terminal portion of the propeptide with a chelated zinc atom in the active site of the catalytic domain. Cysteine 106-109 matrix metallopeptidase 3 Homo sapiens 11-37 7929438-1 1994 Latency of matrix metalloproteinase 3 (MMP-3) is regulated by the interaction of a free cysteine residue (Cys-75) in the conserved amino acid sequence Pro-Arg-Cys-Gly-Val-Pro-Asp located in the COOH-terminal portion of the propeptide with a chelated zinc atom in the active site of the catalytic domain. Cysteine 106-109 matrix metallopeptidase 3 Homo sapiens 39-44 7929438-1 1994 Latency of matrix metalloproteinase 3 (MMP-3) is regulated by the interaction of a free cysteine residue (Cys-75) in the conserved amino acid sequence Pro-Arg-Cys-Gly-Val-Pro-Asp located in the COOH-terminal portion of the propeptide with a chelated zinc atom in the active site of the catalytic domain. prolylarginine 151-158 matrix metallopeptidase 3 Homo sapiens 11-37 7929438-1 1994 Latency of matrix metalloproteinase 3 (MMP-3) is regulated by the interaction of a free cysteine residue (Cys-75) in the conserved amino acid sequence Pro-Arg-Cys-Gly-Val-Pro-Asp located in the COOH-terminal portion of the propeptide with a chelated zinc atom in the active site of the catalytic domain. prolylarginine 151-158 matrix metallopeptidase 3 Homo sapiens 39-44 7929438-1 1994 Latency of matrix metalloproteinase 3 (MMP-3) is regulated by the interaction of a free cysteine residue (Cys-75) in the conserved amino acid sequence Pro-Arg-Cys-Gly-Val-Pro-Asp located in the COOH-terminal portion of the propeptide with a chelated zinc atom in the active site of the catalytic domain. Cysteine 159-162 matrix metallopeptidase 3 Homo sapiens 11-37 7929438-1 1994 Latency of matrix metalloproteinase 3 (MMP-3) is regulated by the interaction of a free cysteine residue (Cys-75) in the conserved amino acid sequence Pro-Arg-Cys-Gly-Val-Pro-Asp located in the COOH-terminal portion of the propeptide with a chelated zinc atom in the active site of the catalytic domain. Cysteine 159-162 matrix metallopeptidase 3 Homo sapiens 39-44 7929438-1 1994 Latency of matrix metalloproteinase 3 (MMP-3) is regulated by the interaction of a free cysteine residue (Cys-75) in the conserved amino acid sequence Pro-Arg-Cys-Gly-Val-Pro-Asp located in the COOH-terminal portion of the propeptide with a chelated zinc atom in the active site of the catalytic domain. Glycine 163-166 matrix metallopeptidase 3 Homo sapiens 11-37 7929438-1 1994 Latency of matrix metalloproteinase 3 (MMP-3) is regulated by the interaction of a free cysteine residue (Cys-75) in the conserved amino acid sequence Pro-Arg-Cys-Gly-Val-Pro-Asp located in the COOH-terminal portion of the propeptide with a chelated zinc atom in the active site of the catalytic domain. Glycine 163-166 matrix metallopeptidase 3 Homo sapiens 39-44 8063713-7 1994 The second substrate, NFF-2 (Mca-Arg-Pro-Lys-Pro-Tyr-Ala-Nva-Trp-Met-Lys(Dnp)-NH2, where Nva is norvaline), was hydrolyzed 60 times more rapidly by MMP-3 (kcat/Km = 59,400 s-1 M-1) than MMP-1. Methylcholanthrene 29-32 matrix metallopeptidase 3 Homo sapiens 148-153 7929438-1 1994 Latency of matrix metalloproteinase 3 (MMP-3) is regulated by the interaction of a free cysteine residue (Cys-75) in the conserved amino acid sequence Pro-Arg-Cys-Gly-Val-Pro-Asp located in the COOH-terminal portion of the propeptide with a chelated zinc atom in the active site of the catalytic domain. Val-Pro-Asp 167-178 matrix metallopeptidase 3 Homo sapiens 11-37 7929438-1 1994 Latency of matrix metalloproteinase 3 (MMP-3) is regulated by the interaction of a free cysteine residue (Cys-75) in the conserved amino acid sequence Pro-Arg-Cys-Gly-Val-Pro-Asp located in the COOH-terminal portion of the propeptide with a chelated zinc atom in the active site of the catalytic domain. Val-Pro-Asp 167-178 matrix metallopeptidase 3 Homo sapiens 39-44 7929438-1 1994 Latency of matrix metalloproteinase 3 (MMP-3) is regulated by the interaction of a free cysteine residue (Cys-75) in the conserved amino acid sequence Pro-Arg-Cys-Gly-Val-Pro-Asp located in the COOH-terminal portion of the propeptide with a chelated zinc atom in the active site of the catalytic domain. Carbonic Acid 194-198 matrix metallopeptidase 3 Homo sapiens 11-37 7929438-1 1994 Latency of matrix metalloproteinase 3 (MMP-3) is regulated by the interaction of a free cysteine residue (Cys-75) in the conserved amino acid sequence Pro-Arg-Cys-Gly-Val-Pro-Asp located in the COOH-terminal portion of the propeptide with a chelated zinc atom in the active site of the catalytic domain. Carbonic Acid 194-198 matrix metallopeptidase 3 Homo sapiens 39-44 7929438-1 1994 Latency of matrix metalloproteinase 3 (MMP-3) is regulated by the interaction of a free cysteine residue (Cys-75) in the conserved amino acid sequence Pro-Arg-Cys-Gly-Val-Pro-Asp located in the COOH-terminal portion of the propeptide with a chelated zinc atom in the active site of the catalytic domain. propeptide 223-233 matrix metallopeptidase 3 Homo sapiens 11-37 7929438-1 1994 Latency of matrix metalloproteinase 3 (MMP-3) is regulated by the interaction of a free cysteine residue (Cys-75) in the conserved amino acid sequence Pro-Arg-Cys-Gly-Val-Pro-Asp located in the COOH-terminal portion of the propeptide with a chelated zinc atom in the active site of the catalytic domain. propeptide 223-233 matrix metallopeptidase 3 Homo sapiens 39-44 7929438-2 1994 Proteolytic activation of full-length human pro-MMP-3 involves the removal of approximately 35 amino acids from the NH2-terminal portion of the propeptide, forming a 53-kDa unstable intermediate that undergoes intermolecular autocatalysis to form the 45-kDa mature active enzyme. propeptide 144-154 matrix metallopeptidase 3 Homo sapiens 48-53 7929438-4 1994 Full-length human pro-MMP-3 was expressed in Escherichia coli and refolded to form latent pro-MMP-3 capable of activation by chymotrypsin or aminophenylmercuric acetate. Acetates 161-168 matrix metallopeptidase 3 Homo sapiens 22-27 7929438-4 1994 Full-length human pro-MMP-3 was expressed in Escherichia coli and refolded to form latent pro-MMP-3 capable of activation by chymotrypsin or aminophenylmercuric acetate. Acetates 161-168 matrix metallopeptidase 3 Homo sapiens 94-99 7929438-5 1994 Renaturation of pro-MMP-3 expressed in bacteria with 20 or more amino acids removed from the NH2-terminal region of the propeptide yielded only an active enzyme. propeptide 120-130 matrix metallopeptidase 3 Homo sapiens 20-25 8063713-5 1994 The first of these substrates, NFF-1 (Mca-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Lys-(Dnp)-Gly, where Mca is (7-methoxycoumarin-4-yl)acetyl and Dnp is 2,4-dinitrophenyl), was hydrolyzed equally well by MMP-3 and MMP-2 (kcat/Km approximately 11,000 s-1 M-1). Methylcholanthrene 38-41 matrix metallopeptidase 3 Homo sapiens 199-204 8063713-5 1994 The first of these substrates, NFF-1 (Mca-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Lys-(Dnp)-Gly, where Mca is (7-methoxycoumarin-4-yl)acetyl and Dnp is 2,4-dinitrophenyl), was hydrolyzed equally well by MMP-3 and MMP-2 (kcat/Km approximately 11,000 s-1 M-1). Proline 42-45 matrix metallopeptidase 3 Homo sapiens 199-204 8063713-5 1994 The first of these substrates, NFF-1 (Mca-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Lys-(Dnp)-Gly, where Mca is (7-methoxycoumarin-4-yl)acetyl and Dnp is 2,4-dinitrophenyl), was hydrolyzed equally well by MMP-3 and MMP-2 (kcat/Km approximately 11,000 s-1 M-1). Lysine 46-49 matrix metallopeptidase 3 Homo sapiens 199-204 8063713-5 1994 The first of these substrates, NFF-1 (Mca-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Lys-(Dnp)-Gly, where Mca is (7-methoxycoumarin-4-yl)acetyl and Dnp is 2,4-dinitrophenyl), was hydrolyzed equally well by MMP-3 and MMP-2 (kcat/Km approximately 11,000 s-1 M-1). Proline 50-53 matrix metallopeptidase 3 Homo sapiens 199-204 8063713-5 1994 The first of these substrates, NFF-1 (Mca-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Lys-(Dnp)-Gly, where Mca is (7-methoxycoumarin-4-yl)acetyl and Dnp is 2,4-dinitrophenyl), was hydrolyzed equally well by MMP-3 and MMP-2 (kcat/Km approximately 11,000 s-1 M-1). Glutamine 54-57 matrix metallopeptidase 3 Homo sapiens 199-204 8063713-5 1994 The first of these substrates, NFF-1 (Mca-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Lys-(Dnp)-Gly, where Mca is (7-methoxycoumarin-4-yl)acetyl and Dnp is 2,4-dinitrophenyl), was hydrolyzed equally well by MMP-3 and MMP-2 (kcat/Km approximately 11,000 s-1 M-1). Glutamine 58-61 matrix metallopeptidase 3 Homo sapiens 199-204 8063713-5 1994 The first of these substrates, NFF-1 (Mca-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Lys-(Dnp)-Gly, where Mca is (7-methoxycoumarin-4-yl)acetyl and Dnp is 2,4-dinitrophenyl), was hydrolyzed equally well by MMP-3 and MMP-2 (kcat/Km approximately 11,000 s-1 M-1). phe-phe-gly-leu-lys 62-81 matrix metallopeptidase 3 Homo sapiens 199-204 8063713-5 1994 The first of these substrates, NFF-1 (Mca-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Lys-(Dnp)-Gly, where Mca is (7-methoxycoumarin-4-yl)acetyl and Dnp is 2,4-dinitrophenyl), was hydrolyzed equally well by MMP-3 and MMP-2 (kcat/Km approximately 11,000 s-1 M-1). Glycine 70-73 matrix metallopeptidase 3 Homo sapiens 199-204 8063713-5 1994 The first of these substrates, NFF-1 (Mca-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Lys-(Dnp)-Gly, where Mca is (7-methoxycoumarin-4-yl)acetyl and Dnp is 2,4-dinitrophenyl), was hydrolyzed equally well by MMP-3 and MMP-2 (kcat/Km approximately 11,000 s-1 M-1). Methylcholanthrene 99-102 matrix metallopeptidase 3 Homo sapiens 199-204 8200951-0 1994 Ovarian steroid-modulated stromelysin-1 expression in human endometrial stromal and decidual cells. Steroids 8-15 matrix metallopeptidase 3 Homo sapiens 26-39 8200951-1 1994 This study examined steroid-regulated expression of the metalloproteinase stromelysin-1 in primary human endometrial stromal and decidual cells. Steroids 20-27 matrix metallopeptidase 3 Homo sapiens 74-87 8200951-2 1994 Immunoblot analysis using a specific polyclonal antibody against stromelysin-1 revealed that the progestin medroxyprogesterone acetate (MPA) produced a time-dependent reduction in a band at 50,000 mol wt. Medroxyprogesterone Acetate 107-134 matrix metallopeptidase 3 Homo sapiens 65-78 8200951-2 1994 Immunoblot analysis using a specific polyclonal antibody against stromelysin-1 revealed that the progestin medroxyprogesterone acetate (MPA) produced a time-dependent reduction in a band at 50,000 mol wt. Medroxyprogesterone Acetate 136-139 matrix metallopeptidase 3 Homo sapiens 65-78 8200951-7 1994 After suppression of stromelysin-1 expression in the stromal cell monolayers by E2 plus MPA, steroid withdrawal led to a several-fold enhancement of stromelysin-1 mRNA by 4 days and of the stromelysin-1 protein by 7 days. Steroids 93-100 matrix metallopeptidase 3 Homo sapiens 21-34 8200951-7 1994 After suppression of stromelysin-1 expression in the stromal cell monolayers by E2 plus MPA, steroid withdrawal led to a several-fold enhancement of stromelysin-1 mRNA by 4 days and of the stromelysin-1 protein by 7 days. Steroids 93-100 matrix metallopeptidase 3 Homo sapiens 149-162 8200951-7 1994 After suppression of stromelysin-1 expression in the stromal cell monolayers by E2 plus MPA, steroid withdrawal led to a several-fold enhancement of stromelysin-1 mRNA by 4 days and of the stromelysin-1 protein by 7 days. Steroids 93-100 matrix metallopeptidase 3 Homo sapiens 149-162 8200951-8 1994 Given its actions in degrading several extracellular matrix components and activating other MMP zymogens, steroid withdrawal-enhanced stromelysin-1 activity could mediate a proteolytic cascade that promotes the rapid tissue destruction and vascular disruption associated with menstruation. Steroids 106-113 matrix metallopeptidase 3 Homo sapiens 92-95 8200951-8 1994 Given its actions in degrading several extracellular matrix components and activating other MMP zymogens, steroid withdrawal-enhanced stromelysin-1 activity could mediate a proteolytic cascade that promotes the rapid tissue destruction and vascular disruption associated with menstruation. Steroids 106-113 matrix metallopeptidase 3 Homo sapiens 134-147 7656014-2 1994 The global fold consists of three helices, a five stranded beta-sheet and a methionine located in a turn near the catalytic histidines, classifying stromelysin-1 as a metzincin. Methionine 76-86 matrix metallopeptidase 3 Homo sapiens 148-161 7656014-2 1994 The global fold consists of three helices, a five stranded beta-sheet and a methionine located in a turn near the catalytic histidines, classifying stromelysin-1 as a metzincin. Histidine 124-134 matrix metallopeptidase 3 Homo sapiens 148-161 8045973-5 1994 Identities of MMP-1 and MMP-3 were confirmed by Western blots, by comparison of mol wt with those of purified enzymes on casein zymography, and by inhibition of these activities with EDTA and 1,10-phenanthroline. Edetic Acid 183-187 matrix metallopeptidase 3 Homo sapiens 24-29 8045973-5 1994 Identities of MMP-1 and MMP-3 were confirmed by Western blots, by comparison of mol wt with those of purified enzymes on casein zymography, and by inhibition of these activities with EDTA and 1,10-phenanthroline. 1,10-phenanthroline 192-211 matrix metallopeptidase 3 Homo sapiens 24-29 8045973-6 1994 Northern analysis demonstrated specific messenger ribonucleic acid for pro-MMP-1 and pro-MMP-3 in phorbol myristate acetate-stimulated stromal cells. Tetradecanoylphorbol Acetate 98-123 matrix metallopeptidase 3 Homo sapiens 89-94 8033891-8 1994 However, MMP-3 previously activated by mast cell proteinases was shown to activate pMMP-9, but not pMMP-2. pmmp-9 83-89 matrix metallopeptidase 3 Homo sapiens 9-14 8024499-1 1994 An inhibitory activity toward matrix metalloproteinases such as interstitial collagenase, 72-kDa gelatinase/type IV collagenase, and stromelysin-1 was detected in an EDTA extract of pulverized roots of human teeth, and identified as TIMP-1 by sodium dodecyl sulphate-polyacrylamide gel electrophoresis and immunoblotting. Edetic Acid 166-170 matrix metallopeptidase 3 Homo sapiens 133-146 8024499-1 1994 An inhibitory activity toward matrix metalloproteinases such as interstitial collagenase, 72-kDa gelatinase/type IV collagenase, and stromelysin-1 was detected in an EDTA extract of pulverized roots of human teeth, and identified as TIMP-1 by sodium dodecyl sulphate-polyacrylamide gel electrophoresis and immunoblotting. Sodium Dodecyl Sulfate 243-266 matrix metallopeptidase 3 Homo sapiens 133-146 8024499-1 1994 An inhibitory activity toward matrix metalloproteinases such as interstitial collagenase, 72-kDa gelatinase/type IV collagenase, and stromelysin-1 was detected in an EDTA extract of pulverized roots of human teeth, and identified as TIMP-1 by sodium dodecyl sulphate-polyacrylamide gel electrophoresis and immunoblotting. polyacrylamide 267-281 matrix metallopeptidase 3 Homo sapiens 133-146 8063713-7 1994 The second substrate, NFF-2 (Mca-Arg-Pro-Lys-Pro-Tyr-Ala-Nva-Trp-Met-Lys(Dnp)-NH2, where Nva is norvaline), was hydrolyzed 60 times more rapidly by MMP-3 (kcat/Km = 59,400 s-1 M-1) than MMP-1. Arginine 33-36 matrix metallopeptidase 3 Homo sapiens 148-153 8063713-7 1994 The second substrate, NFF-2 (Mca-Arg-Pro-Lys-Pro-Tyr-Ala-Nva-Trp-Met-Lys(Dnp)-NH2, where Nva is norvaline), was hydrolyzed 60 times more rapidly by MMP-3 (kcat/Km = 59,400 s-1 M-1) than MMP-1. lys-pro-tyr-ala-nva-trp-met-lys 41-72 matrix metallopeptidase 3 Homo sapiens 148-153 8063713-7 1994 The second substrate, NFF-2 (Mca-Arg-Pro-Lys-Pro-Tyr-Ala-Nva-Trp-Met-Lys(Dnp)-NH2, where Nva is norvaline), was hydrolyzed 60 times more rapidly by MMP-3 (kcat/Km = 59,400 s-1 M-1) than MMP-1. norvaline 57-60 matrix metallopeptidase 3 Homo sapiens 148-153 8063713-7 1994 The second substrate, NFF-2 (Mca-Arg-Pro-Lys-Pro-Tyr-Ala-Nva-Trp-Met-Lys(Dnp)-NH2, where Nva is norvaline), was hydrolyzed 60 times more rapidly by MMP-3 (kcat/Km = 59,400 s-1 M-1) than MMP-1. norvaline 96-105 matrix metallopeptidase 3 Homo sapiens 148-153 8063713-9 1994 The third substrate, NFF-3 (Mca-Arg-Pro-Lys-Pro-Val-Glu-Nva-Trp-Arg-Lys(Dnp)-NH2), was hydrolyzed rapidly by MMP-3 (kcat/Km = 218,000 s-1 M-1) and very slowly by MMP-9 (kcat/Km = 10,100 s-1 M-1), but there was no significant hydrolysis by MMP-1 and MMP-2. Glutamic Acid 52-55 matrix metallopeptidase 3 Homo sapiens 109-114 8063713-9 1994 The third substrate, NFF-3 (Mca-Arg-Pro-Lys-Pro-Val-Glu-Nva-Trp-Arg-Lys(Dnp)-NH2), was hydrolyzed rapidly by MMP-3 (kcat/Km = 218,000 s-1 M-1) and very slowly by MMP-9 (kcat/Km = 10,100 s-1 M-1), but there was no significant hydrolysis by MMP-1 and MMP-2. norvaline 56-59 matrix metallopeptidase 3 Homo sapiens 109-114 8063713-9 1994 The third substrate, NFF-3 (Mca-Arg-Pro-Lys-Pro-Val-Glu-Nva-Trp-Arg-Lys(Dnp)-NH2), was hydrolyzed rapidly by MMP-3 (kcat/Km = 218,000 s-1 M-1) and very slowly by MMP-9 (kcat/Km = 10,100 s-1 M-1), but there was no significant hydrolysis by MMP-1 and MMP-2. Tryptophan 60-63 matrix metallopeptidase 3 Homo sapiens 109-114 8063713-9 1994 The third substrate, NFF-3 (Mca-Arg-Pro-Lys-Pro-Val-Glu-Nva-Trp-Arg-Lys(Dnp)-NH2), was hydrolyzed rapidly by MMP-3 (kcat/Km = 218,000 s-1 M-1) and very slowly by MMP-9 (kcat/Km = 10,100 s-1 M-1), but there was no significant hydrolysis by MMP-1 and MMP-2. Lysine 40-43 matrix metallopeptidase 3 Homo sapiens 109-114 8063713-9 1994 The third substrate, NFF-3 (Mca-Arg-Pro-Lys-Pro-Val-Glu-Nva-Trp-Arg-Lys(Dnp)-NH2), was hydrolyzed rapidly by MMP-3 (kcat/Km = 218,000 s-1 M-1) and very slowly by MMP-9 (kcat/Km = 10,100 s-1 M-1), but there was no significant hydrolysis by MMP-1 and MMP-2. 2,4-Dinitrophenol 72-75 matrix metallopeptidase 3 Homo sapiens 109-114 7939136-3 1994 Pretreatment with rhIL-4 reduced the subsequent tumour necrosis factor alpha (TNF alpha) stimulation of prostaglandin E (PGE) and matrix metalloproteinase-3 (MMP-3) production by RSF. (3r,3as,6ar)-Hexahydrofuro[2,3-B]furan-3-Ol 179-182 matrix metallopeptidase 3 Homo sapiens 158-163 8280080-6 1993 The expression of MMP-3 and MMP-1 was further enhanced by phorbol 12-myristate 13-acetate (PMA). Tetradecanoylphorbol Acetate 91-94 matrix metallopeptidase 3 Homo sapiens 18-23 8280080-13 1993 On the other hand, forskolin suppressed the PMA-mediated induction of MMP-1 and MMP-3 in synovial fibroblasts, while it enhanced or did not affect this induction in various types of human endothelial cells. Colforsin 19-28 matrix metallopeptidase 3 Homo sapiens 80-85 8280080-13 1993 On the other hand, forskolin suppressed the PMA-mediated induction of MMP-1 and MMP-3 in synovial fibroblasts, while it enhanced or did not affect this induction in various types of human endothelial cells. Tetradecanoylphorbol Acetate 44-47 matrix metallopeptidase 3 Homo sapiens 80-85 8241165-1 1993 We report the NMR assignments for the main-chain 13C, 15N, and 1H resonances (1HN, 1H alpha, 15N alpha, 13C alpha, 13CO) for the 19.5-kDa catalytic domain of human stromelysin-1, a zinc endoproteinase thought to be involved in pathologic tissue degradation. 13c 49-52 matrix metallopeptidase 3 Homo sapiens 164-177 8241165-1 1993 We report the NMR assignments for the main-chain 13C, 15N, and 1H resonances (1HN, 1H alpha, 15N alpha, 13C alpha, 13CO) for the 19.5-kDa catalytic domain of human stromelysin-1, a zinc endoproteinase thought to be involved in pathologic tissue degradation. 15n 54-57 matrix metallopeptidase 3 Homo sapiens 164-177 8241165-1 1993 We report the NMR assignments for the main-chain 13C, 15N, and 1H resonances (1HN, 1H alpha, 15N alpha, 13C alpha, 13CO) for the 19.5-kDa catalytic domain of human stromelysin-1, a zinc endoproteinase thought to be involved in pathologic tissue degradation. Hydrogen 63-65 matrix metallopeptidase 3 Homo sapiens 164-177 8241165-1 1993 We report the NMR assignments for the main-chain 13C, 15N, and 1H resonances (1HN, 1H alpha, 15N alpha, 13C alpha, 13CO) for the 19.5-kDa catalytic domain of human stromelysin-1, a zinc endoproteinase thought to be involved in pathologic tissue degradation. 1-Hydroxy-2-naphthoic acid 78-81 matrix metallopeptidase 3 Homo sapiens 164-177 8241165-1 1993 We report the NMR assignments for the main-chain 13C, 15N, and 1H resonances (1HN, 1H alpha, 15N alpha, 13C alpha, 13CO) for the 19.5-kDa catalytic domain of human stromelysin-1, a zinc endoproteinase thought to be involved in pathologic tissue degradation. Hydrogen 78-80 matrix metallopeptidase 3 Homo sapiens 164-177 8241165-1 1993 We report the NMR assignments for the main-chain 13C, 15N, and 1H resonances (1HN, 1H alpha, 15N alpha, 13C alpha, 13CO) for the 19.5-kDa catalytic domain of human stromelysin-1, a zinc endoproteinase thought to be involved in pathologic tissue degradation. 15n 93-96 matrix metallopeptidase 3 Homo sapiens 164-177 8241165-1 1993 We report the NMR assignments for the main-chain 13C, 15N, and 1H resonances (1HN, 1H alpha, 15N alpha, 13C alpha, 13CO) for the 19.5-kDa catalytic domain of human stromelysin-1, a zinc endoproteinase thought to be involved in pathologic tissue degradation. 13c 104-107 matrix metallopeptidase 3 Homo sapiens 164-177 8241165-1 1993 We report the NMR assignments for the main-chain 13C, 15N, and 1H resonances (1HN, 1H alpha, 15N alpha, 13C alpha, 13CO) for the 19.5-kDa catalytic domain of human stromelysin-1, a zinc endoproteinase thought to be involved in pathologic tissue degradation. 13co 115-119 matrix metallopeptidase 3 Homo sapiens 164-177 8408046-11 1993 The affinity of MMP-3 for calcium is decreased about 10-fold at pH 5.3 compared to neutral pH. Calcium 26-33 matrix metallopeptidase 3 Homo sapiens 16-21 8399171-1 1993 Matrix metalloproteinases (MMPs) are activated in vitro from their precursors (proMMPs) by multiple means such as treatment with proteinases, mercurial compounds, chaotropic agents, sodium dodecyl sulfate, HOCl, and heat. Sodium Dodecyl Sulfate 182-204 matrix metallopeptidase 3 Homo sapiens 27-31 8399171-1 1993 Matrix metalloproteinases (MMPs) are activated in vitro from their precursors (proMMPs) by multiple means such as treatment with proteinases, mercurial compounds, chaotropic agents, sodium dodecyl sulfate, HOCl, and heat. Hypochlorous Acid 206-210 matrix metallopeptidase 3 Homo sapiens 27-31 8440730-1 1993 Role of calcium in promatrix metalloprotease-3 (pro-MMP-3, prostromelysin-1) activation and thermostability of the low mass catalytic domain of MMP-3. Calcium 8-15 matrix metallopeptidase 3 Homo sapiens 144-149 8280080-6 1993 The expression of MMP-3 and MMP-1 was further enhanced by phorbol 12-myristate 13-acetate (PMA). Tetradecanoylphorbol Acetate 58-89 matrix metallopeptidase 3 Homo sapiens 18-23 8426746-6 1993 Comparison of the findings with those for the promoters of other TPA-inducible matrix metalloproteinases, interstitial collagenase and stromelysin 1, revealed that the signal to the AP-1 sites is common for the TPA-inducibility of the genes but that the signals to the kappa B or Sp-1 sites, which are not present in interstitial collagenase and stromelysin 1 promoters, are the unique determinant for the inducibility of the 92 kDa type IV collagenase gene. Tetradecanoylphorbol Acetate 65-68 matrix metallopeptidase 3 Homo sapiens 135-148 8273564-2 1993 We have successfully modified a previously described assay [1] which used an internally quenched peptide substrate (Dnp-PYAYWMR) that, upon cleavage by MMP-3, produces the products, Dnp-PYA (quiet) and YWMR (a fluorophore at 360 nm). dnp-pya 116-123 matrix metallopeptidase 3 Homo sapiens 152-157 8273564-3 1993 This improved assay uses purified human MMP-3 in the presence of either 5% methanol or 5% DMSO. Methanol 75-83 matrix metallopeptidase 3 Homo sapiens 40-45 8273564-3 1993 This improved assay uses purified human MMP-3 in the presence of either 5% methanol or 5% DMSO. Dimethyl Sulfoxide 90-94 matrix metallopeptidase 3 Homo sapiens 40-45 8273564-5 1993 We have determined a Km of 39.2 microM and Kcat/Km of 4.6 microM/h for MMP-3 (in 5% MeOH) using this peptide substrate. Methanol 84-88 matrix metallopeptidase 3 Homo sapiens 71-76 8426746-6 1993 Comparison of the findings with those for the promoters of other TPA-inducible matrix metalloproteinases, interstitial collagenase and stromelysin 1, revealed that the signal to the AP-1 sites is common for the TPA-inducibility of the genes but that the signals to the kappa B or Sp-1 sites, which are not present in interstitial collagenase and stromelysin 1 promoters, are the unique determinant for the inducibility of the 92 kDa type IV collagenase gene. Tetradecanoylphorbol Acetate 65-68 matrix metallopeptidase 3 Homo sapiens 346-359 8426746-6 1993 Comparison of the findings with those for the promoters of other TPA-inducible matrix metalloproteinases, interstitial collagenase and stromelysin 1, revealed that the signal to the AP-1 sites is common for the TPA-inducibility of the genes but that the signals to the kappa B or Sp-1 sites, which are not present in interstitial collagenase and stromelysin 1 promoters, are the unique determinant for the inducibility of the 92 kDa type IV collagenase gene. Tetradecanoylphorbol Acetate 211-214 matrix metallopeptidase 3 Homo sapiens 135-148 8426746-6 1993 Comparison of the findings with those for the promoters of other TPA-inducible matrix metalloproteinases, interstitial collagenase and stromelysin 1, revealed that the signal to the AP-1 sites is common for the TPA-inducibility of the genes but that the signals to the kappa B or Sp-1 sites, which are not present in interstitial collagenase and stromelysin 1 promoters, are the unique determinant for the inducibility of the 92 kDa type IV collagenase gene. Tetradecanoylphorbol Acetate 211-214 matrix metallopeptidase 3 Homo sapiens 346-359 1805789-2 1991 The addition of linoleic acid hydroperoxide significantly increased the production of MMP-1 (tissue collagenase) and MMP-3 (stromelysin), while it rather decreased that of MMP-2 (gelatinase of 72 kDa; so-called "type IV collagenase"). linoleic acid hydroperoxide 16-43 matrix metallopeptidase 3 Homo sapiens 86-122 8356391-4 1993 Subcultured synovial fibroblasts, devoid of macrophages, did not produce MMP-9 as judged by zymography and immunolocalisation; but when stimulated with phorbol myristate acetate and interleukin-1 alpha both MMP-9 and MMP-3 were co-expressed. Tetradecanoylphorbol Acetate 152-177 matrix metallopeptidase 3 Homo sapiens 217-222 1371271-3 1992 MMP-3 initially cleaves proMMP-9 at the Glu40-Met41 bond located in the middle of the propeptide to generate an 86-kDa intermediate. propeptide 86-96 matrix metallopeptidase 3 Homo sapiens 0-5 1371271-6 1992 This stepwise activation mechanism of proMMP-9 is analogous to those of other members of the MMP family, but the action of MMP-3 on proMMP-9 is the first example of zymogen activation that can be triggered by another member of the MMP family. prommp-9 38-46 matrix metallopeptidase 3 Homo sapiens 123-128 1371271-6 1992 This stepwise activation mechanism of proMMP-9 is analogous to those of other members of the MMP family, but the action of MMP-3 on proMMP-9 is the first example of zymogen activation that can be triggered by another member of the MMP family. prommp-9 38-46 matrix metallopeptidase 3 Homo sapiens 93-96 1371271-6 1992 This stepwise activation mechanism of proMMP-9 is analogous to those of other members of the MMP family, but the action of MMP-3 on proMMP-9 is the first example of zymogen activation that can be triggered by another member of the MMP family. prommp-9 132-140 matrix metallopeptidase 3 Homo sapiens 123-128 1371271-6 1992 This stepwise activation mechanism of proMMP-9 is analogous to those of other members of the MMP family, but the action of MMP-3 on proMMP-9 is the first example of zymogen activation that can be triggered by another member of the MMP family. prommp-9 132-140 matrix metallopeptidase 3 Homo sapiens 93-96 1371271-7 1992 The results imply that MMP-3 may be an effective activator of proMMP-9 in vivo. prommp-9 62-70 matrix metallopeptidase 3 Homo sapiens 23-28 1468208-5 1992 Stromelysin-1 was isolated from plasma by Matrex green A affinity chromatography. matrex green a 42-56 matrix metallopeptidase 3 Homo sapiens 0-13 1284126-4 1992 In contrast, MMP-3, MMP-9 and TIMP-1 activities were markedly stimulated by TPA in most of the tumor cell lines and human umbilical vein endothelial cells (HUVEC), whereas the fibroblast lines were minimally stimulated or unresponsive to TPA. Tetradecanoylphorbol Acetate 76-79 matrix metallopeptidase 3 Homo sapiens 13-18 1284126-14 1992 This activity was maximal at 6 h. An association was observed between AP-1 binding activity and increased expression of MMP-1, MMP-3 and MMP-9, which possess TPA-responsive elements (TRE). Tetradecanoylphorbol Acetate 158-161 matrix metallopeptidase 3 Homo sapiens 127-132 1581308-0 1992 Characterization of zinc-binding sites in human stromelysin-1: stoichiometry of the catalytic domain and identification of a cysteine ligand in the proenzyme. Cysteine 125-133 matrix metallopeptidase 3 Homo sapiens 48-61 1874716-6 1991 N-terminal sequencing of the G2 fragment derived from the action of recombinant human stromelysin-1 revealed that cleavage between G1 and G2 occurred at the N-terminal end of the interglobular domain, close to the last cysteine in G1. Cysteine 219-227 matrix metallopeptidase 3 Homo sapiens 86-99 1757492-3 1991 A low level of MMP-3 activity was released from the cells (0.12 +/- 0.02 unit per 10(6) cells per 48 h; 1 unit degrades 1 microgram of reduced, carboxymethylated transferrin min-1 at 37 degrees C), but following stimulation by phorbol myristate acetate (PMA) a mean 4.4-fold increase in MMP-3 production was observed (to 0.53 +/- 0.13 unit per 10(6) cells per 48 h). Tetradecanoylphorbol Acetate 227-252 matrix metallopeptidase 3 Homo sapiens 15-20 1757492-3 1991 A low level of MMP-3 activity was released from the cells (0.12 +/- 0.02 unit per 10(6) cells per 48 h; 1 unit degrades 1 microgram of reduced, carboxymethylated transferrin min-1 at 37 degrees C), but following stimulation by phorbol myristate acetate (PMA) a mean 4.4-fold increase in MMP-3 production was observed (to 0.53 +/- 0.13 unit per 10(6) cells per 48 h). Tetradecanoylphorbol Acetate 254-257 matrix metallopeptidase 3 Homo sapiens 15-20 34917160-8 2021 Finally, six genes, namely, CXCL1, HIF1A, IL-6, MMP3, NOX4, and PTGS2, were selected to validate the treatment effects of the resveratrol. Resveratrol 126-137 matrix metallopeptidase 3 Homo sapiens 48-52 2005102-2 1991 Stromelysin-1 cleaved salt-soluble native molecules of type IX collagen into two main triple-helical fragments, COL1 and COL2,3. Salts 22-26 matrix metallopeptidase 3 Homo sapiens 0-13 2005102-4 1991 Stromelysin-1 also acted as a "telopeptidase," in that it efficiently clipped intact molecules of types II and XI collagens at sites just inside their terminal cross-linking hydroxylysine residues. Hydroxylysine 174-187 matrix metallopeptidase 3 Homo sapiens 0-13 1666284-6 1991 The removal of a portion of propeptides results in conformational changes around the Gln80-Phe81 and His82-Phe83 bonds in respective intermediates of MMP-1 and MMP-3 and render them to rapid specific cleavage by MMP-3 to generate stable, fully active enzymes. propeptides 28-39 matrix metallopeptidase 3 Homo sapiens 160-165 1666284-6 1991 The removal of a portion of propeptides results in conformational changes around the Gln80-Phe81 and His82-Phe83 bonds in respective intermediates of MMP-1 and MMP-3 and render them to rapid specific cleavage by MMP-3 to generate stable, fully active enzymes. propeptides 28-39 matrix metallopeptidase 3 Homo sapiens 212-217 33942503-4 2021 Iron overload would promote the expression of chondrocytes catabolic markers, MMP3 and MMP13 expression. Iron 0-4 matrix metallopeptidase 3 Homo sapiens 78-82 33588937-10 2021 Stimulation by ThCM clearly changed the metabolic profile of both RASF and OASF by inducing a shift towards aerobic glycolysis with strongly increased lactate production together with a rise in IL-6 and MMP3 secretion. thcm 15-19 matrix metallopeptidase 3 Homo sapiens 203-207 2176865-9 1990 This indicates that the removal of a portion of the propeptide of procollagenase induces conformational changes around the Gln80-Phe81 bond, rendering it readily susceptible to MMP-3 activation. propeptide 52-62 matrix metallopeptidase 3 Homo sapiens 177-182 34897721-6 2021 In addition, molecular docking also showed that 6,6"-bieckol could bind to MMP-1, MMP-3, and MMP-9. 6,6'-bieckol 48-60 matrix metallopeptidase 3 Homo sapiens 82-87 34917160-10 2021 In addition, in these chondrocytes, CXCL1, HIF1A, IL-6, MMP3, NOX4, and PTGS2 were reduced considerably, but HIF1A was significantly increased after resveratrol treatment. Resveratrol 149-160 matrix metallopeptidase 3 Homo sapiens 56-60 34917160-11 2021 Conclusions: Our data indicates that CXCL1, HIF1A, IL-6, MMP3, NOX4, and PTGS2 are all targets of resveratrol therapy. Resveratrol 98-109 matrix metallopeptidase 3 Homo sapiens 57-61 34712131-8 2021 Pirfenidone only reduced mRNA expression for MMP3 and -13. pirfenidone 0-11 matrix metallopeptidase 3 Homo sapiens 45-57 34848464-5 2021 CTAB reduced expression of matrix metalloproteinases (MMPs) such as MMP3, MMP7, and MMP14 in a concentration-dependent manner, while it increased expression of tissue inhibitors of metalloproteinase 3 (TIMP3). Cetrimonium 0-4 matrix metallopeptidase 3 Homo sapiens 54-58 34848464-5 2021 CTAB reduced expression of matrix metalloproteinases (MMPs) such as MMP3, MMP7, and MMP14 in a concentration-dependent manner, while it increased expression of tissue inhibitors of metalloproteinase 3 (TIMP3). Cetrimonium 0-4 matrix metallopeptidase 3 Homo sapiens 68-72 34608503-15 2021 The results indicated that lncRNA AL355711 promoted VSMC migration and atherosclerosis partly via the ABCG1/MMP3 pathway. al355711 34-42 matrix metallopeptidase 3 Homo sapiens 108-112 34537380-15 2021 Lastly, in OA hFLS, HU308 treatment inhibited IL-1beta-induced CCL2, MMP1, MMP3, and IL6 expression and further inhibited TNF-alpha-induced CCL2, MMP1, and GMCSF expression, demonstrating human OA-relevant anti-inflammatory effects by targeting CB2. HU 308 20-25 matrix metallopeptidase 3 Homo sapiens 75-79 34940120-6 2021 Primary ESC cultures treated with E2 + medroxyprogesterone acetate (MPA), a potent P4 receptor agonist, showed significant down-regulation of MMP3, MMP10, MMP11, MMP12, MMP20, and MMP27 in decidualized ESCs, as assessed by quantitative reverse transcription PCR. e2 + medroxyprogesterone acetate 34-66 matrix metallopeptidase 3 Homo sapiens 142-146 34940120-6 2021 Primary ESC cultures treated with E2 + medroxyprogesterone acetate (MPA), a potent P4 receptor agonist, showed significant down-regulation of MMP3, MMP10, MMP11, MMP12, MMP20, and MMP27 in decidualized ESCs, as assessed by quantitative reverse transcription PCR. Medroxyprogesterone Acetate 68-71 matrix metallopeptidase 3 Homo sapiens 142-146 34792864-11 2022 CXCL13 and MMP-3 were increased during treatment with prednisone, independent of disease activity. Prednisone 54-64 matrix metallopeptidase 3 Homo sapiens 11-16 34509913-4 2021 HFO also decreased MMP-1, MMP-3, MMP-13 and ADAMTS-5 expression, and increased Col2 and aggrecan expression. 1,3,3,3-tetrafluoropropene 0-3 matrix metallopeptidase 3 Homo sapiens 26-31 34680530-8 2021 Remarkably, certain bDMARDs were as efficient as JAKi in suppressing the IL-6 and MMP3 secretion of SF stimulated by Th (adalimumab, secukinumab) or B cells (canakinumab) and combining bDMARDs with JAKi had synergistic effects. Thorium 117-119 matrix metallopeptidase 3 Homo sapiens 82-86 34384823-5 2021 Incubation with selected nucleic acid extraction buffers or extraction buffers supplemented with ethanol reduced the infectivity of high-titer wild poliovirus type 1 (WPV1), wild poliovirus type 3 (WPV3), Sabin 1 (SL1), and Sabin 3 (SL3) cell culture isolates below the limit of detection in CCID50 assays. Ethanol 97-104 matrix metallopeptidase 3 Homo sapiens 214-217 34504537-8 2021 EFE inhibited the expression of MMP-1, MMP-3, and proinflammatory cytokines (TNF-alpha, IL-6, and IL-8) in IL-1beta-stimulated HGFs through the inhibition of IL-1beta-induced MAPK/STAT-3 activation. EFE 0-3 matrix metallopeptidase 3 Homo sapiens 39-44 34440823-6 2021 In addition, MMP3 regulates the L-type calcium channel-dependent form of LTP as well as the plasticity of neuronal excitability. Calcium 39-46 matrix metallopeptidase 3 Homo sapiens 13-17 34442348-3 2021 Two alleles regulate matrix metalloproteinase-3 (MMP-3) activity: one with five adenosine bases (5A; associated with higher MMP-3 activity and decreased fibrosis) and another with six adenosine bases (6A; associated with lower MMP-3 activity and increased fibrosis). Adenosine 80-89 matrix metallopeptidase 3 Homo sapiens 21-47 34442348-3 2021 Two alleles regulate matrix metalloproteinase-3 (MMP-3) activity: one with five adenosine bases (5A; associated with higher MMP-3 activity and decreased fibrosis) and another with six adenosine bases (6A; associated with lower MMP-3 activity and increased fibrosis). Adenosine 80-89 matrix metallopeptidase 3 Homo sapiens 49-54 34442348-3 2021 Two alleles regulate matrix metalloproteinase-3 (MMP-3) activity: one with five adenosine bases (5A; associated with higher MMP-3 activity and decreased fibrosis) and another with six adenosine bases (6A; associated with lower MMP-3 activity and increased fibrosis). Adenosine 80-89 matrix metallopeptidase 3 Homo sapiens 124-129 34442348-3 2021 Two alleles regulate matrix metalloproteinase-3 (MMP-3) activity: one with five adenosine bases (5A; associated with higher MMP-3 activity and decreased fibrosis) and another with six adenosine bases (6A; associated with lower MMP-3 activity and increased fibrosis). Adenosine 184-193 matrix metallopeptidase 3 Homo sapiens 21-47 34257809-17 2021 Besides, in vivo studies also showed that when applied in combination, curcumin and probucol could block the PI3K-AKT-mTOR signaling pathway; promote COL-II expression; suppress P62, MMP-3, and MMP-13 expression; and inhibit TNF-alpha-stimulated cartilage degradation. Curcumin 71-79 matrix metallopeptidase 3 Homo sapiens 183-188 34257809-17 2021 Besides, in vivo studies also showed that when applied in combination, curcumin and probucol could block the PI3K-AKT-mTOR signaling pathway; promote COL-II expression; suppress P62, MMP-3, and MMP-13 expression; and inhibit TNF-alpha-stimulated cartilage degradation. Probucol 84-92 matrix metallopeptidase 3 Homo sapiens 183-188 34205079-7 2021 Blood levels of MMP-1 and MMP-3 were associated with calcium levels, MMP-9 with osteoprotegerin and osteonectin, MMP-7 and MMP-10 with osteoprotegerin, MMP-12 with osteocalcin, and MMP-13 with osteopontin. Calcium 53-60 matrix metallopeptidase 3 Homo sapiens 26-31 34079267-10 2021 Similarly, serum concentrations of MMP-3 and ADAMTS-4 demonstrated the same tendency of TT > TC > CC genotype. Technetium 93-95 matrix metallopeptidase 3 Homo sapiens 35-40 34121975-8 2021 Candesartan suppressed tumor cell proliferation and migration by modulating Cyclin D1, MMP3/9, and E-cadherin. candesartan 0-11 matrix metallopeptidase 3 Homo sapiens 87-93 34262394-0 2021 Sphingosine kinases negatively regulate the expression of matrix metalloproteases (MMP1 and MMP3) and their inhibitor TIMP3 genes via sphingosine 1-phosphate in extravillous trophoblasts. sphingosine 1-phosphate 134-157 matrix metallopeptidase 3 Homo sapiens 92-96 34671630-10 2021 We demonstrated that OC significantly downregulated the gene/protein expression of alpha-SMA, COL1A1, MMP2, MMP3, MMP7 and VEGF as well as the oxidative enzymes NOX1 and 4 in TGFbeta1-activated LX2 cells, and reduced the production of ROS by HepG2. oleocanthal 21-23 matrix metallopeptidase 3 Homo sapiens 108-112 34688464-5 2021 The results suggested that Neo decreased the levels of interleukin IL-1beta, IL-6, IL-8, TNF-alpha, MMP-3, MMP-9 and MMP-13 in FLSs. neohesperidin 27-30 matrix metallopeptidase 3 Homo sapiens 100-105 34384998-0 2021 Cell-based assays and molecular simulation reveal that the anti-cancer harmine is a specific matrix metalloproteinase-3 (MMP-3) inhibitor. Harmine 71-78 matrix metallopeptidase 3 Homo sapiens 93-119 34384998-0 2021 Cell-based assays and molecular simulation reveal that the anti-cancer harmine is a specific matrix metalloproteinase-3 (MMP-3) inhibitor. Harmine 71-78 matrix metallopeptidase 3 Homo sapiens 121-126 34384998-3 2021 We therefore investigated harmine for its effects on MMP-3 and the molecular interaction was also simulated. Harmine 26-33 matrix metallopeptidase 3 Homo sapiens 53-58 34384998-5 2021 These results showed that although harmine stimulation in vitro has very little or no effects on MMP-3 expression by U-87 MG cells, the treatment of harmine decreases MMP-3 activity in a dose dependent manner. Harmine 149-156 matrix metallopeptidase 3 Homo sapiens 97-102 34384998-5 2021 These results showed that although harmine stimulation in vitro has very little or no effects on MMP-3 expression by U-87 MG cells, the treatment of harmine decreases MMP-3 activity in a dose dependent manner. Harmine 149-156 matrix metallopeptidase 3 Homo sapiens 167-172 34384998-7 2021 Using a molecular dynamic simulation approach, we identified the N2, methyl of C1 and benzene ring of harmine interact with Zn2+ (2.4 A), His205 (2.4 A) and His211 (2.4 A) as well as Val163 (2.7 A) at the active site of MMP-3, respectively, and thus conferred a striking specific binding advantage. Nitrogen 65-67 matrix metallopeptidase 3 Homo sapiens 220-225 34384998-7 2021 Using a molecular dynamic simulation approach, we identified the N2, methyl of C1 and benzene ring of harmine interact with Zn2+ (2.4 A), His205 (2.4 A) and His211 (2.4 A) as well as Val163 (2.7 A) at the active site of MMP-3, respectively, and thus conferred a striking specific binding advantage. Benzene 86-93 matrix metallopeptidase 3 Homo sapiens 220-225 34384998-7 2021 Using a molecular dynamic simulation approach, we identified the N2, methyl of C1 and benzene ring of harmine interact with Zn2+ (2.4 A), His205 (2.4 A) and His211 (2.4 A) as well as Val163 (2.7 A) at the active site of MMP-3, respectively, and thus conferred a striking specific binding advantage. Harmine 102-109 matrix metallopeptidase 3 Homo sapiens 220-225 34384998-7 2021 Using a molecular dynamic simulation approach, we identified the N2, methyl of C1 and benzene ring of harmine interact with Zn2+ (2.4 A), His205 (2.4 A) and His211 (2.4 A) as well as Val163 (2.7 A) at the active site of MMP-3, respectively, and thus conferred a striking specific binding advantage. Zinc 124-128 matrix metallopeptidase 3 Homo sapiens 220-225 34384998-8 2021 Taken altogether, the present study evidences that harmine acts as an MMP-3 inhibitor specially targeting the enzymatic active site and possibly efficiently ameliorates MMP-3-driven malignant and inflammatory diseases. Harmine 51-58 matrix metallopeptidase 3 Homo sapiens 70-75 34384998-8 2021 Taken altogether, the present study evidences that harmine acts as an MMP-3 inhibitor specially targeting the enzymatic active site and possibly efficiently ameliorates MMP-3-driven malignant and inflammatory diseases. Harmine 51-58 matrix metallopeptidase 3 Homo sapiens 169-174 34405891-10 2022 Apatinib enhanced apoptosis, diminished migration and invasion of HGC-27R cells, elevated proapoptotic protein expression, and reduced Bcl-2, vimentin, snail, MMP-3, MMP-2, and MMP-9 expressions. apatinib 0-8 matrix metallopeptidase 3 Homo sapiens 159-164 34372688-9 2021 RESULTS: Suramin inhibited IL-1beta-induced apoptosis, downregulated matrix metalloproteinase (MMP)-3, MMP-13, a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS)-4, and ADAMTS-5, and upregulated collagen 2A (Col2a1) and aggrecan in IL-1beta-treated NP cells. Suramin 9-16 matrix metallopeptidase 3 Homo sapiens 69-101 34372688-11 2021 Suramin suppressed IL-1beta-mediated proteoglycan depletion and the induction of MMP-3, ADAMTS-4, and pro-inflammatory gene expression in ex vivo experiments. Suramin 0-7 matrix metallopeptidase 3 Homo sapiens 81-86 34442348-9 2021 We found an association between MMP-3 5A/6A polymorphisms and QTc, independent of adjustments for age, gender, alcohol consumption, smoking status, body mass index and blood pressure. Alcohols 111-118 matrix metallopeptidase 3 Homo sapiens 32-37 34801997-10 2021 (2) A negative correlation between the eGFR and MMP-2, MMP-3, and TIMP-2 and a positive correlation between creatinine and MMP-3 levels indicate the role of MMPs and TIMP-2 in renal dysfunction. Creatinine 108-118 matrix metallopeptidase 3 Homo sapiens 123-128